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Executive Summary
european region countries
This report covers the following 54 countries of the World Health Organization 
(WHO) European Region and Liechtenstein:
Western Europe: Andorra, Austria, Belgium, Denmark, Finland, France, 
Germany, Greece, Iceland, Ireland, Israel, Italy, Liechtenstein, Luxembourg, 
Malta, Monaco, the Netherlands, Norway, Portugal, San Marino, Spain, Sweden, 
Switzerland, the United Kingdom
Central Europe: Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, 
the Czech Republic, Hungary, Kosovo, the former Yugoslav Republic of Macedonia, 
Montenegro, Poland, Romania, Serbia, the Slovak Republic, Slovenia, Turkey
Eastern Europe and Central Asia: Armenia, Azerbaijan, Belarus, Estonia, 
Georgia, Kazakhstan, the Kyrgyz Republic, Latvia, Lithuania, Moldova, the 
Russian Federation, Tajikistan, Turkmenistan, Ukraine, Uzbekistan
Hiv in europe
Despite decreases in the rate of the spread of human immunodeficiency virus 
(HIV) in the last decade, the number of new diagnoses in Europe continues to 
increase, and by 2011, reached over 1.2 million individuals, with over a half 
 million diagnoses reported in the last five years. Between 2006 and 2010, there 
have been an average of 127 new diagnoses each year per million people in 
Europe. Our review of national case reports indicates that the continuing 
increase in new HIV cases in Europe is fueled by epidemics in the East, which 
numbered 273 new diagnoses per million people during this time period. 
Western and Central Europe, on the other hand, have reported relatively stable 
increases, with an average of 74 and 11 new diagnoses, respectively. In this 
time period, new diagnoses have increased (by around 30%) in the East, with the 
 highest rates of new diagnoses in Estonia, Russia, and Ukraine. The proportion of 
cases among women is declining in the West and Central Europe, but remains 
consistent in the East (at 41%).
xvi Executive Summary
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Hiv Diagnoses and prevalence among Key populations
Between 2006 and 2010, 25% of case reports in Europe were associated with 
injecting drug use, with higher proportions in the East (33%) than in the West 
(5%) and Central Europe (7%). During this period there was an annual average 
of 89 reported HIV diagnoses associated with injecting drug use per million 
people in the East, 3.6 per million in the West, and 0.8 per million in Central 
Europe. The countries with the highest levels of reported diagnosed cases among 
people who inject drugs (PWID) in Europe were Ukraine (153 per  million 
 people), Russia (98 per million people), and Kazakhstan (78 per million people).
Findings from HIV-prevalence studies show that prevalence among PWID is 
highest in Estonia (55.3%), Spain (34.5%), Russia (28.9%), Moldova (28.6%), 
and Ukraine (22.9%) (see map ES.1). Our review of multivariate risk factors 
linked to HIV among PWID shows that a history of injecting with previously 
used injecting equipment, injecting with greater frequency, and a longer history 
of injecting were linked to HIV. When aggregated across multivariate studies, 
being female emerges as a risk factor.
Heterosexual exposure was the reported risk factor for 29% of HIV diagnoses 
in the region. There has been a slight decline in the proportion of cases attributed 
to heterosexual exposure as well as the number of HIV cases in the West; both 
have remained stable in Central Europe and increased in the East. During this 
period the annual average of cases per million people was 74 in the West, 11 in 
Central Europe, and 273 in the East. The countries with the highest levels of 
6%–20%
0%–1%
2%–5%
>20%
No data
map es.1 Average Hiv case prevalence across europe among pWiD (2006–10)
Source: Table B.6.
Note: PWID = people who inject drugs.
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reported cases in Europe were Ukraine (161 per million people), Moldova (145 
per million people), and Portugal (91 per million people). The highest propor-
tion of cases with heterosexual exposure among women was reported in the East 
(60%), followed by the West (50%), and lowest in Central Europe (43%). The 
proportion of reports among people 30 years old or less at diagnosis declined in 
all three subregions.
With few exceptions, European countries do not collate risk-factor informa-
tion concerning sex work as part of case reporting. Our review of HIV-prevalence 
studies shows that HIV remains low among female sex workers (FSWs) who do 
not inject drugs, at less than 1% in the West [1–12]. HIV prevalence among 
FSWs in the East is generally higher than in the West and Central Europe, rang-
ing from around 2% to 8% (map ES.2). Our review shows a clear relationship 
between higher HIV prevalence and higher prevalence of injecting drug use 
among sex workers (SWs). In the West, HIV prevalence is higher among male 
and transgender SWs than FSWs, irrespective of injecting drug use, reflecting the 
higher prevalence of HIV among men who have sex with men (MSM), the main 
client group of male sex workers (MSWs).
Case-reporting data show that MSM was reported for 10% of all HIV diagno-
ses in Europe, and higher in the West (36%) than in Central Europe (22%) or the 
East (0.5%). Between 2006 and 2010, the annual average number of diagnoses 
linked to MSM per million people was 27 in the West compared with 2.5 in 
Central Europe and 1.4 in the East, and highest in the United Kingdom (43.4), 
the Netherlands (43), and Spain (37.3) (map ES.3). But Central Europe and the 
0%–1%
2%–5%
6%–10%
11–20%
No data
map es.2 prevalence of Hiv among FsWs in europe (2006–10)
Source: Table B.6.
Note: FSWs = female sex workers; HIV = human immunodeficiency virus.
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East have witnessed marked increases in the number of reported diagnoses asso-
ciated with MSM in the last five years. Despite these increases our findings sug-
gest that case reports remain underreported in this region among MSM. An 
indication of the extent of underreporting can be seen in the high numbers of 
case reports with no known exposure group (including in Estonia, Poland and 
Russia), which may reflect MSM-associated cases hidden due to social and legis-
lative issues related to homosexuality.
Our review also shows that estimates of HIV prevalence among samples of 
MSM are highest in the West, but vary from as low as 1.6% in Switzerland to 
nearly 20% in Spain. We also noted a relative lack of targeted HIV prevalence 
and risk-behavior surveys among MSM throughout the region. Our review of 
multivariate analyses investigating HIV risk factors among MSM linked HIV to 
inconsistent condom use, unprotected anal intercourse (UAI), and a history of 
sexually transmitted infections (STIs). Findings from our systematic review also 
suggest that the epidemics among MSM in the West may be perpetuated by a 
core group of MSM and HIV-positive MSM engaging in high-risk behaviors with 
a high number of sex partners [13, 14].
The evidence shows that HIV epidemics of Europe are greatest in their bur-
den and momentum in the East, where transmission remains primarily linked to 
injecting drug use. While the epidemics in the West remain primarily linked to 
MSM, we see recent increases in such case reports in the East and Central 
Europe. It is important to note that such case report data are only as robust as 
0%–1%
2%–5%
6%–10%
11%–20%
No data
map es.3 Hiv prevalence across europe among msm (2006–10)
Source: Table B.6.
Note: MSM = men who have sex with men.
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the HIV surveillance systems producing them. Underreporting risk status, espe-
cially among MSM, is likely in settings where social stigma is greatest, arguably 
in the East of the region. Our synthesis of case report and HIV-prevalence data 
suggests that the allocation of HIV-prevention resources should concentrate on 
bolstering and expanding prevention responses targeting PWID and their sexual 
partners in Eastern Europe, introducing prevention responses among MSM 
there and in Central Europe, and reinvigorating prevention responses among 
MSM in the West.
There is also emerging evidence in Europe of the potential for sexual trans-
mission of HIV among PWID involved in sex work [15]. In Estonia, HIV was not 
associated with injecting drug use among SWs and they had a correspondingly 
lower prevalence of hepatitis C virus (HCV) suggesting less risky injecting 
behaviors [16]. A similar pattern has been observed in Russia: a study showed 
reduced odds of HCV among women who inject drugs associated with sex work, 
but increased odds of syphilis pointing to the potential for sexual transmission 
[17, 18]. The high prevalence of syphilis reported along with HIV was observed 
in the Central Asian republics, Moldova, Russia, and Ukraine, suggesting that 
conditions may exist for increased sexual transmission of HIV among SWs in 
the East.
We have not reviewed surveillance activities focused on groups that reflect the 
general population—such as pregnant women or prisoners. Surveillance activities 
among such groups—particularly pregnant women—should be regularly 
reviewed as they can provide insights into whether an epidemic might be gener-
alizing. Monitoring pregnant women may also provide insights into migrants, as 
they often have higher fertility rates. In countries where there is evidence that 
indicates generalization of the epidemic, or the potential for the epidemic to 
generalize, then surveillance among such groups should be incorporated as a 
response to the epidemic.
Our review shows that SWs involved in injecting drug use have higher HIV 
prevalence than SWs who do not inject drugs, and that HIV prevalence among 
SWs is highest in the East where HIV prevalence is highest among PWID. There 
is considerable overlap between sex work and drug injecting in the East, with 
some studies of SWs suggesting that the majority are also PWID [19], and stud-
ies of PWID suggesting that between one quarter and one half have exchanged 
sex for money or drugs [20, 21]. Our review finds that SWs who inject drugs are 
more vulnerable not only to HIV, but also prone to violence, increased problems 
with mental health, reduced condom use, and unwanted pregnancies [22–24]. 
Further, a high proportion of male and transgender SWs report injecting drugs 
[25–29]. HIV-prevention interventions need to give priority to targeting the 
intersection of sex work and injecting drug use.
Taken together, HIV-surveillance systems need to increase the accuracy of 
risk-factor data among heterosexual exposures as well as target surveillance 
among the sexual partners of PWID. It is fundamental that HIV-prevention 
responses should integrate sexual health and drug-related health. Among SWs, 
sexual risk-reduction interventions need to better address sexual transmission 
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risk in nonpaying and regular relationships. While our review shows consistent 
condom use with clients is generally the norm among SWs, it is much less com-
mon with nonpaying partners. Among PWID, sexual health concerns have been 
eclipsed by an almost exclusive focus on preventing viral transmission linked to 
the shared use of injecting equipment, and this may be particularly the case in 
the East, where currently the potential for the progression of sexual transmission 
appears to be the greatest [30]. The majority of PWID in surveys across the 
region report inconsistent condom use with their regular partners, the majority 
of whom are noninjectors for male PWID.
Hiv and migration
European HIV case reports indicate the potential significance of migration. 
Among MSM in the West, 5.8% of diagnoses in 2010 were among men who 
originated from elsewhere in the West, and 2.8% were among men from 
Central Europe or the East. Among diagnoses in the West associated with 
injecting drug use, 4.3% originated elsewhere in the West and 20% in Central 
Europe or the East. Among cases associated with heterosexual exposure in the 
West, over one-third were among people who originated from a country with 
a generalized HIV epidemic. Evidence internationally indicates that local and 
international migration can have important effects on the dynamics of HIV 
transmission, both among vulnerable groups and in relation to heterosexual 
exposure [31–33].
There is a pattern among MSM to migrate into the cities, and from cities in 
the East toward the large cities of Western Europe. An effect of homophobia in 
the region is generating mobility among MSM who tend to move or travel to 
urban centers, which are often considered more gay-friendly and less stigmatizing 
[25, 34, 35]. The surveys we reviewed suggested that a significant minority of 
MSM are migrants—as much as 15% in many locations [25, 36–38]. Studies of 
MSM in some cities show a higher prevalence of HIV among migrant MSM [39].
In the last twenty years, there are increasing numbers of migrant women 
working in the European sex industries. In the West, the majority of SWs are 
migrant women, most of whom are East European and African. In some studies 
of SWs, being a migrant emerges as a risk factor for HIV, but in other studies 
there is no such association, most likely reflecting the HIV prevalence within 
country of origin [2, 33, 40, 41]. A systematic review examining the effect of 
migration on the risk of HIV among migrant SWs found that there was a higher 
prevalence of HIV among some FSWs originating from high-prevalence coun-
tries, likely due to infection at home. However, there were no consistent differ-
ences in risk, highlighting the importance of the local context such as the 
availability of services to migrants, immigration policies, and the local organiza-
tion of the sex industry in mediating risk among migrant FSWs [42].
Taken together, there is a need to better monitor migrant status in HIV surveil-
lance as well as to increase the accessibility of HIV-prevention responses to 
migrant PWID, SWs, and MSM. These methods include the translation of existing 
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prevention-related materials, messaging via the Internet, and contact with travel 
companies, including those servicing the gay tourist market [12, 41, 43].
monitoring and surveillance of Hiv among pWiD, sW, and msm
During the period from 2000 to 2010, HIV-surveillance studies were found to 
be better established among PWID than among SWs and MSM, with very little 
data available among migrants and male SWs.
Among the 21 countries where HIV prevalence was higher than 5% among 
PWID, the majority had conducted repeated studies monitoring HIV prevalence 
(18) and risk behavior (16) among PWID. HIV prevalence and behavioral studies 
need to be conducted in Ireland and Turkey where no recent surveys have been 
conducted, and in Iceland or Turkmenistan where no surveys at all were identi-
fied for PWID. In the context of economic decline across the region and the 
recent outbreaks of HIV in Greece and Romania, in part attributed to recession 
and reduction in services, we recommend vigilance in monitoring HIV-case 
reports as well as one-time behavioral/prevalence surveys to anticipate changes 
in risk behaviors across the region. This is particularly important in countries 
where prevalence is higher than 5% among PWID. It is also important among 
countries hardest hit economically, such as Iceland, Italy, and Spain, and in coun-
tries where routine surveillance is not implemented, such as Iceland and 
Turkmenistan.
Ten countries were identified with high HIV prevalence (>5%) among SWs, 
and among these, six have conducted repeated HIV-prevalence studies, and seven 
have conducted studies to monitor risk behaviors. Studies to monitor HIV or 
behavior among FSWs need to be implemented in Portugal and Turkey and 
improved in Estonia and the Netherlands. This is particularly important given the 
lack of routine HIV/STI epidemiological data in relation to sex work in Europe 
[44]. Studies of MSWs were only found in six countries across the region, all 
these studies found high prevalence of HIV (>5%). Three of these studies were 
conducted in countries with the highest annual average number of HIV-case 
reports per million people (the Netherlands, Spain, and the United Kingdom). 
Denmark, France Greece, Ireland, Luxembourg, Portugal, and Switzerland also 
report high numbers of HIV cases among MSM and should consider implement-
ing targeted prevalence studies among male SWs.
Only 2 countries in the West had undertaken either repeated surveys or stud-
ies at different points in time that could be used to monitor prevalence among 
MSM, compared to 7 countries in Central Europe and 10 in the East. Italy, 
Poland, Luxembourg, and the Slovak Republic, countries of high HIV prevalence 
(>5%), need to implement repeated targeted studies that could be used to moni-
tor prevalence or risk behaviors.
Our review noted the need for a systematic assessment of the robustness of 
methods used to monitor HIV prevalence and risk in key populations over time. 
We also noted the need to expand or introduce repeated studies to measure these 
methods, as well as indicators of HIV incidence, in some countries. Establishing 
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mechanisms for repeated measures of HIV prevalence and risk is especially 
important, as is the development of a centralized portal for the synthesis of such 
data to enable cross-regional comparisons. Moreover, HIV-surveillance systems 
provide unrealized opportunities to collate data on indicators of HIV-prevention 
intervention coverage, as outlined in third generation surveillance guidelines 
[45]. Data on the coverage of combination interventions is especially important. 
Where feasible, surveillance systems should also be geared toward monitoring 
indicators of how the social and structural context mediate HIV, for instance, by 
estimating the prevalence of violence among SWs and MSM and of police 
 contact among PWID.
A key challenge in collecting data to inform interventions is the political con-
text in which sex work, drug use, and MSM take place. In contexts where, for 
example, sex work is heavily regulated or MSM is stigmatized, conducting HIV-
related surveillance studies among people with few rights or representation may 
create ethical or safety challenges. Proposals for HIV-related surveillance studies 
need to be conducted with full consultation with affected populations and with 
appropriate rights protections in place [44]. There are some useful lessons in 
good surveillance practice in Europe, including for instance, the European Men 
Who Have Sex with Men Internet Survey (EMIS) among MSM, the sentinel 
surveillance of HIV and risk among PWID in Italy, Spain, and the United 
Kingdom, and the sentinel surveillance among SWs in Central Asia [40, 46–49]. 
All countries within the region should regularly assess and estimate the sizes of 
the three main key populations at high risk—MSM, PWID, and SW. The plausi-
bility of the estimates generated should be assessed robustly by a range of stake-
holders including civil society groups from within the populations of interest. 
The estimation process should be undertaken at least every 10 years.
Our review of surveillance data shows higher rates of HIV testing in the East, 
especially in Russia. This may result from mandatory testing of migrants and 
the practice of “opt-out” rather than “opt in” testing policies at  various clinic 
and health service settings; it may also result from occupational requirements 
[50, 51]. Evidence reviewed tends to show the protective effect of HIV testing 
in reducing HIV risk among PWID and SWs and UAI among MSM; however, the 
cost of this widespread testing of general population groups in the East should 
be evaluated [52]. Any increase in HIV testing needs to occur simultaneously 
with increasing access to treatment, reducing the stigma associated with HIV 
positivity, and removing structural barriers to employment and  discrimination for 
those diagnosed.
environmental risk Factors shaping Hiv risk
Our review points to regional differences, suggesting that levels of risk behavior 
among key populations tend to be highest in the East. While the frequency of 
reported needle or syringe sharing is highly variable across Europe, there are 
instances of especially high levels of sharing in the East and Central Asia. 
Among SWs, the systematic review showed that condom use with clients was 
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consistently higher in the West than in the East or Central Europe. Among 
MSM, the highest rates of condom use during anal sex emanate from studies in 
the West, with rates around 15% higher than those reported in the East. 
Reports of UAI are also higher in the East than West or Central Europe. Most 
PWID across the region report inconsistent condom use with their regular 
partners, with a substantial minority reporting inconsistent condom use with 
their casual partners.
While the epidemiological studies we reviewed rarely explicitly embraced 
exploration of social determinants, our synthesis of data on HIV-risk factors 
nonetheless points to the potential role of environmental-level factors in 
HIV transmission (chapter 3). Our discussion of HIV-prevention responses 
(chapter 4) also highlights that the development and impact of interventions can 
be shaped by social and structural contexts.
Our review identified a number of crosscutting environmental factors as key 
domains of future social epidemiological research investigating HIV vulnerability 
in the region: (a) criminalization of key populations at high risk for both drug use 
and sexual practices; (b) the experience of social stigma and discrimination; 
(c) migration; (d) gender inequalities; and (e) material inequalities. In our eco-
logical analysis, the strongest and most consistent association we found was a 
linear relationship between an increased number of people imprisoned per 
100,000 population and increased HIV prevalence among PWID and FSWs 
(“HIV-Prevention Responses among People Who Inject Drugs” and "HIV-
Prevention Responses among SWs” sections in chapter 4). Imprisonment—an 
effect of the criminalization of drug use and sex work—can make prisons riskier 
environments for the acquisition of HIV. This is not an exhaustive list and does 
not discount the potential importance of multiple other structural factors. Future 
epidemiological and intervention studies of HIV among key populations need to 
better systematically delineate how micro- and macroenvironmental factors 
combine to increase or reduce HIV risk.
Among PWID, our review of multivariate studies pointed to unemployment, 
gender, and aspects of the legal environment as potentially important factors in 
the acquisition of HIV. Regarding gender, women who inject drugs tend to be 
younger than their male counterparts, engage in higher rates of needle and 
syringe sharing, are more likely to share their sex partners’ injecting equipment, 
and engage in riskier sexual practices [53–60]. Regarding the legal environment, 
ever having been arrested and ever having spent time in prison emerged as risk 
factors for HIV. Rates of arrest were high among PWID surveyed, especially in 
the East. Qualitative studies in the region link arrest, as well as the fear or experi-
ence of police violence, with reduced capacity for risk reduction [61–63]. There 
is a need to systematically document the prevalence and contexts of policing 
practices, including extrajudicial practices, which may violate the human rights 
of PWID as well as potentially impact their HIV-risk reduction capacity. The data 
also suggest that there is an urgent need to maximize the coverage and intensity 
of HIV-prevention interventions in prison settings. These findings are corrobo-
rated by international studies [61, 62, 64–68].
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Among SWs, violence emerges as an important contextual determinant of 
HIV risk, linking to HIV both directly and indirectly. Reported levels of sexual 
and physical violence among SWs were high in the East and appeared most com-
monly among minority groups (transvestites, Roma) [12, 43, 69–71]. Evidence 
also points to aggressive policing practices, especially in the East, which exacer-
bated a woman’s potential for HIV risk, forcing them to work longer hours to 
make up lost income after arrest. They are also more likely to have unprotected 
sex in order to make more money, and they are reluctant to carry condoms as 
they may be used as evidence of sex work [64, 72, 73]. Explicitly linked to polic-
ing is legislation regulating sex work, which is a key structural determinant of 
violence and HIV risk. The practice of criminalizing activities related to sex work 
can reduce opportunities for communication between SWs and often results in 
the concentration of sex work into tolerance zones [74, 75]. The evidence sug-
gests that where sex work is unregulated and accompanied by police corruption, 
as it is in the East, the environments are most risky [73, 76]. Legislation may also 
influence community attitudes towards SWs with criminalization of sex work, 
reinforcing negative attitudes and violence towards SWs and thereby reinforcing 
the implementation of targeted services for SWs, as reflected in fewer numbers 
of targeted services for SWs in Russia [77, 78]. Repressive policies will reduce 
SWs’ access to HIV services particularly, as often reported in the East, when HIV 
testing is enforced following detention by police. The punitive approach to HIV 
testing following arrest or detention must be stopped in the East in favor of 
facilitating voluntary counseling and testing (VCT).
Among MSM, the reviewed evidence suggests that social stigma in relation to 
male homosexuality emerges as a key factor influencing men’s capacity for risk-
reduction efforts. The stigma felt by these men also constrains the potential 
impacts of HIV-surveillance and prevention efforts, discouraging MSM from 
seeking help for HIV prevention as well as encouraging the underreporting of 
same sex activity as risk factors in HIV-surveillance efforts. Institutionalized 
social stigma experienced by MSM can be viewed as a form of “structural vio-
lence” mediating HIV risk indirectly as well as directly.
strengthening Hiv prevention among pWiD
Findings from our modeling analysis show that high but achievable coverage 
levels of needle and syringe exchange programs (NSP) can result in large 
decreases (>30%) in HIV incidence and prevalence in settings with high HIV 
prevalence among PWID. Required coverage levels are much lower when inter-
ventions are combined or in lower prevalence settings. The analysis also high-
lights the importance of combination interventions for reducing HIV incidence 
and prevalence to low levels in high-prevalence settings, with no single interven-
tion (or only at high coverage in the lower prevalence setting of Dushanbe, 
Tajikistan) being able to reduce HIV incidence to less than 1% or prevalence to 
less than 10% in 20 years. Modeling shows that when core interventions are 
delivered in combination, coverage targets become more feasible, although still 
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remain considerable, with about 60% coverage of all three core interventions 
being required in Tallinn, Estonia, and St. Petersburg, Russia, over 20 years and 
about 30% coverage in Dushanbe, to reduce HIV prevalence to less than 10%. 
The effectiveness of HIV-prevention policies depends on the combined effects of 
multiple integrated interventions, including HIV testing to identify those in need 
of antiretroviral therapy (ART), and bringing these to scale [79].
Intervention availability and coverage is shaped by policy and social the envi-
ronment, and we have noted, for instance, how law enforcement, policing prac-
tices, and national commitments to HIV prevention can limit HIV-prevention 
coverage potential. We have noted how in Russia—a setting of a major HIV 
epidemic—the legal and social environment has constrained, even prohibited, 
the development of proven-to-be-effective HIV-prevention interventions, such 
as opioid substitution therapy (OST). Structural interventions that bring about 
policy, legal, or social change are required to enable the scale-up of sufficient 
HIV prevention, and this is arguably most urgent in the East. The package of 
combination HIV-prevention interventions promoted by the World Health 
Organization (WHO) and other international agencies as core to national HIV-
prevention programming (which includes NSP, OST, and ART) underempha-
sizes the potential role of social and structural intervention approaches.
Moreover, combination HIV-prevention approaches should consider including 
interventions fostering policy reform as well as legal change. While lacking in 
rigorous evaluation, interventions targeting changes in the criminal justice envi-
ronment include: (a) the establishment of police HIV-prevention training and 
partnerships; (b) the development of alternatives to prison programs, including 
coerced or mandated entry to drug treatment via community penalties and court 
orders; (c) the provision of sterile injecting equipment in prisons which has been 
linked by meta-analyses to positive rather than adverse risk-reduction effects; 
(d) the provision of OST in prisons, which has been linked to improved drug 
treatment outcomes including post release; and (e) the initiation of interventions 
enabling legal aid and legal rights literacy to protect against rights violations, 
though the HIV-prevention impact of these interventions remains unknown.
Interventions that bring about change in the legal environment seek to mini-
mize the iatrogenic health effects of the criminalization of drug users and of the 
prohibition of HIV-prevention interventions. Legal restrictions to the provision 
of sterile needles and syringes need to be relaxed in order to increase availability 
and accessibility. HIV risks are, in part associated with the criminalization of 
drug use per se, as increasingly evidenced internationally [80–83]; therefore 
the decriminalization of drug use as a strategy to reduce such harm needs to be 
considered [82, 84].
strengthening Hiv prevention among sWs
The importance of SW-specific services cannot be overstated—they are impor-
tant not only in the provision of services and reducing HIV and STIs but also in 
facilitating access to SWs for monitoring of harms and risks associated with 
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sex work. To date the majority of interventions focus on reducing prevalence of 
STIs and HIV, outcomes that may have an onward effect on non-sex working 
communities. The ecological analysis suggests a decrease in HIV prevalence 
among FSWs with increasing numbers of sex work services that address not only 
STIs and HIV but broader harms associated with sex work. More interventions 
are needed that do not focus solely on sexual risk behaviors, STIs, and HIV, but 
rather on broader health outcomes including reducing violence and unwanted 
pregnancies, and improving mental and emotional health. These need to be 
 properly evaluated.
Indicators of coverage by SW services across the region was limited. Data on 
HIV testing suggested that over one third of SWs across the region had been 
tested for HIV, but this may reflect testing following arrest or detainment or as a 
result of mandatory testing through regulation, as in Greece, rather than volun-
tary testing. We recommend the routine collation of reported HIV or STI testing 
at SW services, in order to facilitate an estimate of the effective coverage of ser-
vices in relation to HIV prevention, taking into account the need for consultation 
with SWs and protection of privacy. Routinely monitoring condom use with 
clients and nonpaying partners would also give an insight into sexual risk 
 behaviors, as the high prevalence of gonorrhea underscores the persistent sexual 
 vulnerability of SWs.
New approaches to health service provision are needed across the region to 
adapt to the changing sex-work scene and the increasing number of off-street 
and migrant SWs. Projects in the United Kingdom have attempted to target off-
street populations by conducting outreach online and contacting women via 
their websites and circulating frequent emails about services, checkup appoint-
ments, and other information. Catering for the needs of migrant SWs requires 
the incorporation of translation and interpreters into services particularly in 
Western Europe. In the East, the focus of services has been via existing harm-
reduction projects and on addressing specific problems relating to drug use and 
HIV/STI testing rather than broader issues relating to sex work and sexual 
health. It is fundamental that HIV-prevention interventions specifically target 
SWs, including those not involved in drug use and who may not define them-
selves as connected to the sex industry. It is also important that drug and sexual 
health services are sufficiently integrated to maximize their coverage potential.
Research from Europe and around the world has shown that criminalization 
and enforcement-based approaches toward sex work can increase risks of both 
physical and sexual violence against women [75, 85, 86], as well as risk of STIs 
[17, 87]. Policies and legislation connected to sex work should focus on facilitat-
ing safer working environments rather than enforcement approaches that can 
further marginalize women. Legislation of sex work in Europe is largely charac-
terized by a prohibitive model that may not criminalize the act of selling sex, but 
criminalizes activities around it such as working in groups or running brothels, 
which can limit SWs’ ability to organize their work safely. In countries where sex 
work is regulated, the benefits of this are denied to migrant SWs without legal 
residency rights, as they are not accorded the same rights as nonmigrants. 
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There is evidence that decriminalization of sex work can reduce incidences of 
violence and improve mental health of SWs. A long-term strategy needs to 
decriminalize sex work across the region. Managed street sex-work zones have 
been effective in reducing incidences of violence and providing a safer place to 
work and should be introduced as a short-term strategy.
Reports show that SWs experience violence not only in relation to sex work 
but also by boyfriends, husbands, and family. Broader structural interventions to 
reduce violence among women as a whole are needed as well as targeted inter-
ventions for SWs. Policies are needed that address the social welfare of SWs and 
social determinants of health such as disparities in employment opportunities, 
wage, access to welfare, and domestic violence [87–89]. The inclusion of these 
kinds of structural interventions often have an indirect benefit of reducing harms 
among peripheral members of key population groups who may not identify 
themselves as SWs. This is of paramount importance in populations as diverse 
and fluid as SWs.
strengthening Hiv prevention among msm
Effective measures to estimate coverage of services among MSM are urgently 
needed in order to monitor uptake of services. Standardized indicators are cur-
rently lacking across the region. An important finding of the review is that access 
to mainstream sexual health provision for MSM can be impeded by staff hostility 
borne out of the dual stigma of homosexuality and HIV, and patient fears con-
cerning breaches of confidentiality [90–92]. Such concerns appear more acute in 
the East. For instance, social stigma appears to act as a deterrent to timely HIV 
testing and levels of HIV testing are lower in Central Europe and the East. There 
is a need to more systematically document how stigma and violence is experi-
enced by MSM, how this affects HIV risk reduction capacity, and how a greater 
emphasis on stigma reduction initiatives can be a core element of HIV-prevention 
programming. Stigma-reduction interventions should be promoted throughout 
all sectors of society and within criminal justice agencies in particular. Protective 
laws (those against discrimination based on sexual orientation) may assist in 
prevention efforts through their impact on the perceived acceptability of stigmas 
against MSM and should be supported throughout the region.
Our review notes a varied environment in relation to the criminalization and 
social regulation of homosexuality throughout Europe. Legal changes to decrimi-
nalize homosexuality in the parts of the region where such laws remain 
(Turkmenistan, Uzbekistan) need to be made. Shifts in Western Europe toward 
recognizing the social inclusion of MSM—for instance, through the legalization of 
civil partnerships between men—are important social interventions in that they 
contribute to an enabling context for health and citizenship, including potentially 
for HIV prevention. Community-level interventions may facilitate some of the 
social changes required to enable the wider social acceptance of homosexuality, 
including regarding the day-to-day practices of health, welfare, and regulatory 
institutions, and especially the practices of police and health care professionals. 
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Aside from HIV-prevention capacity, our review notes that HIV surveillance sys-
tems are much more likely to correctly attribute transmission of HIV between 
MSM, and thus better allocate treatments, in settings less socially stigmatized.
Evidence suggests that HIV testing can increase condom use for anal inter-
course [93, 94], but for HIV-negative men it is a more effective HIV-prevention 
strategy when accompanied by effective counseling on risk reduction [95]. 
Dedicated MSM-only test facilities are needed in countries where most physi-
cians are inclined to be hostile toward MSM. For full impact, it is essential that 
links are made with other prevention services appropriate to the needs of MSM, 
particularly in the East where many MSM appear poorly informed of the HIV 
risks linked to certain practices [96]. Paying for tests and other medical care are 
major barriers to prevention and should be discontinued. Condoms should be 
made freely available in all gay venues and known meeting places and required 
as a condition of local authority licensing to reduce UAI. Additionally, strategies 
other than a reliance on 100% condom use are needed such as encouraging 
slower rates of partner change, fewer partners, and especially the avoidance of 
multiple concurrent partnerships. Concurrency is a key risk factor in the spread 
of HIV because people are more inclined to use condoms in casual relationships 
[14, 97], but the establishment and maintenance of trust in a relationship 
encourages unprotected intimacy and then sets up barriers to honesty about any 
infidelity [98, 99]. Other strategies should involve encouraging the practices of 
sex acts other than anal sex [100].
In the West, social stigma appears less prominent as a factor shaping access to 
help and risk reduction; HIV testing is more common, knowledge of the risks 
posed by UAI is higher, and condoms are widely available [101, 102]. However, 
many MSM continue to have unprotected sex frequently with casual partners. In 
a context of the widespread availability of highly active antiretroviral therapy 
(HAART), there may also be a misplaced reliance on negative HIV results when 
selecting sex partners [103, 104]. Interventions need to question how strategies 
of “serosorting” are applied in practice, for they may promote a false sense of 
security, and counseling alongside HIV testing is necessary to address any miscon-
ceptions regarding the safety of relying on recent HIV-negative test results as a 
rationale for unprotected sex.
Complacency about infection and treatment availability complicates preven-
tion messages in the West. There is some evidence that good adherence to 
HAART can reduce viral load to undetectable levels, resulting in some protection 
against HIV [105, 106]. However, patients with undetectable viral loads may 
have detectable levels of the virus in their semen and may therefore be infectious 
[107, 109]. Many of the studies providing the evidence of effectiveness of treat-
ment as prevention are based on mathematical modeling rather than observed 
data, which are highly sensitive to the parameters and underlying assumptions 
of the model, while the remainder are ecological studies that give mixed 
results overall, and are unable to demonstrate causality [105, 106, 110, 111]. An 
assumption that treatment is protective is particularly problematic in the case of 
MSM, given that the per-act probability of transmission is so much higher for 
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anal sex [112] than for vaginal sex [113], and that partner numbers are typically 
higher. Therefore, the promotion of HIV treatment as a strategy for HIV preven-
tion in Europe needs to be approached with some caution.
One difficulty with the targeting of HIV prevention in parts of the European 
region is that it tends to be based on “Western” models of experience, and these 
historically tend to be based on interventions targeting men identified as homo-
sexuals. Such approaches may overrepresent men who mainly or only perform 
the receptive role, since those who tend to take the insertive role may be more 
likely to identify themselves as heterosexual [114]. It is fundamentally important 
to recognize the heterogeneous nature of populations of MSM and to tailor inter-
ventions accordingly in different parts and local settings of Europe. MSM HIV-
prevention programs need to go beyond gay-scene settings (bars, clubs, saunas, 
shops) to reach a significant and diverse proportion of the population. Websites 
for MSM are an essential part of HIV-prevention programs since they are used 
both by men who are active in the gay-scene and those who are not. Finally, 
educational mass media messaging targeting all sexually active men can also be 
designed to benefit MSM through sensitive use of language and imagery [91].
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Introduction
Background
This report aims to describe the dynamics of human immunodeficiency virus 
(HIV) epidemics among vulnerable and key populations at high risk in the 
European region, focusing specifically on people who inject drugs (PWID), sex 
workers (SWs), and men who have sex with men (MSM). It does so to inform 
future HIV prevention, treatment, and care responses as well as to guide future 
HIV-prevention surveillance and research.
A Focus on Key Populations in Concentrated HIV Epidemics
This report focuses specifically on reviewing European epidemiological evidence 
in relation to HIV among populations of PWID, SWs, and MSM. These popula-
tions are most at risk in concentrated rather than generalized HIV epidemics 
(see box 1.1). As shown in map 1.1, the HIV epidemics of Europe are largely 
concentrated HIV epidemics.
A Focus on Exploring Evidence in Relation to the HIV Risk Environment
A growing body of research substantiates relationships between environmental 
factors and HIV vulnerability [2–3]. The heuristic of the HIV risk environment, 
for example, has emerged as one way to envisage HIV risk as the product of 
reciprocal relationships between micro- and macro-level influences in the physi-
cal, social, economic, and policy environments, which contextualize individual 
and community actions in relation to risk [2–8]. Recent reviews have called for 
a shift toward social epidemiological approaches capable of capturing how ele-
ments of the risk environment affect HIV in vulnerable and key populations 
[2, 9]. This approach requires investigating how the distribution of HIV in such 
populations is in part shaped by “social factors”—that is, forces that extend 
beyond “proximal” individual-level factors and their biological mediators. 
Conscious that HIV epidemiological research may often lack sufficient focus on 
the study of social determinants, this report explores the extent to which recently 
published European evidence on HIV among key populations of PWID, SWs, 
and MSM captures indicators of the HIV risk environment.
c H A p t e r  1
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Box 1.1 Definitions of Hiv epidemic
In generalized epidemics, where HIV is over 1% in the general population, surveillance systems 
concentrate on monitoring HIV infection and risk behavior in the general population. This 
usually includes HIV sentinel surveillance among pregnant women in antenatal care.
In concentrated epidemics, where HIV is over 5% in any subpopulation at higher risk of 
infection (such as, PWID, SW, and MSM), but under 1% in the general population, surveillance 
systems should monitor infection in those groups and their behavioral links with the general 
population. Surveillance systems may also monitor the general population for high-risk sexual 
behaviors that might lead to rapid spread of the virus if it were introduced and trends in 
sexually transmitted infections (STIs).
In low-level epidemics, where relatively little HIV is measured in any group, surveillance 
systems should focus on key populations at high risk and their associated behaviors, looking 
for changes in behavior that may increase the transmission of HIV infection.
Source: UNAIDS/WHO [1]. Guidelines for Second Generation HIV Surveillance: The Next Decade.
map 1.1 the state of Hiv epidemics in europe
Low
Concentrated
No data
Source: See chapter 3 of this report (for MSM, self–reported as well as those from biologically verified prevalence estimates have been used).
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men.
A Focus on Exploring Evidence to Generate HIV Enabling Environments
Recognizing HIV epidemics as features of their social and structural contexts 
emphasizes the potentially pivotal role of social and structural interven-
tions in creating environments which are enabling, rather than constraining, of 
 evidence-based HIV-prevention [10–12]. Key dimensions of “enabling” policy 
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environments conducive to effective HIV prevention among vulnerable and key 
populations at high risk include: the meaningful engagement of the main stake-
holders and affected populations in policy formation and programming; a coordi-
nated multisectoral HIV-prevention strategy emphasizing an evidence-based 
public health and rights-oriented approach; the generation of research and surveil-
lance on HIV epidemic spread and response; and the development and scale-up 
of a package of evidence-based interventions, including the removal of structural 
obstacles limiting their implementation, such as the criminalization of affected 
populations [11, 13–15]. This report considers the implications of the epidemio-
logical evidence it reviews for the development of HIV-prevention responses, 
including those incorporating social and structural intervention approaches.
Outline of the Report
In addition to a description of methods (below), the report comprises three 
main sections. Chapter 2 synthesizes evidence drawn from European HIV sur-
veillance data (chapter 2.1) and targeted HIV prevalence studies (chapter 2.2). 
Chapter 3 synthesizes evidence drawn from systematic reviews of epidemiologi-
cal studies among PWID, SWs, and MSM. Chapter 4 draws on the evidence 
reviewed in chapter 3 as well as the international literature more broadly to 
consider implications for strengthening responses, including in relation to HIV 
surveillance and HIV prevention for PWID, SWs, and MSM. In chapter 5, we 
draw our conclusions.
methods
This report draws on four main methods of data collection and analysis: (a) a 
review of HIV surveillance in Europe; (b) a systematic review of published and 
unpublished epidemiological literature; (c) an ecological analysis exploring the 
relationship between structural indicators and HIV prevalence; and (d) focusing on 
PWID specifically, mathematical modeling of the impact of needle and syringe 
exchange programs (NSP), opioid substitution therapy (OST) and antiretroviral 
therapy (ART) on HIV incidence and prevalence.
For the purposes of this report, we adopt the World Health Organization’s 
(WHO) definition of Europe. This definition includes 55 countries in total: 24 
from Western Europe (Andorra, Austria, Belgium, Denmark, Finland, France, 
Germany, Greece, Iceland, Ireland, Israel, Italy, Liechtenstein,1 Luxembourg, 
Malta, Monaco, the Netherlands, Norway, Portugal, San Marino, Spain, 
Sweden, Switzerland, and the United Kingdom); 16 from Central Europe 
(Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, the Czech 
Republic, Hungary, Kosovo,2 the former Yugoslav Republic of Macedonia, 
Montenegro, Poland, Romania, Serbia, the Slovak Republic, Slovenia, and 
Turkey); and 15 from Eastern Europe and Central Asia (Armenia, Azerbaijan, 
Belarus, Estonia, Georgia, Kazakhstan, the Kyrgyz Republic, Latvia, Lithuania, 
Moldova, the Russian Federation, Tajikistan, Turkmenistan, Ukraine, 
and Uzbekistan).
4 Introduction
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8
Throughout the report, we provide selective illustrative case studies. The fol-
lowing countries are included in the case studies: Estonia, Portugal, Russia, 
Ukraine, and the United Kingdom, as well as the Central Asian republics. A case 
study approach enables us to draw on unpublished and review material not avail-
able to the systematic review and to explore the dynamics of the HIV epidemic 
and vulnerability across key populations.
Review of HIV Surveillance Data
HIV Case Reports
We examine public health surveillance data related to HIV in Europe using pub-
lished information as well as gray literature with the aim to exploring the burden 
of HIV case reports attributed to injecting drug use, MSM, and heterosexual 
exposure, with particular focus on trends in the years 2006–11. These analyses 
are synthesized in chapter 2 of this report.
The reporting of HIV diagnosis has been examined using the following data 
sources:
•	 Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/
AIDS) surveillance data from the European Centre for Disease Prevention and 
Control (ECDC)/WHO Regional Office for Europe (data up to 2010) [16]
•	 HIV diagnoses reports to the Federal AIDS Centre for Russia (data up to 
2010) [17]
•	 EuroHIV 2006 survey on HIV and AIDS surveillance in the WHO European 
region [18]
Biological and Behavioral Studies
Alongside HIV case reports, we examine the extent and methods of directly 
assessed HIV prevalence and related risk behaviors from targeted studies among 
PWID, SW, and MSM. This analysis enables us to assess the extent of second-
generation surveillance activities in place [1].
Sources used to identify biological and behavioral HIV surveillance activities 
include:
•	 Results of systematic searches of the published literature (both scientific jour-
nal and gray literature) undertaken for each of the three main population 
groups: MSM, PWID, and SW
•	 The ECDC report on behavioral surveillance in the European Union (EU) 
and European Free Trade Association (EFTA): for data on PWID, MSM, and 
SW [19]
•	 EuroHIV reports on HIV prevalence studies: for data on HIV serosurveillance, 
2000–06 inclusive [20–22]
•	 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
Drug Related Disease Key Indicator: for data on HIV prevalence studies among 
PWID in the EU, Norway, and EU accession countries [23]
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Excluded from our analysis were studies using self-reported HIV results to mea-
sure prevalence, surveys with sample sizes less than 50, or studies where the sam-
pled population was unclear or was likely to be unrepresentative of the population 
concerned. Our analyses are limited in that they only draw on published sources in 
English, Spanish, French, and Russian identified through searches for documents 
(scientific journal articles and gray literature) published since 2000. The analyses 
here may underestimate the extent to which surveys have been undertaken to 
directly measure HIV prevalence or risk behaviors as they exclude publications in 
other languages, studies that could not be identified through the searches under-
taken, and very recent and other unpublished surveys. Our analyses reported in 
chapter 3 focuses on 50 countries in the region, excluding the four smallest coun-
tries, which all have populations less than 100,000 people (Andorra, Liechtenstein, 
Monaco, and San Marino). Such small population numbers are likely to make 
undertaking targeted surveys impractical among PWID, SWs, and MSM.
Assessing the Extent and Quality of HIV Surveillance
We examine the extent of biological and behavioral studies among PWID, SWs, 
and MSM by documenting the activity in each country and the extent of 
repeated surveys that provide a system of ongoing monitoring. The quality of 
the studies that was considered during the process of selecting the best HIV 
prevalence estimates is discussed below. We used the data extracted during this 
process and selected case studies to explore the range and robustness of the 
methodologies used.
Best Estimates of HIV Prevalence
In order to better compare prevalence estimates across the region as well as 
explore the quality of estimates used by each country, we selected what we 
defined as the best national-level prevalence estimates. An appendix of all such 
scored studies is available on request. Our criteria for selection included wide geo-
graphic coverage, most recent study, population sampled, and recruitment setting. 
We allocated up to three points for most recent studies, up to three points for the 
population sampled, up to three points for country coverage, and up to three 
points for the range of settings sampled. We deducted one point for treatment-only 
samples due to the potential bias associated with recruiting from such settings.
We used these indicators in order to gain some insights into the quality of 
second-generation surveillance in the country and to determine what further 
work may be needed (summarized in chapter 2) as well as to select a “best esti-
mate” of HIV prevalence among key populations (summarized in chapter 3).
Taking HIV case reporting systems and biological and behavioral surveillance 
studies together, we categorize surveillance systems according to whether they are
•	 Comprehensive (case reports plus prevalence and behavioral surveillance in 
two or more geographical sites, clear definition of population group, two 
or more recruitment methods used, multiple years, as well as estimates of 
population size)
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•	 Extensive (case reports plus prevalence and/or behavioral surveillance in at 
least one area, clear definition of population group, clear recruitment methods, 
not repeated)
•	 Focused (case reports plus prevalence and/or behavioral surveillance in one 
site, not repeated)
•	 Basic (only case reports) or
•	 None
By drawing on the quality assessment of the range of prevalence estimates 
identified, national epidemics among each population were classified to allow for 
easier comparison. Using the best quality estimate(s) available to us, the HIV 
prevalence in PWID, SWs, and MSM were classed as (a) low (<1%); (b) medium 
(1% to <5%); (c) high (5% to <20%); or (d) very high (20% or more). This defini-
tion of the magnitudes of national epidemics was compared alongside HIV case 
reports and our assessment of the quality of the national surveillance systems in 
order to assess the appropriateness of the system in place to effectively monitor 
HIV in that population. This analysis of quality assessment and improvement is 
presented in chapter 4.
Estimates of PWID and SW Population Sizes
Data on PWID between the ages of 15–64 in a country were obtained from 
national estimates as reported by the EMCDDA, Reference Group to the 
United Nations on HIV and injecting drug use [24] or by country coordination 
mechanisms (CCMs) in their most recent grant proposals to the United 
Nations Global Fund to Fight AIDS, Tuberculosis and Malaria (GFAMT) [24]. 
The prevalence of PWID in a country was obtained by dividing the PWID 
population by the total population (ages 15–64) and expressed as a rate per 
1,000 individuals.
Missing values were imputed based on other available data or by using esti-
mates from neighboring countries with similar epidemiological profiles. When 
a range of values as available, the midpoint value was taken or more complex 
estimations were sought to arrive at acceptable estimates. For example, the 
estimated size of the PWID population in Latvia was unavailable, although the 
population of problem drug use (PDU, which includes PWID and long-term 
use of opioids, cocaine, or amphetamines according to the EMCDDA) was 
estimated at 7,191, or 4.6 per 1,000 adults. In neighboring Lithuania, whose 
PWID epidemic has similar features, the PWID population is estimated at 2.2 
per 1,000 adults. Extrapolating this figure to the Latvian adult population, we 
assumed that the size of the PWID population in Latvia would be about 
3,429, a figure around half the size of the PDU population, which seemed a 
plausible estimate. When data on the main drug injected were unavailable, 
data from the EMCDDA on treatment demand, which indicate the propor-
tion of patients entering treatment, stratified by primary drug and proportion 
injecting, were used to obtain a country-level estimate. This estimate assumes 
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that treatment demand is relatively equal across groups of drug users 
 throughout the country.
Data on the number of female sex workers (FSWs) in a country were 
obtained from estimates of the proportion of FSWs in the adult population pro-
vided by Vandepitte et al. [25]. Actual numbers were calculated using these 
estimates, multiplied by the female adult population (ages 15–64) then divided 
by 1,000 to give a rate per 1,000 people. Other estimates were derived from 
project reports collated by the European Network for HIV/STI Prevention and 
Health Promotion among Migrant Sex Workers (TAMPEP) and projects funded 
by the Global Fund. When estimates varied widely across the three sources, a 
midpoint was taken and low- and high-range estimates were presented. Data on 
the profile of FSWs were taken from the systematically reviewed literature 
(see 1.1.2 below). Missing data on levels of injecting or violence among FSW 
populations were imputed using the same methods applied to missing PWID 
indicators.
Systematic Review of Epidemiological Literature
We conducted a systematic review to assess published and unpublished epide-
miological and behavioral research data (both quantitative and qualitative stud-
ies) addressing vulnerable and key populations at high risk; to examine the 
prevalence and incidence of HIV and risk behaviors among PWID, SWs, and 
MSM; and to establish what factors (from behavioral to structural) are driving 
the HIV epidemic among key populations in Europe.
The specific research questions to be answered through the review exercise are
•	 What is the prevalence and incidence of HIV among key populations (PWID, 
SWs, MSMs, prisoners, and migrants) in Europe?
•	 What are the individual, social, and environmental risk factors associated with 
HIV and HIV risk factors among these populations?
•	 How does risk differ within subpopulations of each population?
Searches and Inclusion Criteria
The databases searched are as follows: MEDLINE (1950–2008), EMBASE, 
Social Science Citation Index, Popline, CINAHL, Global Health, and an online 
search combining terms for injecting drug users, sex work, MSM, HIV, and risk 
factors for acquiring HIV. We drew on thesaurus and non-thesaurus terms as 
appropriate (a summary of our full search terms is attached in appendix A). 
Reference lists of found articles were also searched and experts in the field con-
sulted to identify other relevant studies. We conducted a systematic search of 
websites of research institutes, service providers, and donor organizations work-
ing with the risk groups across the region. In addition, we searched conference 
abstracts from the International Conference on the Reduction of Drug Related 
Harm (2005–10) and the International AIDS Conference (2006, 2008, and 
2010). A list of the websites searched is attached in appendix A.
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Quantitative Studies
We included reports written in English, Spanish, French, and Russian published 
from 2005 to 2011 based on studies undertaken in WHO-defined Europe that 
reported rates among PWID, SWs (male, female, or transgendered selling sex 
to men or women), and MSM on any of the following: HIV prevalence or 
incidence, sharing needles/syringes; unprotected anal intercourse, and unpro-
tected vaginal intercourse. PWID were defined as individuals who have ever 
injected drugs for nonmedical purposes. A SW was defined as someone who 
has ever exchanged sex for money, drugs, or goods. MSM are defined as chro-
mosomal males who have ever had penetrative sex with other chromosomal 
males (i.e., it includes male-to-female transgendered people and heterosexually 
identified men). Studies were included if they reported crude or adjusted 
associations.
For SWs, we broadened search terms to include composite measures of HIV 
and sexually transmitted infections (STIs) and risk associated with acute STIs 
[26, 27]. We examined composite measures of HIV and STIs in order to assess 
vulnerability associated with infection rather than as biologically plausible risk 
factors. We also included studies published up to 2000, after which there were 
no recent estimates available.
Qualitative Studies
We drew selectively (rather than systematically) on qualitative studies that 
explored how PWID, SW, and MSM experienced risk and the harms associated 
with increased risk of HIV.
Exclusion Criteria
Manuscripts that were commentaries or editorials were excluded as were review 
papers containing no primary data, although these were collected in order to 
gather references for primary studies not identified by the search. Papers not fit-
ting the inclusion criteria were coded according to whether they contained infor-
mation on HIV interventions or coverage. These papers were set aside to aid in 
the interpretation of the systematic review findings.
Results of Search and Data Extraction
From the included quantitative studies, we extracted data from the following 
categories: setting (specifying city/region and country); date (of publication and/
or fieldwork); study aim, design, sampling strategy, sample size, data-collection 
methods, and analytic strategy; population and definition used; measures of HIV 
prevalence and incidence; receipt of HIV testing; and author-reported study limi-
tations. Demographic characteristics, risk behaviors, and experience of other 
harms extracted varied according to individual risk groups. Information on the 
numbers of papers identified and the process of the systematic review 
are included in figures A.1–A.3. For the qualitative studies we extracted data on 
the main themes, concepts, and findings on the social contextual factors linked 
to risk practices and HIV vulnerability.
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A total of 5,644 studies were identified in the systematic review of PWID. 
Among these, 128 were used to generate estimates of HIV/STI prevalence and 
demographic and risk profile of PWID. We extracted data on the duration of 
injecting career, main drug injected, regular income, the proportion HIV tested, 
needle/syringe sharing, inconsistent condom use, sex work, arrests, prison and 
history of drug treatment, and sample characteristics (gender, age, sampling 
methodology, drug user inclusion criteria).
A total of 1,993 studies were identified in the systematic review of SWs. Among 
these, 73 papers were used to generate estimates of HIV/STI prevalence and 
demographic and risk profile of SWs. We extracted data on unprotected vaginal 
intercourse, unprotected anal intercourse (UAI) with clients and nonpaying part-
ners, experience of violence from clients or police, injecting drug use, time in sex 
work, location of sex work, and sample characteristics (age, nationality, and educa-
tion). In addition we extracted data from qualitative papers to interpret findings 
from the systematic review, particularly in relation to experience of violence and 
mental health that were not well documented in the epidemiological data.
A total of 3,200 papers were identified in the systematic review of MSM. 
Among these, 73 papers were used to generate estimates of HIV prevalence and 
demographic and risk profile of MSMs. We extracted data on UAI, female part-
ners, unprotected vaginal intercourse, experience of violence, alcohol and drug 
use including injecting drug use, selling, buying and trading sex, and sample 
characteristics (age, nationality, education, socioeconomic position).
Ecological Analysis
We collected selected indicators of structural interventions and social- structural 
factors across the region. The primary method used for collating up-to-date 
 indicators was to synthesize routine coverage estimates produced by interna-
tional agencies, governmental and nongovernmental organizations (NGOs), and 
umbrella organizations working in Europe. Indicators were  collated from the 
World Health Organization Regional Office for Europe; the ECDC/EMCDDA; 
Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM); International 
HIV/AIDS Alliance; the International Harm Reduction Association (IHRA); the 
United Nations Reference Group on HIV Prevention Among Injecting Drug 
Users; International Gay and Lesbian Association; the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) Stigma index; national censes; the Global 
Network of People Living with HIV; and TAMPEP.
Coverage and Policy Indicators
Data on intervention coverage including numbers of services and PWID access-
ing those services for NSP and OST were obtained from the EMCDDA and the 
UN Reference Group [28]. Data on PWID accessing ART was obtained from 
WHO-Europe. The majority of variables are not complete for all countries. The 
presence and quantity of NSP, OST, and ART sites in a country as well as the 
estimated number of people accessing them were obtained from the EMCDDA 
and the UN Reference Group [28] for the most recent year available.
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Data on different legislative models regulating sex work and services working 
with SWs in the region were collated from our systematic review as well as the 
Global Fund Project Monitoring Reports; a directory of health and social support 
services for SWs in Europe (services4sexworkers.org); surveys produced by the 
International HIV/AIDS Alliance; and TAMPEP [29–32].
Data on the extent of HIV testing among MSM were extracted from the sys-
tematic review and the European Men’s Internet Survey [33]. We extracted data 
on the coverage achieved of MSM by HIV programs through United Nations 
General Assembly Special Session (UNGASS) indicators collected through the 
Dublin Declaration [34].
Outcome
The primary outcomes of HIV prevalence among PWID, FSWs, and MSMs were 
drawn from our systematic review of recent published and gray literature. Best 
estimates of HIV prevalence and injecting drug use (for FSWs only) were 
selected according to the criteria described to assess the quality and extent of 
biological and behavioral surveillance. In the case of multiple studies with equal 
scores, a weighted average of HIV and injecting drug use was taken. For FSWs 
this applies to Georgia, Russia, Spain, Ukraine, and the former Yugoslav Republic 
of Macedonia. The relationship between HIV prevalence and selected structural 
indicators are described using linear regression models. Findings from this analy-
sis are used to illustrate key points in chapter 4.
Policy Environment Index for PWID
We generated a simple index of “enabling” policy environment. Our 
 interpretation of an enabling policy environment drew on guidelines gener-
ated by WHO [35], UNAIDS [36], international NGOs [37], and peer-
reviewed papers in this field [9, 12, 14, 38]. As outlined in box A.1, the core 
items of the index included country-level indicators of (a) coordinated 
national strategy for HIV prevention and drug use (indicated by evidence of 
explicit inclusion of “harm reduction” in national-level strategy and monitor-
ing and evaluating HIV epidemics); (b) meaningful engagement of stakehold-
ers in HIV prevention policy formation and programming (indicated by 
evidence of a national organization of drug users); and (c) evidence-based 
HIV prevention intervention approaches (indicated by presence of OST 
and NSP, presence of OST and NSP in prison settings, and evidence of de- 
emphasizing criminalization through the use of administrative penalties for 
drug use possession for personal use).
Indicator data were obtained from a combination of sources, including global 
reports of harm reduction policy and coverage [39]; country profiles collated and 
updated by the EMCDDA [40]; our systematic review of research studies; and 
the International Network of People who Use Drugs [41]. The index was con-
structed by allocating equal weight to each of the six items and aggregating a 
score for each country, with higher scores indicating a more enabling environ-
ment conducive to evidence-based public health approaches.
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Key indicators of supportive policy environment for MSM were selected as 
follows:
•	 Legislation against male-male sex
•	 Legislation that predates 1981
•	 Legislation against discrimination on the grounds of sexual orientation
•	 The presence of an annual Gay Pride activity
•	 The recognition of civil partnership or marriage between people of the same 
gender
The index was constructed by allocating equal weight to each of the items and 
aggregating a score for each country, with higher scores indicating a more liberal 
legislative and social environment. The findings of the policy index are presented 
in chapter 4.
Modeling Analysis
We conducted a simple modeling analysis to consider the potential impact of 
OST, NSP, and ART on HIV incidence and prevalence in three illustrative 
epidemic scenarios: Estonia (Tallinn); Russia (St. Petersburg); and Tajikistan 
(Dushanbe). At baseline, the model is calibrated to detailed HIV prevalence 
and incidence data from each setting, adjusting for the possible decrease in 
HIV incidence resulting from heightened coverage of NSP in Tallinn [42] or 
moderate coverage of NSP in Dushanbe. The model also adjusts for possible 
longer duration of injecting drugs in Tallinn and St. Petersburg than Dushanbe 
[43–45]. In accordance with NSP data from Tallinn [42], the effect of NSP in 
Tallinn was assumed to scale up from 2003 to 2009 with the final efficacy 
estimated on the basis of fitting the model to observed prevalence and inci-
dence trends in Tallinn. It was also assumed that the efficacy in intermediate 
years was proportionate to the relative number of syringes distributed in that 
year compared to 2009. The same assumptions for the effect of NSP on HIV 
transmission were made for Dushanbe, but the syringe distribution scaled up 
more slowly, from 0 in 1999 to about 7 syringes per PWID per year in 2006. 
By 2010 and 2011, the distribution rapidly scaled up to about 32 syringes per 
PWID per year. The model was fit to HIV prevalence and incidence data by 
adjusting (a) the HIV seeding prevalence in 1996 (to shift when the epidemic 
started), (b) the infection rate per month in the latent phase of HIV, and 
(c) the duration of injecting (both used to change the rate at which the epi-
demic progresses and the prevalence at which it stabilizes). The effect of NSP 
expansion in Tallinn was used to fit the model to the downturn in HIV inci-
dence (and possibly prevalence) in Tallinn. The adjusted parameter values 
used for the model fits are shown in table A.1, while all other parameters were 
kept constant and are shown in table A.2. A comparison of the model (base-
line projections) with prevalence and incidence data from each setting is 
shown in figure 1.1 below. It is important to note that the model runs should 
only be seen as illustrative for the type of epidemic occurring in these different 
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settings, that is, the Tallinn epidemic represents a high-prevalence epidemic 
with high-coverage NSP, whereas the St. Petersburg and Dushanbe epidemics 
represent high and moderate HIV prevalence epidemics, respectively, with no 
or moderate NSP.
Assumptions underlying the modeling of the impact of scaling up OST, NSP, 
and ART are summarized as follows:
•	 Receipt of OST reduces by 50% the chances of PWID becoming infected, 
based on a recent unpublished meta-analysis of cohort studies that estimates 
the reduction in HIV incidence among people currently on OST [46]. Any 
scale-up of OST and NSP is assumed to occur over a 7 year period from 
Figure 1.1 comparison of Hiv prevalence and incidence projections in 
three sites in eastern europe (1996–2020)
Note: HIV = human immunodeficiency virus.
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2012 to 2019 to mimic the scale-up of NSP in Tallinn [42]; the impact of dif-
ferent final coverage levels are also considered
•	 High-coverage NSP (assumed to correspond to 70 syringes distributed per 
PWID per year as achieved in Tallinn in 2008/09) is assumed to reduce by 40% 
the chances of a PWID becoming infected, based on the possible effect of wide-
spread NSP on HIV incidence in Tallinn [42] as calibrated through fitting the 
model to observed trends in HIV incidence in that setting. This effect is assumed 
to occur at the highest NSP coverage achieved in Tallinn in 2008–09 (~70 
syringes distributed per PWID per year), whereas for lower coverage levels a 
linear relationship is assumed between syringe distribution per PWID per year 
and the relative decrease in transmission risk. This is likely to be a simple 
approximation of the likely real relationship between level of syringe distribu-
tion and resulting decrease in HIV incidence, but unfortunately no suitable data 
exist to parameterize the model more precisely. Therefore, any coverage of NSP 
is assumed to be relative to the maximum coverage of NSP achieved in Tallinn, 
with 100% coverage assumed to have the same efficacy as that achieved in 
Tallinn in 2008–09 (40% reduction in infection risk to all PWID) and 50% cov-
erage assumed to have half this efficacy, that is, a 20% reduction in HIV infec-
tion risk among all PWID. In other words, 50% of PWID have a 40% reduction 
in risk. Receipt of ART reduces the infectivity of HIV-positive PWID by 80%. 
This number is based on results of recent trials [47, 48] adjusted downward for 
the lower adherence levels characteristic of PWID [49–51], which has been 
shown to increase viral load [52–55]. For simplicity, it is assumed that all HIV-
positive PWID (except those in the initial acute phase) can be recruited for 
ART at a fixed rate. ART coverage is only measured among HIV-positive PWID.
It is worth noting that estimates of the NSP- and OST-HIV effect roughly 
coincide with the published effect of OST or high-coverage NSP in decreasing 
HCV incidence among PWID in the United Kingdom [56]. For each interven-
tion, we consider the coverage needed separately or in combination with 
(a) achieve a 30% or 50% relative reduction in HIV incidence or prevalence over 
10 years; and (b) reduce HIV incidence to below 1% or HIV prevalence below 
10% after 20 years.
Model Equations
The model stratifies the PWID population into those that are susceptible to HIV 
infection (stage x) and those that are HIV infected. The HIV-infected individuals 
can either be in the (a) initial high-viremia phase of infection (stage h with aver-
age duration 1/ν); (b) longer latent stage of low viremia (stage y with average 
duration 1/γ); (c) a short late phase of high-viremia pre-AIDS (stage a with aver-
age duration 1/η); or (d) on ART (stage τ with average duration 1/Δ). PWID enter 
the population at a rate Ω(t) that is set to balance all PWID leaving the popula-
tion due to non-HIV causes (at a rate μ—includes cessation and overdose) and 
HIV mortality/morbidity (at a rate η) if there was no ART. PWID can be recruited 
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for ART (at a rate r) once they enter the long latent phase of HIV, at which stage 
they have reduced infectivity (cofactor ω). Those in the initial and late phases of 
high viremia have heightened transmission (cofactors δ and θ, respectively) com-
pared to the infection rate of those in the latent phase of HIV (β). OST and NSP 
are assumed to have specific coverage levels (n[t] and o[t]—independent of each 
other but varying over time) and reduce HIV transmission by cofactors ψo and 
ψn, respectively, when not in combination, and by ψon if in combination. OST 
and NSP are not modeled explicitly because PWID move between these groups 
with quite fast turnover, so incorporating them as average coverage levels is a 
reasonable approximation. The model equations are shown below:
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Where N is the total PWID population size (n = x + h + y + a + τ), and Φ(t) 
is the overall cofactor effect of NSP and OST and has the following form (where 
the coverage of OST and NSP, o and n, vary over time):
 t o n on o n n o ono n on1 1 1( ) ( ) ( ) ( )Φ = − − + + − ψ + − ψ + ψ   
The inflow into the PWID population (Ω[t]) is defined below as a’, is the 
number of people who would have AIDS if no ART were present:
 t N a
1( )Φ = µ + η  
Limitations
The modeling described here is relatively simple, so the projections should be 
seen as indicative of the impact that could be expected from scaling up interven-
tions in settings with different HIV prevalences. First, the model only incorpo-
rates heterogeneity with respect to stages of HIV and ART status, so the effect of 
risk heterogeneity in relation to injecting is not accounted for. It is likely that risk 
heterogeneity would reduce the projected impact of these interventions but may 
be a lesser concern if PWID transition between different categories of risk [57]. 
Second, only single-model fits were obtained for each setting—allowing for mul-
tiple model fits would quantify the degree of uncertainty that is present in our 
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impact projections [58]. However, because the model is fit to multiple estimates 
for the HIV prevalence and incidence for each setting, the level of uncertainty 
due to not obtaining multiple model fits should be reduced. Third, minimal risk 
behavior data from each setting were used in the model fitting. This was because 
normal measures of syringe and equipment sharing are generally biased and 
are unreliable for parameterizing models. Instead, the HIV prevalence and inci-
dence data from each setting were used to calibrate the modeled HIV epidemic 
by adjusting the average monthly risk of HIV transmission between any suscep-
tible and infected PWID, the time at which the epidemic started, and the esti-
mated leaving rate for HIV-uninfected PWID.
The current duration of injecting reported in each setting was used to evaluate 
the likely difference in the leaving rate of each setting. Fitting the model to 
the HIV prevalence and incidence data suggests that the model can portray the 
type of epidemic that occurred in each setting. Lastly, we do not consider uncer-
tainty in the efficacy estimates for the different interventions. This is of most 
concern for ART and NSP because there is little evidence assessing the impact of 
ART on parenteral HIV transmission, and it is hard to assess the efficacy of spe-
cific levels of syringe distribution on an individual’s risk of acquiring HIV. 
Despite this issue, the efficacy estimate for NSP seems reasonable because it 
coincides with the possible HIV-impact of widespread NSP in Tallinn [42] and 
the impact of high-coverage NSP on other blood-borne infections [56]. It also 
seems reasonable that ART will have a large impact on parenteral HIV transmis-
sion, as evidence shows a huge decrease in plasma viral load when individuals 
start treatment, and ecological studies have shown associations between PWID-
community viral load and HIV incidence at the population level in Vancouver, 
British Columbia, and Baltimore, Maryland [59]. Due to the uncertainty in the 
exact effect of ART on HIV transmission in PWID, and because of the low adher-
ence observed among PWID [49], we used a conservative estimate of 80% for 
the efficacy of ART in reducing HIV transmission risk among PWID.
notes
 1. Liechtenstein data are reported via Switzerland; there are therefore 53 country 
reports, with Switzerland reporting for two countries.
 2. Kosovo became a member of the World Bank Group in 2009. As far as WHO is con-
cerned, references to “Kosovo” shall be understood to be in the context of UN Security 
Council resolution 1244 (1999).
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HIV Surveillance
Hiv Diagnoses and AiDs case reporting
This chapter summarizes the human immunodeficiency virus (HIV) surveillance 
systems across European countries, before examining recent surveillance data for 
what these systems indicate regarding the burden and pattern of HIV diagnoses 
in key populations, especially in the five-year period from 2006 to 2010.
AIDS Case Reporting Systems
All European countries developed systems to monitor the number of acquired 
immune deficiency syndrome (AIDS) diagnoses soon after the first cases were 
recognized in the early 1980s. However, while AIDS case report data remain 
useful, their utility has declined over the past 15 years due to better monitoring 
of HIV diagnoses and the introduction of highly active antiretroviral therapy 
(HAART) in 1996. The increasing use of HAART since then has resulted in 
fewer people developing AIDS and an increase in the recovery of people diag-
nosed with an AIDS-defining illness. Countries continue to collect AIDS case 
data [1] because such data provide insight into the extent of late diagnosis and 
the impact of HIV treatment, particularly if data on CD4 cell counts or viral load 
are not routinely monitored (in 2010, 25 countries in the region collected data 
on CD4 cell counts at HIV diagnosis). However, in most European countries the 
primary focus of surveillance is new HIV diagnoses rather than AIDS cases. In 
Sweden, for instance, the reporting of AIDS cases ceased to be mandatory in 
2000 [1].
HIV Diagnoses Reporting Systems
Robust HIV diagnoses reporting data assist countries producing estimates of the 
numbers of people living with HIV (and thus the prevalence of diagnosed infec-
tion), as well as providing numbers for overall HIV prevalence (i.e., including 
both diagnosed and undiagnosed cases). If such reports include CD4 count data, 
they also provide insight into the extent of late diagnosis. HIV case reporting is 
a fundamental feature of public health intelligence on the HIV epidemics of 
Europe. At the same time, it is important to appreciate that country HIV 
c H A p t e r  2
20 HIV Surveillance
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8
diagnoses reports need not reflect current patterns of HIV transmission, since 
they include new as well as past infections.
All countries in the World Health Organization (WHO) European region, 
except Monaco and Liechtenstein, have established systems for monitoring the 
number of new HIV diagnoses. A few countries established HIV diagnoses report-
ing systems soon after the first tests for HIV infection became available in the early 
1980s (Israel, Portugal, and San Marino in 1983; the United Kingdom in 1984). 
Most countries established systems in the late 1980s and early 1990s. By 1990, 41 
(79%) of the 52 countries that now have HIV diagnoses reporting systems had a 
system operating in at least part of the country. In 11 countries (see map 2.1), HIV 
diagnoses reporting started after 1990, and a few of these countries have only 
established HIV case reporting systems more recently (Andorra and Malta in 
2004, France in 2003, and the Netherlands in 2002). In some countries, systems 
have undergone significant revision in the way that they operate; as a result, data 
from different time periods are not always comparable [1]. Spain and Italy have 
regionally based surveillance with no national coverage as data are not available for 
all regions. However, the number of regions covered in both of these countries has 
increased over time [1], and Italy is reported to be establishing a national HIV 
notification system that will provide countrywide data in the future [2].
Countries use different methods to collate their HIV diagnoses data. In par-
ticular, risk-group information may not always be available or recorded. Due to 
variations in these systems, their data need to be compared cautiously for the 
following four reasons: (a) there will be differences in the timeliness of the 
map 2.1 introduction of Hiv case reporting system in europe by Year
Sources: EuroHIV [3]; table B.1.
Note: HIV = human immunodeficiency virus.
Before 1985
1985–1989
1990–1999
Since 2000
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reporting; (b) there will be differences in the extent of overreporting and the 
effectiveness of approaches for eliminating duplication (which may be especially 
difficult to avoid when anonymous testing for HIV is common); (c) there may 
be underreporting of cases, for example due, because of administrative errors; 
and, (d) national variations in the accessibility of HIV testing will affect the pro-
portion of cases recognized. That is, countries with the largest number of diag-
nosed cases could be more successful at case finding than countries that do not 
have the worst epidemics (see also chapter 4).
The ECDC and the WHO European office systematically collate HIV diag-
noses report data across the region, and we draw on these data here [1]. Most 
countries in the region provide data for inclusion in this European data set, with 
the exception of the Russian Federation (which only provided the total number 
of diagnoses for 2010), Austria (data not available due to legal issues), and 
Liechtenstein (where because of the small population, public health data are 
reported to Switzerland) [1]. We have added data for Russia, obtained from the 
Russian Federal AIDS Centre [4]. When possible, we have combined these data 
with the aggregate data from the ECDC/WHO data set in order to present the 
available data for all countries in the region except Austria, Liechtenstein, and 
Monaco (though the data do not cover all regions of Italy and Spain). HIV diag-
noses report that data for the period 2006–10 are thus available for the vast 
majority of countries in the region, with data available for countries and areas 
covering 95% (841,383,300–889,201,000 people) of the population of the 
WHO European region.
AIDS Cases
By the end of 2010, almost 366,000 people had been reported as diagnosed with 
AIDS in the region (excluding Russia) [1]. Of these, almost 197,000 were 
known to have died by the end of 2010 [1]. It is thought that around 165,000 
people were living with an AIDS diagnosis at the end of 2009 [1]. The number 
of AIDS cases reported has declined in recent years, dropping from 14,147 in 
2006 to 7,714 in 2010 [1]. This decline almost certainly reflects the ongoing 
impact of the improved HIV treatment options on disease progression [5]. It 
may also reflect in part improved case finding, resulting in earlier diagnoses and 
help in seeking treatment.
The decline in AIDS cases overall was also seen in all three subregions of 
Europe between 2006 and 2010, from 7,598 to 4,249 in Western Europe; from 
652 to 584 in Central Europe; and from 5,897 to 2,881 in Eastern Europe 
(excluding Russia). Declines in the number of AIDS cases over this five-year 
period are seen among both men and women overall and in each of the three 
subregions [1]; these declines have occurred even though access to HAART var-
ies greatly across the region [6]. The annual number of AIDS cases associated 
with injecting drug use or acquired heterosexually has declined markedly in all 
three of the subregions [1]. While the annual number of AIDS cases associated 
with men who have sex with men (MSM) has fallen markedly in the West (from 
1,838 to 1,222), it has been fairly stable in the East (23 in 2006 to 31 in 2010, 
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excluding Russia), and has increased slightly in Central Europe (from 79 in 2006 
to 134 in 2010) [1]. Although this is a relatively small number of cases, the rea-
son for this increase in Central Europe needs to be examined.
Analysis of AIDS cases reported in the countries of the European Union (EU) 
indicates that migrants from Sub-Saharan Africa account for a considerable 
 proportion of the HIV cases associated with heterosexual exposure and mother-
to-child transmission. The analysis also indicates that, while MSM cases are 
largely from within Europe, there are also many men of Latin-America origin [7].
Number of HIV Tests Undertaken
HIV testing practices can vary widely between countries [8–10]. Many European 
countries collect data on the number of diagnostic HIV tests undertaken annually, 
while other countries estimate this number [11]. In 46 countries, recent data exist 
on the actual or estimated number of HIV tests performed in a year, suggesting 
an average of 57 HIV tests per 1,000 people annually (table 2.1). The number of 
tests undertaken varied across the subregions, ranging from 18 per 1,000 people 
in Central Europe (all countries had data) to 33 per 1,000 in the West (only 16 
countries had data) to 119 per 1,000 in the East (all countries had data). 
However, the annual number of tests performed varied greatly between countries 
ranging from less than 0.2 (Greece) to 178 (Russia) per 1,000 people. Of all the 
reported tests undertaken, 53% were reported from Russia, which accounted for 
only 19% of the population of countries with data on the number of tests.
This variation in rates of diagnostic testing reflects a number of factors includ-
ing differences in the accessibility of HIV testing, HIV testing practices including 
occupational requirements, and the stigma associated with HIV and HIV testing 
[8–10, 12]. While these findings should be interpreted cautiously as the numbers 
of tests conducted relate to different years and are derived from a variety of 
methods, they show that HIV testing is much less common in Central Europe.
Cumulative Number of Reported HIV Diagnoses
By the end of 2010, over 1,280,000 diagnosed HIV infections had been 
reported in Europe since the start of reporting in the early 1980s. Among 
these, 30% (379,353) of all diagnoses have been recorded in the West, 3% 
(33,308) in Central Europe, and 69% (867,457) in the East. This figure is 
table 2.1 Annual number of Diagnostic tests for Hiv in europe by subregion
Subregion
Number of 
countries with data 
on number of tests
Number of 
HIV tests
Proportion 
of total (%)
Tests per 1,000 
people 
(average)
Tests per 1,000 
people (country 
range)
West 16 10.616,260 22 33 0.19–164
Central Europe 15 3.382,477 7.1 17 0.99–49
East 15 33.624,312 71 119 5.9–178
Total 46 47.623,049 100.1 57
Sources: ECDC/WHO European Office HIV Report 2011, and Russian AIDS Centre Report 2011; Data on number of tests relates 
to different years; see table B.1.
Note: HIV = human immunodeficiency virus.
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an underestimate since country data sets will not include information on all 
diagnosed infections.1
Russia has reported the largest number of HIV diagnoses (630,222), consti-
tuting around half (49%) of diagnoses ever reported in the region. Russia also has 
the highest population in the region—at over 140 million—accounting for 16% 
of the total. The cumulative total of reported HIV diagnoses in Russia equals 
4,457 diagnoses per million population. Ukraine, with 5% of the region’s popula-
tion (46 million), has the second largest cumulative number of reported HIV 
diagnoses (153,108), at 3,329 per million people. There are three other countries 
where the cumulative reported diagnoses exceed 2,500 per million people: 
Estonia (5,736 diagnoses reported per million people), Switzerland (4,272 diag-
noses reported per million people), and Portugal (2,607 diagnoses reported per 
million people). Only 3% of the cumulative reported HIV diagnoses are from 
Central Europe, where 23% of the region’s population reside. Central Europe has 
lower levels of reported HIV than elsewhere in Europe, but as noted above, it 
also has the lowest level of HIV testing (table B.2).
Overall, one-third (410,869) of all the HIV diagnoses reported since the start 
of the epidemic have been associated with injecting drug use. Heterosexual trans-
mission is the next most common exposure category, accounting for one-quarter 
of all diagnoses (306,966). Sex between men is associated with just over 
 one-in-ten (138,286) of diagnosed infections reported. Mother-to-child transmis-
sion, receipt of contaminated transfusions and blood products, and nosocomial 
infections accounted for around 1% of reported diagnoses. However, nearly 32% 
of diagnoses reported lacked risk factor information.
Regional Variation
The proportion of diagnoses associated with the different exposure categories 
varies across the region. In the West, heterosexual transmission and then MSM 
have been the most reported exposure categories. In Central Europe, the most 
reported categories are heterosexual transmission and then injecting drug use, 
with few reports attributed to MSM. In the East, 43% of all reported diagnoses 
were associated with injecting drug use, 17% with heterosexual transmission, and 
almost 39% not attributed to any exposure category (figure 2.1). The vast major-
ity of the reported diagnoses associated with injecting drug use (90%) were from 
the East, with only 2% from the Central region. Of the diagnoses associated with 
heterosexual transmission, 49% were from both the West and East subregion, 
whereas for the diagnoses associated with MSM, almost all (93%) were reported 
from the West (data not shown).
Age and Gender
Most HIV diagnoses in Europe to date have been among men, with one-third 
among women (33%, or 424,775 of all reported diagnoses with information on 
gender). The proportion of women among the cumulative total of diagnoses var-
ies slightly by subregion: 27% in Central Europe; 35% in the East, and 30% in the 
West. Approximately half of all of those who have received HIV diagnoses in the 
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region were aged less than 30 years at the time of their diagnosis (51%, or 
586,299 of all the reported diagnoses with information on age at diagnosis).
Trends in Reported HIV Diagnoses, 2006–10
Between the five-year period from 2006 to 2010, the annual total of reported 
HIV diagnoses increased from 89,185 in 2006 to 115,701 in 2010 (figure 2.2), 
with over one-half million (533,181) diagnoses reported during the five-year 
period. There was an annual average of approximately 107,000 diagnoses, equat-
ing to an average of 127 new diagnoses each year for every one million people 
living in the region. It should also be noted that the potential for reporting delays 
means that the number of diagnoses in the most recent years, particularly 2010, 
may yet be revised upward.
Eastern Europe has carried the greatest burden of newly diagnosed HIV infec-
tions during recent years with an annual average of 77,371 new diagnoses (273 
per million people), compared to 27,046 in Western Europe (74 per million 
people) and 2,220 in Central Europe (11 per million people). Overall, the coun-
tries with the highest annual average number of reported new HIV diagnoses 
during this period were Estonia (392 per million people), Russia (372 per million 
people), and Ukraine (328 per million people) (map 2.2, table B.3). While the 
annual number of diagnoses reported has been relatively stable in the West and 
Figure 2.1 cumulative total of major exposure categories among All Hiv cases 
in europe by subregion since the early 1980s
Sources: ECDC/WHO European Office HIV Report 2011, and Russian AIDS Centre Report 2011. Data for the 
most recent years may be revised because of delays in case reporting (table B.3).
Note: HIV = human immunodeficiency virus.
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Central Europe, it has increased in the East, from 60,941 in 2006 to 87,564 in 
2010. In 2010, 76% of diagnoses were reported from the East (map 2.2).
Gender and Age
Between 2006 and 2010, the proportion of women among reported HIV diag-
noses has decreased in the West and Central Europe, from 33% to 27% and from 
27% to 19%, respectively. In the East, the proportion of women diagnosed during 
Figure 2.2 Hiv case reports in europe and proportions by subregion (2006–10)
Source: Table B.4.
Note: HIV = human immunodeficiency virus.
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this period remained the same, at 41% (figure 2.3). However, between 2006 and 
2010, the East reported 79% of all diagnoses among women—more than any 
other region in Europe.
The proportion of reported HIV diagnoses in people under 30 years of age 
gradually declined between 2006 and 2010, suggesting that the average age at 
diagnosis is increasing over time. This decline was seen in Central Europe (from 
43% to 38%) and in the East (from 51% to 43%), but in the West the number 
dropped to 27% (figure 2.3). Thus, those diagnosed in the West during the five-
year period have generally been older than 30 years (32% of the reported cases 
compared to 25% of all reported diagnoses elsewhere in the region).
Distribution of HIV Diagnoses by Exposure Category, 2006–10
HIV Diagnoses Associated with Injecting Drug Use
Between 2006 and 2010, 25% (133,900) of reported HIV diagnoses were associ-
ated with injecting drug use. This proportion varies by region, with 5% of diag-
noses in the West associated with injecting drug use, 7% in Central Europe, and 
33% in the East. Overall, more than 90% of the reports where the exposure was 
injecting drug use were from the East, and this proportion has increased over 
time. In 2010, 96% (28,238) of the diagnoses reported were associated with 
injecting drug use; of these, 27,211 were reported from the East, 921 from the 
West, and only 106 from Central Europe. The number of reports associated with 
injecting drug use has increased in recent years in the East, while it has been fall-
ing in the West and Central Europe (figure 2.4).
Looking at the period between 2006 and 2010, there was an annual average 
of 89 reported HIV diagnoses associated with injecting drug use per million 
Figure 2.3 proportion of Hiv case reports among Women, by Age and by european subregion (2006–10)
Sources: ECDC/WHO European Office HIV Report 2011 and Russian AIDS Centre Report 2011. Data for the most recent years may be revised 
because of delays in case reporting (appendixes A.2.4 and A.2.5).
Note: HIV = human immunodeficiency virus.
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people in the East, compared to 3.6 per million in the West and 0.8 per million 
in Central Europe. The countries with the highest levels of reported diagnosed 
cases associated with injecting drug users (IDUs) during this period were Ukraine 
(153 per million people), Russia (98 per million people), and Kazakhstan (78 per 
million people). The focus of HIV among people who inject drugs (PWID) is in 
the East (map 2.3), where almost all countries report large numbers of such 
cases. However, a number of countries in Central Europe and the West have 
reported outbreaks of HIV among PWID in recent years [11]. In Greece, for 
example, there was been a marked increase in the number of diagnoses associated 
with injecting drug use reported during 2011, while Romania has also docu-
mented recent outbreaks of HIV among PWID [11].
The reported HIV diagnoses associated with injecting drug use in 2010 were 
predominantly among the male population; among women the proportions 
ranged from 19% in the East, 22% in the West, and 14% in Central Europe (data 
not shown). In 2006–10, the proportion of IDUs under the age of 30 varied by 
subregion, with the majority of cumulative cases reported in Central Europe 
(57%), compared with 27% in the East and 19% in the West (figure 2.5). This 
distribution did not change significantly across the period. In the West, data on 
the country of origin of cases are often available, and in 2010, 62% were diag-
nosed in their country of origin, while 4.3% originated from elsewhere in the 
West and 20% (181) from Central Europe or the East.
HIV Diagnoses Associated with Heterosexual Transmission
During the five-year period from 2006 to 2010, heterosexual exposure was 
reported for 29% (155,639) of HIV diagnoses in the region. In the West, the 
proportion and number of reported diagnoses associated with heterosexual 
exposure has shown a slight decline during this period, with 10,214 reports in 
Figure 2.4 Hiv case reports and proportion Associated with injecting Drug Use (2006–10)
Sources: ECDC/WHO European Office HIV Report 2011 and Russian AIDS Centre Report 2011. Data for most recent years may be revised because 
of delays in case reporting (appendix A.2.6).
Note: HIV = human immunodeficiency virus.
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map 2.3 Average Hiv case reports in europe Attributed to injecting Drug Use per million (2006–10)
Source: ECDC/WHO European Office HIV Report 2011 and Russian AIDS Centre Report 2011, see appendix A.2.6.
Note: HIV = human immunodeficiency virus.
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Figure 2.5 cumulative Hiv case reports in europe Attributed to injecting Drug 
Use, by Age and subregion (2006–10)
Sources: ECDC/WHO European Office HIV Report 2011. Data exclude Austria, Liechtenstein, Monaco, Russia, 
and Turkmenistan (appendix A.2.6).
Note: HIV = human immunodeficiency virus.
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2010 compared to 12,281 in 2006 (figure 2.6). In Central Europe, the number 
of reported diagnoses associated with heterosexual exposure has been relatively 
stable, with 605 reports in 2010. The East has seen an increase in the proportion 
and number of diagnoses attributed to heterosexual exposure, with reports 
increasing from 13,610 in 2006 to 23,499 in 2010 (map 2.4). There was an 
annual average of 66 reported HIV diagnoses associated with heterosexual 
Figure 2.6 Hiv case reports and proportion Attributed to Heterosexual exposure (2006–10)
Sources: ECDC/WHO European Office HIV Report 2011, and Russian AIDS Centre Report 2011. Data for the most recent years may be 
revised because of delays in case reporting.
Note: HIV = human immunodeficiency virus.
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map 2.4 Average Hiv case reports in europe Attributed to Heterosexual sex per million (2006–10)
Sources: ECDC/WHO European Office HIV Report 2011, and Russian AIDS Centre Report 2011. Data for the most recent years may be revised 
because of delays in case reporting (appendix A.2.6).
Note: HIV = human immunodeficiency virus.
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exposure per million people in the East, compared to 32 per million in the West 
and 3 per million in Central Europe. The countries with the highest annual aver-
age number of reported new HIV diagnoses associated with heterosexual expo-
sure during the period from 2006 to 2010 were Ukraine (161 per million 
people), Moldova (145 per million people), and Portugal (91 per million people), 
(map 2.4, based on data in table B.6).
In many systems, particularly in the West, reported HIV diagnoses attributed 
to heterosexual transmission are further categorized into exposure subcategories 
such as (a) people from countries with generalized HIV epidemics; (b)  people 
with partners from countries with generalized HIV epidemics; (c) people with 
high-risk partners (e.g., PWID or MSM); and (d) other or undetermined. This 
data should be interpreted with caution as they are not collected by all coun-
tries, are often incomplete, and are not collected at all in some subregions (such 
as the East). In the West over one-third of the reported HIV diagnoses associ-
ated with heterosexual transmission have information indicating that they are 
among people who originate from a country with a generalized HIV epidemic. 
These cases account for over one-quarter of the diagnoses reported from 
Belgium, Finland, Germany, Greece, Ireland, Israel, Luxembourg, Malta, the 
Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom. 
More than 10% are among people whose partner originates from a country with 
a generalized HIV epidemic (with these accounting for over one-quarter of 
cases in Denmark and France). These individuals could have been infected 
either abroad, likely in the country with the generalized epidemic, or in Europe 
with a partner from abroad.
Figure 2.7 Hiv case reports in europe Attributed to Heterosexual sex among 
Women and by Age (2006–10)
Sources: ECDC/WHO European Office HIV Report 2001. Data excludes Austria, Liechtenstein, Monaco, Russia, and Turkmenistan. Data for the most 
recent years may be revised because of delays in case reporting.
Note: HIV = human immunodeficiency virus.
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The proportion of the reports associated with heterosexual exposure among 
women varies by subregion (figure 2.7). The highest proportion is in the East and 
was constant over the period, with 63% of diagnoses among women in 2006 and 
61% in 2010. The West had the second highest proportion among women, with 
56% of diagnoses in 2006 and 52% in 2010. Central Europe reported 46% of 
diagnoses among women in 2006 and 40% in 2010. The proportion of reports 
associated with heterosexual exposure among people aged 30 years or less at 
diagnosis declined in all three subregions during this period. In 2010 this propor-
tion was highest in the East (43%), followed by Central Europe (36%) and the 
West (22%).
HIV Diagnoses Associated with MSM
Between 2006 and 2010, 10% of HIV diagnoses were attributed to MSM as fol-
lows, 36% in the West, 22% in Central Europe, and 0.5% in the East. During this 
time there were 53,244 reports associated with MSM, of which 91% (48,841) 
were from the West, though this proportion has declined from 94% in 2006 to 
89% in 2010 (figure 2.8). The reported HIV diagnoses associated with MSM are 
concentrated in the West, where between 2006 and 2010 the annual average was 
27 diagnoses per million people, compared with only 2.5 diagnoses in Central 
Europe and 1.4 in the East. However, these last two subregions have seen marked 
increases in such reported diagnoses over this period, with reports in Central 
Europe increasing from 330 in 2006 to 722 in 2010, and in the East from 215 
to 529.
The countries with the highest average annual number of new HIV diagno-
ses associated with MSM were the United Kingdom (43.4 per million people), 
the Netherlands (43.2 per million people) and Spain (37.3 per million 
Figure 2.8 Hiv case reports in europe and proportion Attributed to msm (2006–10)
Sources: ECDC/WHO European Office HIV Report 2011, and Russian AIDS Centre Report 2011. Data for the most recent years may be revised 
because of delays in case reporting (appendix A.2.6).
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men.
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 people), (map 2.5). In the West, data on country of origin are often available, 
and in 2010, 68% of MSM were diagnosed in their country of origin, while 
5.8% of the diagnoses originated from elsewhere in the West and 2.8% (281) 
came from Central Europe or the East. This might reflect the movement for 
MSM toward seemingly more liberalized social environments in the region 
(see also chapter 4).
The proportion of HIV diagnoses associated with exposure through MSM in 
men 30 years old or less varies by subregion. Between 2006 and 2010, the pro-
portion of these MSM was lower in the West than elsewhere and changed little 
over time, fluctuating between 27% and 29% (figure 2.9). In Central Europe the 
proportion fluctuated between 36% and 42% and declined in the East, from 50% 
in 2006 to 39% in 2010. During this time, there was wide variation between 
countries in the proportion of reports associated with exposure through MSM 
that were under 30 years old at the time of diagnosis, from 19% in Finland to 
62% in Belarus.
Those with Missing Exposure Data
Between 2006 and 2010, around 35% (187,202 of 533,181) of reported HIV 
diagnoses in Europe were not allocated to a main exposure category (sex 
between men, injecting drug use, heterosexual, mother-to-child, hemophiliac/
transfusion recipient, nosocomial infection). Only a small minority of these 
might be due to other exposures, with most lacking information on exposure. 
map 2.5 Average Hiv case reports in europe Attributed to msm per million (2006–10)
Source: ECDC/WHO European Office HIV Report 2011 and Russian AIDS Centre Report 2011. Data for the most recent years may be revised 
because of delays in case reporting (appendix A.2.6).
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men.
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Figure 2.9 proportion of Hiv Diagnoses in europe Attributed to msm 30 Years 
old or less (2006–10)
Sources: ECDC/WHO European Office HIV Report 2011 and excludes Austria, Liechtenstein, Monaco, 
Kazakhstan, Russia, Turkmenistan and Ukraine). Data for the most recent years may be revised because of 
delays in case reporting.
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men.
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In total, proportionally fewer HIV diagnoses reported in the West lacked infor-
mation on exposure (15%), compared to Central Europe (42%) and the East 
(42%) (figure 2.10). The proportions lacking this information changed little over 
the past five years (data not shown). This lack of information limits the capacity 
to monitor and compare HIV patterns over time. Overall, information on expo-
sure category is available for 90% or more of reports from 22 countries, and in 
another 16 countries it is available for between 80% and 90% of diagnoses 
reported. A substantial lack of exposure information is limited to the following 
countries: France, Georgia (where more than 75% of HIV diagnoses have missing 
exposure data), Greece, Poland, Romania, Russia (where exposure data are miss-
ing for 57% diagnoses), San Marino, Turkey, and Uzbekistan (with exposure data 
missing in over 30% of diagnoses).
Case Studies: Estonia, Tajikistan, Ukraine, and United Kingdom
We select here four brief case studies reflecting changing patterns in HIV diagnoses 
among key populations in Estonia, Tajikistan, Ukraine, and the United Kingdom. 
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To do this, we extracted data from EuroHIV and ECDC reports on the proportion 
of HIV diagnoses in these countries in the 15-year period from 1995 to 2010.
Case Study: United Kingdom and Ukraine
In the United Kingdom, the number of HIV diagnoses has grown from 2,655 
in 1995 to 6,654 in 2010, though in the past 5 years the total number of 
reports has declined from a high of 7,451 in 2006. The most commonly 
reported exposure category in the mid-1990s was MSM; however, by the late 
1990s this category was overtaken by heterosexual exposure. This change 
reflected a marked increase in the number of infections diagnosed in 
 individuals who had migrated from or had close links to countries with gen-
eralized epidemics [1]. The proportion of diagnoses associated with injecting 
drug use was low throughout the whole period and the number of these 
diagnoses has declined in recent years from 198 in 2005 to 141 in 2010. The 
United Kingdom has a low proportion of diagnoses associated with other or 
unknown exposure categories. The proportion of new diagnoses associated 
with MSM has gradually increased since 2004 and is currently almost equal 
to the proportion associated with heterosexual exposure (figure 2.11). 
While the absolute number of HIV diagnoses attributed to heterosexual 
exposure has declined from 4,329 in 2006 to 3,018 in 2010, the absolute 
numbers of reports attributed to MSM has been more consistent (2,590 in 
2006 and 2,702 in 2010). These data thus suggest that the HIV epidemic 
Figure 2.10 major exposure category among cumulative Hiv case reports in 
europe (2006–10)
Sources: ECDC/WHO European Office HIV Report 2011 and Russian AIDS Centre Report 2011. Data for the 
most recent years may be revised because of delays in case reporting (appendix A.2.6).
Note: HIV = human immunodeficiency virus.
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Figure 2.11 exposure categories among Hiv case reports in the United Kingdom
Sources: Data extracted from EuroHIV and ECDC reports on the proportion of HIV diagnoses in the United Kingdom in 
the15-year period 1995–2010.
Note: 1995–2007 data are by year of report; 2008–10 data are by year of diagnosis. Data for the most recent years may be 
revised because of delays in case reporting. HIV = human immunodeficiency virus.
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in the United Kingdom is in a concentrated phase—mostly affecting MSM 
and migrants.
In Ukraine, the total number of diagnoses reported during 1995 was 1,490, 
and there were 16,643 new diagnoses made in 2010, with only a small propor-
tion of these without exposure category information (figure 2.12). In the past 
5 years, the absolute number of diagnoses reported has increased from 13,256 
in 2006. The vast majority of diagnosed HIV infections in Ukraine have been 
among PWID, which is the most common exposure throughout 1995–2010. 
However, the absolute number of HIV case reports attributed to injecting drug 
use declined between 2006 and 2010 (7,127 to 6,938, respectively), while cases 
attributed to heterosexual exposure have increased by over 60% (from 5,646 to 
9,122). While the majority of cases among PWID remain among men, the 
majority of heterosexual cases are among women. There have been very few 
infections reported associated with MSM, though it is possible this might reflect 
underreporting due to the stigma faced by MSM.
Figure 2.13 shows that the proportion of HIV diagnoses attributed to hetero-
sexual exposure among women is at a similar level in the United Kingdom and 
Ukraine. However, the absolute number of cases is decreasing in the United 
Kingdom and increasing in Ukraine. Data from Ukraine suggests that the HIV 
epidemic is growing and though it has been concentrated—among PWID—it 
would now appear to be starting to generalize within the population as a whole, 
with increasing numbers of diagnoses among women who have acquired HIV 
through heterosexual sex.
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Figure 2.13 Hiv case reports and Heterosexual exposure among Females: 
United Kingdom and Ukraine (2006–13)
Source: Data extracted from EuroHIV and ECDC reports.
Note: HIV = human immunodeficiency virus.
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Figure 2.12 exposure categories among Hiv case reports in Ukraine (1995–2010)
Source: Data extracted from EuroHIV and ECDC reports on the proportion of HIV diagnoses in Ukraine in the 15-year 
period from 1995 to 2010.
Note: 1995–2007 data are by year of report; 2008–10 data are by year of diagnosis. Data for the most recent years may be 
revised because of delays in case reporting. HIV = human immunodeficiency virus.
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Case Study: Tajikistan
The total number of HIV diagnoses made in Tajikistan ranged from 7 in 2000 to 
1,004 in 2010. Based on the population size, this is an increase from just over one 
diagnosis per million people in 2000 to 147 diagnoses per million people in 
2010. To date, no cases have been attributed to sex between men (figure 2.14), 
and injecting drug use has been the most commonly attributed route of transmis-
sion. Since 2006, heterosexual transmission is becoming a more important route 
with 52 cases reported in 2006 and 249 in 2010. The proportion of cases with 
other or unknown transmission routes remains reasonably high (>10%).
Case Study: Estonia
The total number of HIV diagnoses made in Estonia increased from 12 or less 
during 1995–99 to 372 in 2010, peaking in 2001 with a total of 1,474 diagnoses. 
Based on the population size, this is an increase from 8 diagnoses per million 
people in 1995 to 1,099 diagnoses per million people in 2001, decreasing to 277 
diagnoses per million people in 2010. Injecting drug use was the major route of 
transmission from 2000 for several years, although since 2003, the proportion of 
new diagnoses not attributed to any route grew from nearly 60% to over 90% in 
2008 and about 65% in 2010 (figure 2.15). This lack of data severely undermines 
an understanding of the HIV epidemic in Estonia as well as efforts to respond to 
the epidemic. In 2007, for example, there were no cases attributed to heterosexual 
exposure: however, cases grew to 3 in 2008, 17 in 2009, and 69 in 2010. Prior to 
this, cases associated with heterosexual exposure were not reported consistently.
Figure 2.14 exposure categories among Hiv case reports in tajikistan 
(2000–10)
Source: Data extracted from EuroHIV and ECDC reports.
Note: 1995–2007 data are by year of report; 2008–10 data are by year of diagnosis. Data for the most recent 
years may be revised because of delays in case reporting. Data on risk factors are only reported from 2000. 
HIV = human immunodeficiency virus.
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Assessing Hiv prevalence and risk Behavior
In order to understand the dynamics of HIV epidemics in key populations, 
including undiagnosed infections, it is important to directly assess HIV preva-
lence and the extent of risk practices. According to WHO guidelines on second-
generation HIV surveillance, surveys to directly measure HIV prevalence and 
risk should be undertaken periodically in all countries and regularly in countries 
with concentrated epidemics [13]. In this section we examine whether coun-
tries have undertaken targeted studies to directly assess HIV prevalence and/or 
risk behaviors in key populations of PWID, sex workers (SWs), and MSM. We 
also explore whether countries have monitored their HIV epidemics over time 
by generating estimates of HIV prevalence and risk behavior through repeated 
studies or through comparable studies undertaken at different points in time. 
We also comment on the quality of the studies directly measuring HIV preva-
lence by selecting the best available estimates (see chapter 1 for further descrip-
tion). The characteristics of the studies included in our analysis here are 
summarized in tables B.7–B.10.
According to the studies we identified through the systematic literature 
review (see chapter 1 for a description of methods), and during the period 
2000–10, more studies directly assessing HIV prevalence and risk behavior were 
undertaken among PWID (149 studies) than SWs (101 studies) or MSM (67 
studies). There was little difference in number of studies conducted by region. 
Figure 2.15 exposure categories among Hiv case reports in estonia 
(1995–2010)
Source: Data extracted from EuroHIV and ECDC reports.
Note: 1995–2007 data are by year of report; 2008–10 data are by year of diagnosis. Data for the most recent 
years may be revised because of delays in case reporting. HIV = human immunodeficiency virus.
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More studies have been conducted among PWID (16 studies) and SWs (17 stud-
ies) in Russia than in any other country, with the United Kingdom conducting a 
notably higher number of studies across all vulnerable and key populations.
People Who Inject Drugs
Between 2000 and 2010, 48 countries in Europe (96%), with the exception of 
Iceland and Turkmenistan, had undertaken a study to directly assess HIV preva-
lence and/or risk behavior among PWID. Of the 48 (96%) countries in Europe 
having undertaken a study to assess HIV prevalence, 19 were in the West (95% 
of countries in that subregion), 15 were in Central Europe (all countries of that 
subregion), and 14 were in the East (93% of countries in that subregion). Recent 
(that is, within the last 3–5 years) estimates of HIV prevalence were found 
among PWID in the majority of countries (44), while estimates dated back to 
2003 in Ireland, Israel, Latvia, and Lithuania.
Of the 149, HIV prevalence studies among PWID, 48 were selected as con-
stituting “best estimates.” The characteristics of these studies show that more 
than half (29) had national coverage. The majority of studies in the West (13) 
had national coverage comprising large samples [14, 15]. This in part reflects the 
better established sentinel surveillance systems in place at drug treatment cen-
ters or HIV testing clinics. Just over half the studies had national coverage in 
Central European countries [14, 16–18], with large samples from 3 treatment 
centers (>1,000), for instance, in the Czech Republic (1,363) and Poland 
(1,713). Just under half (7) of the studies in the East had national coverage, with 
large samples recruited from drug treatment centers in Latvia and Lithuania 
(>1000) [14, 19–22]. For practical reasons it is easy to recruit PWID from treat-
ment centers but large community samples were also reported, including in 
Belarus (1,770), Bosnia and Herzegovina (780), Bulgaria (1,421), Georgia 
(1,289), Kazakhstan (4,860), Serbia (960), and Ukraine (6,459) [17, 20, 22–26]. 
Large community samples reported from the West were not included as best 
estimates. Small sample sizes were documented in Cyprus, Ireland, and the 
Slovak Republic, possibly reflecting small populations [14]. While national cov-
erage will provide a more representative estimate of national HIV prevalence, it 
is not necessarily an appropriate indicator of quality of the surveillance system; 
if a population is known to be concentrated, sampling a single city may be suf-
ficient. Estimates of the size and location of the population at risk are thus 
needed in order to assess the most appropriate study site. In some cases where 
the geographic coverage was reported to be national, the sample size was also 
small, thus limiting the confidence with which inferences can be made to the 
wider population (for example, studies in Cyprus and Turkey).
In the absence of a representative sampling frame, a key consideration when 
estimating HIV prevalence among PWID is the recruitment and sampling strat-
egy. Sampling strategies that recruit from multiple sites and networks will mini-
mize geographic and network bias, and surveys recruiting from a broad range of 
locations may be able to claim wider applicability of their results than those 
recruiting from only one or two settings [27, 28]. In particular, studies that only 
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recruit from clinical settings may find their samples biased toward higher risk 
individuals or those who feel they need to access testing or treatment services. 
Evidence suggests that drug users in treatment systematically differ from those 
not currently in treatment [29–33]. Sampling PWID from opioid substitution 
therapy (OST) clinics may, for example, bias the sample away from stimulant 
injectors who may form an important group, albeit with different characteristics 
and risks than those faced by opiate users [33]. A wide range of recruitment 
approaches were used in the 48 studies selected as best estimates from recruit-
ment via clinical settings to low threshold services and community-based recruit-
ment. Recruitment took place via treatment-drug or low-threshold needle and 
syringe exchange programs (NSP) in all the studies in the West, except for 
France, where recruitment took place in both community and low-threshold 
services. In some countries, such as Greece, Luxembourg, Lithuania, Sweden, and 
the United Kingdom, recruitment took place from multiple sites including drug-
treatment and HIV-testing centers, NSP, and prisons [14, 34]. In contrast the 
majority (9 out of 14) of the best estimate studies in the East were recruited 
from community settings [14, 19–20, 22–23, 34–36]. In case studies 2.1 and 2.2 
below, we show how different recruitment strategies, as well as the effect of dif-
ferent sample sizes, can result in variance in HIV estimates.
Seven of the studies used in Estonia, the Kyrgyz Republic, Moldova, 
Montenegro, Romania, Russia, and Tajikistan employed respondent-driven sam-
pling (RDS) to recruit PWID from community settings [20, 37–42]. In RDS, 
sampling begins with a set of initial subjects who serve as seeds for an expanding 
chain of referrals recruited through dual incentives, one received for participating 
in the study and subsequent ones for each person recruited. Respondents from 
each link in the chain, or wave-referring respondents, form subsequent waves. 
Information on the relationships between recruiters and recruited and their esti-
mated network size is collected during the interview to allow for the calculation 
of selection probabilities [43]. This information is used to assess homophily, or 
the extent to which recruiters are likely to recruit individuals similar to them-
selves, and to weight the sample to compensate or control for differences in 
network size, homophily, and recruitment success. RDS has been increasingly 
used in Europe and internationally to recruit samples of SWs [44, 45], MSM 
[46] and PWID [47–50], and it has been championed for its ability to provide 
more representative estimates of risk behavior and HIV prevalence [46, 50–53]. 
There have been recent ethical concerns that the use of incentives may nega-
tively affect participants’ social and economic relationships in populations of 
PWID. Incentives may also lead to a questioning of the assumption that partici-
pants can accurately recall detailed information on the composition of their 
network, including size and relationship, in order to fulfill the condition of ran-
domly recruiting a participant within their social network [54–56]. In addition 
some evidence shows that RDS is less effective at recruiting populations with 
small social networks, such as SWs [57, 58].
In addition to direct measures of HIV prevalence, at least one behavioral 
survey had been undertaken among PWID in 37 (74%) countries: 50% (10) in 
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case study 2.1 estimating Hiv prevalence among pWiD in st. petersburg, 
the russian Federation
St. Petersburg is the Russian Federation’s second largest city, with a population of around 
4.2  million. Some studies have estimated a three-fold increase in people who inject drugs 
(PWID), and a nine-fold increase in teenaged PWID, between 2000 and 2005, and an estimated 
70,000 PWID as of 2005 [59]. The first case of HIV was reported in 1996, and since then there 
have been multiple estimates suggesting high numbers of cases and high HIV prevalence 
among PWID. Our review identified eight studies [38, 60–66] reporting HIV prevalence among 
PWID from 2002 to 2009. Even within this one city the estimates vary widely from 30.1% in 2002, 
down to 14.6% in 2005 and up to 61.1% in 2009. More recent data not collected in the review 
from St. Petersburg (a 2008–10 cohort) suggest that prevalence is around 35% [37, 67, 68].
Are these shifts in prevalence a true reflection of trends or is there an alternative explanation? 
If the samples were truly representative of the population from which they were selected then 
there is a 95% likelihood that the true population prevalence lies on the orange line represent-
ing the confidence interval (see below). The larger the study sample, the smaller the confidence 
intervals represented by the bar and the more accurate the proportion estimated: thus the 2002 
[60] and 2004–08 [64] estimates are likely to be (statistically) the most precise as their confidence 
intervals are the narrowest and thus the margin for error the smallest. However, this assumes the 
representativeness of the population and as with any hidden population with no explicit sam-
pling frame, it is impossible to assess the representativeness of the sample. While the studies in 
2002 [60, 69], 2004 [61, 70], 2007 [63], and 2009 [71] are limited to those who have injected drugs 
relatively recently, the 2005 [62] study recruited participants from narcology hospitals, only 40% 
of whom admitted to ever having injected drugs. Of the remaining four studies, those from 2002 
and 2007 recruited participants from the community and social services as well as through 
snowball sampling. The 2004 study recruited participants from primary health care centers only, 
and the recruitment procedures used in the 2009 study were not clearly described.
Note: HIV = human immunodeficiency virus.
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the West, 97% (13) in Central Europe, and 93% (14) in the East. Thus, in the 
West and Central Europe, HIV prevalence among PWID had been more 
widely measured than risk behavior. Obtaining repeated measures of HIV 
prevalence is critical in concentrated epidemic situations, and such measures 
were observed in 42 (84%) countries. Two-thirds of the countries (33) also had 
repeated surveys of risk behavior. As shown in table 2.2, 44 (88%) countries 
had studies that allowed monitoring of HIV prevalence, risk behaviors, or both 
among PWID, SWs, and MSM (80% in the West; 93% in both Central Europe 
case study 2.2 estimating Hiv prevalence among pWiD in riga, latvia
The United Nations General Assembly Special Session (UNGASS) 2010 Country Report for 
Latvia [72] reported two sets of prevalence figures provided by the Infectology Centre of Latvia 
(ICL) among PWID in Riga for the period 2001–08. Both estimates appear to have stabilized by 
the end of the decade, but the biological survey data show significantly higher prevalence 
than the routine voluntary counseling and testing (VCT). Despite a larger sample size from the 
routine VCT (mean sample size of 644 versus 265), the studies both present feasible estimates 
of the HIV prevalence in the population. One possible explanation for the differences is that the 
studies may have recruited participants from different settings that may influence or be influ-
enced by HIV status. Participants recruited through routine VCT may not be current injectors, 
and evidence shows that PWID not in touch with services tend to engage in higher risk inject-
ing behaviors reflected in the higher prevalence of the survey sample. The figure below high-
lights the heterogeneity in prevalence estimates obtained with different recruitment strategies, 
emphasizing the importance of drawing estimates from multiple different methods, even in 
relatively small locations, before defining or delineating an estimate of prevalence.
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and the East). Table 2.2 also shows that evidence of monitoring over time was 
common across all three subregions as follows: 75% of the countries in the 
West, 93% in Central Europe and 87% in the East monitored HIV prevalence; 
50% of the countries in the West, 62% in Central Europe and 93% in the East 
monitored risk behaviors. An example of a successful biological-behavioral 
system among PWID used annually in the United Kingdom is summarized in 
case study 2.3.
Sex Workers
Three-quarters of the countries conducted studies to estimate HIV prevalence or 
risk behavior among SWs in the period from 2000 to 2010, equaling 76% of the 
50 countries across Europe. An HIV prevalence study was found in just over one-
half of the countries (13) in the West, two-thirds (11) of those in Central Europe, 
almost all (14 out of 15) of those in the East. The majority of countries in the 
East conducted 13 either repeated surveys or studies at multiple points in time, 
but only four in Central Europe and one in the West had done so. Three coun-
tries with populations of less than 1 million (Cyprus, Iceland, and Malta) did not 
publish studies, likely because it is impractical to conduct surveys in countries 
with small populations. The other eight countries without such studies were 
Albania, Denmark, Finland, France, Ireland, the Slovak Republic, Sweden, 
Slovenia, and Turkmenistan. We identified few studies (15) conducted in the last 
3–5 years among SWs. Of these, most had been conducted in the East, with 
estimates from Austria, the Netherlands, Portugal, Spain, the Czech Republic, 
and Poland dating back to 2000–01.
Of the HIV prevalence studies among SWs identified (101), 38 were selected 
as best estimates. The characteristics of these studies show that only 8 out of 38 
had national coverage [17–18, 32, 76–81]. As with PWID, these samples were 
mostly recruited via sexually transmitted infection (STI) clinics, such as studies 
table 2.2 number of countries with studies measuring and monitoring Hiv and 
Behaviors among pWiD, sWs, and msm in europe
Sub-region
Number of countries with a 
direct measure of prevalence 
(monitoringa)
Number of countries that 
measured behaviors 
(monitoringa)
Number of countries that have 
measured either behaviors or 
prevalence (monitoringa)
PWID SW MSM PWID SW MSM PWID SW MSM
West (n = 20) 19 (15) 13 (1) 8 (2b) 10 (10) 8 (7) 15 (12) 19 (16) 13 (7) 16 (12)
Central Europe 
(n = 15) 15 (14) 11 (4) 13 (7) 13 (9) 9 (2) 13 (5) 15 (14) 11 (4) 13 (7)
East (n = 15) 14 (13) 14 (13) 12 (10) 14 (14) 13 (11) 14 (11) 14 (14) 14 (14) 14 (12)
Total 48 (42) 38 (18) 33 (19) 37 (35) 30 (20) 42 (28) 48 (44) 38 (25) 43 (31)
Source: Tables B.7–B.10.
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men; n = sample size; PWID = people who inject drugs; 
SWs = sex workers.
a. They have either undertaken a study that has been repeated at regular intervals, or they have undertaken a number of separate studies at 
different time points that have used comparable methodologies.
b. Unclear.
44 HIV Surveillance
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8
in Austria (1,184), Germany (3,880), Kazakhstan (1,960), Russia (4209), and 
Spain (4,485), and a large community-recruited sample in Ukraine (2,278) [3, 
32, 77, 78, 82, 83]. Studies in the former Yugoslav Republic of Macedonia and 
Armenia, described as national samples, were limited by small sample sizes 
[3, 18]. Recruitment sites for SWs focused on STI clinics, work settings, and 
outreach projects for male sex workers (MSWs). Community surveys employed 
a range of methods, including recruiting from sex work venues, for example, 
street sites were used in Portugal or Romania [84]; gay clubs and bars were used 
in studies in France, Italy, or the United Kingdom [10, 85, 86], and respondent-
driven sampling RDS) was used in Moldova and Albania [44, 45]. As with 
PWID (see above), recruiting SWs at their places of work and in the community 
overcomes potential bias linked to recruiting those in contact with STI clinics 
and helping services. Especially vulnerable SWs, such as migrant SWs, for 
instance, are less likely to be in contact with clinics [87–89].
An HIV-related behavioral survey of SWs was identified in three-fifths (30) of 
the countries: two-fifths (8) in the Western subregion, three-fifths (9) in the 
case study 2.3 two Decades of serobehavioral monitoring of infections among 
pWiD in the United Kingdom
National serobehavioral surveillance among PWID in England and Wales was started in 1990 
[73]. Around 3,000 PWID have been recruited annually through over 50 needle and syringe 
exchange programs and prescribing services. Consenting PWID provide a  biological sample 
and self-complete a behavioral questionnaire.
This survey found that HIV prevalence among PWID fell from 1.8% in 1991 to 0.61% in 1996; 
it then remained at or below 1% until 2002, before rising to 1.6% in 2005. Prevalence has 
remained at around that level since then. Trends in hepatitis C virus (HCV) prevalence showed 
a similar pattern, falling from 61% in 1992 to 38% in 1999, before rising to 47% in 2009. 
Reported needle and syringe sharing fell from 24% in 1991 to 17% in 1997, before rising to 
34% in 2002 and then declining to 19% in 2009. Uptake of HIV testing was found to have 
increased in recent years after being relatively stable through 2003 with around half of PWID 
ever tested; it then rose to 75% in 2009.
These surveillance data have influenced policy and responses, and have reflected their 
impacts. For example, reducing the sharing of needles and syringes was a policy target from 
1992 to 1997, but in 1998 the policy focus shifted to criminal justice issues. This policy shift 
coincided with the rise in sharing levels and subsequent rise in prevalence of HIV. In response 
to increased levels of infections among PWID, in 2003 the publication of an annual surveillance 
report on infections among PWID was started [74]. The resultant increase in the profile of 
 injection related harm among PWID contributed to the development of Action Plans on HCV 
and drug-related harms. In response, harm reduction services were improved, and access to 
drug treatment was made easier. Needle/syringe sharing has recently declined and the preva-
lence of both HIV and HCV are now stable [75]. Serobehavioral surveillance has thus been 
important in both monitoring and informing the development of interventions and policy.
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Central subregion, and the majority (13 out of 15) in the Eastern subregion. 
More countries had undertaken either repeated surveys or studies at different 
points in time that could be used to monitor behaviors in the West (7) and the 
East (11) than in Central Europe (2). So while overall HIV prevalence among 
SWs had been more widely measured than risk behaviors in all three subregions, 
more countries in the West monitored behaviors more than HIV prevalence. One 
example of behavioral monitoring conducted in the region is TAMPEP, the 
European Network for HIV/STI Prevention and Health Promotion among 
Migrant Sex Workers. TAMPEP conducts quantitative and qualitative research 
via SW-oriented services in 25 EU member countries every two years. Data are 
collated on the size of populations as well as the profile of male, female, and 
transgender SWs across the region, documenting increases in violence, problems 
with the police, changes in the profiles of SWs, and the organization of SWs [90]. 
Another example of a successful surveillance system used to measure HIV and 
related risk behaviors among SWs in Kazakhstan is given below in case study 2.4.
Only six studies were identified among MSWs, five of which were in the West 
and one in Russia. The studies in Russia and the Netherlands were limited by 
case study 2.4 serobehavioral monitoring of infections among 
FsWs in Kazakhstan
In 2009, Kazakhstan had an estimated population size of 16,250 female sex workers (FSWs) in 
the country. Between 2005 and 2009, annual biobehavioral surveillance surveys were imple-
mented among FSWs involving large sample sizes; in 2009, 2,249 FSWs were recruited, but 
sample sizes for previous years were not specified [91]. Eligibility criteria included women with 
a self-reported history of provision of sex work at least once in the past 6 months and women 
who were recruited across multiple sites nationally [91, 92]. This biobehavioral surveillance 
survey collected information to monitor the impact of the responses to HIV (with similar sur-
veys among men who have sex with men (MSM) and people who inject drugs (PWID). Similar 
studies were conducted in the Kyrgyz Republic and Tajikistan.
The findings for the period from 2006 to 2009 indicate that among FSWs the prevalence of 
HIV decreased from 2.5% to 1.3%, the prevalence of HCV from 17% to 11%, and the prevalence 
of syphilis from 26% to 18%. During this period, the self-reported coverage of FSWs with HIV-
prevention activities consistently increased from 51% in 2006 to 88% in 2009, with 90% of the 
participants reporting that they received free condoms in 2009. Over three-quarters (76%) of 
the participants reported having had a voluntary HIV test in the past 12 months in 2009.
These changes probably reflect the ongoing investment in prevention services, including 
provision of condoms, information and advice, and syndromic (or clinical) STI management [92]. 
For example, in 2009, 5,090,026 condoms were distributed among SWs in Kazakhstan, or 
313 condoms per SW. Continued surveillance will allow the ongoing assessment of the situation 
and monitoring of intervention impact. Both the surveillance system and programs are sup-
ported through funding via the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM). 
Since funding for this has been cut in 2011, the future of these projects is uncertain.
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small sample sizes. All studies were conducted prior to 2007 and all were at 
single sites with the exception of Spain where a large national sample was taken 
from an HIV clinic. All studies collected linked behavioral data.
Men Who Have Sex with Men
Between 2000 and 2010, the majority (43, or 86%) of the 50 countries in the 
European region had publications reporting on studies conducted that were 
related to HIV or behaviors among MSM. The countries without published stud-
ies of either directly measured HIV prevalence or behaviors among MSM were 
Austria, Cyprus, Iceland, Luxembourg, Malta, Montenegro, and Turkmenistan.
Of the identified HIV prevalence studies among MSM (67), 33 were selected 
as best estimates. Proportionally fewer countries in the West (8 out of 20) had 
assessed HIV prevalence among MSM, compared to Central Europe (13 out 
of 15) and Eastern subregions (12 out of 15). Very few countries in the West (2) 
had undertaken either repeated surveys or studies at different points in time that 
could be used to monitor prevalence, while 7 countries had done so in Central 
Europe and 10 in the East. The majority of studies (27) were conducted within 
the last 3 years with the exception of the following countries: Croatia, the 
Netherlands, Poland, Portugal, Spain, and Switzerland, where studies were con-
ducted between 2000 and 2006.
The characteristics of these studies showed that only 9 out of 33 countries had 
national health coverage [3, 16–18, 22, 25, 93, 94], and only three had a sample 
size greater than 1,000 (the Netherlands, Spain, and Switzerland) [3]. A large 
sample had been recruited from five cities in the United Kingdom as well as 
Russia [79, 95, 96]. Clinic-based recruitment centered around STI clinics and 
HIV testing centers [3, 17, 97] and one community health service [35]. Unlike, 
PWID and SWs, the majority of samples were recruited from community set-
tings [16, 18, 21–22, 24, 36, 79, 95, 96, 98–105].
Recruitment from community settings used time location sampling (TLS) in 
the Czech Republic, Italy, the Slovak Republic, and Slovenia, and RDS in 
Albania, Croatia, Georgia, and the Kyrgyz Republic [16, 96, 99, 102–104, 106]. 
TLS works by conducting extensive mapping of venues where the research 
population congregates, recruiting from randomly selected venues, and then sys-
tematically recruiting participants from those venues [27]. Evidence from this 
review shows that TLS was possible in cities with well-developed gay scenes such 
as Barcelona, London, and Verona, and with cities with fewer gay venues and less 
liberal attitudes to MSM in Bratislava, Bucharest, and Ljublijana [96, 102].
Across the whole region behavioral surveys had been more extensively under-
taken than prevalence studies, with published studies originating from 42 (84%) 
countries of the region. This is particularly so in the West where three-quarters 
(15) of the countries in the subregion had assessed behaviors among MSM, as 
had the majority of countries in Central Europe (13 out of 15) and the East (14 
out of 15). Approximately two-thirds of the countries had evidence to indicate 
that they could monitor HIV-related behaviors among MSM through either 
repeated surveys or studies undertaken at different points in time.
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One example of a successful behavioral survey of MSM in the West is the 
European Men Who Have Sex with Men Internet Survey (EMIS) [107]. The 
survey collected data from MSM in 38 countries and was advertised on a range 
of “gay-orientated” Internet sites, mainly sites where MSM meet sexual partners, 
and through community organizations. Data from Internet surveys need to be 
interpreted with caution as the sample is self-selecting; as a result, the represen-
tativeness of such samples is unclear and the data are also likely to differ between 
countries and possibly over time (e.g., due to varying and evolving patterns in 
Internet access and use). However, the EMIS survey has the potential to provide 
broadly comparable data on behaviors among MSM across much of the region. 
Repeating EMIS on an annual basis would provide a European-wide behavioral 
surveillance system for MSM that complements the existing national systems.
Limitations of This Assessment
Public health surveillance studies typically use pragmatic approaches to ensure 
efficient use of the available resources, to allow data to be collected and made 
available relatively quickly, and to ensure their sustainability over time. Thus, 
these studies have to balance robustness (i.e., representativeness and geographic 
coverage) against efficient use of resources, timeliness, and sustainability as well 
as consider the population context. This need for a pragmatic approach often 
leads to studies that use sentinel sites and accessible subgroups of the population 
to produce data that can produce nationally useful insights when combined with 
other available data (e.g., HIV case reports, data on HIV testing, service usage 
data [NSP, OST, STI testing, etc.], estimates of population size). However, there 
are problems with making national estimates of HIV prevalence in countries 
with highly diverse HIV epidemics between cities; this point is illustrated in 
case study 2.5. Our review focused on synthesizing data from published studies 
and so we identify estimates from both public health surveillance activities and 
from studies using more sophisticated epidemiological research designs. As a 
consequence, data on prevalence and behaviors are not always comparable either 
between or within countries. This analysis is further limited since information on 
the methodologies used in the studies was often not provided in full, making it 
difficult to systematically assess quality.
Measurement of HIV Incidence among High-Risk Groups
Incidence, the rate at which new infections occur in a population, can be directly 
measured using two approaches. The most established approach is to follow-up 
on a group of people at risk over time. However, such studies are costly to under-
take, and with marginalized populations it can be particularly difficult to get a 
representative sample and keep track of it over time. Retrospective cohorts can 
also be constructed through use of case-note reviews and record linkage, but they 
are affected by similar biases. More recently it has been possible to measure HIV 
incidence using a laboratory test that assesses whether an HIV infection is recent 
(STARHS [Serological Testing Algorithm for Recent HIV Sero-conversion] or 
RITA [Recent Infection Testing Algorithm]). It is also possible to indirectly 
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estimate incidence from HIV prevalence data using a number of approaches 
including force of infection modeling [108, 109] and measuring prevalence 
among people who have recently started injecting, assuming that that they 
would not have been infected via another route [57, 110]. An example where 
this approach has been used is described in case study 2.6. Incidence can also be 
estimated through back-calculation approaches using data on HIV diagnoses, 
clinical status at diagnosis, and AIDS [111]. Here the literature review was used 
to explore whether countries had reported incidence among PWID, MSM, and 
SWs since 2000, from either a cohort study or the application of the RITA test.
There were only a few countries where studies had been undertaken to 
directly measure HIV incidence since 2000. The literature review indicated that 
among PWID, incidence had been directly measured in five countries: Ireland 
(retrospective cohort, case note) [112], the Netherlands (prospective cohort) 
case study 2.5 estimating Hiv prevalence in the Kyrgyz republic and tajikistan
This case study illustrates the diversity of HIV prevalence estimates generated within a country 
or region, especially in a context of rapidly evolving localized epidemics, accentuating the 
 limits of relying on composite national estimates of HIV prevalence when assessing program-
matic needs and responses.
Kyrgyz republic: Annual sentinel surveillance of HIV prevalence among PWID is carried 
out in the Kyrgyz Republic. HIV prevalence among PWID was estimated to be 7.7% in 2007, 
declining to 6.8% in 2008 and increasing to 14.3% in 2009. However, by examining the surveil-
lance methods more closely we can see that the apparent decline in 2008 was an artifact of the 
methodology and the inclusion or exclusion of certain sites. Initially only the cities of Bishkek 
and Osh were included in the survey, but in 2007 the sample increased to include Batken, Chui, 
and Jalal-Abad. In 2008, however, Osh was not included. The HIV prevalence among PWID in 
Osh is high, reported as 12% as early as 2004, increasing to 14% in 2005 and 2006, and decreas-
ing back down to 12.9% in 2007. By excluding Osh in the 2008 survey, the results for that year 
are artificially lowered.
tajikistan: Sentinel surveillance of HIV among PWID has been in place in Tajikistan since 
2005, although studies in the capital, Dushanbe, from 2004 indicate that prevalence there was 
12.1%. National reported prevalence among PWID was 15.8% in 2005, increasing to 23.5% in 
2006 and then decreasing to 19.4% in 2007, 17.6% in 2008, and 17.3% in 2009. Similar to the 
Kyrgyz Republic, the number of sites included in the surveillance has changed several times 
over the time period, starting in 2007 with the inclusion of four high to very high prevalence 
cities in the survey, causing the national prevalence to increase. In 2009 an additional two 
 cities, this time with medium-level HIV prevalence, were included, leading to the appearance 
of a reduced national prevalence among PWID.
The diversity of HIV epidemics between cities, even in relatively small countries such as the 
Kyrgyz Republic and Tajikistan, highlights the unsuitability of using a composite national prev-
alence in describing the HIV epidemic among PWID in many settings.
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[113], Russia (prospective cohort) [37], Spain (retrospective cohort, record link-
age) [114], and the United Kingdom (prospective cohort) [115]. There were 
three countries with published incidences among MSM; Italy (retrospective 
cohort, case note), the Netherlands (prospective cohort) [117], and the United 
Kingdom (STARHS/RITA) [118]. There were also [116] two counties with 
papers reporting direct incidence measures among MSWs: Russia (prospective 
cohort) [119] and the United Kingdom (retrospective cohort, case note) [120].
Measuring Population Sizes for MSM, PWID, and SWs
Knowing the size of the population at risk is important for planning HIV preven-
tion and care services as well as for measuring the harms associated with the 
population or risk behavior [121, 122]. Without a denominator it is difficult to 
case study 2.6 Using Biobehavioral surveys to measure Hiv incidence among 
pWiD in estonia
Serial cross-sectional studies of PWID were conducted in Tallinn, Estonia, in 2005 (n = 350), 
2007 (n = 35), and 2009 (n = 327) [39, 110]. Eligibility criteria were defined as injecting in the 
last 4 weeks (2005) and last 2 months (2007 and 2009). Recruitment took place in community 
settings using RDS. Biological data were collected using dried blood spots (2005) and whole 
serum samples in the other 2 years. Comparable measures of injecting risk behaviors and 
access to services were collected in all 3 years although a different questionnaire was used in 
2005. Results of the surveys suggest that HIV prevalence among the samples was consistently 
high at 54% in 2005, 55% in 2007, and 50% in 2009. HIV incidence was calculated among recent 
initiates into injected (defined as those injecting for 3 years or less) and estimated, assuming 
new injectors were HIV negative when they began injecting and that seroconversion took 
place at the midpoint between first injection and recruitment into the study [110]. HIV 
 incidence per 100 person years was 20.9 (95% CI 13.5020.8) in 2005, 26.5 (95% CI 16.6–40.1) in 
2007, and 9 (95% CI 3.3–19.6) in 2009.
Behavioral data suggested that demographic characteristics of new injectors remained 
the same over time, with the exception of age. For example, there were proportionally more 
new injectors in 2009 who were older than 20 years than there were in 2005. The use of HIV-
prevention services changed and proportionally more new injectors reported ever using a 
needle and syringe exchange program (NSP) (70% in 2005 and 97% in 2009) and that the NSP 
was their main source of new needles/syringes (44% in 2005 and 76% in 2009). There was no 
difference in the proportion reporting receptive sharing of daily injecting over the years. 
These observed changes in incidence coincided with an increase in the number of needles/
syringes  distributed in Tallinn over time: for example, the number distributed in 2009 was 
3 times greater than in 2005 and 43 times greater than in 2003. Increases in condom distribu-
tion have also been observed, as well as the introduction of opiate substitution therapy. This 
example shows how the use of serial cross-sectional surveys can be useful for informing the 
evaluation of HIV-prevention services as well as for giving a measure of HIV incidence. 
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know whether HIV prevalence at a general population level is increasing and/or 
whether the size of the population group is increasing. While almost all countries 
have robust data on the size of their overall population, measurement of the size 
of high-risk groups is not a routine demographic activity in part because of the 
associated challenges.
Due to the illicit and marginalized nature of injecting drug use and sex work, 
and common discrimination against MSM, the sizes of these groups are difficult 
to estimate. In the case of SWs, estimation problems are further complicated by 
the mobile nature of the group. Estimates of the population sizes of these groups 
typically use indirect estimation approaches such as capture-recapture and mul-
tiplier methods. A number of countries have looked at measuring the extent of 
same-sex behaviors through household surveys; however, the robustness of this 
measure is unclear [122]. We identified most recent published estimates for the 
three main risk groups, presenting the year the estimates were given. Estimates 
of PWID and SWs typically relate to individuals who are either currently or have 
recently injected drugs or sold sex (e.g., injected in last month, or sold sex in last 
year). Estimates of MSM may relate to sexual behavior, (e.g., had sex with 
another man in last five years), or identity (e.g., identify as gay or bisexual). As 
many of the estimates identified were derived from secondary sources or lacked 
methodological details the findings should be interpreted with caution. We focus 
on documenting whether a recent estimate was available rather than comment-
ing on the plausibility of the estimate or the robustness of the method used to 
obtain it—there is, however, likely to be considerable variability in the quality 
and comparability of the estimates.
Overall 43 (86%) countries had published estimates of the size of their PWID 
populations, with 37 of these estimates relating to 2000 or later (table 2.3). Since 
2000, 55% of countries in the West (85% if pre-2000 estimates are included) had 
estimated the sizes of their PWID populations, as had 87% of the countries in 
both Central Europe and the East. Overall 5 (10%) countries had published 
estimates of the size of their MSM populations (none of the countries in the 
West, 7% in Central Europe and 27% in the East), while 43 (86%) countries had 
done so for SW (75% of countries in the West, 87% in Central Europe and all 
the countries in the East).
Estimates of the size of the PWID population suggest that the largest popula-
tions are in the East, particularly in Russia, Baltic states, and Central Asian 
table 2.3 number of countries with estimates of population sizes of pWiD, FsWs, and msm
Subregion
Number of countries with 
PWID estimates
Number of countries 
with MSM estimates
Number of countries 
with FSW estimates
West (n = 20) 11 (plus 6 pre-2000) 0 15
Central Europe (n = 15) 13 (4 years unclear) 1 13
East (n = 15) 13 4 15
Source: Literature Review. See table B.11.
Note: FSWs = female sex workers; MSM = men who have sex with men; n = sample size; PWID = people who inject drugs.
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republics, corresponding to high HIV prevalence in those regions. The pattern is 
slightly different for FSWs, as larger populations of FSWs have been recorded in 
Central Europe, particularly in Austria, Germany, and Luxembourg (>10 per 
1,000 people [map 2.6]).
note
 1. In a few countries, HIV diagnoses reporting systems are not implemented nationally 
(e.g., Italy, Spain) and administrative errors may have resulted in reports being missed. 
In addition, in 11 countries HIV diagnoses reporting started after 1990, more than five 
years after HIV testing first became available (see figure 2.1). Data are not currently 
available for all countries (such as Austria, Liechtenstein, and Monaco).
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Epidemiology of HIV in Key 
Populations at High Risk
people Who inject Drugs
Injecting drug use is a major global health concern, with between 11 and 
21  million people injecting drugs worldwide [1]. Overall, there are approxi-
mately 4.8 million people who inject drugs (PWID) in the European region, with 
over 1.8 million of these living in the Russian Federation [1]. In Europe the 
estimated prevalence of injecting drug use among the adult population varies 
widely from almost 0 in some Central European countries (for instance Hungary) 
to more than 1 in 20 adults in others (for instance Azerbaijan) [1].
Blood-borne viruses, including HIV, contribute significantly to the excess mor-
bidity and mortality experienced by PWID [2, 3]. HIV has the potential to 
spread rapidly via the sharing of needles or syringes between PWID as well as via 
unprotected sex between PWID and their injecting and noninjecting partners. 
Sexual contact between PWID and noninjecting populations may in part explain 
the rise in HIV cases among heterosexual noninjectors in areas where injecting 
drug use was previously thought to be the principal route of transmission of HIV 
[4]. The risk of HIV infection after injecting with a contaminated needle is high, 
estimated to be around 1 in 125 injections [5], compared with unprotected sex 
between heterosexuals, which carries a risk of transmission of about 1 in 
2,000–5,000 sex acts [6]. This goes some way to explain the disproportionate 
burden of HIV among PWID in the region.
Demographic Characteristics
Age and Sex
Studies suggest that three times as many men as women inject drugs in Europe. 
Males make up a higher proportion of PWID in southeastern Europe, Central 
Asia, and the Caucasus. Data from Georgia and Azerbaijan suggested over 95% 
of respondents were male [7–13]. Most research among PWID tends to recruit 
through services or in the community via drug-user networks, so those who are 
poorer or lack access to services or who have weak ties to such networks may be 
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less likely to be included in a study. Female PWID are generally harder to reach 
than males and use services less and may thus be underrepresented in studies. 
In Georgia, for example, it is estimated that there are about 8,000 female PWID, 
which is roughly 20% of problem drug users, yet women only constitute around 
8% of participants reached by harm reduction programs and 1% of participants 
reached by methadone programs [14].
PWID tend to be older in the West where the median age was over 30 years, 
but younger in Central Europe (mid-20s) and in the East (late 20s). Sentinel 
surveillance from Kazakhstan, the Kyrgyz Republic, and Tajikistan in 2006 sug-
gested that the median age of PWID ranged between 29 and 34 years. In 2009 
the median age ranged from 31 to 37 years, suggesting that either the PWID 
population was aging with fewer new initiates, or that sampling methods 
excluded younger people [15]. Many studies restrict recruitment to PWID 
18 years or over, so populations of younger injectors may be inadequately repre-
sented. A study of street-based adolescents (10–19 years old) in four cities in 
Ukraine reported that 15.5% had ever injected drugs and over half of those had 
done so in the previous month. The average age of first injection was between 
14 and 16 years [16]. If this pattern is common throughout the region it is likely 
that a significant part of the PWID population has been underrepresented in 
studies to date.
The evidence suggests that the average age of male PWID is older than 
females: studies from Belarus [18], England and Wales [19], France [17], Russia 
[18], and Ukraine [18] all showed male respondents to be more than one year 
older than females on average. Evidence also suggests that age differs by type of 
drug used, with amphetamine users tending to be younger than opiate users. 
A study of cocaine and heroin users (not all PWID) from Barcelona, Madrid, and 
Seville in Spain showed that cocaine only users were generally younger than 
those who also used some heroin in addition to cocaine [20]. A study from 
Tallinn in Estonia reported amphetamine (psychostimulants) users as younger on 
average than fentanyl (synthetic opiate) users [21]. Studies that recruited exclu-
sively from drug treatment centers tended to report respondents with higher 
average ages than those recruiting from the street and  low-threshold services. 
All demographic characteristics of PWID in European studies captured are 
 presented in tables C.4–C.6.
Income and Employment
The proportion of PWID who report having a regular income was generally low, 
although it is important to note the likelihood for underreporting of illegal earn-
ings as well as the effect of low levels of employment within the wider commu-
nity. In the West, the proportion of PWID reporting regular income ranged 
between 2% and 30%. Exceptions to this included Italy where higher levels of 
employment were reported at 79% (Northern Italy) and 56% (Southern Italy) 
[22, 23]. In Marseille, France, 65% reported receiving benefits in addition to the 
18% who were employed [24]. In Central Europe the proportions of employed 
PWID was generally between 20% and 35%. Similarly, in the East, regular 
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income and employment was generally less than 50%, although studies in 
Ukraine reported that 6–7 respondents out of 10 were employed full or part time 
[25, 26]. A study in St. Petersburg, Russia, reported that 44% of PWID were 
employed, although 76% reported having a legal income [27].
A study comparing PWID from Volgograd and Barnaul with a random sample 
of respondents from a Russian national household survey [28] provides more 
detail on the economic activities of PWID. PWID were likely to have a similar 
level of income as noninjectors of the same age, and although they were less 
likely to have a regular job, those out of work were more likely to be actively 
seeking one. PWID without regular work had a greater variety of additional 
sources of income than noninjectors who relied heavily on state support in the 
form of pensions and child benefits. PWID relied more on illegal activities such 
as selling sex or drugs and on money from parents or friends. These studies 
emphasize caution in generalizing that PWID are without income or employ-
ment and without the potential to contribute to the economy. Recent research 
from Vancouver, British Columbia, suggests that PWID involved in the labor 
market experience lower levels of HIV risk and prevalence than those not 
involved in the labor market, and that there is a relationship between increasing 
frequency of employment and decreasing HIV risk [29].
Risk Profile
Contact with Criminal Justice Systems
Previous reviews suggest that prisons and other closed settings may act as struc-
tural determinants in the production of HIV risk, especially linked to drug inject-
ing [30–32]. While drug use, and injecting, may continue in prison, access to 
harm-reduction resources are reduced, with levels of risk consequently higher. 
A number of international studies link incarceration with an increased risk of 
HIV transmission among PWID [32–34]. Additionally, a strong emphasis on law 
enforcement—including intense street policing of PWID resulting in caution, 
arrest, fine, or detention—has been linked (directly and indirectly) with HIV 
vulnerability. Evidence, for example, links intensity of police contact and arrest 
with increased odds of syringe sharing among PWID [35–39].
The data reviewed from Eastern Europe and the former Soviet Union suggest 
that between half and three-quarters of PWID have been arrested (see tables 3.1 
and C.7–C.9). For instance, in Dushanbe, Tajikistan, 45% of PWID had ever been 
arrested [41], while in Tallinn, Estonia, 50% of amphetamine users reported 
table 3.1 contact with the criminal Justice systems in case study countries
PWID ever arrested (%) PWID ever in prison (%)
Harm reduction services 
available in prisons [40]
Estonia 49–66 58–66 OST
Russian Federation 27–76 6–37 Not available
Tajikistan 44.5 Not available Not available
Source: PWID publications as per tables C.7–C.9.
Note: OST = opioid substitution therapy; PWID = people who inject drugs.
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being arrested in the last year, compared with 66% of fentanyl users [21]. A study 
in Odessa, Ukraine, (n = 600) found that police beatings were common, with 
nearly 50% of respondents reporting at least one beating; police beatings were 
linked to elevated levels of syringe sharing [30, 39]. Studies in other regions also 
suggest relatively high rates of police arrest. In Serbia and Montenegro (histori-
cally), for example, 64% of PWID in Belgrade and 58% in Podgorica had been 
arrested by police in the past 12 months [42]. Qualitative studies in Russia, as 
elsewhere, link police arrest and police violence to reduced capacity for risk 
reduction as well as increased risk behavior [43–45].
No reports on the prevalence of arrests among PWID in the West were identi-
fied although between 11% and 70% of PWID reported having spent time in 
prison. Elevated risk of injecting-related harm while in prison is well docu-
mented; between 1% and 56% of prisoners report ever injecting while in prison 
[46]. In Estonia, between 58% and 66% of PWID have been in prison at least 
once. Even among new injectors with less than three years of injecting between 
32% and 40% have been incarcerated [47]. Reports of arrest or imprisonment, 
although varied, were consistently high across the region: in Georgia between 6% 
and 21% of PWID were arrested and in Russia the number was between 6% and 
37%. The number of PWID imprisoned in 2007 ranged from 50% in Belgrade to 
over 70% in Lithuania, 43% in Podgorica, and 18% in Sofia [42, 48, 49].
Some studies showed increased vulnerability associated with prison: in 
Finland 84% of HIV-positive PWID and 67% of HIV-negative PWID had been 
in prison [50]; in Spain, experience of prison was associated with increased risk 
of recent injection of heroin (past 12 months) compared to only using cocaine 
among a sample of injectors and noninjectors [20]. In Russia in 2003 a study 
suggested male PWID were almost three times more likely to report ever having 
been in prison than female PWID [44].
HCV Infection
While the main focus of the review is HIV vulnerability, PWID in Europe are 
also vulnerable to hepatitis C virus (HCV) [51]. Reviewed studies show HCV 
prevalence estimates between 52% and 94% among PWID in the West, 37% and 
74% in Central Europe, and between 54% and 96% in the East. There is generally 
a high prevalence of HCV co-infection among HIV-positive PWID [52, 53].
Injecting Drug Use Practices
Duration of Injecting
The duration of injecting careers varies across the region, and also at country 
level, but evidence suggests that PWID in the West have been injecting on aver-
age for over 10 years and in the East for between 2 and 8 years. In Central 
Europe, the duration of injecting varied from 5 to 10 years [42, 54, 55]. A review 
of hospital records in Israel reported a mean duration of injecting of less than a 
year among Israeli PWID [56]. Generally studies suggest that on average female 
PWID had been injecting for a shorter time than their male counterparts, 
although one study from St. Petersburg reported both males and females having 
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mean injecting careers of five years [18]. A study from Estonia highlighted 
 differences in injecting careers between stimulant and opiate users, with 16% of 
amphetamine users injecting for less than two years and 33% injecting for more 
than five years, compared with only 3% of fentanyl users injecting for less than 
two years and 68% injecting for more than five years [21]. A study in the United 
Kingdom found that PWID who reported getting most of their injecting equip-
ment through secondary distribution had shorter injecting careers (median 
6.4 years) than PWID who got most of their equipment from pharmacies 
(median 9.2 years) or low-threshold services (median 9.0 years) [57].
Drugs Injected
Historically, heroin has been the main drug injected in the West and South of 
Europe, with amphetamines being more common in northern countries, and 
home-produced opiates and/or misuse of medicines in Central Europe and the 
East. Since the late 1990s, there has been an increase in heroin or opiate use in 
Central Europe and the East, as well as increases in cocaine use as the predomi-
nant stimulant in South and Western Europe, compared to amphetamines in the 
North, Central Europe and the East [58]. Case study 3.1 considers how stimu-
lant use and effects may link with HIV risk and transmission.
Heroin is noted as the drug of choice among injectors in Europe, although 
there are subregional differences, and the use of more than one drug (poly-drug) 
is common (table 3.2). Poly-drug use can be associated with increased harm to 
health through interactions between drugs, psychoactive substances increasing 
risk behaviors, and reduced cognition that can lead to injury [59]. Cocaine use is 
also associated with cardiovascular problems [60]. In the West, poly-drug use was 
reported by 83.5% of PWID in Italy in 2005 [61] and 55% in Sweden in 
2002–03 [62]. Speedball (a mix of cocaine and heroin) emerged as a key trend 
and is reported for instance among 52% of PWID in the Netherlands [63], 
43%–68% in Spain [20, 64], and 84.2% in Luxembourg [65]. There is an 
 emerging culture of crack-based speedball injection that appears almost unique 
to the United Kingdom [66], though a minority of PWID in France also report 
crack use [17]. Recent evidence in Finland suggests that there is increased 
buprenorphine use and injection among those with a history of buprenorphine 
treatment; one report estimates that PWID attending syringe exchanges used 
buprenorphine most frequently (73%), amphetamines (24%) and other opioids 
(2%) [67]. Another study in Finland shows differences in drug use linked to HIV 
prevalence, with HIV-positive PWID reporting amphetamines as their main drug 
(52%), buprenorphine (11%) and heroin (3%). Among the HIV-negative PWID, 
they reported buprenorphine as their main drug (44%), followed by amphet-
amines (36%), and heroin (16%) [50].
In Belarus, Moldova [68], and Russia, the injection of home-produced opioids 
such as “hanka” or “shirka” (a liquid poppy extract) is reported alongside heroin 
injection, and in Ukraine, this is reported as the primary pattern of injection by 
PWID (between 79% and 94%) [25, 69]. In Estonia, and initially following a 
heroin shortage, the use of the synthetic opiate, fentanyl (China White), has 
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become common (among 61% to 74% of respondents in Tallinn and Kohtla-
Jarvë), along with amphetamine injection [70, 71]. Anecdotal reports in Russia 
also suggest recent shifts away from heroin injection toward the injection of 
liquid opioid solutions derived from pharmaceutical medicines [72]. Sentinel 
surveillance in Central Asia shows that heroin is injected by over 90% of PWID 
in Kazakhstan, the Kyrgyz Republic, and Tajikistan [15].
case study 3.1 stimulant injection and Hiv risk in europe
The term “stimulants” includes both amphetamines and cocaine (including crack). While there 
is little evidence of physical dependence on amphetamines, unlike opiates there is no 
pharmacological substitute that can be used for treatment purposes; once a tolerance is 
developed withdrawal may be uncomfortable and linked to depression [82]. Cocaine injection 
is associated with more frequent and uncontrolled injection due to the shorter half-life of the 
drug, which can lead to more injection and dosage-related harms [83]. Although there is 
limited data on harms associated with injecting amphetamine-group substances, there is 
some evidence of high dependency, increased frequency of injecting, and among men who 
have sex with men (MSM) in particular, increased sexual risk behaviors [77].
The type of drug injected may be associated with HIV as well as distinct behavioral risks 
[84]. Among drug users followed for a year in St. Petersburg, frequent stimulant use was the 
primary factor linked to HIV seroconversion [85]. The majority of stimulant users were also 
users of heroin and opiates, but those using stimulants three or more times a week were eight 
times more likely HIV seroconvert (HR 8.1, CI 2.4–27.3). Having three or more sexual partners 
was also linked to HIV seroconversion (HR 2.6, CI 0.9–7.8).
Studies in Ukraine also associate rising levels of HIV prevalence with the injection of 
amphetamine-group substances [74, 77]. A comparison of stimulant injectors with opiate 
injectors found that stimulant users had shorter injection careers, were younger, and engaged 
in higher levels of drug and sexual risk behavior [86]. PWID in Ukraine link the cheaper price 
and availability of stimulants as factors shaping the growing popularity of stimulants relative 
to opioids [74, 87].
Studies outside Europe have also reported stimulant use as a correlate for HIV risk and 
seroconversion [85, 88, 89], though there are exceptions, and in Estonia, amphetamine users 
were less likely to have ever shared a needle than fentanyl users (24% as opposed to 34%) [21].
table 3.2 injecting practices in case study countries
Mean career duration Main drugs injected
Percentage reporting 
daily injecting (%)
Estonia 7.9 years Fentanyl, mak, heroin, 
amphetamines
61
Russian Federation 5.5–7.2 years Heroin 15–92
Tajikistan 4.6–11.6 years Heroin 39
Source: PWID publications as per tables C.4–C.6.
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There are few reports of cocaine use in the East, but injection of methamphet-
amine is more common. The injection of home-produced liquid forms of meth-
amphetamine (vint) or methcathinone (jeff or boltushka) derived from 
ephedrine or pseudoephedrine, are also reported in parts of Ukraine and Russia 
[73]. Some studies in Ukraine link home-produced cathinone-based injection 
(naturally occurring amphetamine contained in Khat, a flowering plant) with 
legal restrictions on the sale of ephedrine-based medications [74]. In Central 
Europe, heroin is reported as the main drug injected by PWID (between 48% 
and 97%), followed by amphetamines (between 30% and 50%) [55, 75, 76]. 
In the Czech Republic, for instance, the injection of crystal methamphetamine 
(pervitin or piko) is common [58]. The Czech Republic also has the highest 
prevalence of methamphetamine use in Europe [73, 77, 78]. Around 30% of 
PWID in Central Europe report poly-drug use [79].
Home-produced drugs have been linked with increased health harms 
 including the inclusion of variable quantities of unregulated ingredients; the use 
of human blood in the preparation in some areas; and the communal aspect of 
preparing and using the drugs, such as injecting from a common container or 
with common needles [74, 80, 81].
Frequency of Injection
The frequency of injection varies widely throughout and within countries. 
Frequency of injecting will depend on multiple factors including availability and 
quality of drugs, what drugs are injected, and stage of injecting career. Data from 
the review suggested that daily injecting was more common among female 
PWID involved in sex work compared to those who were not sex workers (SWs) 
and male PWID [90]. Studies in Hungary and Estonia report more frequent daily 
injecting among heroin or opioid users than amphetamine users [21, 79].
Risk Practices
Data on risk practices concerning needle sharing, unprotected sex, and sex work 
are summarized in table 3.3 for three case-study countries.
Needle/Syringe Sharing
In the West between 5% and 32% of PWID report sharing needles/syringes in the 
past four weeks (tables C.4–C.6). Frequency of needle sharing in the East is more 
varied, ranging between 2% and 79% [48, 85] and in Russia alone between 
8% and 79% [85, 91]. The estimate of 2% from Vilnius, Lithuania, refers to 
receptive sharing in the past four weeks [48], and most estimates range between 
20% and 30%, with one study estimating sharing (receptive or distributive) in 
the past 30 days at 98% [92]. Among the Russian studies, frequency of sharing 
increased with age: the lowest reported frequency was from a study restricted to 
recent initiates (injecting for less than 3 years) [91], who were over 5 years 
younger on average than those reporting the highest frequency of needle sharing 
[85] (19.6 years versus 24.3 years). Excluding these extreme results, the majority 
of studies from Russia reported rates ranging from 12% [93] and over 50% [18]. 
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In Tajikistan, 65% of PWID reported injecting with a previously used needle/
syringe in the past six months [41]. Data from Uzbekistan and Tajikistan suggest 
that while only 10% of young PWID shared a needle/syringe at their last injec-
tion, sharing paraphernalia is considered a social norm [94]. In Central Europe, 
between 15% and 67% of PWID reported sharing a needle or syringe when they 
injected in the previous four weeks (tables C.4–C.6).
Unprotected Sex
Reported rates of risky sexual practices (generally measured by reported unpro-
tected vaginal or anal sex) were generally much higher among PWID in the 
region than unsafe injecting practices. However, PWID throughout Europe were 
consistently more likely to use a condom with their casual partners than with 
regular ones. In the West rates of inconsistent condom use were between 72% 
and 83% with regular partners, and between 28% and 44% with casual partners 
(tables C.7–C.9). In the East, rates varied, with between 28% and 94% reporting 
inconsistent condom use with regular partners and 2% and 87% with casual 
partners. In Central Europe, a study from Sofia, Bulgaria, showed that males 
reported less inconsistent condom use than females: 72% compared with 90% 
with regular partners and 44% compared with 61% with casual partners [49]. 
Conversely in Tashkent, Uzbekistan, 90% of males and 82% of females reported 
inconsistent condom use with their regular partners, and 80% of males and 60% 
of females reported it with their casual partner(s) [94, 95].
Sex Work
In the West between 15% and 20% of PWID had exchanged sex either for 
money or drugs, although no studies differentiated between males and females 
(tables C.7–C.9). Studies in the East suggest that proportionally more female 
PWID exchange sex than their male counterparts. In Tallinn, 6% of men reported 
receiving money for sex compared with 72% of women [96]. Additionally, this 
study reported that 34% of the males had paid for sex themselves. Studies from 
Russia show that between 25% and 32% of female PWID in St. Petersburg and 
between 1% and 5% of men reported selling sex in the last 6 months [18, 12, 
90]. In Togliatti, 50% had ever exchanged sex for money, drugs, or goods and 43% 
had done so in the last month [85]. Elsewhere in the region, reported rates of sex 
work were generally much lower; for instance, in Uzbekistan only 3% of 
table 3.3 risk practices in case study countries
Percent
Sharing needles in 
past four weeks
Reporting unprotected 
sex with casual partner Sex work
Estonia 18–32 26–58 (new injectors ≤3 
years; 28 days)
2–17
Russian Federation 8–79 34 (6 months) Females: 24–32; males: <1–5
Tajikistan 37 last injection 55–100 Females 31; males 13
Source: Tables C.4–C.9.
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respondents reported having exchanged sex for drugs, and in Ukraine, 5% 
reported having paid for sex and 3% reported having sold sex in the past three 
months [26, 95]. In Central Europe rates varied from as low as 0.2% in the 
Czech Republic in 1999–2000 [97] to 10% in Belgrade in 2005 [42].
HIV Prevalence
A total of 91 sources identified by our systematic review (see chapter 1) reported 
unique, primary HIV-prevalence estimates among PWID in Europe; 24 from 
Western Europe [17, 20, 22–24, 56, 61, 63, 64, 98–113], 44 from Eastern Europe 
and Central Asia [7–12, 15, 25–27, 41, 48, 69, 70, 85, 91, 93, 96, 114–140], 
21 from Central Europe [42, 49, 76, 79, 97, 141–156], one that included data 
from Central and Eastern Europe [92], and the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA), Statistical Bulletin 2011, which pro-
vided estimates for many countries across the region [46].
The review generated many and diverse prevalence estimates, with large varia-
tions seen across the subregions, countries, and even cities. However, a discernible 
trend emerged with low to medium prevalence in the Central region, high to very 
high prevalence in the East, and prevalence evenly spread between low, medium, 
and high in the West (tables C.1–C.3). It is important to note that, based on the 
available estimates, some countries fall within multiple categories (in the case of 
Spain, all four), and this may be due to city or area variations or to differing study 
methodologies. In order to better compare prevalence estimates across the region, 
we selected the best national level prevalence estimates. Map 3.1, figures 3.1–3.3 
and table 3.4 show the best estimates of HIV prevalence among PWID in Europe.
map 3.1 Best estimates of Hiv prevalence among pWiD across europe
Source: Data from reports, as shown in tables C.1–C.3.
Note: HIV = human immunodeficiency virus; PWID = people who inject drugs.
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Eastern Europe
HIV prevalence among PWID is highest in the East, only Georgia, Kazakhstan, 
and Lithuania can claim to have medium-level epidemics, according to the stud-
ies examined here (figure 3.1). The remaining 11 countries with data are catego-
rized as high-level epidemics (no data exists for Turkmenistan); of these, 4 have 
prevalence estimates of over 20% and Estonia has a prevalence of over 50%.
Central Europe
Central Europe appears to have the lowest level of epidemics among PWID 
within the region. Only Poland and Bulgaria appear to have high-level epidemics, 
and neither of these exceeds 10% prevalence (figure 3.2). Several countries 
(Albania, Croatia, Cyprus, Hungary, the former Yugoslav Republic of Macedonia, 
and Slovenia) report 0% HIV prevalence among PWID. However, this is the region 
with the fewest studies, and in general smaller sample sizes, so the estimates gener-
ated are less reliable than the best estimates generated in the East or the West.
Western Europe
There is greater diversity in HIV prevalence in the West than in the East or 
Central Europe. Only Spain is identified here (by the study with the widest cov-
erage) as having a very high epidemic among PWID, although other city-specific 
Figure 3.1 Best estimates of Hiv prevalence among pWiD in eastern europe
Source: Table C.3.
Note: HIV = human immunodeficiency virus; PWID = people who inject drugs.
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studies yield a range that includes far lower estimates (figure 3.3). City-level 
estimates from Spain range from as low as 7% among female PWID in Valencia 
[105] to 58% among male and female PWID in Barcelona [104]. The majority 
of the remaining countries have either low- or medium-level epidemics among 
PWID, although Ireland and Italy still appear to have prevalence levels of over 
10%. Although there is no estimate of HIV among PWID in the Netherlands 
recent enough to be included in this review, data from 2003 indicate that preva-
lence in Rotterdam was 9.5% among PWID recruited from the street and drug 
treatment centers [157].
Factors Linked to HIV
Because of low prevalence estimates, no studies examined risk factors linked to 
HIV in Central Europe, and so we summarize the findings of the 22 multivariate 
HIV-risk factor analyses identified by our review in the West and the East 
(see also tables C.10 and C.11).
The review identified 15 papers presenting multivariate analyses of factors 
associated with HIV in the East [25, 26, 41, 70, 85, 90, 93, 121, 134, 137, 138, 
161–164], although two [41, 162] present new analyses of data already published 
in other papers and also presented here [90, 163]. The review identified seven 
Figure 3.2 Best estimates of Hiv prevalence among pWiD in central europe
Source: Table C.2.
Note: HIV = human immunodeficiency virus; PWID = people who inject drugs.
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papers presenting multivariate analyses of factors associated with HIV preva-
lence [22, 61, 99, 102, 103, 105] in the West, although two described different 
analyses of the same data set [102, 103], and one paper presented multivariate 
analyses of HIV incidence [63].
Synthesizing the Associations
The forest plots summarized in figures 3.4 and 3.5 summarize the effects of 
individual and structural risk factors on HIV identified through the multivariate 
studies. Although studies measure similar risk factors, it is important to note that 
Figure 3.3 Best estimates of Hiv prevalence among pWiD in Western europe
Source: Table C.1.
Note: HIV = human immunodeficiency virus; PWID = people who inject drugs.
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table 3.4 Hiv epidemics in case study countries
Total population, 
2006 (thousands) 
[158]
PWID adult 
prevalence (%) 
[89]
Best estimate of 
PWID HIV 
prevalence (%)
PWID HIV-
prevalence 
estimates range 
(%) (see table C.3)
HIV case reports 
(2010) attributed to 
PWID per million 
people [159, 160]
Estonia 1,341 1.5 53.5 27–90 46
Russian Federation 141,394 1.8 28.9 9–61 109
Tajikistan 6,836 0.6 17.3 12.1–17.3 77
Source: Table C.3.
Note: HIV = human immunodeficiency virus; PWID = people who inject drugs.
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each may have carried out analyses differently and may have adjusted for differ-
ent confounding variables. Full details of the studies and factors presented can be 
found in tables C.10 and C.11.
Figure 3.4 summarizes individual-level risk factors. Many studies investigated 
the link between HIV and injecting with a used needle, or sharing a needle, 
Figure 3.4 Adjusted effect estimates of individual-level risk Factors among pWiD
Source: Tables C.10 and C.11.
Note: Mak is the liquid derivative of opium poppy straw, and Vint is a liquid methamphetamine. See original papers for full details of models. 
CI = confidence interval; ES = estimate; HCV = hepatitis C virus; HCV+ = HCV-positive; HIV = human immunodeficiency virus; HIV+ = HIV-positive; 
PWID = people who inject drugs; ref. = reference.
* = new people who inject drugs (PWID) (≤3 years); ** = male people who inject drugs (PWID); †=female (non-sex workers [non-SWs]) PWID; 
‡ = female sex workers (FSWs) PWID.
Injecting frequency
Daily
Daily
Daily
Daily
Daily
Daily
Daily
Daily (ethnic Tajik)
Daily (opiates)
Daily*
Needle or syringe sharing
Ever shared
Ever shared
Ever shared
Ever shared
Injected with used needle in past 4 weeks‡
Injected with used needle in past 4 weeks
Injected with used needle in past 4 weeks
Injected with used needle in past 4 weeks
Injected with used needle in past 4 weeks**
Injected with used needle in past 4 weeks**
Injected with used needle in past 4 weeks†
Injected with used needle in past 6 months
Injected with used needle of a sex partner in past 4 weeks
Injected with used needle of a sex partner in past 4 weeks
Shared in past 4 weeks
Shared in past 4 weeks
Needle or syringe sharing with known risk
Injected with used needle from known HIV+ person‡
Injected with used needle from known HIV+ person**
Injected with used needle from known HIV+ person†
Injected with used needle with known HCV+ person‡
Injected with used needle with known HCV+  person**
Injected with used needle with known HCV+ person†
Shared with HIV+ person in past year
Primary drug injected in past 4 weeks
Heroin (ref. Mak/Vint)
Heroin (ref. Mak/Vint)
Opioid (ref. amphetamine)
Opioid (ref. amphetamine)
Number of sex partners
Higher number of sex partners in past 6 months
Higher number of sex partners in past year
Higher number of sex partners in past year
Higher number of sex partners in past year
Higher number of sex partners in past year
Higher number of sexual partners in past month
Risk factor
0.60 (0.19, 1.60)
6.90 (1.91, 25.08)
0.80 (0.32, 1.86)
1.16 (0.83, 1.62)
1.49 (1.03, 2.17)
1.10 (0.70, 2.00)
0.87 (0.72, 1.05)
2.16 (1.00, 4.66)
2.20 (1.05, 4.46)
0.90 (0.45, 1.95)
3.40 (2.20, 5.30)
3.50 (1.40, 8.40)
0.50 (0.10, 1.94)
1.00 (0.57, 1.57)
1.70 (0.32, 8.57)
0.50 (0.18, 1.50)
0.30 (0.02, 3.21)
0.90 (0.61, 1.37)
0.80 (0.41, 1.69)
0.80 (0.35, 1.85)
4.10 (1.01, 16.60)
2.51 (1.86, 3.37)
9.60 (2.00, 47.00)
2.40 (1.40, 4.30)
1.10 (0.60, 2.00)
1.54 (1.00, 2.36)
0.10 (0.01, 1.35)
0.60 (0.14, 2.13)
2.30 (0.17, 30.60)
2.60 (0.42, 16.30)
2.90 (1.45, 5.85)
1.20 (0.28, 4.85)
3.40 (1.24, 9.30)
1.00 (0.56, 1.78)
1.00 (0.39, 2.38)
3.30 (1.70, 6.40)
4.43 (2.74, 7.18)
2.66 (0.91, 7.79)
1.20 (0.56, 2.39)
1.40 (0.38, 5.03)
0.71 (0.36, 1.49)
1.50 (0.90, 2.60)
1.05 (0.76, 1.46)
ES (95% CI)
Moscow
Volgograd
Barnaul
Tashkent
3 cities
Tallinn
16 cities
Dushanbe
Vinnitsya
Togliatti
3 cities
Moscow
Volgograd
Barnaul
Togliatti
Moscow
Volgograd
Barnaul
Togliatti
Togliatti
Togliatti
Tallinn
Volgograd
Tallinn
Tallinn
St. Petersburg
Togliatti
Togliatti
Togliatti
Togliatti
Togliatti
Togliatti
Vinnitsya
Barnaul
Moscow
Tallinn
Tallinn
St. Petersburg
Moscow
Volgograd
Barnaul
Tallinn
Tashkent
City
Russian Federation
Russian Federation
Russian Federation
Uzbekistan
Ukraine
Estonia
Ukraine
Tajikistan
Ukraine
Russian Federation
Spain
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Estonia
Russian Federation
Estonia
Estonia
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Ukraine
Russian Federation
Russian Federation
Estonia
Estonia
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Estonia
Uzbekistan
Country
93
93
93
138
134
161
26
163
25
162
102
93
93
93
90
93
93
93
90
162
90
121
93
161
161
164
90
90
90
90
90
90
25
93
93
161
121
85
93
93
93
161
138
Reference
Increased association with HIV10.1 0.5 5 10 25 50Reduced association with HIV
74 Epidemiology of HIV in Key Populations at High Risk
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8
Figure 3.5 Adjusted effect estimates of social-structural risk Factors among pWiD
Note: See original papers for full details of models. CI = confidence interval; ES = estimate; HIV = human immunodeficiency virus; 
PWID = people who inject drugs; vs. = versus.
* = new people who inject drugs (PWID) (≤3 years); ** = male people who inject drugs (PWID); † = female (non-sex workers [non-SWs]) PWID; 
‡ = female sex workers (FSWs) PWID; †† = sample does not include 100% of injectors.
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not always specifying whether this was done distributively or receptively. The 
majority of studies suggest increased HIV risk associated with sharing needle/
syringes, though most results are inconclusive. Injecting with the used needle of 
a sex partner was found in Volgograd [93] and Tallinn [161] to clearly increase 
an individual’s odds of contracting HIV. More definitively, injecting with a needle 
previously used by someone known to have HIV or HVC is shown in most 
 studies to be clearly positively correlated with contracting HIV [25, 90], Daily 
injecting is also found to be linked to increased risk of HIV. For instance, another 
study in Volgograd [93], found that daily injectors have seven times the odds of 
contracting HIV than those who inject less frequently (95% CI 1.9–25.1). Many 
reviewed studies also associate longer injecting careers with greater odds of 
 contracting HIV, a risk that increases with each additional year of injecting (data 
not shown) [90]. This is usually explained as a function of increased risk- 
exposure time.
Studies in Estonia found that primary injectors of an opiate (such as fentanyl) 
had between 3 and 4.5 times greater odds of contracting an HIV infection than 
individuals who primarily inject amphetamines [161, 165]. A study in Ukraine 
(Kiev, Makeevka/Donetsk, and Odessa) identified injecting a sedative/opiate mix 
in the past 30 days (adjusted odds ration [AOR] 1.63, 95% CI 1.13–2.35) as 
associated with HIV [134]. However, a study in Russia found no difference in an 
individual’s odds of  contracting HIV based on the primary drug they inject [93]. 
An analysis of a St. Petersburg cohort examining multivariate associations with 
HIV incidence found that frequency of injecting psychostimulants was the only 
risk factor significantly associated with HIV (reference group: none, one to two 
times adjusted hazard ratio 1.98, 95% CI 0.7–5.57; three or more times adjusted 
hazard ratio 8.15, 95% CI 2.43–27.34) following adjustment for number of sex 
partners and sex work in the past six months [85].
In relation to HIV and sexual risk, most multivariate analyses examined the 
effect of exchanging sex for drugs or money, the number of sexual partners, and 
unprotected vaginal or anal sex, as risk factors. Although several strong univariate 
associations were found, these tended not to hold in the multivariate models 
once adjustments were made for confounding. This could be because sample 
sizes were insufficient or because much sexual behavior risk is determined by 
other factors such as gender, socioeconomic status, or injecting behavior.
Figure 3.5 summarizes the social structural-level risk factors. Although most 
studies presented adjusted odds ratios identifying female gender as a risk factor 
for HIV, the results are generally inconclusive with confidence intervals (CIs) 
that straddle one. This association is likely to have indirect, rather than biological, 
causative roots through pathways involving multiple linked socioeconomic dif-
ferences related to gender. Qualitative data from Ukraine report that female 
PWID are at risk of psychological, physical (including sexual), and economic 
violence from their partners. It is harder for them to negotiate safer sex or safer 
injecting practices or to access services, which elevates risk of HIV [166]. 
A global review on the lives of female PWID supports this research and 
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promotes harm minimization measures and drug treatment for women including 
psychological services to deal with violence, while programs for men should 
include services around anger management, domestic abuse counseling, and part-
ner support programs [167].
Multiple studies link HIV to the socioeconomic status of PWID, though eco-
nomic status is defined through different measures, including level of education, 
employment (regular or not), and income (regular or not, legal or not). Of these 
measures only an individual’s employment status showed a consistent association 
with HIV, with unemployed individuals or those having a main source of income 
other than legitimate work, showing greater odds of HIV than others [22, 26, 61, 
121, 138, 164]. The effects of not having a regular source of income on the odds 
of being HIV-infected are unclear, appearing to have no association, or possibly a 
negative one. The lack of association with income may be an anomaly or unique 
to these settings, though it is important to note that the ways in which HIV links 
to wealth and poverty is shaped by social context, and in some settings—arguably 
in these cases—drug injecting has been diffused among those populations whose 
economic status may be more generally comparable to the wider local popula-
tion [93]. An Estonian multilevel study included neighborhood-level data in its 
analyses and found that neighborhood-level effects of unemployment (10% 
increment in unemployment AOR 5.95, 95% CI 2.47–14.31) and habitat change 
since 1989 (10% change AOR 1.89, 95% CI 1.09–3.26), were both associated 
with HIV prevalence (results not presented) [121].
Several studies have examined contact with law enforcement agencies as a 
structural factor linked with the odds of being HIV infected, although the 
results shown have large CIs and are inconclusive. The strongest individual 
association between history of incarceration and HIV is seen in a study from 
Spain [102], with weaker results from Moscow, Russia [93]. Few studies exam-
ined the effect of arrest; however, evidence from qualitative research in the 
region supports relationships between policing practices, including extrajudi-
cial ones such as police violence and increased vulnerability to HIV, and 
through reduced capacity for risk avoidance as a consequence of safety short-
cuts and rushed injections borne out of a fear of detection or arrest [39, 43, 44, 
168, 169].
The association between some structural risk factors including ethnicity and 
HIV were found to be context specific. A study in Tajikistan found that respon-
dents identifying as Tajik (AOR 7.06, p<0.001) or other ethnicity (AOR 6.05, 
p<0.001) as opposed to Russian were at higher risk of testing HIV positive, 
once data were adjusted for other factors including gender [41]. A study in 
Uzbekistan similarly found respondents of Uzbek ethnicity to have higher odds 
of HIV than their Russian counterparts (AOR 1.20, 95% CI 0.80–1.80) [138]; 
however, a study in Estonia found that ethnic Estonians had a reduced odds of 
HIV compared with those of Russian or other backgrounds (AOR 0.63, 95% 
CI 0.28–1.25) [71]. An association between HIV among PWID who also 
belong to an ethnic minority that cannot otherwise be explained by needle/
syringe sharing has been noted elsewhere, and linked to material as well as 
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other social inequalities, including access to support services [170, 171]. A sub-
sequent analysis identified ever having experienced drug treatment as a risk 
factor for HIV among the ethnic Tajik subset of this study (AOR 2.75, 95% CI 
1.22–6.22) [163].
This association could be interpreted in a number of ways, including patients 
sharing contaminated needles for covert injecting while in treatment, or possibly 
medical staff using contaminated equipment themselves [172]. In parts of 
Eastern Europe where PWID are often required to register as such to obtain drug 
treatment or are forced to register through contact with police, this can lead to 
increased social marginalization as well as reducing their ability to gain employ-
ment or even to drive a car [173]. In Moscow and Tallinn ever having registered 
as a PWID for drug treatment was found to be associated with more than double 
the odds of HIV (AOR 2.4, 95% CI 1.3–4.7; AOR 2.4, 95% CI 1.5–3.8 [161]) 
[93]. Conversely, a study in Togliatti in Russia conducted among 96 new (<three 
years) injectors found that having been in drug treatment in the past was nega-
tively associated with risk of HIV (AOR 0.4, 95% CI 0.1–1.0 [91]).
Risk Associated with HCV
Evidence from Ireland, Russia, and Serbia suggests that the odds of being HCV-
positive increase with age or duration of injecting career [42, 101, 174]. Other 
individual risk factors for HCV positivity include daily or frequent injection [41, 
169], and sharing injecting equipment [10, 25, 41, 52, 169]. Structural factors 
have also found to be associated with risk of HCV. Experience of imprisonment 
or contact with criminal justice agencies emerges as a risk factor for HCV posi-
tivity in some settings. In Georgia, and Serbia, increased risk of HCV was associ-
ated with ever having been in prison [8, 42]; in Montenegro, this risk was 
associated with having been detained by police in the last year [42], and in 
Tajikistan with ever having been arrested [41]. Risk of HCV was also higher 
among female PWID [41, 169].
Concluding Comment
The systematic review of epidemiological literature among PWID finds that HIV 
prevalence varied widely in Europe, with generally low or medium (<5%) preva-
lence in the West and Central Europe and high (>10%) prevalence in the East, 
especially in Estonia, Moldova, Russia, and Ukraine. We found evidence for a 
number of structural factors associated with HIV, including  gender, contact with 
criminal justice systems, and socioeconomic position.
sex Workers
In many parts of the world, HIV prevalence has been documented to be 
higher among SWs than non-sex working populations. This pattern also occurs 
among male and transgender SWs. Women account for an increasingly dispro-
portionate number of HIV infections globally [1]. Of particular concern are 
dramatic increases in HIV among young women, who now make up over 60% 
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of 15- to 24-year-olds living with HIV. Globally, young women are 1.6 times 
more likely to be living with HIV than young men. In Europe the majority of 
people living with HIV (PLHIV) are men, but this pattern is changing with 
an increasing number of cases among women, mostly in the East [1]. Factors 
known to increase SWs’ vulnerabilities to HIV infection are a lack of protec-
tive policies and legislation, limited information, and lack of access to services, 
as well as lifestyle factors [2]. With this mind, we examine here the extent and 
risk of HIV among SWs across Europe within a broader sexual health frame-
work that encompasses vulnerability as it also relates to stigma, mental health, 
sexual health, violence and drug use.
Demographic Characteristics
The European Network for HIV/STI Prevention and Health Promotion among 
Migrant Sex Workers (TAMPEP) estimates that 87% of SWs in the European 
Union (EU) member states are women, 7% are male, and 6% are transgender. 
The distribution of sex work in this part of the region varies: Austria, Denmark, 
Estonia, Finland, and Lithuania report almost exclusively female sex workers 
(FSWs); while countries in the West, such as Belgium, France, Greece, Italy, and 
Luxembourg, report more transgender sex workers [3].
Across the region women working in the sex industry are predominantly 
between 20- and 30-years-old. The range of midpoint ages was wider in the West 
than in Central Europe and the East, suggesting a slightly younger population in 
those regions. The mean or median age of SWs in studies in Catalonia [8], Israel 
[9–10], London [4–6], and Milan [7], range between 20 and 30 years. Data from 
the East suggest that street-based FSWs are younger with a midpoint age ranging 
between 21 and 27 years [11–15]. The only exception was Armenia where the 
population was older at 33.7 years. In Central Europe, the average age of SWs 
ranges between 22 and 28 years [16–18]. There is some evidence to suggest that 
age varies among subpopulations of SWs. In the Netherlands, nondrug-using 
FSWs and transgender SWs were younger than their drug-using counterparts 
(median age = 30 versus 37 years) [19]. In Athens and London migrant women 
from Eastern Europe and the former Soviet Union were younger than their Greek 
or United Kingdom-born counterparts [4, 20]. However, migrant street SWs in 
Barcelona were older than nonmigrants with a median age of 38.5 years [21]. For 
male sex workers (MSWs), midpoint ages ranged between 22 and 30 years. All 
demographic and risk behaviors are summarized in tables C.19 and C.20.
Risk Profile
Drug Use
Evidence shows that drug misuse and particularly injecting drug use occurs more 
frequently among street-working women than off-street SWs across the region, 
with managers of off-street establishments less tolerant of drug use [6, 22–26] 
(case study 3.2).
Studies in Western Europe suggested a decline in injecting among street-
working women with the increasing number of migrant women in the sex 
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industry [7, 21, 27–29]. Some drug use is reported among migrant SWs: in 
the Netherlands, 18% of FSWs, including some migrant women, working in a 
range of street and off-street locations reported using drugs in the last six months 
and had a history of injecting [19]. In London, some injecting drug use was 
reported among off-street SWs including migrants (between 4% and 11% had 
case study 3.2 sex Work and Drug Use
In the United Kingdom, SWs who misuse drugs are at increased risk of violence, unsafe sexual 
practices, pregnancy terminations, and problems with the police [38, 39]. In terms of broader 
sexual health indicators, international evidence shows drug dependence as the key factor 
influencing street-SWs’ decisions to continue selling sex during pregnancy and postnatally 
[40], as well as adverse health outcomes on pregnancy and the fetus [41].
Data from five cross-sectional studies of SWs and PWID in three Russian cities (Barnaul, 
Moscow, and Volgograd) collected during 2003 and 2004 (n = 280) indicated that SWs who 
inject drugs may lead a more “chaotic” or “transitional” lifestyle: they are younger, less likely to 
have completed secondary education, and more likely to live in temporary accommodations. 
They engaged in higher levels of sexual risk. They report having fewer clients for vaginal or 
anal sex per month but are less likely to use condoms consistently with clients. They report 
significantly more nonpaying casual sex partners in the last year and more nonpaying sex 
partners who also inject drugs, suggestive of sex being exchanged for drugs or as a means to 
obtain drugs and not simply for economic gain, arguably pointing to a less professional 
approach to sex work.
comparison of Demographic characteristics and sexual risk Behaviors between iDU and 
non-iDU sWs in the russian Federation
Characteristic
Sex workers
Non injecting drug users Injecting drug users
p valuen % or mean (SD) n % or mean (SD)
Total 89/280 31.8 191/280 68.2
Completed secondary 
education 31/81 38 41/189 22 <0.01
Live in temporary 
accommodations 6/89 7 57/191 30 <0.001
Inconsistent use of condoms 
with clients in last month 16/82 20 28/76 38 0.02
Age (years) — 24.2 (6.3) — 22.7 (4.6) 0.03
Number of clients per month — 65.6 (70.2) — 45.0 (47.8) 0.01
Number of nonpaying sex 
partners per year — 4.6 (16.2) — 7.9 (16.5) 0.12
Number of casual sex partners 
in last year — 0.5 (1.1) — 3.0 (7.8) <0.01
Number of IDU sex partners in 
the last year — 0.2 (0.7) — 2.1 (5.8) <0.01
Note: IDU = injecting drug user; n = sample size; % = percentage; p = probability value; SD = standard deviation; 
SW = sex worker; — = not available.
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ever injected) but little current injecting was reported (1%) [4, 30]. Limited data 
were available on drug use among SWs in Central Europe. One study specifically 
targeting young 15- to 24-year-olds suggested a highly vulnerable population; 
almost one-quarter of the sample had ever injected [31], and another study in 
the Czech Republic suggested that 10% of FSWs and 38% of MSWs had a 
 history of injecting drug use [18]. Studies of street FSWs in Eastern Europe sug-
gest a closer link between sex work and injecting drug use, but levels of injecting 
vary at a city level. A high prevalence is reported in Vinnitsa in Ukraine (71%) 
[32] and 97% in St. Petersburg [33], while prevalence is lower in Samara and 
Saratov (between 7% and 14%) [34] and around 6% in Estonia and Georgia [35, 
36]. Overall an average of 15% of FSWs had injected in the last 30 days across 
multiple cities in Ukraine [24]. Studies of PWID, particularly in Russia, show 
consistently high levels of sex work among female PWID ranging between 24% 
and 50% [13, 14]. Estimates from Central Asian republics suggest that 62% of 
female drug users in the Kyrgyz Republic (n = 73) and 89% in Azerbaijan 
(n = 150) also engage in sex work [37].
Violence
There is a growing body of international evidence demonstrating the association 
between risk of HIV and experience of violence among SWs [42–46]. Experience 
of violence has similarities with HIV in that it is concentrated among marginal-
ized, vulnerable populations [45]. The interplay of violence and HIV among 
SWs has direct pathways, such as forced unprotected sex, as well as indirect 
pathways, such as reducing self-esteem and the ability to negotiate safer practices 
for fear of further violence, increasing drug use, or forced relocation of sex work 
to less familiar or safe areas [46–49].
Data from Europe show that levels of sexual and physical violence among 
SWs were universally high, particularly among minority groups such as Roma 
populations and transvestites [47, 50]. Qualitative data from Western Europe 
suggest that violence among SWs is ubiquitous and compounded by drug use 
and the stigma associated with sex work [25, 26, 51]. Violence was the most 
frequently reported risk associated with work by respondents of the TAMPEP 
study who reported violence from clients, robberies, and verbal abuse from the 
police. In London, one-third of SWs (n = 268) had experienced some form of 
physical or sexual violence from clients in the last 12 months [4].
In Central Europe and the East, higher levels of violence are reported than in 
the West. In Ekaterinburg, Moscow, Samara, and Saratov in Russia between 20% 
and 76% of street SWs reported an incidence of sexual violence in the last 
12 months [11, 15, 52]. In Armenia, 30% of street SWs reported a lifetime expe-
rience of forced sex from clients [53], and 54% had experienced violence from 
clients in Moldova [11]. In Croatia, between 30% and 52% of FSWs reported 
incidents of physical abuse in the last 12 months [54], and in Kosovo 16% of 
street and off-street SWs reported being forced to have sex in the last 12 months 
[17]. Younger SWs may be more vulnerable to violence: in Romania 46% of a 
sample of FSWs (aged 16- to 24-year-olds) had been forced to have sex in the 
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last 12 months [31]. In Moscow, 28% of MSWs had ever experienced violence 
from clients [55]. Qualitative data from Central and Eastern Europe and Central 
Asian republics suggested that physical violence from the police was ubiquitous 
among male and transgender SWs, and in some countries (Bulgaria, the Kyrgyz 
Republic, Lithuania, FYR Macedonia, Russia, and Ukraine) police were cited as 
the main threat to personal safety [56]. Qualitative interviews among female 
Roma and transvestite SWs from Serbia highlight the practice by police of using 
violence and threats of violence to discourage women from engaging in sex work 
and extorting money. This “moral enforcement” forces women to work in unfa-
miliar locations to avoid police harassment as well as working longer hours [50] 
and hurrying to negotiate with a client and thus reducing the time available to 
assess the potential risks [56].
Mental Health and Stigma
Research has shown the link between violence, fear of violence and psychological 
stress associated with sex work [23, 57]. Some research has focused on how the 
stigmatized nature of working in the sex industry affects women’s mental health. 
Evidence shows how stigma can cause women to be socially isolated, prevents 
them talking openly and honestly about their work, and limits the opportunities 
to talk to peers, particularly for street workers and migrant women [26, 58]. Fear 
of exposure as a SW to friends and family and concerns about losing children 
prevents women from talking to authorities and social services, thus limiting 
opportunities for psychological and emotional support [25, 26]. In Central 
Europe and the East, police threaten to expose SWs as a method to exert control 
and extort money [25, 26]. Some studies have found that psychological and 
emotional risks were of greater significance than safety risks as women feel less 
able to control the former [59], and while the risk of violence ends after work, 
the psychological impact continues [60].
Drug-using SWs are doubly stigmatized and any mental health issues may be 
compounded by neglect of basic health needs such as diet and adequate sleep, as 
well as lack of permanent accommodations and increased vulnerability to 
 violence [25, 26]. In some countries of the former Soviet Union, registration as 
a drug user provides sufficient grounds for authorities to remove newborn babies 
and children from female PWID [37]. Qualitative studies in Ireland showed how 
drug use helped women manage the stress associated with sex work, but at the 
same time made them more prone to violence or sexual risk behaviors. These 
studies highlighted the frequency of mental health issues (depression and suicide 
attempts) among street-working women [61, 62]. A study in Switzerland sug-
gested that mental health problems (defined as a range of disorders) were associ-
ated with the working location and migrant status of SWs [63].
HIV Prevalence
HIV prevalence among SWs in Western Europe is generally low, with prevalence 
of 1% or less consistently reported across the subregion [4, 9, 20, 21, 27, 28, 
64–69]. Prevalence was higher among a sample of SWs in Portugal, Spain and the 
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Netherlands (figure 3.6) where higher prevalence of injecting drug use was 
recorded; in Italy and Spain, this prevalence was found among migrant street and 
transgender SWs [19, 65, 70–71].
Prevalence of HIV is low in countries in Central Europe at less than 1% in 
Albania, Bosnia and Herzegovina, Bulgaria, the Czech Republic, Kosovo, 
Romania, and Serbia (figure 3.7) [17, 18, 64, 68, 72–74]. No cases were reported 
in a sample in Hungary [64]. Prevalence was 2% in Croatia and Poland, and 
between 0% and 1.8% in FYR Macedonia, though these studies involved small 
sample sizes [68, 75, 76].
HIV prevalence among SWs in countries in Eastern Europe is consistently 
higher than in the Western region (figure 3.8). HIV prevalence ranged between 
2.5% and 8% in Azerbaijan (Baku) [33, 77], 7.6% in Estonia (Tallinn) [36], and 
4.6% in Moldova (Chisinau) [33]. A lower prevalence of less than 2% was 
reported in Armenia and Georgia [68, 78], and 0% in Belarus and Lithuania [68, 
79]. A higher prevalence of 6.4% was reported in 2009 in Minsk (Belarus), where 
15.5% of the sample reported injecting [80]. In both Russia and Ukraine, preva-
lence varied by city, ranging from 2% to 60% in Russia and between 0% in 
Chernitz, Kharkov, and Uzhgorod, and 42% in Donetsk, Ukraine, (see figure 3.8 
below) suggesting outbreaks remain contained at a city level. In Ukraine, preva-
lence ranged from 13% to 20% [24, 81, 82].
Map 3.2 presents the best estimates of HIV prevalence among FSWs from 
each country. The HIV epidemic among FSWs is characterized as a low-level 
Figure 3.6 Best estimates of Hiv prevalence among FsWs in Western europe
Source: Table C.12.
Note: Some ranges included SWs who inject and transgender people; FSW = female sex worker; 
HIV = human immunodeficiency virus; SW = sex worker.
Austria
Belgium
France
Germany
Greece
Israel
Italy
Netherlands
Norway
Portugal
Spain
Sweden
United Kingdom
0 5 10 15 20 25 30
Prevalence (percentage)
Best estimate Range of estimates
Epidemiology of HIV in Key Populations at High Risk 83
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8 
Figure 3.7 estimates of Hiv prevalence among FsWs in central europe
Source: Table C.13.
Note: Some ranges included SWs who inject. FSW = female sex worker; HIV = human immunodeficiency virus; 
SW = sex worker.
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Figure 3.8 Best estimates of Hiv prevalence among FsWs in eastern europe
Source: Table C.14.
Note: Some ranges included SWs who inject. FSW = female sex worker; HIV = human immunodeficiency virus; 
SW = sex worker.
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epidemic in the majority of countries in the West and Central Europe, with the 
exception of Spain, which has a medium-level epidemic and Portugal and Italy, 
which are characterized as high. The majority of countries in the East are char-
acterized by high-level epidemics, with the exception of the Central Asian 
republics, which have a medium-level epidemic. This study is explored in more 
detail in case study 3.3.
HIV and Injecting Drug Use
There is a clear relationship between HIV and injecting drug use across the 
region (figure 3.9). Where prevalence of injecting drug use is higher, so is HIV. 
In the Netherlands, HIV prevalence was reported to be 5.7% overall and higher 
among transgender SWs (18.8%) and FSWs with a history of drug use (13.6%) 
[19]. In Spain and the United Kingdom small samples of SWs suggested a far 
higher HIV prevalence of 15% [27] in London, HIV prevalence was 4% and 24% 
among heroin or crack users respectively [83], and in Portugal the prevalence was 
13.5% compared to people who did not inject drugs [5]. The same patterns 
occur in the East, with the exception of Azerbaijan (Baku), Estonia (Tallinn), and 
Moldova (Chisinau) which have high HIV rates (2.5–8%) despite relatively 
lower levels of injecting drug use (<10) [33, 36, 77].
Studies conducted in the Netherlands, Ukraine, the United Kingdom, and 
Uzbekistan,1 examining risk factors for HIV among SWs, show more evidence of 
increased risk of HIV associated with injecting drug use [19, 84–86]. Among 
FSWs currently injecting drugs, risk of HIV is higher among those reporting 
map 3.2 Best estimates of Hiv prevalence among FsWs across europe
Source: Tables C.12–C.15.
Note: FSW = female sex worker; HIV = human immunodeficiency virus.
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specifically selling sex for drugs and injecting daily [87], and among those inject-
ing home-made drugs in Russia (figure 3.10) [13]. In Ukraine, having a sex 
partner who also injects drugs was associated with increased risk of HIV [24].
HIV among Male and Transgender SWs
In Western Europe, prevalence of HIV is higher among male and transgender 
SWs than FSWs, even where injecting is lower. This reflects the higher preva-
lence of HIV among men who have sex with men (MSM), the main client group 
of MSWs [19, 90–91]. HIV prevalence is low in the Czech Republic despite 
case study 3.3 central Asian republics
Serial cross-sectional studies conducted in Kazakhstan, the Kyrgyz Republic, and Tajikistan 
between 2006 and 2009 [68, 88] suggest that prevalence of HIV remains consistently low at 
less than 3% in all three countries, but marginally higher in Tajikistan. The proportion of sex 
workers (SWs) reporting injecting drug use is higher in Kazakhstan than the other two coun-
tries. In Tajikistan the trajectory of hepatitis C virus (HCV) reflects levels of injecting drug use in 
the population. In all countries, prevalence of syphilis is higher than HIV, with some evidence 
of a decline in prevalence between 2006 and 2008 and then a sharp increase in 2009; this is 
particularly marked in the Kyrgyz Republic. Evidence suggests prevalence of HIV is higher in 
Uzbekistan at 4.7% among samples of SWs recruited across multiple sites between 2005 and 
2007 [89]; 6% among female and male SWs in Samarkand [85]; and in Tashkent HIV prevalence 
was 10% overall among female sex workers but significantly higher among those with experi-
ence of injecting (58%) compared to those without (5.2%) [84].
repeated prevalence of Hiv, syphilis, Hcv, and injecting Drug Use 2006–09
Source: Ongoeva [88], Regional AIDS Centre, the Kyrgyz Republic.
Note: HCV = hepatitis C virus; HIV = human immunodeficiency virus; IDU = injecting drug user.
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higher levels of injecting drug use [18, 86]. Figure 3.11 summarizes HIV preva-
lence estimates among male and transgender SWs along with estimates of inject-
ing drug use. Multivariate analysis of risk factors associated with HIV among a 
diverse group of SWs (including male, transgender, female drug users, and non-
drug users) in the Netherlands suggested that the odds of contracting HIV were 
significantly higher among female injecting drug user (IDU) and transgender 
SWs compared to nondrug users. This was adjusted by years in sex work and 
whether or not anal techniques (defined as insertive or receptive anal sex) were 
practiced with clients [19]. In Spain an analysis that adjusted for age suggested 
that the risk of contracting HIV was no higher among transvestite or transgender 
MSWs than it was among a sample of MSWs [92].
Incidence of HIV and Chlamydia
A study of MSWs in London suggested that there were 49 incident cases of HIV 
over 1,309 person years or 3.7 cases per 100 person years [86]. The only signifi-
cant risk factor associated with seroconversion was if the MSW first attended the 
clinic between 1994 and 1996, compared to men who attended between 1997 
and 1999 or between 2000 and 2003. In Belgium, the incidence of chlamydia 
was 98 episodes in 1,347 person years or an incidence rate of 7.3 cases per 
100 person years. Baseline prevalence of chlamydia was higher than general 
population samples in Belgium, the Netherlands, and the United Kingdom [93].
Figure 3.9 the relationship between Hiv and injecting Drug Use among FsWs
Source: Tables C.12–C.14.
Note: FSW = female sex worker; HIV = human immunodeficiency virus; IDU = injecting drug user.
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HIV and Syphilis
Studies in Spain and Italy show a high prevalence of HIV and syphilis among 
transgender SWs from South America; the prevalence of syphilis is also notably 
higher in Spain than Italy (figure 3.12) [65, 90]. Prevalence of HIV was compa-
rable among MSWs in Belgium and the United Kingdom, and, but syphilis was 
far higher among MSWs in London, potentially as a result of increased oral sex 
transmission that had been documented since 2000 [86, 94, 95].
Structural Factors Linked to HIV and STIs
It is clear that while injecting drug use is the main risk factor associated with HIV 
among FSWs, other structural factors are important in mediating risk of HIV and 
sexually transmitted infections (STIs) and vulnerability among SWs. We examine 
studies that used multivariate analyses since these adjust for confounding factors 
to explore the association between risk factors and HIV.
Figure 3.10 Adjusted effect estimates of Hiv with injecting risk Behaviors among sWs
Note: DU = drug user; FSW = female sex worker; HIV = human immunodeficiency virus; IDU = injecting drug user; MSW = male sex worker; 
SW = sex worker.
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Nationality/Migration
Among studies reporting prevalence data only, some evidence showed a higher 
HIV prevalence among SWs in Spain, which reflected a higher prevalence 
among migrant SWs from Sub-Saharan African countries and Ecuador [65]. 
A higher prevalence was found among migrant SWs from a street-based sample 
in Palermo and Rome [71, 91]. No data on country of origin or injecting drug use 
Figure 3.11 prevalence of Hiv and Drug Use among male and transgender sWs
Source: Table C.15.
Note: HIV = human immunodeficiency virus; IDU = injecting drug user; MSW = male sex worker; SW = sex worker.
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Figure 3.12 prevalence of Hiv and syphilis among male and transgender sWs
Source: Table C.16.
Note: HIV = human immunodeficiency virus; MSW = male sex worker; SW = sex worker.
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were reported in the latter two studies. Studies that analyzed associations 
between migration and HIV adjusting for confounders suggested that risk of HIV 
among migrants varied depending on background prevalence of HIV/STIs in the 
country of origin [13, 19, 24, 28, 65, 92] (figure 3.13). Other factors relating to 
migration were important risk factors for HIV including language skills of 
migrants and access to health insurance [19, 69].
Health Service Provision
The majority of studies showed that using a health service reduced risk of 
HIV (figure 3.14). The only exception is in Uzbekistan where the relation-
ship between using needle and syringe exchange programs and HIV risk was 
unclear [84]. In London, FSWs with no contact with an outreach worker at 
their place of work had higher odds of being infected with HIV/STIs [4]. 
This effect was maintained even after adjusting for screening at an STI clinic 
in the last six months, suggesting that outreach services play an important 
role in reducing HIV/STIs on top of the advantages provided by fixed-site 
services.
Figure 3.13 Adjusted effect estimates of Hiv/sti Associated with migration among sWs
Note: EE = Eastern Europe; FSU = former Soviet Union; FSW = female sex worker; HIV = human immunodeficiency virus; IDU = injecting drug user; 
incl. = including; MSW = male sex worker; STI = sexually transmitted infection; SW = sex worker; WE = Western Europe.
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Location of Sex Work
TAMPEP estimates that just under two-thirds of SWs work off-street in the 25 
EU member countries in which they operate. They note a shift away from street-
work to off-street work since 2003 [3], caused by an increase in the number of 
migrants as well as policy changes in some countries that criminalize clients and 
SWs and specifically target street SWs. Changes in technology such as the 
increased use of the Internet and mobile phones to advertise services have also 
facilitated off-street work [3, 24]. Street-based sex work is more commonly 
reported across countries of the FSU as well as the Central Asian republics; it is 
characterized by involvement of criminal gangs, police, and a close overlap with 
IDUs [11, 13–14, 52, 88, 96, 97]. Risk-factor analyses suggest that risk of HIV or 
STIs were higher among SWs working on the street in Estonia (Tallinn), 
Germany, Ukraine, and Uzbekistan (Tashkent) (figure 3.15) [36, 69, 84].
Sexual Vulnerability
While HIV prevalence remains low among FSWs who do not inject drugs, it 
is also harder to transmit HIV sexually than other STIs, specifically gonorrhea, 
chlamydia, and syphilis [98, 99]. Below we examine the prevalence of syphilis, 
gonorrhea, and chlamydia to examine the extent of sexual vulnerability 
among SWs.
Figure 3.14 Adjusted effect estimates of Hiv/sti Associated with Attending Health services
Note: FSWs = female sex workers; HIV = human immunodeficiency virus; IDU = injecting drug user; MSWs = male sex workers; NSEP = needle 
syringe exchange program; STI = sexually transmitted infection.
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Past and Current Infection with Syphilis
Prevalence of syphilis is highest among samples of FSWs in the East. Across the 
region, prevalence of syphilis is higher than HIV with the exception of Ukraine, 
although this varied considerably at a city level (see figure 3.16). In 2001, a high 
prevalence of syphilis was found among a group of migrant street-SWs in Italy 
(12%); these cases were among migrants from Eastern European countries 
(countries not specified), and infection was attributed to infections contracted in 
their countries of origin [100]. In Greece no cases of HIV were found among 
off-street SWs in Athens, but a high prevalence of syphilis was observed (18%) 
[20]. Among this sample, 20% were migrants from Eastern Europe but preva-
lence did not differ by country of origin. In Russia and Moldova the data suggest 
a concurrent epidemic of syphilis and HIV occurring among samples of SWs; all 
the study samples included SWs who inject drugs [11, 14]. Figure 3.17 summa-
rizes selected studies that measured both prevalence of syphilis and HIV among 
FSWs in Europe. All studies report prevalence of antibodies to Treponema 
Pallidum and detect current and past infection with syphilis.
Chlamydia and Gonorrhea
Across countries in Western Europe, prevalence of chlamydia remains low at 
under 7% among FSWs (figure 3.18). Two older studies in Italy suggested a 
Figure 3.15 Adjusted effect estimates of Hiv/sti Associated with location of sex Work
Note: FSWs = female sex workers, HIV = human immunodeficiency virus; IDU = injecting drug user; incl. = including; 
STI = sexually transmitted infection.
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prevalence of 14% of chlamydia among migrant SWs [29, 100] and a high preva-
lence (45%) among off-street and street-working SWs in three cities in Kosovo, 
a sample that was recruited from STI clinics [17]. Prevalence of gonorrhea is 
reported at 5% or less across the region, with the exception of Georgia, where a 
higher prevalence of 12% and 18% were reported among samples of street and 
off-street SWs and a prevalence of just over 20% of chlamydia [35, 101]. 
Prevalence of gonorrhea is between 10 and 100 times higher than in general 
population samples [102].
The high prevalence of STIs relative to the general population suggests that 
SWs remain sexually vulnerable.
Sexual Risk Behaviors
A few studies showed increased risk related to sexual risk behaviors during sex 
work. In Spain, risk of chlamydia and gonorrhea was higher among SWs having 
unprotected sex with clients [28], and risks of a single or coinfection with gonor-
rhea, chlamydia, or active syphilis were higher among those reporting more than 
30 clients a week and not regularly using a condom for vaginal intercourse [66]. 
A study in Estonia suggested, counterintuitively, that consistent condom use was 
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Figure 3.16 prevalence of Hiv and syphilis among FsWs in Ukraine
Source: International HIV/AIDS Alliance; behavioral monitoring and HIV infection prevalence among FSWs as a component of second generation 
surveillance. 2009, International HIV/AIDS Alliance: Kiev.
Note: FSW = female sex worker; HIV = human immunodeficiency virus.
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associated with increased odds of HIV, most likely as a result of misclassification 
or underreporting or as a result of women made aware of their HIV status, modi-
fying their behavior to use condoms more frequently. Figure 3.19 summarizes 
data for eight countries, including different types of FSW populations.
Condom Use with Clients
Behavioral data from our systematic review suggested regional differences in 
condom use with clients: use was consistently higher among samples of SWs in 
Western Europe (<17% reported inconsistent condom use with clients) com-
pared to those in the East (0%–78% inconsistent use) and the Central European 
countries (ranging between 5% and 38% inconsistent condom use). Evidence 
suggests the interplay between drug use and sex work in condom use: SWs who 
use drugs are less likely to use condoms than noninjecting SWs, and IDUs who 
sell sex are less likely to use condoms than their non-sex-working counterparts 
[13, 25]. In the West, lower levels of condom use with clients were reported 
among samples of SWs who used drugs in London and the Netherlands, as well 
Figure 3.17 prevalence of Hiv and syphilis among FsWs across multiple sites in europe
Sources: Tables C.16 and C.17.
Note: FSW = female sex worker; HIV = human immunodeficiency virus.
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among transgender SWs [6, 19, 25]. Differences in condom use by gender were 
observed in a study of migrant SWs in Rome: male and transgender SWs were 
less likely to report condom use with clients than females [91]. However, con-
dom use among MSWs with clients is high, with inconsistent condom use 
reported by <25% in the Netherlands [19] and Italy [90, 91].
Reasons for not using condoms were generally economically motivated, but 
pressure from clients was also reported in both Central and Eastern European 
countries as well as from qualitative data from studies in Ireland and the United 
Kingdom [61, 103]. Concerns about condom breakages are also a factor as illus-
trated by a study from the Netherlands [19]. Data suggest that condom breakage 
can occur in up to 5% of use and is associated with incorrect application [104, 
105]. Policing practices such as the confiscation of condoms as evidence of sex 
work was reported as a disincentive for carrying condoms, therefore limiting 
opportunities for their use [50, 56].
Condom Use with Nonpaying Sex Partners
Across all the countries, condom use with nonpaying partners was less common 
than with clients. Qualitative data have shown how condoms are used as barriers 
Figure 3.18 prevalence of chlamydia and Gonorrhea among FsWs in europe
Source: Table C.18.
Note: FSWs = female sex workers.
FSWs (including migrants)
FSWs (unregistered)
FSWs (registered)
FSWs (street)
Migrant FSWs 
(street/indoor)
Migrant FSWs
Migrant FSWs
FSWs (indoor)
FSWs (street)
FSWs (indoor)
FSWs (including migrants)
0 10 20 30 40 50
Prevalence percentage
United
Kingdom
Turkey
Spain
Serbia
Italy
Israel
Georgia
Belgium
Chlamydia Gonorrhea
Epidemiology of HIV in Key Populations at High Risk 95
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8 
to STIs and also as a barrier to intimacy, with women opting not to use condoms 
with boyfriends and nonpaying partner in order to clearly demarcate sex for 
work and sex in their personal lives [59]. Condom use for anal sex was the norm 
among MSWs in London for commercial sex, but 37% reported not using con-
doms for anal sex with regular partners (table C.19) [86].
Risk Factors Associated with Unprotected Sexual Intercourse
We identified four studies that examined risk factors associated with unprotected 
sexual intercourse measured by consistency or inconsistency of condom use 
( figure 3.20) [7, 19, 54, 106]. Inconsistent condom use was associated with lower 
education, not being tested for HIV, more clients and nonpaying partners [7, 54]. 
Drug users were less likely to use condoms in the Netherlands as well as people 
Figure 3.19 Adjusted effect estimates of Hiv/sti Associated with sexual Health
Note: FSW = female sex worker; HIV = human immunodeficiency virus; HIV+ = HIV-positive; IDU = injecting drug user; incl. = including; 
MSWs = male sex workers; STI = sexually transmitted infection.
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experiencing regular condom failure or practicing anal sex techniques with 
 clients (receptive or insertive sex) [19]. More consistent condom use was associ-
ated with being married or a migrant and among those who considered them-
selves at higher risk of HIV infection [54, 106]. Greater knowledge of HIV 
transmission routes was associated with more consistent condom use as was not 
sharing drugs with clients [106].
Concluding Comment
The systematic review demonstrates that HIV remains low among FSWs who do 
not inject drugs, (<1%) but high among FSWs who inject drugs (>10%) and male 
and transgender SWs. Structural risk factors associated with HIV among SWs 
included lack of contact with outreach and HIV/STI services, working on the 
Figure 3.20 Adjusted effect estimates of condom Use among sWs in europe
Note: FSW = female sex worker; HIV = human immunodeficiency virus; SWs = sex workers. 
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street, and originating from a country with a high HIV prevalence. SWs remain 
sexually vulnerable as the high prevalence of gonorrhea demonstrates, and they 
remain highly vulnerable to physical and sexual violence from clients, nonpaying 
partners, and police.
men Who Have sex with men
MSM are primarily at risk of HIV infection through unprotected anal intercourse 
(UAI). The estimated per-contact risk of acquiring HIV through receptive UAI 
with a known HIV-positive partner is 1-in-70 sexual contacts for a receptive 
partner (with ejaculation) and 1-in-909 for the insertive partner [1]. The risk of 
transmission for oral sex is low: one study determined it to be 0 [2], while 
another calculated it to be 1-in-2,500 [3].
Demographic Characteristics
Below we describe the characteristics of the men sampled by the studies 
reviewed (see tables C.24–C.26). Because many studies were undertaken in rela-
tively high-prevalence settings including cities with noted “gay communities”, 
and with recruitment often undertaken in gay venues or health care settings, 
survey findings may not be generalizable beyond such settings. This may mean 
that younger men, and those more socially and maybe sexually active, are over-
represented, whereas men who are not as engaged in their communities may be 
underrepresented.
Age
In the West, the median age of MSM participating in studies was between 
28 and 33 years. In Central Europe, the median age is slightly lower, between 
25 and 30 years, with mean age ranging between 26 and 29. In Eastern Europe 
the age range was very similar to Central Europe’s, with medians ranging from 
24 (in the Kyrgyz Republic) to 30 (in Estonia), and the mean age around 
28 years [a little more than 10 years younger than the mean age of respondents 
in the West].
Education
In the West, respondents tended to be highly educated; between 38% and 58% 
had university degrees or higher levels of education, with a minority (9%–21%) 
reporting no qualifications. In Central Europe, a lower proportion of MSM had 
degrees ranging between 27% and 39% and in Hungary the mean number of 
years spent in education was 15.3. In Turkey, although 58% reported having a 
degree, 5% had no qualifications, and 11% reported finishing only primary 
school indicating considerable educational heterogeneity in the levels achieved 
by respondents. In the East, between 51% and 56% completed post-secondary 
education, which could include more academic or vocational training. Between 
5% and 17% reported only that they had not completed a secondary 
education.
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Occupation and Income
In the West, studies from Spain and the United Kingdom suggest that between 
73% and 84% of MSMs are employed and between 5% and 20% of respondents 
are students. Unemployment ranged from 5% to 18% in some studies. Only one 
study (Hungary) in the review reported similar levels of employment in Central 
Europe: 61% in “white collar” jobs and; 16% in “blue collar” jobs; 50% of the 
respondents were students, at least part time. In the East the story varies a little 
more. Studies from Estonia and Russia indicate high levels of employment, 66% 
of the respondents in Estonia reporting an annual salary of over US$750. Central 
Asia reports lower median incomes: US$324 in Kazakhstan and US$114 in the 
Kyrgyz Republic, with 8%–13% having no income at all and 4%–18% having no 
certain occupation. This may reflect national-level employment patterns rather 
than characteristics of the MSM community itself.
Nationality or Ethnicity
The majority of MSM samples included in the systematic review originated from 
the country in which the research took place, with a small proportion of migrants 
sampled. In Spain between 20% and 24% of respondents were migrants, princi-
pally from Latin America (9%–12%) and other parts of Europe (4%–7%) [4–6]; 
the exception to this was a study that recruited from sex-worker apartments in 
Valencia, where nearly 80% of respondents were Latin American [7]. Swiss stud-
ies recruited a small proportion of migrants (16%–17%) from other European 
countries [8, 9]. Dutch and British studies recruited a smaller proportion of 
migrants (17%–13% and 4%–15%, respectively), and 10% were reported in 
Israel. However, some of the Dutch studies were limited to respondents who 
could speak and write in Dutch [10–17]. Few studies in Central Europe exam-
ined the country of origin of respondents. A study in Turkey, for instance, 
included 7% migrants [18]. In the East, migrants tended to originate from other 
countries in that region. One study in Estonia recruited 21% ethnic Russians and 
8% of other origins [19]. Similarly, a Georgian study found that 17% of respon-
dents were nonnationals, including 4% ethnic Armenians, 4% ethnic Russians and 
9% from elsewhere. A study of MSWs in Moscow reported 38% of respondents 
not originating from Russia [20].
Risk Practices
Drug and Alcohol Use
Alcohol and drug use are frequently reported among MSM in the review. This 
may in part reflect bias associated with recruiting participants in gay venues 
where alcohol and drugs are available. The papers described here highlight 
recreational use, though detailed information on amount or frequency of 
use was lacking. In the West, alcohol use is most common with only 1 in every 
10 men abstaining from alcohol [15]. In the past 12 months in Spain, 64% of 
respondents reported drinking alcohol before or during sex, compared to 54% 
of respondents in Italy [6, 21]. Amylnitrate or “Poppers” are the next most 
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common drug: during the same time period in Spain, 41% of respondents 
took amylnitrate either before or during sex [6]. From 2012 to 2014 in the 
United Kingdom, 80% of respondents also took the drug in past two years. 
Poppers are favored by MSM since they have a side effect of relaxing the anal 
sphincter muscle, thereby facilitating anal sex [15]. While the Spanish and 
Italian studies show other drugs being used at relatively low levels (<20%), 
studies from the United Kingdom (2012–13) show high levels of Ecstasy use 
(44%–67%), cocaine (46%–59%), ketamine (3%–55%), Viagra (33%–53%), 
speed (18%–25%) and GHB (17%–25%), as well as lesser amounts of other 
drugs [15].
Several studies in Central Europe address alcohol and drug use among respon-
dents. As it is in the West, alcohol is most popular in Central Europe, where 
47%–85% of respondents reported drinking alcohol before or during sex in the 
past six months [17, 21]. A study in Hungary and Russia reported that 96% of 
respondents had used alcohol in the past month (not disaggregated by country) 
[22]. Proportionally fewer (42%) respondents in Albania drank daily [23]. 
Poppers were also common in Albania, where 21%–70% of respondents reported 
using them recently [17, 21]. Cannabis use was reported by 24% of respondents 
in Israel, in comparison to 10%–20% in most other countries. Other drugs used 
were similar to those reported in Western Europe.
In the East, alcohol use was again high, with 86%–96% having used it in the 
past month [22, 24], and between 4% and 8% reporting daily drinking [19, 22, 
24, 25], In Georgia 89% of respondents reported using marijuana and 22% used 
buprenorphine; however, drug use was not explored further.
Buying and Selling Sex
Few data were found in the studies from Western Europe on frequency of sex 
work; however a study from Catalonia, Spain, found that 4.1% of respondents 
had charged for sex [6]. Another Spanish study in Valencia included participants 
from “prostitution apartments”; although no information was provided on the 
frequency of this practice, respondents recruited from these apartments tended 
to be younger, migrants, and more likely to have had an HIV test than the refer-
ence group recruited from saunas [4].
A study from Tirana, Albania, reported that 74% of respondents had anal 
intercourse (AI) with a commercial partner in the previous six months, although 
the proportions buying and selling were not clear [23]. In Croatia, 5% reported 
ever having sold sex [26]. In Israel, 11% reported having paid for sex [17]. Sex 
work was more common among the respondents in the Turkish samples, with 
44% having sold sex, both as insertive and receptive partner, with more than one 
partner; 37% reported taking the receptive role only and 16% the insertive [18]. 
Three studies in Eastern Europe addressed the question of commercial sex: 21% 
reported having sold sex in the past year; 16% had paid for sex in the past 
12 months in Russia; and 21% of respondents sold sex in Ukraine in the past 
6 months [22, 24].
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A man’s relationship with sex work may change over time, with younger 
cohorts trading sex with older, richer cohorts. A qualitative study suggests that 
receiving payment in kind, such as drinks, rent, accommodations or presents 
from their partners is common among Balkan MSM [27]. This study also found 
that where sex is usually transactional, partner change-rates tend to be higher, a 
tendency which also correlates inversely with age across Bulgaria, Kosovo, FYR 
Macedonia, and Romania. It was noted that in a commercial encounter between 
men, it is the buyer who will dictate the terms of the sexual contact including 
type of sex act; who takes the insertive or receptive role, and condom use. Other 
studies confirm that decisions on condom use are made by clients in Georgia, and 
Russia [28, 29].
Prevalence and Incidence of HIV and STIs among MSM
We identified HIV prevalence data measured using biological samples in 33 
countries and through self-report in 38 countries (see map 3.3, figures  3.21–3.24). 
Comparisons should be interpreted with caution because of the range of recruit-
ment methods and settings as well as limitations associated with self-reported 
data. It should be noted that while gay venues generally refer to places that cater 
predominantly to self-identifying gay and bisexual men, these may be context 
specific and vary considerably across countries and even within cities.
Self-Reported Diagnosed HIV Prevalence
Self-reported HIV prevalence collected in 38 countries through the European 
Men Who Have Sex With Men Internet Survey (EMIS) varied from below 1% 
map 3.3 self-reported Hiv prevalence among msm in europe, european msm internet survey
Source: Reference [30].
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men.
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in Bosnia and Herzegovina to over 15% in the Netherlands (map 3.3) [30]. 
Absolute sample sizes ranged from 123 in Malta and FYR Macedonia to over 
55,000 in Germany. This translated to a response rate of 0.28 per 10,000 total 
population in Turkey to 6.82 per 10,000 total population in Germany. For the 
sake of accuracy and consistency, self-reported HIV prevalence estimates have 
been excluded from the results presented here.
HIV Prevalence and Incidence Studies Using Biological Samples among MSM
Our systematic review identified 65 sources containing HIV prevalence or inci-
dence data among MSM in Europe, of which 55 were unique. Twenty-two papers 
were in Western Europe, with 19 reporting prevalence [103, 105–106, 275, 278, 
283, 285, 297–308] and 3 reporting HIV incidence [11, 12, 31]; 14 papers were 
in Central Europe [18, 23, 32–43] and 14 were in Eastern Europe [20, 44–56], 
as well as 2 regional [57, 58] and 3 multicounty sources [21, 22, 59].
Evidence suggests that HIV incidence was 1.3 per 100 person years among a 
cohort in Amsterdam recruited between 1995 and 2002, with little increase 
from those recruited prior to 1995 (1.1 per 100 person years). However, signifi-
cant increases in the incidence of syphilis (0–1.4 per 100 person years) and 
gonorrhea (1.1–6.0 per 100 person years) were recorded [11]. Another study in 
Amsterdam reported Increased incidence among MSM attending an STI clinic 
between 1999 and 2005; the estimated incidence was 3.8 per 100 person years 
and associated with older men (≥35 years) [12]. In Rome a retrospective cohort 
study of men recruited at an STI clinic showed incident rate to be 5.0 per 
100 person years between 2000 and 2003 and a significant increase in HIV 
cumulative incidence in comparison with the period 1984–1995 (incidence rate 
ratio 2.20, P<0.001) [31].
HIV prevalence among MSM in Europe varies from below 1% in Bosnia and 
Herzegovina [33] and Kazakhstan [50] up to nearly 20% in France [60]. In some 
countries, such as France, the Netherlands, and Switzerland, the self-reported 
HIV prevalence exceeds the prevalence estimated through biological testing. 
However, in other countries, for example, Spain and the United Kingdom, the 
multiple samples produce comparable results. These differences may reflect the 
different characteristics of the populations sampled.
Estimates of HIV Prevalence among MSM
With a wide variety of estimates from a wide range of biobehavioral studies of 
variable quality, it is challenging to draw conclusions about the state of the epi-
demic among MSM in Europe. To allow for better comparison of HIV prevalence 
across the region we selected the best estimates available to us for comparison. 
These are presented in figures 3.21–3.23, alongside the range of estimates 
reported where more than one estimate was identified.
In the West, eight countries had HIV prevalence s from biobehavioral surveys 
(figure 3.21). Prevalence among MSM was generally highest among countries in 
this subregion with recent estimates ranging from as low as 1.6% in a sauna-
based sample in Valencia, Spain [4], and anonymous voluntary counseling and 
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testing (VCT) clinics in Switzerland [9], up to nearly 20% in several community 
studies from Barcelona and Catalonia [21, 61].
Thirteen countries in Central Europe have HIV prevalence estimates for 
MSM from biobehavioral surveys (figure 3.22). The prevalence among MSM in 
this subregion was lower than in the West. There were no cases of HIV among 
small community samples in Pristina in Kosovo [62], and FYR Macedonia [39]. 
Prevalence was over 5% among community samples in the capitals of Serbia 
[41], the Slovak Republic, and Slovenia [21]. Samples from Budapest, Hungary, 
showed varied prevalence estimates of 10.4% [22] and 2.6% [38].
Twelve countries in Eastern Europe have estimates for HIV prevalence among 
MSM from biobehavioral surveys (figure 3.23). Prevalence varied from 0.2% in 
community studies in Kazakhstan [59] and 0% in gay venues in Tomsk, in Russia 
[58] to 10% and over in a community-based study in Krivoy Rog and Nikolayev 
and as high as 30% in Kiev, in Ukraine [63].
Prevalence of STI Infections and HVC among MSM
STI infection among respondents is drawn from both biological data and self-
reports of recent and older infections. Self-reported results may suffer from some 
Figure 3.21 Best estimates of Hiv prevalence among msm in Western europe
Source: Table C.21.
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men.
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level of recall bias, with some participants remembering details of their infections 
more accurately than others, which may or may not be related to their HIV 
serostatus. Certain STIs can increase an individual’s susceptibility to HIV trans-
mission, and high levels of STIs in a population can indicate higher levels of 
sexual risk (including lower condom use) [64].
A study in Valencia, Spain, found syphilis prevalence to be 4% [4], while in 
Catalonia a study drawn from self-reported data suggested prevalence of syphilis 
was 3.3%, gonorrhea was 4.8%, and chlamydia was 2.5% (see figure 3.24) [6]. 
A study in the United Kingdom comparing newly diagnosed HIV cases to con-
trols (newly diagnosed HIV negative) found a high prevalence of coinfection 
among HIV cases. Coinfection with gonorrhea was 27% among the cases and 9% 
in the controls, syphilis was far higher with 7% in the cases and 1% in the con-
trols; chlamydia was lower in the cases (10%) than in the controls (19%) [15]. 
A study in Croatia found the prevalence of chlamydia was 9%, syphilis 10.6%, 
gonorrhea 13.2%, and HCV 3% [35]. A study in Albania found the prevalence 
of syphilis was 2.6% and HCV 3.5% [23]. In Turkey a study found prevalence of 
syphilis was 10.8%, gonorrhea 3%, and chlamydia 1.8% [18]. In the East, in 
Azerbaijan, HCV was 14% and syphilis 8%, although the study methods were 
Figure 3.22 Best estimates of Hiv prevalence among msm in central europe
Source: Table C.22
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men.
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unclear [45]. In Georgia, the prevalence of syphilis was 31.4% (35.1% among 
those 25 years-old and under and 28.9% among those over 25-years old) and 
prevalence of HCV was 15.7% (14% among those 25-years-old and under and 
16.9% among older age groups) [25]. Sentinel surveillance in Kazakhstan and the 
Kyrgyz Republic found prevalence of syphilis was 4.1% and 10.7%, respectively, 
and HCV was 4.2% and 1.2%, respectively [59]. A study among MSWs in 
Moscow found prevalence of syphilis was 12%, and antibodies to HCV 8% [20]. 
The lack of uniformity in the measures presented here make interpretation 
 difficult. However, the relatively high proportions of respondents reporting par-
ticular infections imply low condom use or high rates of unsafe injecting by 
certain groups.
Factors Associated with HIV
Factors Associated with HIV: Multivariate Associations
Few of the identified studies examined risk factors associated with HIV or STI 
incidence and prevalence in multivariate models that adjust for confounding fac-
tors. Those that did are summarized in tables C.30–C.32. All the studies were 
conducted in Western Europe and tended to be in areas of high HIV prevalence 
among MSM recruited from gay venues or STI clinics, limiting the generalization 
of results to the wider MSM population. However, the results of these papers can 
be generalized to similar settings and to individuals attending similar sites.
Figure 3.23 Best estimates of Hiv prevalence among msm in eastern europe
Source: Table C.23
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men.
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Individual-Level Risk Factors
Individual risk factors associated with HIV prevalence include age, number of sex 
partners, use of condoms, drug use, and past experience of STIs. A Swiss study 
based in five cities [9] found that HIV prevalence was less common among 
16–24 year olds than older age groups (25–34 and 35–44 years).
A U.K. study examining HIV prevalence in two Scottish cities [65] found older 
age to be associated with HIV prevalence. Studies from the Netherlands (based on 
a variety of settings in Rotterdam and Amsterdam [11, 12]) showed inconsistent 
relationships between HIV incidence and age. Studies from Amsterdam showed 
the same increased risk among 30- to 34-year-olds compared with younger MSM, 
but it found divergent findings with regards to those 35 years and older. The 
Rotterdam study showed decreased risk among both older-age groups compared 
with the respondents who were under 30 years old.
Figure 3.24 prevalence of stis among msm in europe
Source: Tables C.24–C.26.
Note: MSM = men who have sex with men; STI = sexually transmitted infection.
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Several studies examined numbers of sex partners as a risk factor as well as 
condom use. In Switzerland, respondents with 1 or less or 6 or more partners had 
elevated odds of HIV compared with those reporting between 2 and 5 partners, 
and having a partner known to be HIV positive was linked to twice the odds of 
contracting HIV. Having a history of gonorrhea and to a lesser extent, syphilis, 
was associated with higher odds of HIV [9]. Risk of HIV was lower among MSM 
always using a condom with occasional partners than those reporting never or 
sometimes using a condom, but risk was higher compared to those reporting no 
occasional partners. In the United Kingdom, no real difference was seen among 
those having more than 10 sex partners in the past 12 months and those having 
less than 10; however, those reporting having more than 10 anal sex partners in 
that period had over four times the odds of higher HIV prevalence than those 
with less than 10 anal sex partners. The number of partners for UAI did not 
appear to be associated with HIV prevalence; however, respondents reporting an 
STI in the past year had over three times the odds of increased HIV prevalence 
than those without [65].
UAI with more than one partner, casual partners, and partners of unknown or 
discordant status were all independently associated with elevated odds of HIV 
prevalence. A study based in the same cities [15] found that HIV seroconversion 
was associated with some ancillary sexual behaviors including oral-anal contact, 
“rimming”; or “being fisted”; meeting men in “cruising grounds” [outdoor public-
sex environments], or “backrooms” [indoor public-sex environments], or online; 
using certain drugs (poppers, Ecstasy, ketamine, and lysergic acid diethylamide 
[LSD]) before and during sex; and testing positive for certain STIs (gonorrhea 
and syphilis). Some factors were found to be protective of seroconversion includ-
ing meeting men in gyms or public restrooms, using other drugs (marijuana and 
mushrooms), and the presence of certain STIs (chlamydia and pubic lice). In the 
Netherlands, reported UAI with a casual partner and STI coinfection were all 
found to be associated with increased risk of HIV [11, 12].
Structural Risk Factors
Structural factors associated with HIV included migration status, city, and use of 
STI clinics. In Switzerland, native Swiss MSM had lower odds of HIV than immi-
grants [9]. In Scotland there is some association between increased HIV preva-
lence and living in Edinburgh or outside of Scotland compared with Glasgow, 
and some association between lower HIV prevalence and living in Scotland 
outside of Glasgow or Edinburgh. No strong differences were found between the 
respondents surveyed in Glasgow or Edinburgh or between those surveyed in a 
sauna or a bar [65].
Two studies showed Dutch respondents to be at greater risk of contracting 
HIV than respondents born elsewhere, and a college-level education was shown 
to be associated with reduced risk of HIV prevalence [11, 12]. Another U.K. 
study based in three English cities [66] that adjusted for age and ethnicity found 
education after the age of 16 to be associated with reduced HIV prevalence. 
Employment was also associated with reduced prevalence. Having an STI in the 
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previous 12 months and having attended a genitourinary medicine clinic (GUM) 
clinic in the past 12 months were both associated with HIV prevalence.
Sexual Vulnerability
Number of Sex Partners
Many studies collected data on numbers of sex partners (table 3.5). While time 
frames of either 6 or 12 months are generally used, there is much variation in 
table 3.5 number of sexual partners reported by msm in europe
Country (or city)
Time 
period 
(months) Regular partners Casual partners
Commercial 
partners
(%/median/mean)
Western Europe
Italy [21] 6 1 median, 2.6 mean 6 median, 12.0 mean
Spain [21] 6 1 median, 1.6 mean 10 median, 16.3 mean
Denmark [67] 12 Median 3, mean 9.4 
France [68] (HIV+ men in regular 
relationships)
12 1–4, 23.1%
5+, 25.7%
Netherlands [10] 12 10+, 51%
Netherlands [69] 12 Median 4
Netherlands [69] 12 Median 5
Spain (Barcelona, Catalonia) [6] 12 20+, 45%
Switzerland (Zurich) [8] 12 Median range 4–10
Switzerland [70] 12 Mean 11+ 
United Kingdom (Brighton) [71] 12 13+, 32%–35%
United Kingdom (nationwide) [71] 12 1, 33.6%; 10+, 22.8% 
United Kingdom (southern England) [72] 12 Median range 10%–29%
Central Europe 
Albania [23] 6 5+ noncommercial, 34%
Czech Republic [21] 6 1 median, 2.7 mean 4 median, 7.5 mean
Romania [21] 6 2 median, 3.3 mean 3 median, 7.1 mean
Slovak Republic [21] 6 1 median, 2 mean 3 median, 6.1 mean
Slovenia [21] 6 1 median, 2.1 mean 3 median, 5.7 mean
Croatia (Zagreb) [26, 35] 12 0 AI partners 23%; 1 AI partner 21%–27%; 3–10 AI partners 21%–23%
Eastern Europe
Georgia [25] 6 1–5, 69%
Lithuania (7 cities) [73] 6 10+, 4.7%
Moldova (Chisinau) [74] 6 Mean 3.8
The Russian Federation (Moscow) [75] 6 Mean 1.5 Mean 10.7
The Russian Federation (Sochi) [75] 6 Mean 2.2 Mean 23.9
Ukraine [24] 6 Median 4 Median 3
Kazakhstan[76] 12 Mean 2.2 Mean 5.8 Mean 8.1
Kyrgyz Republic [76] 12 Mean 2.3 Mean 4.5 Mean 2.4
Tajikistan [76] 12 Mean 5.1 Mean 20.2 Mean 21.4
Note: AI = anal intercourse; HIV+ = HIV-positive; MSM = men who have sex with men.
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classification and quantification of partners. While this makes comparison very 
difficult, it is possible to see that where both measures are reported, means are 
generally higher than medians, showing that while the majority of respondents 
may report quite low numbers of partners, a small minority report very large 
numbers. There is little evidence of any pattern by region, although evidence of 
very high partner numbers in towns with well-known gay scenes such as Brighton 
and Amsterdam are visible, although this may reflect the characteristics of those 
attending the study recruitment locations only, and not the surrounding com-
munity (see tables C.21–C.23).
Condom Use
Many studies focused on the prevalence of condom use between men for AI. This 
was measured in a variety of ways, often disaggregated by a number of factors, 
which makes comparisons among the various studies complex. Many studies, 
including EMIS, measure condom use through the percentage of MSM reporting 
condom use the last time they had AI with another male (limited to the past six 
months), corresponding to an United Nations General Assembly Special Session 
(UNGASS) indicator [77]. Other studies chose to focus on participants report-
ing if they had any acts of UAI within a particular time frame, generally 6 months 
but ranging from 1 to 24 months. Both approaches have advantages and disad-
vantages: indicators covering longer time periods may be more representative of 
an individual’s general risk practices: however, this may be subject to recall bias, 
and condom use at the last instance of AI may be a more valid measure.
UAI in the Past Six Months
Data for this indicator came from a variety of studies. Therefore, they have been 
disaggregated into the proportion reporting UAI over (a) 3 months; (b) 6 months; 
and (c) 12 months. UAI is also consistently more common with regular or steady 
partners than with casual partners (figure 3.25). UAI over a six-month period 
was slightly less frequently reported in the West (Israel, Italy, the Netherlands, 
and Norway) than in Central Europe (the Czech Republic, Romania, the Slovak 
Republic, and Slovenia). Similarly UAI over a 12-month period was higher in 
Estonia and Georgia than France, Spain, and Switzerland.
Condom Use At Last Anal Intercourse
Findings of the EMIS study provide further evidence for this pattern with higher 
median condom use at the last act of AI in countries in the West, followed by 
Central Europe and then the East (figure 3.26). Among other countries, the 
Central Asian countries were not included in this study so these results cannot 
be generalized. The highest median condom use, as noted above, is found in the 
West, around 15% more than the reported use in the East. The minimum 
reported proportion in the West was 41% (Sweden), Central Europe 6% (FYR 
Macedonia), and 37% in the East (Belarus). The maximum reported proportions 
were 69% in the West (Greece), 60% in Central Europe (FYR Macedonia), and 
58% in the East (Ukraine). Generally there is little difference between those 
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Figure 3.25 proportion of UAi during varying time periods specified, by partner type
Source: Tables C.27–C.29.
Note: UAI = unprotected anal intercourse.
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under and over 25 years old, although in Central Europe it appears that younger 
MSM are less likely to report condom use than their older counterparts.
Studies from outside the systematic review show that in some poorer coun-
tries, condoms may be unaffordable. For instance, “average” quality condoms cost 
US$0.30–0.40 in Georgia, in comparison with an average monthly salary of 
US$50–70 [79]. Qualitative data suggest that condom use among Georgian 
MSM was particularly rare in rural areas and among younger, more economically 
disadvantaged MSM, many of whom have emigrated from these rural areas [80].
Factors Associated with Unprotected Sex
Eleven studies that examined risk factors associated with unprotected sexual 
intercourse measured by reported condom use at last anal intercourse (AI) or 
UAI were identified by the systematic review [6, 10, 17, 22, 24, 26, 81–85]. 
These studies are presented in figures 3.27–3.30.
Individual Risk Factors Associated with UAI
Individual risk factors associated with UAI among MSM in the region included 
partner types and numbers, drug use, HIV testing history, condom availability, 
and HIV status. Studies from the United Kingdom and Switzerland [82, 83] 
 suggest that HIV-negative respondents and those who have not been tested are 
less likely to report UAI than their HIV-positive counterparts. A Spanish study 
focusing on men with steady male partners found that serodiscordant or both 
HIV-positive couples were less likely to practice UAI than both HIV-negative 
couples [81]. Although data from Israel [17] showed men with casual or steady 
and casual partners having higher odds of reporting UAI, a French study among 
Figure 3.26 condom Use at last Ai among msm
Source: EMIS [78].
Note: AI = anal intercourse; MSM = men who have sex with men.
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HIV-positive respondents reported that those who had sex with a casual partner 
while in a relationship had lower odds of reporting UAI [84]. Although the asso-
ciation between number of partners and UAI is unclear, studies showing separate 
models according to serostatus show that HIV-positive respondents with a higher 
number of partners have higher odds of reporting UAI than their HIV-negative 
counterparts with similar partner numbers [82, 84] (figure 3.27).
A French study found that engaging in a variety of ancillary sexual behav-
iors was associated with increased odds of UAI regardless of HIV status [84]. 
A Spanish study [81] found respondents reporting a combination of two or 
more drugs (poppers, alcohol, and others) had higher odds of UAI, ranging from 
2.4 to 4.9 times greater than those who did not report any drug use. A later study 
in the same location [6] showed a clear increase in risk of UAI with number of 
Figure 3.27 Adjusted effect estimates for individual-level Factors for UAi among msm (A)
Note: CI = confidence interval; ES = estimate; HIV = human immunodeficiency virus; HIV+ = HIV-positive; HIV– = HIV-negative; 
MSM = men who have sex with men; ref. = reference; UAI = unprotected anal intercourse.
† = HIV negative respondents only; ‡ = HIV positive respondents only; * = sample of Central and Eastern European immigrants only.
Age
One year increase
One year increase*
HIV status
HIV+ (ref.: HIV–) self-report
Unknown (ref.: HIV–) self-report
HIV– (ref.: HIV+)*
Untested (ref.: HIV+)*
HIV+ (ref.: HIV–) self-report
Unknown (ref.: HIV–) self-report
Couple both HIV+ (ref.: both HIV–)
Couple discordant (ref.: both HIV–)
One or both partners untested (ref.: both HIV–)
HIV+ (ref.: HIV–/unknown) self-report
Partner type
Stable relationship in past 12 months
Sex with a casual partner while coupled‡
Casual partners in past 6 months
Steady partners and casual partner(s)
Number of partners
Above median # partners in past year
HIV+ and # partners
HIV– and # partners
11–20 (ref.: 1–10) in past year
21+ (ref.: 1–10) in past year
>10 casual in the past year†
>10 casual in the past year‡
Number sexual encounters
>20 partners in past 6 months
Risk factor
0.89 (0.83, 0.97)
1.04 (0.98, 1.04)
1.65 (0.66, 4.14)
1.09 (0.65, 1.81)
0.16 (0.07, 0.38)
0.23 (0.09, 0.56)
2.12 (1.07, 4.20)
0.40 (0.15, 1.02)
0.27 (0.08, 0.90)
0.09 (0.04, 0.21)
0.26 (0.15, 0.47)
1.77 (1.14, 2.74)
0.73 (0.46, 1.14)
0.82 (0.64, 1.05)
2.45 (1.12, 5.43)
2.80 (2.10, 3.69)
0.78 (0.46, 1.30)
6.14 (1.93, 19.60)
1.67 (0.70, 3.97)
0.71 (0.42, 1.21)
1.56 (1.03, 2.38)
0.99 (0.86, 1.13)
1.83 (1.43, 2.35)
1.88 (1.52, 2.27)
1.50 (1.10, 2.30)
ES (95% CI)
Switzerland
United Kingdom
Switzerland
Switzerland
United Kingdom
United Kingdom
Spain
Spain
Spain
Spain
Spain
Spain
Switzerland
France
Israel
Israel
Switzerland
Switzerland
Switzerland
Spain
Spain
France
France
Israel
Israel
Country
82
83
82
82
83
83
81
81
81
81
81
6
82
84
17
17
82
82
82
6
6
84
84
17
85
Reference
Reduced association with UAI Increased association with UAI10.01 0.5 5 20
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drugs used. Compared with respondents not using drugs, those using 1–3 drugs 
reported 1.1 times the odds of UAI; those using 4–6 drugs reported 1.76 times 
the odds; and those using 7 or more drugs reported nearly 5 times the odds of 
UAI [6]. Other studies in France and the United Kingdom found drug and alco-
hol use associated with increased odds of UAI [83, 84]. A study among Central 
and Eastern European migrants in the United Kingdom found that a history of 
injecting in particular increased the likelihood of reporting UAI. The French 
study examined the associations for HIV-positive and HIV-negative respondents 
separately, and the association between drug and alcohol use and UAI appear to 
be stronger among HIV-positive respondents than the HIV-negative respondents. 
Sex work and having a history of STIs were both associated with greater odds of 
reporting UAI (figure 3.28).
Structural Factors Associated with UAI
Structural factors associated with UAI included level of education, country of 
origin, living arrangements; city of residence, recruitment site, venues used to 
meet sex partners, and experience of homophobic violence (figure 3.29). Studies 
in France and Israel clearly identified higher levels of education as being associ-
ated with lower odds of UAI [17, 84]; however, a study in Hungary and Russia 
found the opposite: additional years of education may be associated with 
increased odds of UAI [22]. Internet partner-seeking was associated with higher 
odds of UAI in Western European studies [6, 82], and although little difference 
could be observed between different gay venues in France where men may seek 
sex, HIV-positive men appeared to face a greater association between attending 
these venues and higher odds of UAI [84]. A Spanish study found little differ-
ence in risk of UAI based on recruitment site (sauna, sex shop, or cruising spot in 
the park), although respondents recruited via a gay organization’s mailing list had 
lower odds of UAI (AOR 0.65, 95% CI 0.33–1.30) than those respondents 
recruited from a sauna [81]. A study in the United Kingdom found similar results 
[83] although an online study from France found that respondents recruited 
through special interest websites had higher odds of UAI than those recruited 
through general interest gay websites, particularly if they were HIV positive [84]. 
Respondents who reported that they were victims of aggression or verbal assaults 
in the past year had 1.7 times the odds of reporting UAI than their counterparts 
who had not been victims [81]. Internalized homophobia, or feeling negatively 
about oneself because of homosexuality, was also associated with increased odds 
of UAI in a Spanish study [6]. A Spanish study showed that nonnegative nation-
als were more likely to be at risk of UAI than nationals, with Latin American 
respondents in particular having over twice the odds of reporting UAI than 
Spanish respondents [6].
Multivariate Associations with Condom Use at Last AI
Factors associated with condom use at last AI include younger age, ever having 
had an HIV test or knowing where to obtain one, having occasional male rather 
than regular male or female partners, not using alcohol, and not engaging in sex 
Epidemiology of HIV in Key Populations at High Risk 113
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8 
work (figure 3.30). A Ukrainian study suggested that younger age was associated 
with condom use at last AI, and younger respondents were more likely to report 
using a condom at last AI, for example, 15–19 year olds had twice the odds of 
reporting condom use compared to those over 25 years old, and those 20–24 
years old had 1.1 times the odds compared to their older counterparts [24]. 
A study in Croatia among HIV-negative men found that older respondents had 
higher odds of condom use at last AI with casual partners than did younger men 
[26]. Respondents reporting insertive AI in the past six months had higher odds 
Figure 3.28 Adjusted effect estimates for individual-level Factors for UAi among msm (B)
Source: Table C.33.
Note: CI = confidence interval; ES = estimate; MSM = men who have sex with men; ref. = reference; STI = sexually transmitted infection; 
UAI = unprotected anal intercourse.
† = HIV-negative respondents only; ‡ = HIV-positive respondents only; * = sample of Central and Eastern European immigrants only.
Risk factor ES (95% CI) Country Reference
Reduced association with UAI Increased association with UIA10.1 0.5 5 20
Type of sexual contact
Sensation-seeking in the past year†
Barebacked with a couple in the past year†
Oral contact with sperm in the past year†
Esoteric activity in the past year†
Sensation-seeking in the past year‡
Barebacked with a couple in the past year‡
Oral contact with sperm in the past year‡
Esoteric activity in the past year‡
Drug or alcohol use 
Ever injected drugs 
Recreational drug use in the past year
Poppers only before/during sex (ref.: none) in the past year
Alcohol only before/during sex (ref.: none) in the past
Poppers and alcohol only before/during sex (ref.: none) 
in the past year
Poppers and other drugs before/during sex (ref.: none) 
in the past year
Alcohol and other drugs before/ during sex (ref.: none) 
in the past year
Alcohol, poppers, and other drugs before/during sex 
(ref.: none) in the past year
Other drugs before/during sex (ref.: none) in the past year
1–3 drugs used (ref.: none) in the past year
4–6 drugs used (ref.: none) in the past year
7+ drugs used (ref.: none) in the past year
Used drugs in the past year†
Had >5 units alcohol in one sitting at least weekly†
Used drugs in the past year‡
Had >5 units alcohol in one sitting at least weekly‡
Sex work
Paid for sex
Traded sex†
Traded sex‡
STI history
Had an STI†
Had an STI‡
1.31 (1.15, 1.49)
2.62 (2.28, 3.02)
3.33 (2.84, 3.92)
1.35 (1.18, 1.55)
1.31 (1.04, 1.68)
4.10 (2.96, 5.69)
6.80 (4.88, 9.49)
1.52 (1.13, 2.04)
2.11 (0.91, 4.88)
2.07 (1.40, 3.06)
2.27 (0.77, 6.67)
1.07 (0.44, 2.59)
1.77 (0.56, 5.59)
4.88 (1.39, 17.16)
2.60 (0.97, 6.99)
2.38 (1.08, 5.32)
1.21 (0.20, 7.20)
1.11 (0.76, 1.62)
1.76 (0.95, 3.25)
4.90 (1.23, 19.50)
1.10 (0.96, 1.26)
1.01 (0.86, 1.17)
1.93 (1.39, 2.68)
1.23 (0.91, 1.67)
2.20 (1.29, 3.77)
1.33 (1.03, 1.72)
1.50 (0.88, 2.55)
1.51 (1.23, 1.86)
2.68 (1.99, 3.61)
France
France
France
France
France
France
France
France
United Kingdom
United Kingdom
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
France
France
France
France
United Kingdom
France
France
France
France
84
84
84
84
84
84
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83
83
81
81
81
81
81
81
81
6
6
6
84
84
84
84
83
84
84
84
84
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of reporting condom use at last AI compared to those reporting receptive AI, 
maybe reflecting decision-making roles that accompany positions [24]. MSM 
respondents reporting a regular or female partner in the past six months had 
lower odds of condom use at last AI than their counterparts who reported male 
casual partners or no partners. Conversely, respondents reporting occasional 
Figure 3.29 structural-level Adjusted effect estimates for UAi among msm
Source: Table C.33.
Note: CI = confidence interval; ES = estimate; M/F = male or female; MSM = men who have sex with men; ref. = reference; 
UAI = unprotected anal intercourse.
† = HIV-negative respondents only; ‡ = HIV-positive respondents only; * = sample of Central and Eastern European immigrants only.
Education
Education in years
Completed higher education*
Some university (ref.: none)†
Higher-level (ref.: lower)
Employment
Employed*
Locations to meet sex partners
Internet partner-seeking
Internet partner-seeking
Sought sex/socialized at: outdoor sex venue†
Sought sex/socialized at: bathhouse†
Sought sex/socialized at: venue with a backroom†
Sought sex/socialized at: outdoor sex venue‡
Sought sex/socialized at: bathhouse‡
Sought sex/socialized at: venue with a backroom‡
Living arrangements
Lives with with partner (m/f) (ref.: alone)
Lives with friends (ref.: alone)
Lives with parents/family (ref.: alone)
Does not live alone
City of residence
London (ref.: elsewhere in United Kingdom)*
Paris (ref.: elsewhere in France)†
Tel Aviv (ref elsewhere in Israel)
Recruitment site
Online at GayRomeo (ref.: Gaydar)*
Sex shop (ref.: sauna)
Cruising site in park  (ref.: sauna)
Mailing list from gay organization (ref.: sauna)
Specialist interest website (ref.: general website)†
Specialist interest website (ref.: general website)‡
Violence
Victim of aggression or verbal assaults in past 12months
Internalized homophobia (ref.: low) high
Country of origin
Latin America (ref.: Spain)
Other (ref.: Spain)
Risk factor
1.17 (0.99, 1.37)
1.02 (0.69, 1.51)
0.68 (0.60, 0.78)
0.57 (0.44, 0.73)
0.71 (0.45, 1.15)
1.52 (1.03, 2.25)
1.45 (1.10, 2.06)
1.10 (0.96, 1.26)
0.90 (0.87, 1.04)
1.03 (0.89, 1.20)
1.34 (1.05, 1.72)
1.25 (0.95, 1.65)
1.18 (0.89, 1.57)
1.84 (1.02, 3.31)
1.12 (0.47, 2.70)
1.03 (0.44, 2.43)
0.72 (0.56, 0.94)
1.02 (0.66, 1.59)
0.94 (0.79, 1.14)
1.37 (1.06, 1.78)
0.80 (0.53, 1.20)
0.98 (0.42, 2.28)
1.24 (0.53, 2.86)
0.65 (0.33, 1.30)
1.23 (1.08, 1.41)
3.38 (2.65, 4.31)
1.67 (0.76, 3.67)
2.40 (1.25, 4.64)
2.10 (1.24, 3.56)
1.86 (1.04, 3.32)
ES (95% CI)
Hungary and 
Russian Federation
United Kingdom
France
Israel
United Kingdom
Switzerland
Spain
France
France
France
France
France
France
Spain
Spain
Spain
Israel
United Kingdom
France
Israel
United Kingdom
Spain
Spain
Spain
France
France
Spain
Spain
Spain
Spain
Country
22
83
84
17
83
82
6
84
84
84
84
84
84
81
81
81
17
83
84
17
83
81
81
81
84
84
81
6
6
6
Reference
Reduced association with UAI Increased association with UAI10.25 5
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Figure 3.30 Adjusted effect estimates for condom Use at last Ai among msm
Source: Table C.33.
Note: AI = anal intercourse; CI = confidence interval; ES = estimate; HIV = human immunodeficiency virus; MSM = men who have sex with men; 
ref. = reference.
† = HIV-negative respondents only; ‡ = HIV-positive respondents only; * = Sample of Central and Eastern European migrants only.
Age
(ref.: 25+) 20–24
(ref.: 25+) 15–19
<25 years‡
(ref.: 18–25) 26–33
(ref.: 18–25) 34+
HIV test
Knows where to get an HIV test
Ever had an HIV test
Ever had an HIV test
Partner type
Partner type in past 6 months: main
Partner type in past 6 months: occasional
In a stable relationship
Sexual contact with females
In the past 6 months
Ever
Number of partners
1 (ref.: 8+) in past 5 years
2–3 (ref.: 8+) in the past 5 years
4–7 (ref.: 8+) in the past 5 years
Education
Higher-level (ref.: lower)
Type of sexual contact
Insertive AI in past 6 months
Receptive AI in past 6 months
Drug or alcohol use
Alcohol in the past month
Locations to meet sex partners
Internet partner-seeking
Frequency of cruising (ref.: never) rarely
Frequency of cruising (ref.: never) sometimes
Frequency of cruising (ref.: never) often
Sex work
Sold sex
Risk factor
1.10 (0.80, 1.40)
2.20 (1.40, 3.50)
1.51 (0.78, 2.90)
1.77 (0.64, 4.88)
1.70 (0.46, 6.04)
1.30 (0.90, 1.80)
1.70 (1.30, 2.20)
1.67 (0.70, 3.99)
0.30 (0.20, 0.40)
1.60 (1.20, 2.10)
1.23 (0.56, 2.71)
0.60 (0.50, 0.80)
1.54 (0.68, 3.49)
0.17 (0.02, 1.45)
0.44 (0.13, 1.47)
0.22 (0.08, 0.59)
1.25 (0.46, 3.36)
1.20 (0.90, 1.80)
0.80 (0.60, 1.10)
0.50 (0.30, 0.80)
0.91 (0.42, 1.95)
1.06 (0.35, 3.19)
0.66 (0.21, 2.08)
4.52 (0.40, 50.71)
0.41 (0.07, 2.45)
ES (95% CI)
Ukraine
Ukraine
France
Croatia
Croatia
Ukraine
Ukraine
Croatia
Ukraine
Ukraine
Croatia
Ukraine
Croatia
Croatia
Croatia
Croatia
Croatia
Ukraine
Ukraine
Ukraine
Croatia
Croatia
Croatia
Croatia
Croatia
Country
24
24
84
26
26
24
24
26
24
24
26
24
26
26
26
26
26
24
24
24
26
26
26
26
26
Reference
Reduced association with
condom use at last AI
Increased association with
condom use at last AI
10.01 0.25 5 10 25 60
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partners in the same time period had higher odds of using a condom at the last 
AI. Finally, while using alcohol in the last month was associated with lower odds 
of using a condom at last intercourse, ever having had an HIV test and knowing 
where to get an HIV test were associated with higher odds of condom use at 
last AI.
Ukrainian and Croatian studies found that respondents reporting ever having 
had an HIV test were associated with less risky behavior: the odds of using a 
condom at last AI were around 1.7 times higher among respondents reporting a 
history of testing [24, 26]. Although respondents reporting rare or occasional 
cruising were not at increased or decreased risk of condom use, respondents 
who cruised often had higher odds of condom use at last AI (odds ratio [OR] = 
4.5 95% CI 0.4–50.71). Other sexual characteristics, such as sex with a woman, 
selling sex, or being in a stable relationship did not appear to be associated with 
condom use at last AI.
Concluding Comment
The systematic review demonstrates that HIV prevalence level is highest in the 
West (9–18%), and generally lower or medium in Central Europe and the East 
(<5%). Structural risk factors associated with UAI included levels of education, 
employment, experience of violence, and country of origin.
note
 1. Odds ratios are not presented in the original Sethi et al. (2006) paper and therefore 
are not presented here.
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Responses to HIV in 
Key Populations
Hiv surveillance responses
As we noted in chapter 2, human immunodeficiency virus (HIV) surveillance 
activities are generally well  established in Europe. The availability of data on HIV 
diagnoses from almost the entire region is a particular strength. We earlier noted 
that two-thirds of countries have undertaken studies to monitor directly mea-
sured HIV prevalence or risk in at least two of the populations most affected by 
HIV. We consider here how HIV surveillance responses among key populations 
can be further strengthened.
Reporting HIV Diagnoses
While comprehensive, data on HIV diagnoses are not without their limitations. 
They indicate the patterns and extent of diagnoses, but do not reflect the current 
patterns or extent of HIV transmission. This is because newly diagnosed HIV 
cases will include both new and past infections. Diagnoses reports also reflect the 
uptake of diagnostic testing for HIV, the effectiveness of case finding, and pat-
terns of reporting, all of which will vary from country to country. Countries with 
the largest number of reported diagnoses could therefore be those most success-
ful at case finding, rather than those with the worst epidemics. Countries across 
the region use different approaches to collate HIV diagnoses data, and these 
variations will affect data comparability.
Timeliness (Reporting Delay)
In 2006, a European-wide survey of HIV surveillance systems in 44 countries 
found that among the 16 countries that had examined reporting delay [1], 75% 
of HIV diagnoses were reported within 6 months, while for 13 countries 90% of 
their diagnoses were reported within 6 months. Data can be adjusted if the 
extent and pattern of past reporting delay is known. All countries should regu-
larly assess and report on reporting delay so that adjustments can be made.
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Completeness (Underreporting)
The extent of underreporting is unknown. In the 2006 survey of European HIV 
surveillance systems, less than 40% of countries had assessed the extent of under-
reporting [1]. In those that had, underreporting ranged from less than 2% in 
Belarus to 37% in France. Furthermore, Italy and Spain currently do not have 
national coverage of diagnoses reporting systems. All countries should periodi-
cally assess and estimate the extent of underreporting, publishing the results. 
When underreporting is high—greater than 10%—efforts should be made to 
reduce this problem.
Duplication (Overcounting)
An individual may have more than one positive HIV test as a result of receiving 
health care in different settings or using both anonymous and named testing 
services. Furthermore, a single positive test could be reported more than once, for 
example, by both the laboratory undertaking the testing and the clinician. To 
overcome duplicative reporting, many systems collect identifiers, such as full 
name and date of birth of the patient, or a code identifier based on a combination 
of identification data. Identifiers are not always possible to collect, when testing 
is anonymous or when subject to privacy-related legal restrictions. A survey of 
40 European countries showed that 28 (72%) used a coded identifier and 12 
(28%) used full names [1]. In countries where reports lack identifiers, the extent 
of overreporting should be assessed periodically.
Consistency of Details on Risk Factors
The type and completeness of the information requested on cases, including risk 
factors, vary between countries. For example, in 2010, 49 of the countries report-
ing data to the European Centre for Disease Prevention and Control (ECDC) 
and the World Health Organization (WHO) [2] provided data on age, with an 
overall completeness ranging from 78% to 100% (99.3% overall), while only 
34 countries provided data on country of birth, with completeness ranging from 
1.5% to 100% (37% overall). Of concern is that, for over one quarter of the 
diagnoses reported in Europe there is no information available on exposure cat-
egory. The proportion of diagnoses lacking exposure information is highest in the 
East and Central Europe, at over a one-third and a one-quarter, respectively. 
Some countries, such as the United Kingdom, provide follow-up reports with 
missing exposure category information, and these reports may then be revised. 
All countries should ensure that their systems collect information on exposure 
category (at minimum, the main risk), and try to follow-up on all reports where 
these data are missing. All countries should also try to collect an exposure sub-
category for all reports associated with heterosexual exposure.
HIV Testing Practices
HIV testing practices have a direct effect on the extent to which HIV infections 
are diagnosed and reported. Approaches to HIV testing vary widely in the region 
[3], but most countries have a policy or strategy to offer HIV testing and 
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counseling to men who have sex with men (MSM), people who inject drugs 
(PWID) and sex workers (SWs) [4–6]. The 2006 survey found that 37 (84%) of 
the 44 countries routinely offered HIV testing to pregnant women; 32 (73%) did 
so for PWID; 26 (59%) did so for patients of sexually transmitted infection (STI) 
clinics; and 21 (48%) did so for tuberculosis (TB) patients [1]. However, testing 
was only routinely offered by health care providers to SW in 17 countries (39%) 
and to MSM in 16 countries (36%) [1]. Mandatory HIV testing of blood donors 
was reported in all countries [1]. In addition, in a few countries mandatory HIV 
testing was reported among immigrants (Andorra, Azerbaijan, and Russian 
Federation), military personnel (Croatia, Lithuania, Moldova, Romania, Ukraine), 
SWs (Austria, Greece, Moldova, and Turkey), and pregnant women (the Czech 
Republic and Estonia) [1]. A survey on testing strategies in Europe found that 
14 countries (from 24 responders) had policies recommending provider-initiated 
opt-out testing in prenatal care and 12 in other settings, such as STI clinics or 
drug treatment centers (Russia) [7]. In addition 19 countries promote HIV test-
ing through outreach, with PWID being the most widely served population [7]. 
Testing is generally provided free of charge, even to nonresidents, but free testing 
may be restricted to certain facilities [7]. Moreover, access to testing services 
 varies between countries reflecting differences in perceptions of risk, levels of 
HIV-related stigma and accessibility of HIV treatment and care [4]. In addition 
to ensuring ease of access to HIV testing, it is important for all countries to moni-
tor the number of diagnostic HIV tests undertaken annually (distinguishing tests 
undertaken during blood screening and antenatal care, and excluding tests under-
taken as part of unlinked anonymous studies).
Regionwide Collation of HIV Case Reports
Since 2008, ECDC and the WHO Regional Office for Europe have been jointly 
collating HIV and acquired immune deficiency syndrome (AIDS) data from 
across the European region. Case-based data are submitted annually to a joint 
database, The European Surveillance System. Four types of data on HIV/AIDS 
are collected in a standardized way: HIV case-based, HIV aggregated, AIDS case-
based, and HIV tests (aggregated). This standardized data collection system 
makes comparisons across the region easier, and improves data quality and con-
sistency; therefore, it is important to maintain this data collection. Every year by 
the end of November, ECDC and the WHO Regional Office jointly publish the 
data in the HIV/AIDS surveillance report. Case study 4.1 illustrates how HIV 
surveillance data can be used to detect outbreaks.
Estimates of HIV prevalence derived directly from targeted studies among key 
populations of PWID, SWs, and MSM help generate more accurate indicators of 
current epidemic patterns than reliance on case reporting alone. Our analysis of 
the published literature indicates that around two-thirds of countries in Europe 
had undertaken studies to either directly measure HIV prevalence or risk behav-
iors in all three populations of PWID, SWs, and MSM. However, only 18 had 
evidence suggestive of monitoring (that is, undertaking several studies over time 
that could provide repeated measures) of either HIV prevalence or risk behaviors 
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in all three of these populations, while another 18 countries had evidence of this 
undertaking among two of these populations (map 4.1). In five (10%) countries, 
no evidence was identified, suggesting monitoring among these populations.
These findings should be interpreted cautiously as our literature review col-
lated documents in English, French, Russian, and Spanish only and thus may 
underestimate the extent to which surveys directly measure HIV prevalence or 
risk behaviors, especially among other vulnerable and key populations such as 
migrants.
Monitoring HIV in Key Populations
Second-generation HIV surveillance systems in countries with either a concen-
trated or a low-level epidemic, such as those found in the Europe, try to combine 
monitoring of HIV diagnoses with monitoring of HIV prevalence and related risk 
in higher risk groups. The 55 countries we considered all had HIV case reporting 
systems. In one-third of the countries (18) there was evidence to suggest “com-
prehensive” surveillance among PWID, MSM, and SWs (i.e., monitoring HIV 
prevalence or risk in all three groups), in another one-third of the countries (18) 
there was “extensive” surveillance (i.e., monitoring HIV prevalence or risk in two 
case study 4.1 Use of Hiv case reports to Detect outbreaks
In 2011 increases in new diagnoses of HIV were reported in Greece and Romania. In Greece 
during the first 10 months of 2011, cases among PWID increased to 190. Historically, Greece 
has been a low-prevalence country. Prior to 2010, between 2 and 5 cases of HIV attributed to 
injecting drug use were reported annually in Romania, but in 2010 this increased to 12 cases 
and in 2011 to 62 cases. Both countries maintain that surveillance has not changed over the 
time period, ruling out the observed increases as a consequence of enhanced surveillance. 
A  behavioral survey undertaken in Bucharest highlighted some changes in drug-taking 
practices, suggesting increased use of amphetamine-type stimulants in place of heroin, with 
reports of more frequent injection and needle/syringe sharing.
Causes of the outbreaks have been attributed to low coverage of opioid substitution 
therapy (OST) among PWID in Greece and Romania (<20 per 100 PWID); long waiting times for 
OST (up to 7 years in Greece and from 1 to 6 months in Romania); and insufficient distribution 
of needles/syringes. The recent economic crisis has been blamed for increasing the vulnerability 
of young people to drug use, especially with the reductions in public health budgets and HIV-
prevention programs in Europe.
While further epidemiological investigation is required to understand the extent of the 
outbreaks and associated risk factors, the benefit of HIV case reports in detecting outbreaks as 
well as the role of behavioral data to interpret changes is evident. Other countries such as 
Iceland or Italy, that have been severely affected by the recession need to be carefully 
monitored, and attempts must be made to ensure that funding cuts do not affect the delivery 
of HIV-prevention and treatment services.
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of the groups); in 9 of the countries there was “focused” surveillance (i.e., moni-
toring HIV prevalence or risk in one of the groups), and in 5 countries there was 
a “basic” approach relying solely on HIV case reports (map 4.1).
Monitoring HIV and the Level of the HIV Epidemic
HIV prevalence was 5% or more in the best estimate studies of PWID in 21 of 
the countries where studies were identified. Of these, 18 had repeated studies 
monitoring HIV prevalence among PWID and 16 of risk behavior (map 4.2). In 
Turkey which had high prevalence (>5%) among PWID, there was no evidence 
found indicating the monitoring of prevalence or risk behavior. In Ireland preva-
lence was over 5% (although the sample size was small), and there was no evi-
dence of repeated measures of HIV prevalence among PWID. The annual 
average of HIV diagnoses linked to injecting drug use was 8.8 per million people 
between 2006 and 2010, a rate higher than the average linked to injecting in the 
rest of Europe (4 per million). Of the 14 countries with moderate HIV preva-
lence (>1% and <5%) among PWID, there was only one country (Israel) with no 
evidence of targeted monitoring of either prevalence or risk behavior. This indi-
cates that studies among PWID to directly monitor risk need to be implemented 
in Israel and Turkey, and expanded in Ireland to include monitoring of prevalence 
among PWID.
map 4.1 monitoring of Hiv prevalence or Behaviors among msm, pWiD, and sWs
Source: Literature Review. See tables B.7–B.10.
Note: All these countries have HIV case reporting systems. HIV = human immunodeficiency virus; MSM = men who have sex with men; 
PWID = people who inject drugs; SWs = sex workers.
No data
Comprehensive
Focused
Basic
Extensive
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In the 10 countries with high HIV prevalence (>5%) among SWs, 6 had under-
taken repeated studies to monitor HIV prevalence, and 7 had undertaken studies 
to monitor risk behavior (see map 4.3 for data on female sex workers [FSWs]). In 
two countries of high prevalence (>5%) among SWs (Portugal and Turkey), there 
was no evidence of direct monitoring of either HIV prevalence or risk behavior. 
Of the 15 countries with moderate HIV prevalence (<1% and >5%) among SWs, 
4 had no direct measures of prevalence or risk behaviors over time (Croatia, the 
Czech Republic, Norway, and Romania). Studies to provide repeated measures 
among SWs thus need to be implemented in Portugal and Turkey, and improved 
in Estonia and the Netherlands. This is particularly important given the lack of 
routine HIV/STI epidemiological data in relation to sex work in Europe [8].
Studies of male SWs were found in only six countries across the region, all of 
which reported high HIV prevalence (>5%). Three of these studies were con-
ducted in the countries with the highest annual average HIV case reports per 
million people between 2006 and 2010 (the Netherlands, Spain, and the United 
Kingdom). Other countries with annual above average cases among MSM (such 
as Denmark, France, Greece, Ireland, Luxembourg, Portugal, and Switzerland) 
should consider implementing targeted prevalence studies among male SWs.
In four countries of high prevalence (>5%) among MSM, there was no evi-
dence of repeated targeted studies to monitor prevalence or risk behaviors (Italy, 
Luxembourg, Poland, and the Slovak Republic) (map 4.4). In Israel, the one 
country without a prevalence estimate but with an annual average of 10 or more 
HIV diagnoses among MSM per million people between 2006 and 2010, there 
was also no evidence of monitoring. Of the 23 countries with moderate HIV 
prevalence among MSM (between >1% and <5%), 8 had no monitoring of either 
Biobehavioral surveillance among PWID in Europe HIV prevalence among PWID
Both
No data
Prevalence only
Behavioral only
None
No data
0%–1%
2%–5%
6%–20%
>20%
map 4.2 monitoring Hiv and risk among pWiD and the extent of the Hiv epidemic
Source: Table B.7.
Note: HIV = human immunodeficiency virus; PWID = people who inject drugs.
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prevalence or risk behaviors (Azerbaijan, Croatia, Cyprus, Finland, Malta, Latvia, 
Romania, and Turkey). There is a need, therefore, to implement studies to 
directly monitor HIV risk among MSM in 12 countries, and to expand monitor-
ing activities to include measures of prevalence in other countries as well.
Evidence thus shows that activities to directly monitor HIV prevalence or risk 
are well established in Europe among PWID, but less so among SWs and MSM. 
It is important that macroeconomic transitions, including spending cuts in the 
Biobehavioral surveillance among FSWs in Europe HIV prevalence among FSWs
Both
No data
Prevalence only
Behavioral only
None
No data
0%–1%
2%–5%
6%–20%
>20%
map 4.3 monitoring Hiv prevalence and risk among FsWs and the extent of the epidemic
Source: Table B.8.
Note: FSWs = female sex workers; HIV = human immunodeficiency virus.
Biobehavioral surveillance among MSM in Europe Estimates of HIV among MSM
Both
No data
Prevalence only
Behavioral only
None
No data
<1%
1%–5%
6%–8%
9%–11.8%
map 4.4 monitoring Hiv prevalence and risk among msm and the extent of the epidemic
Source: Table B.10.
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men.
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area of public health, do not deter nations from resourcing targeted studies to 
directly monitor HIV among key populations, especially in countries where HIV 
prevalence is above 1% in populations at risk.
Strategies for Strengthening Surveillance Studies
There is likely scope to strengthen the methods of targeted surveys used to 
directly measure HIV prevalence and risk in populations at risk. Key indicators 
of quality in the methods of targeted population surveys of prevalence and 
risk include the ability to (a) recruit broadly reflective samples of the popula-
tions; (b) measure biological outcomes; (c) collect reliable behavioral data; and 
(d) obtain sufficient sample sizes. For surveillance studies which may need to be 
sustained over years, if not decades, a pragmatic balance between robustness and 
cost will be needed. Ideally, surveillance systems (a) use a standardized definition 
of the population (if not across different geographical locations at least over 
time); (b) collect repeated data from the same or comparable location(s) in order 
to monitor trends; (c) generate data on risk exposure and practices, including 
structural risk factors; and (d) collect biological indicators in relation to HIV, 
hepatitis C virus (HCV), and STIs while using consistent or comparable meth-
odologies over time [9–16].
Sampling Vulnerable and Key Populations
Of critical importance is consistently using an appropriate sampling methodol-
ogy to obtain a sufficiently large sample [17–18]. Community-based methods, 
such as the use of respondent-driven sampling [19–22] in combination with 
methods to assess recruitment network effects [20, 23], as well as time location 
sampling [24, 25] and chain referral sampling [26–28], are well suited to 
researching key populations. Our review gave particular emphasis to studies of 
prevalence and risk that adopted community-based and multilocation sampling 
methods that seek to avoid potential biases linked to recruiting key populations 
in clinical settings. However, these sampling methods can be relatively complex 
and potentially costly, and thus are often not well suited as routine tools of public 
health monitoring [29]. It is also important to note that these sampling methods 
are subject to their own biases (and may overrecruit particular subpopulations or 
networks). While potentially less robust methodologically, pragmatic and cost-
efficient sampling approaches suitable for surveillance studies typically involve 
recruitment through existing structures, such as low-threshold services, known 
venues and congregational sites, outreach, and Internet sites. However, sampling 
only through clinical and treatment settings (such as STI and OST clinics) should 
be avoided.
Centralizing Data Collation
At present there is no centralized portal for the collation and synthesis of HIV 
prevalence data at the European level, a former responsibility of Euro HIV [30]. 
The development and maintenance of monitoring activities at a national level 
could be aided by the European-wide central collation of core data on HIV 
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prevalence and risk behaviors. The extent of surveillance among PWID in 
European Union (EU) countries, especially in medium-prevalence settings, is 
likely an indirect consequence of the central collation system operated for HIV 
prevalence among PWID by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) [31]. Data on directly measured HIV prevalence 
among key populations of PWID, SW, and MSM should be collated centrally. 
Consideration should also be given to collecting risk behaviors data centrally, as 
well as data from other populations at risk, including migrants.
Measuring HIV Incidence
Consideration should be given to estimating HIV incidence in key populations 
at high risk. Cohort studies are costly and complex, yet incidence can be assessed 
in other ways, including via laboratory testing algorithms and data from serial 
cross-sectional surveys. Laboratory testing algorithms, such as the Serological 
Testing Algorithm for Recent HIV Sero-conversion (STAHRS), may be particu-
larly fruitful [32–34]. Using STARHS to assess HIV incidence in prevalence 
studies of hidden populations of PWID and MSM has proved particularly useful 
[35]. STARHS data should be considered among PWID and MSM along with 
the collection of data on past HIV testing and the uptake of antiretroviral ther-
apy (ART) in countries with high prevalence (<5%) in these populations.
Estimating Population Size
In addition to surveys that directly measure HIV prevalence and risk, a key ele-
ment of an effective public health surveillance program is the capacity to quan-
tify the size of populations at risk. Most countries have published estimates of the 
size of populations of PWID and SWs, although these may not be recent, and few 
countries have published estimates of the size of MSM populations. Without an 
estimate of the denominator, or the population group at risk, it is difficult to 
measure whether HIV prevalence at a general population level is increasing or 
whether it is the size of the population group that is changing. Estimating the size 
of a population at risk not only assists in the allocation of intervention resources 
but is essential for estimating the coverage, and thereby impact of interventions 
[36–38]. As we note further below, intervention coverage, in combination with 
epidemic situation and behavior change, is a critical determinant of HIV preven-
tion [39, 40]. There is now established guidance, as well as evidence, on the 
methods best used to assess the size of hidden populations at risk [41–43].
The Social Context of Surveillance
A key challenge in collecting data to inform interventions is the political context 
in which sex work, drug use, and MSM takes place. In contexts where, for 
example, sex work is heavily regulated or MSM is stigmatized, conducting sur-
veillance among people with few rights or representation may create ethical and 
safety concerns for the populations involved. Proposals for surveillance need to 
be conducted in full consultation with the populations in question and their 
advocates, in order to include appropriate protections in surveillance systems [8].
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Hiv-prevention responses among people Who inject Drugs
To complement our systematic review of epidemiological data presented in 
chapter 3, here we draw on a variety of data sources, including recently published 
systematic reviews [1–5] and HIV-prevention data collated by the EMCDDA [6]. 
We do this in order to synthesize key estimates of intervention “coverage” as well 
as to describe how policy environments mediate the delivery of HIV prevention 
for PWID. We emphasize the potential enhanced impact of HIV-prevention 
interventions that operate in combination and of interventions targeting policy 
and environmental change.
Combination HIV Prevention for PWID
HIV prevention targeting PWID is increasingly envisaged as a product of “com-
bination intervention,” with a strategy comprising a package of interventions 
tailored to local settings and needs [2, 5, 7–9]. This combination of interventions 
may draw on those identified by WHO and other international agencies essential 
to evidence-based HIV-prevention targeting PWID, including needle and syringe 
exchange programs (NSPs), OST, ART, the provision of drug consumption rooms 
(DCRs), peer education and outreach, HIV testing and counseling services, and 
the promotion of public policies and other structural changes conducive to pro-
tecting the health of populations at risk [10]. We will concentrate here on the 
three cornerstone HIV-prevention interventions of NSPs, OST, and ART, but will 
also emphasize the importance of increasing uptake of HIV testing in order to 
identify those in need of ART (box 4.1). The two most recent systematic reviews 
of evidence of the effectiveness of HIV-prevention targeting PWID are those by 
Degenhardt et al. [40] and Kimber et al. (2010) [295].
Reviews conclude that there is strong evidence linking NSPs to reduced levels 
of HIV risk among PWID, as well as evidence linking NSPs with the reduction 
of HIV incidence among PWID [12, 15–17]. Intervention coverage appears piv-
otal, with the intervention effect likely proportional to the volume of needles and 
Box 4.1 Four core Hiv-prevention interventions
nsps provide sterile needles/syringes and other injecting equipment to PWID, via fixed-sites, 
outreach, peer PWID networks, vending machines, and pharmacies. By maximizing the num-
ber of clean injecting equipment in circulation, we minimize the time infected equipment 
remains in use and the proportion of unsafe injections [11].
ost is prescribed to dependent users to diminish the use and effects of illicitly acquired opi-
ates. It is usually taken orally and therefore reduces the frequency of injection and unsafe 
injecting practices [12].
Art is prescribed to HIV-positive PWID to reduce viral load and consequently can reduce HIV 
transmission [13, 14].
Hiv testing is expanded to enable timely start of treatment.
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syringes distributed and in circulation and the proportion of sufficient clean 
versus unclean equipment [2, 18]. There is also a large body of evidence showing 
the effectiveness of OST in HIV prevention [2, 4]. Sufficiently high doses of 
OST in combination with sufficient retention in treatment are linked to reduc-
tions in both drug use and HIV risk [19–21], including a reduction in HIV inci-
dence [4, 22–28]. Given the evidence of effectiveness of both methadone and 
buprenorphine [20, 29], the WHO lists these as essential medicines for the 
treatment of opioid dependence worldwide. Despite this evidence some resis-
tance remains to the provision of OST to PWID in the region, notably in Russia; 
reasons for this are examined in case study 4.2. In addition, regarding the HIV-
prevention impact of ART, evidence suggests that lowering viral load prevents 
HIV transmission in serodiscordant partners, thereby reducing HIV incidence 
[30, 31]. A prospective cohort study found that among PWID, the concentration 
in plasma of HIV-1 RNA predicted community-level HIV incidence, including 
after adjustments for injecting and sexual risk behaviors [32]. This decline 
occurred as the coverage of ART among PWID increased from 43% to 70% and 
as the proportions treated with ART increased from 8% to 99%.
Combination Intervention Effects
Evidence points towards the enhanced impact of HIV-prevention interventions 
when they are delivered in combination [2, 7]. Cohort and modeling studies 
have shown that the impact of NSP and OST on reduced incidence of infectious 
disease among PWID can be modest if delivered as “stand-alone” interventions 
but they are markedly more effective when delivered in combination, with suf-
ficient willingness among PWID to use both methods [2, 7]. This may be espe-
cially the case in reducing the incidence of HCV among PWID [15]. To date, 
there is only one European study showing that “full participation” across com-
bined interventions (NSP and OST) can reduce HIV incidence (by 57%) and 
case study 4.2 the Hiv-prevention impact of introducing ost in the 
russian Federation
One of the strongest voices of policy resistance to OST emanates from Russia, where the use 
of methadone and buprenorphine in treating opioid dependence is legally prohibited. 
Resistance stems from efforts to preserve existing drug treatment systems and to prevent 
the diversion of new medicines (such as methadone or buprenorphine) to the illicit market 
or to monitor the safe use of these drugs. More fundamentally, resistance to substitution 
treatments is grounded in the history and teaching of “narcology,” a subdivision of Soviet 
criminal psychiatry, which conceives of treatment from addiction in abstinence terms. 
Narcologists have opposed the use of methadone in opioid treatment as a “vicious practice,” 
using a “toxic” substance that  creates an even more severe addiction; they also see it as one 
step removed from “legalizing” drug use, as a failing intervention of the West, and most 
 significantly, as a failure to deal with the criminality of drug users [33–35].
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HCV incidence (by 64%) [7]. Based in Amsterdam, this cohort study recruited 
PWID from 1985. The study found that HIV incidence among PWID was inde-
pendently associated with accessing a higher level of HIV prevention and harm-
reducing interventions (see figure 4.1). Multivariate analyses found that after 
adjustment, clients participating “fully” in available services (daily full dose of 
methadone and either no injecting or always using NSPs) were at 57% less risk 
(95% confidence interval [CI] 13%–79%) of HIV than participants not accessing 
such services; those participating in a “limited” fashion (either full NSP and less 
regular methadone, or full methadone and less regular NSP) were at 13% 
reduced risk (95% CI 52% greater risk to 50% less risk) of HIV than participants 
not accessing these services [36]. Similar findings have emerged from a study in 
four Central Asian countries conducted over 18 months [37].
Just as the effectiveness of NSP and OST services may be enhanced when 
combined, there is an enhanced impact relationship between participation in 
OST and adherence to ART among PWID [38–40]. Similarly, low-threshold 
access to HIV testing is an important combinative component of HIV preven-
tion. In Western Europe, there is a considerable level of homogeneity in policy 
priorities regarding measures to limit the spread of infectious diseases among 
drug users, with NSP being offered either in combination with voluntary 
 counseling and testing (VCT) for infectious diseases, or in combination with the 
 dissemination of information, education, and communication materials [41]. 
Additionally, the integration of ART with TB treatment and prevention is a 
 critical feature determining health outcomes in people living with HIV [42], 
especially so in Eastern Europe where TB drug resistance among PWID is most 
frequently reported [43]. While documented examples are sparse, descriptive 
evidence suggests that fully integrating services facilitates retention in treatment. 
For instance, in Dnipropetrovsk, Ukraine, a program combining OST, ART, and 
testing for TB, HIV, viral load, and CD4, with counseling and psychosocial 
 support, reported an overall retention rate of 70% (n = 428) among PWID [44]. 
In figure 4.1 we explore further the effect of different interventions on HIV 
incidence and prevalence among PWID.
Drawing on the exemplar of the Amsterdam cohort noted above [7], recent 
mathematical modeling studies have sought to project the effects of escalating 
Incomplete harm reduction
Full harm reduction
Study or subcategory
0.74 (0.43, 1.27)
Incidence rate ratio (fixed) 95% CI
Favors harm reduction Favors no harm reduction10.1 0.2 0.5 2 5 10
0.32 (0.17, 0.61)
Figure 4.1 effect of Full and partial combined interventions on Hiv incidence
Source: Van Den Berg et al. 2008 [51].
Note: CI = confidence interval; HIV = human immunodeficiency virus.
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coverage of NSP, OST, and ART interventions delivered in combination to 
PWID [2]. Figure 4.2 reproduces these findings, showing the effect of different 
intervention combinations and yearly recruitment rates on HIV incidence 
among PWID after five years. Figure 4.2 shows that single interventions may 
have limited effect, whereas interventions in combination have greater effect, 
and that medium- to high-intervention coverage is required in order to have a 
substantial effect on HIV incidence. In addition, the HIV prevention impacts 
of ART are appreciable (37%), especially when delivered to all HIV-positive 
PWID with CD4 counts lower than 350 cells per μl.
Coverage of HIV-Prevention Interventions among PWID
Coverage has been defined as the proportion of the population at risk reached 
by an intervention, ideally with sufficient intensity to have probable impact, and 
is a critical determinant of assessing HIV-prevention effectiveness [2, 18, 45, 46]. 
Data summarizing the coverage of HIV-prevention interventions was drawn 
primarily from published reviews that emerged from the Reference Group to the 
United Nations (UN) on HIV and Injecting Drug Use. These reviews draw on 
data from a variety of sources including the United Nations General Assembly 
Special Session (UNGASS), WHO, and systematic reviews of scientific literature 
[1] and country-level data collected by the EMCDDA, which draws on data 
from routine reports from European governments [47].
Needle and Syringe Exchange Programs
The systematic review showed [1] that 53 of the 541 European countries (as 
defined by WHO) reported evidence of injecting drug use, and all but 5 have NSPs. 
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Of the five countries not providing NSPs (Andorra, Iceland, Monaco, San Marino, 
and Turkey), only Turkey has a total population of over 500,000.
There is wide variability in the estimated coverage of NSPs, and coverage itself 
can be measured in a variety of ways [46]. The review defined coverage to be the 
number of needles distributed per PWID per year. The data do not include pur-
chases from pharmacies (see map 4.5) which may constitute a significant propor-
tion of the equipment in circulation, especially in Eastern Europe. The operating 
rules of NSPs can also differ with some programs offering unlimited needle/
syringe distributions and others offering exchanges only. Some NSPs limit the 
number of needle/syringes that can be exchanged to only a few at a time, increas-
ing the number of contacts a person has with an exchange program and compel-
ling them to retain used needles for longer periods of time than they might do 
otherwise. This may increase the likelihood of PWID reusing the needles as well 
as increase the likelihood of police harassment in some countries [48–50]. It also 
does not account for possible secondary distribution and may underestimate the 
number of PWID benefiting from NSPs. Finally, the number of syringes a PWID 
needs in order to use a sterile needle for every injection will depend on their 
personal drug use, which may include such factors as duration of injecting, types 
of drugs injected, and whether or not they use OST. Given these limitations, 
comparisons between the coverage data presented here should be interpreted 
cautiously.
In Finland in 2009, over 13,000 PWID (about 85% of the total), received over 
three million syringes, an average of around 230 per person [6]. In Russia in 2008, 
301+
No data
101–300
51–100
6–50
<5
map 4.5 number of needles Distributed per pWiD in 2009 or most recent Year
Sources: EMCDDA Statistical Bulletin [50]; Mathers et al. [36].
Note: PWID = people who inject drugs.
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only 7% of PWID (less than 130,000 individuals) accessed NSPs, receiving an 
average of only 56 needles per person [1]. Coverage estimates vary widely even 
within European subregions. In Eastern Europe, for example, the percentage of 
PWID accessing NSPs is estimated between 1% (0.6%–11%) in Georgia in 2008 
and 68% (52%–97%) in Lithuania in 2007 [1]. In Western Europe access ranges 
from 4% (2%–6%) in France in 2007 to the much higher rate of 81% in Finland 
in 2007. There are less data for Central Europe, but 15% of PWID in the Slovak 
Republic accessed NSPs in 2008 and 50% in Hungary in 2007. The estimated 
number of syringes distributed per estimated PWID in 2009 (or the latest year 
for which data are available), range from under 5 syringes in Russia (a very high 
prevalence country; see chapter 3) to over 300 in Norway and over 500 in 
Moldova.
Social-structural factors may play a large role in why so few needles and 
syringes are accessed by PWID in some parts of the region. Reports from Ukraine 
of unjustified police harassment outside NSPs and narcology clinics where OST 
is administered may deter many PWID from visiting or returning to obtain clean 
needles or treatment. Stories of detention, compulsory drug testing, and subjec-
tion to humiliating procedures are commonplace in cities such as Sumy and 
Ternopil [52]. A mixed-methods study from three cities in Russia involving over 
200 interviews and 1,500 questionnaires with PWID reported 93% of injectors 
accessing clean syringes from pharmacies and only 7% ever having been in con-
tact with city NSPs [48, 53]. Pharmacies were described as being extremely easy 
to access, unlike NSPs that could be situated far away; furthermore, travel costs 
outweighed the benefits of free equipment and using NSPs increased the likeli-
hood of police interference. One-for-one exchange policies at NSPs were also 
described as unreasonable because storing and transporting used syringes 
increased the risk of being discovered as a drug user by relatives or the police. 
NSPs were seen as useful for receiving additional benefits such as health care and 
for being an understanding environment [48, 54].
Given the mixed coverage of NSPs in the region, pharmacies provide a signifi-
cant point of access for sterile syringes in many parts of Europe. Accounts from 
the East often describe pharmacies as the preferred method of obtaining sterile 
injecting equipment and may be the primary source of sterile needles: in a survey 
of three Russian cities involving nearly 1,500 PWID, 93% of respondents used 
pharmacies as their main source of clean injecting equipment [48]. In Northern 
Ireland in the United Kingdom, free syringes are only available through pharma-
cies [55]. In Sweden, however, pharmacy sales are legally restricted, and needles 
are only available through two hospital-based outlets, denying PWID clean 
equipment from this source [45, 55].
Although both NSPs and pharmacies may be accessible to PWID in some 
regions, in other settings the possession of a syringe, especially a used one, may 
constitute evidence of drug use and/or lead to harassment or arrest [48, 50]. In 
Ukraine, for example, the threshold for the offense of legal possession of drugs in 
2010 was reduced to 0.005 g of the most commonly injected drug, hanka, the 
possession of which could potentially lead to a jail term of three years. While this 
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threshold has been increased in recent years, these possession laws worked 
against the widespread transportation and distribution of injecting equipment to 
PWID and have also compromised the work of NSP staff [56].
OST
In Europe, OST comprises methadone- or buprenorphine-based treatments, and 
in fewer cases, heroin-assisted treatment and sometimes morphine. In a system-
atic review of coverage [1], 6 of the 53 countries reporting evidence of injecting 
drug use did not provide OST (including Russia, Turkey, Turkmenistan, and 
Uzbekistan).
As with NSP, the coverage of OST varies greatly throughout the region 
( figure 4.3). It is more complicated to compare the uptake of OST across the 
countries since OST is available to both injectors and those who use opiates 
through other modes of administration. So the denominator is often not stan-
dardized across the countries. In Spain or the Netherlands, for example, less than 
10% of opiate users inject [6]. A country with low-injecting rates among opiate 
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Figure 4.3 ost coverage in europe for 2009 or most recent Year
Sources: [1, 6].
Note: Black bars show the range of estimates available; OST = opioid substitution therapy: PWID = people who inject drugs.
† = Croatia estimate of PWID receiving OST per 100 PWID is implausible; however it is included for completeness.
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users would have an overestimated rate of OST per 100 PWID, compared with 
countries where the majority of opiate users inject. In some central European 
countries including the Czech Republic, the Slovak Republic, and increasingly 
Hungary, many injectors report amphetamines and methamphetamines as their 
primary drug, for which no substitution treatment exists. As a result, these coun-
tries will have a low rate of OST per 100 PWID compared with countries where 
opiates are more common.
The highest reported absolute number of individuals receiving OST are in 
France, Italy, and the United Kingdom, where over 100,000 individuals received 
OST in 2009 or in the last year recorded [6]. Of the countries with reported 
data and excluding Russia and Uzbekistan where OST is unavailable, the small-
est reported absolute numbers of individuals receiving OST are in Ireland, 
Montenegro, and Tajikistan, where less than 50 individuals received OST in the 
last year recorded. Accounting for the number of PWID and estimated rates of 
injecting among opiate users (assuming equal access to OST by injectors and 
noninjectors), Luxembourg had the highest plausible number of PWID receiv-
ing OST (51 out of 100 PWID), followed by Cyprus and the United Kingdom 
(41 each). Without knowing exactly how many opioid-dependent injectors exist 
and are receiving OST in Europe, it is difficult to draw conclusions; however, it 
is clear that generally OST coverage is low and very low outside of the West, 
with no country in the two subregions reporting more than 30 opiate users 
receiving OST per 100 PWID, and it is likely that much fewer injectors receive 
OST. It is not clear why coverage appears low, although limited treatment sites 
as well as geographic location of the service may play a part, or as in the case of 
Kazakhstan, implementation of OST has been limited to pilot projects in need 
of scale-ups [57].
ART
As with NSPs and OST, the global availability of ART for HIV-positive PWID was 
described recently by Mathers, et al., although there are generally less data avail-
able than there are for the other treatment services. Throughout the whole region 
(where data exist) less than 100 PWID receive ART per 100 PWID living with 
HIV. However, data on ART access for other risk groups or the general population 
are not provided, so we cannot draw conclusions about access for PWID com-
pared with other groups. However, a WHO report on PWID access to ART across 
the region [58] describes how in 2002, 46% of HIV cases in the region occurred 
among PWID while only 10% of those receiving ART occurred among PWID. By 
2008 this inequality had decreased, with 42% of HIV cases and 31% of ART 
recipients occurring among PWID. However, this does not include data from 
Russia, which undermines the comparability of the data because of Russia’s mag-
nitude of PWID and HIV among PWID [58]. Data from 2008 indicate that while 
PWID make up 83% of HIV cases in Russia and 60.5% in Ukraine, they only 
constitute between 20% and 30% and 24% of ART recipients, respectively [3].
In Western Europe the number ranges from 10 (6–22) PWID receiving 
ART per 100 HIV-positive PWID in Portugal to 70 in Luxembourg, although in 
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absolute numbers this means only 39 PWID have accessed ART. Spain has the 
most PWID accessing ART at nearly 40,000, although this number may be pro-
portionally smaller because of Spain’s much larger HIV-positive PWID popula-
tion. In Eastern Europe and the former Soviet Union, the rates vary from less 
than 1% (<1–33%) in Russia to 18% (8%–48%) in Armenia. There are less data 
for Central Europe, but the Czech Republic reports 81 PWID receiving ART for 
every 100 HIV-positive PWID, although this is based on very small numbers of 
HIV-positive PWID.
The view that PWID are less likely to adhere to ART unless they have either 
stopped injecting or are receiving full OST services is increasingly challenged. 
A study from Amsterdam, for instance, found that PWID who are currently 
receiving ART are similar in number to drug users regularly accessing OST and 
NSP as well as those who were no longer injecting or relying on harm-reduction 
programs [59].
Combination HIV Prevention for PWID
Despite emerging evidence, especially from mathematical modeling studies [2], 
of the potential impact of developing HIV-prevention interventions in combina-
tion for PWID, data on the coverage of combination interventions are not 
 routinely or systematically collected in the region.
Modeling the Impact of Combination HIV-Prevention
As we have noted above, there is evidence of the effectiveness of OST, ART, and 
NSP in reducing HIV risk and prevalence; yet in most Central and Eastern sub-
regions coverage remains low, especially when these interventions are considered 
in combination. OST is unavailable in Russia and programs in Estonia and 
Ukraine are believed to reach only around 7% and 2% of PWID respectively 
[60]. ART coverage is disproportionately low among PWID in Europe compared 
with the general population [58], and it is particularly low in high-prevalence 
settings where the proportion of HIV-positive PWID receiving ART is estimated 
to be much less than 10% [60].
Drawing on a mathematical modeling analysis, we also consider here the 
potential impact that OST, ART, and NSP prevalence has had on HIV incidence 
in three illustrative epidemic scenarios in Russia, Estonia and Tajikistan. Two of 
the scenarios are based on the high HIV prevalence (>40%) settings of 
St. Petersburg (Russia) and Tallinn (Estonia), whereas the third is based on a 
lower HIV prevalence (<20%) setting of Dushanbe (Tajikistan). All three settings 
currently have very low coverage of OST and ART among PWID at less than 
10%. NSP coverage is high in Tallinn (~70 syringes per PWID per year [61]), 
moderate in Dushanbe (10–20 syringes per PWID per year [62]) and low in 
St. Petersburg (personal communication Robert Heimer).
Figure 4.4 below shows the required coverage over 10 years of different 
intervention combinations for achieving a 30 or 50% relative decrease in HIV 
incidence or prevalence compared to baseline. Different combinations are con-
sidered for each setting because Tallinn already has high baseline coverage NSP, 
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which is taken as the comparator for that setting, while Dushanbe has moderate 
coverage NSP.
For St. Petersburg, the projections highlight that high-coverage levels of NSP 
on their own (79% coverage for a 50% reduction in HIV incidence over 10 years) 
are required to achieve a 30%–50% decrease in incidence over 10 years—similar 
to the high-NSP coverage already achieved in Tallinn. However, if NSP is com-
bined with ART or OST in St. Petersburg, then the required coverage level 
for each intervention is decreased by one-half to two-thirds of what it was for 
NSP only. When all three interventions are combined, the required coverage 
levels decrease further by 25%–50%, with only a 12% coverage of each interven-
tion required to achieve a 30% reduction in HIV incidence over 10 years in 
St. Petersburg.
Similar findings are obtained for Tallinn and Dushanbe except that the cover-
age required for a single additional intervention (OST or ART on top of the 
existing NSP) to reduce incidence by 30% or 50% are about one-half of the levels 
required in St. Petersburg. This can be explained by the lower baseline HIV inci-
dence in Tallinn and Dushanbe in 2012 due both to the preexisting moderate- or 
high-coverage NSP interventions and the lower overall risk of HIV in Dushanbe.
In any of the three settings over a 10 year period, about double the coverage 
level is required in order to achieve the same reductions in HIV prevalence (rela-
tive to previous requirements for achieving the same reduction in HIV incidence 
in each setting). The required increase in coverage is also more pronounced if 
ART is involved because ART extends survival rates, thereby extending the time 
that HIV infected PWID remain in the population.
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Figure 4.5 considers the required coverage of each intervention combination 
to either reduce HIV incidence to less than 1% or HIV prevalence to less than 
10% over 20 years. The projections for single interventions are not shown 
because they were unable to achieve these impact targets, except for Dushanbe, 
where coverage levels of about 85% and 65% of any single intervention reduced 
HIV incidence to <1% or prevalence to <10% after 20 years, respectively. For any 
pair of interventions, projections suggest that very high coverage levels of above 
80% are generally required to achieve these targets for the higher prevalence 
 settings of Tallinn and St. Petersburg, whereas much lower coverage levels 
(30%–50%) are needed in Dushanbe. Lastly, if all three interventions are com-
bined, these coverage requirements are reduced by one-quarter in all settings, 
from 55% to 62% coverage of each intervention being required in Tallinn and 
St. Petersburg to 23%–30% in Dushanbe.
These projections suggest that high but achievable coverage levels of NSP can 
result in large decreases (>30%) in HIV incidence and prevalence in settings with 
high HIV prevalence among PWID. Required coverage levels are much lower 
when interventions are combined or in lower prevalence settings. The analysis 
also highlights the importance of combination interventions for reducing HIV 
incidence and prevalence to low levels in high-prevalence settings. Only high 
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coverage in the lower prevalence setting of Dushanbe (or no single intervention 
elsewhere) is able to reduce HIV incidence to less than 1% or prevalence to less 
than 10% in 20 years. However, in combination these targets become more 
 feasible, although still considerable, with about 60% coverage of all three inter-
ventions being required to achieve these targets in Tallinn and St. Petersburg over 
20 years, and about 30% coverage in Dushanbe.
HIV Testing Services
In Western Europe a high proportion, generally over 90%, of PWID participating 
in studies reported having previously been tested for HIV. An exception to this 
was in 2005 in Italy where only 61% reported being previously tested for HIV 
[63]. In the East levels varied widely, from 11% to 95% of PWID ever having 
previously been tested for HIV. In the previous 12 months, the estimated propor-
tion of PWID who had been tested and who knew the results varied from as low 
as 5% in Baku and Lenkoran in Azerbaijan [64] to as high as 72% in Vilnius, 
Lithuania [65], although more typically the figure varied from around 23% to 
57% [65]. Elsewhere in the region HIV testing among this population was gener-
ally lower. In Central Europe studies from Romania and Serbia showed between 
19% and 22% of PWID who had been tested for HIV in the last 12 months and 
knew the results [66, 67]. In Bosnia and Herzegovina, Bulgaria, and the former 
Yugoslav Republic of Macedonia, the proportion grew to between 36% and 48% 
[68–70]. In Albania in Tirana only about one-third of PWID surveyed in 2005 
and 2008 reported ever having had an HIV test [71, 72]. The highest reported 
proportions in the subregion were in Croatia where 83% of PWID reported ever 
having had a test [73]. Studies from Central Asia varied from the low rates of 
13%–15% of PWID having ever been tested for HIV in Tajikistan and Uzbekistan 
to higher (although still modest) levels of 40%–56% in Kazakhstan and the 
Kyrgyz Republic [74, 75].
High-testing rates in the East generally may be due to mandatory testing of 
migrants and opt-out rather than opt-in testing polices at a variety of locations 
including narcology centers, TB centers, prisons, antenatal clinics, and presurgery 
[76, 77]. Evidence shows that a history of HIV testing has been associated with 
reduced risk of HIV prevalence in some cities in Russia [78], although such high 
levels of HIV testing are at odds with low levels of OST, NSP, and ART avail-
ability for PWID.
A Note on Age and Other Restrictions Regarding Service Access
Despite data from Eastern Europe indicating that initiation to injecting can 
 happen well before the age of 18 [79], young people (under 20 years old) are 
often less able to access the above cornerstone HIV-prevention services than 
their older counterparts. Qualitative data from Ukraine, for example, describe 
multiple barriers keeping vulnerable youth from harm-reduction services includ-
ing the need for parental consent and identity papers; distrust of authorities; fear 
of registration; deportation by the police; forced detoxification; institutionaliza-
tion into state child care facilities; inaccessibility of services; and discriminatory 
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attitudes by health providers [80]. Programs are missing a window of opportu-
nity to prevent vulnerable young people from transitioning to injecting or from 
learning risk-reduction strategies that may help them avoid injecting-related 
harms.
In addition, among some countries in the East—including Georgia, Russia, and 
Ukraine—access to drug treatment requires prior registration as an addict [81]. 
Such registration can last for up to five years and can also result in loss of various 
rights as well as reduce access to employment opportunities, increase feelings of 
being stigmatized, and increase vulnerability to police intervention. Concerns 
about registration are often cited as a significant barrier to accessing harm- 
reduction services [48, 53].
Policy Environments Mediating HIV Prevention among PWID
The policy environment, in combination with other social and structural fac-
tors, mediates the development and impact of HIV-prevention targeting PWID 
[82–84]. Our reviews of evidence have noted the potential role of policing 
practices, law enforcement policies, social–material factors, gender, and social 
stigma as social forces shaping risk and prevention responses. Recognizing HIV 
epidemics as features of their social contexts emphasizes the potentially pivotal 
role of interventions in creating environments that are enabling, rather than 
constraining, of evidence-based HIV prevention [82–84]. As noted in “Methods” 
section a crude index of enabling policy environment for HIV prevention 
among PWID may include, but is not restricted to, the following domains: 
(a) the meaningful engagement of key stakeholders (including PWID) in policy 
formation and programming; (b) a coordinated multisectoral national HIV-
prevention strategy emphasizing an evidence-based public health and rights-
oriented approach; (c) the generation of research and surveillance on HIV 
epidemic spread and response; and (d) the development and scale-up of a 
package of evidence-based interventions, including the removal of structural 
obstacles limiting their implementation [2, 85]. Accordingly, there have been 
increasing calls to de-emphasize the criminalization of PWID by developing 
public policies emphasizing public health above law enforcement dominated 
approaches, and for the rapid scaling-up of HIV prevention along with com-
munity action and social support interventions [2, 85–88].
The findings generated by our simple index of enabling policy environment 
(see “Methods” section) are shown in map 4.6 below. Of the 50 countries to 
which we applied the index, 14 have national organizations for drug users. 
Forty-four explicitly and supportively mentioned harm reduction in their 
national strategies. Thirty-seven countries have carried out at least one HIV 
prevalence and one behavioral study among PWID in the last 10 years. OST 
and NSP are available in 46 countries (OST is unavailable in Russia, Turkey, 
Turkmenistan, and Uzbekistan, and NSPs are unavailable in Turkey), and in 
8 countries, OST and NSP are available. Ten countries use administrative rather 
than criminal penalties for people found possessing small quantities of drugs 
for personal use.
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The index suggests that the country with the most supportive policy environ-
ment is Spain, followed by Moldova, Portugal, and Romania. Spain earned posi-
tive scores for each of the five indicators we used for the index. Spain and 
Moldova are among the five countries that are most negatively affected by HIV 
in Europe. The HIV prevalence among PWID in these countries is extremely 
high at over 20%. The other countries with comparable prevalence levels are 
Estonia, Russia, and Ukraine, which appear to have midrange levels of supportive 
policy environments.
The country with the seemingly least supportive environment is Turkmenistan, 
followed by Iceland and Turkey. Turkmenistan does not exhibit any of the char-
acteristics of a supportive environment; however Turkey has undertaken a bio-
logical prevalence and a behavioral study recently, and OST and NSP are 
available in Iceland, outside of prison settings. Among the other low scoring-
countries, both Russia and Turkey reported having undertaken prevalence and 
behavioral monitoring among PWID in the past 10 years, and in Iceland OST is 
available to PWID.
We do not suggest that countries characterized as being more supportive by the 
index have optimal policy environments for HIV-prevention among PWID, and 
we acknowledge the limits of this crude index of policy environment. Another key 
factor indicating a government’s commitment to HIV prevention is the amount of 
money spent; this is illustrated below in case study 4.3. Some countries (Moldova 
and Spain) receive high scores on the policy index, but they also have high HIV 
prevalence among PWID. These scores may be a result of timing, with changes in 
Most supportive
Least supportive 
map 4.6 policy environments for Hiv among pWiD in europe
Sources: INPUD; HRI; EMCDDA; Mathers et al. [36]; systematic review.
Note: HIV = human immunodeficiency virus; PWID = people who inject drugs.
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case study 4.3 evidence of commitment to Hiv prevention
One of the most straightforward ways to measure the level of a government’s commitment to 
HIV prevention is to measure how much money they spend on it. Examining the amount (U.S. 
dollars) spent per capita on HIV prevention versus HIV prevalence among PWID may allow 
us  to draw crude comparisons between the countries in the region where these data are 
available. The most money spent was reported by Luxembourg and Greece at over US$5.00 
each per capita, followed by Estonia at US$4.93. The least reported amount spent was in Bosnia 
and Herzegovina, Cyprus, and Malta with less than US$0.10 spent in each per capita. Although 
they are relatively low-prevalence countries, Azerbaijan and Poland, with around 1 in 10 PWID 
infected with HIV, reported only marginally more dollars spent, at US$0.10 and US$0.11 per 
capita each, respectively. There was some evidence of an association between the money 
spent on HIV prevention per capita and HIV prevalence among PWID (see figure, below). With 
the exception of Estonia, it is clear that countries with higher reported HIV prevalence among 
injecting drug users (IDUs) are among those reporting HIV prevention spending per capita at 
the lower end of the spectrum. In panel a of the figure below, prevalence appears to increase 
with each extra dollar spent when looking at all the data; when focusing on the interquartile 
range, excluding the more extreme values of expenditure per capita, the prevalence appears 
case study continues next page
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the policy environment being made as a result of high HIV prevalence. However, 
the scores may also reflect aspects of the environment not captured here. For 
example, despite the legal availability of methadone for PWID in prison in 
Moldova, availability is relatively low and access is limited. It is not available in 
community settings, which means that many PWID who may want to use OST 
are unable to, and if they do manage to access it inside or outside of prison, they 
may not be able to continue if those circumstances change [89]. Less than 50% of 
PWID have access to OST in Europe, with coverage lowest in the East (see above).
Furthermore, it is important to note that the distinction made in the index 
between drug use being regulated as an administrative offense is not necessarily 
indicative of a more supportive environment; in fact, this distinction may be 
arbitrary in some settings. Findings from our systematic review show higher rates 
of arrest and incarceration among PWID in the East where drug possession is 
more frequently associated with criminal rather than administrative penalties 
but, even in countries where possession of drugs is an administrative offense, a 
high proportion of PWID report being incarcerated. This suggests that for PWID, 
other factors increase vulnerability to arrest and imprisonment, factors that also 
need to be explored further.
Criminalization as a Feature of the HIV Risk Environment
The data gathered from the systematic review suggest that contact with police 
and time spent in prison can be linked to increased risk of HIV. Case study 4.4 
provides an illustration of how policing practices can mediate risk. Drawing on 
the average national prison populations in the region (see “Methods” section) we 
find a positive relationship between the HIV prevalence among PWID and the 
number of people imprisoned in a country (figure 4.6). For every additional 
person imprisoned per 100,000 population in a country, the HIV prevalence 
to decrease for every US$0.10 spent, suggesting some association that is not best characterized 
by a linear relationship. It could well be that there is an optimum amount of money per capita 
that needs to be spent on HIV prevention before prevalence declines or that expenditure 
needs to be focused on targeted interventions.
It is important to highlight the limitations around this variable, which is subject to 
considerable reporting bias. Data on HIV prevention spending per capita were collated from 
the Dublin Declaration [6] and can include a wide range of interventions. Some countries 
include antiretroviral therapy (ART), while others do not. It may also be that countries receiving 
international funding will more accurately report expenditure than countries without external 
funding or with more integrated health systems that cannot disaggregate HIV prevention 
funding from broader sexual health services.
Source: Dublin Declaration Progress Report 2010 [6].
Note: a = relationship between HIV prevalence among PWID and per capita HIV prevention expenditure among all countries; 
b = restricted to the middle 50% of countries only; HIV = human immunodeficiency virus; PWID = people who inject drugs. 
case study 4.3 evidence of commitment to Hiv prevention (continued)
168 Responses to HIV in Key Populations
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8
among PWID in the country increases by 0.039% (95% CI 0.019%–0.058%). 
The majority of countries with high rates of incarceration are in the East, which 
may influence the relationship. However, by excluding the countries with the 
very high and very low rates the positive association remains, although it is much 
weaker and indicates that even among countries with similar, and moderate, rates 
of incarceration, the relationship with HIV prevalence among PWID exists. The 
links between incarceration and individual risk of HIV are well documented (see 
chapter 3), yet the relationship at a national level is less clear and is likely to be 
mediated by an interplay of social factors, such as historical levels of investment 
in criminal justice and public health systems and national cultural responses 
toward criminal justice.
Interventions that specifically attempt to decrease the occurrence of new 
infections and mitigate the impact of infections that occur among PWID are 
generally aimed at changing the individual behaviors of PWID and may do little 
to alter the broader risk environment [48]. A growing body of evidence substan-
tiates the role played by social-structural factors in shaping HIV risk and by 
social-structural interventions in HIV prevention [2, 49, 82]. Case study 4.5 
provides an illustration of national policy change designed to remove the adverse 
effects of criminalization on HIV risk and HIV prevention.
case study 4.4 contact with criminal Justice systems in central Asia
Kazakhstan has the strictest drug laws in Central Asia with penalties of up to 20 years 
imprisonment possible for possession of between 0.01 g and 1 g of heroin, which is 
considered  a “large amount”; sufficient for criminal rather than administrative punishment 
[92]. In addition to this there are documented reports of police planting drugs on drug users 
as well as extorting bribes from them and their families. Harassment, physical violence, and 
unauthorized arrests of PWID by the police are reportedly common [93]. Qualitative studies 
have noted similar findings in other parts of Eastern Europe [94].
The Kyrgyz Republic reports good working relationships between nongovernment 
organizations (NGOs) working with PWID and Ministry of Interior officials and senior police 
who support harm-reduction services for drug users. However, a study in the high-prevalence 
areas of Osh and Jalal-Abad among 73 female PWID revealed that half had spent time in prison, 
primarily for the possession of small amounts of drugs. There are almost no HIV-prevention 
interventions in prisons for women. Some respondents could recall up to 50 instances of 
detention by the police, many of which took place near drug dealing points although the 
dealers themselves were apparently left alone. Bribes, free sex, and information were required 
by police for their freedom [95]. A study in Bishkek among drug users reported that about 36% 
get their drug supplies directly from the police [96].
Tajikistan also reports police harassment and physical abuse toward PWID, and this is 
recognized in the 2007–10 national HIV-prevention strategy as a major reason for poor uptake 
of HIV-prevention services by PWID [97].
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Figure 4.6 Associations between Hiv prevalence among pWiD and number of prisoners
Source: World Prison Population List (7th Edition), International Centre for Prison Studies.
Note: HIV = human immunodeficiency virus; PWID = people who inject drugs.
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case study 4.5 trends toward an enabling environment: portugal
Despite generally low drug use among the population as a whole compared with the rest of 
Europe, Portugal has suffered from relatively high rates of heroin use and HIV among PWID. 
Following the recommendations of a report by the Commission for the National Strategy to 
Fight against Drugs, the Portuguese government took the significant step of becoming the 
first European country to explicitly decriminalize drug use and personal possession, a law 
that took effect in July 2001 [99, 100]. Crucially, in addition to moving from criminal to 
administrative punishment for using and possessing drugs, the strategy called for a number 
of additional principles for guiding action in this area. The National Operational Plan for 
Integrated Responses (PORI) was put in place, and localized rapid assessments of the 
situation and needs at the structural, community, and individual levels were carried out so 
that Programs of Integrated Response (PRIs) could be put in place. These included access to 
primary prevention and harm reduction interventions and reinforcing social reintegration 
case study continues next page
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and drug treatment for drug users as alternatives to prison as well as a number of other 
measures focusing on supply reduction and increasing the resources invested in the area, 
with an additional 10% increase in funding for treatment and harm-reduction services 
annually for three years [101].
Although the impact of the new policy is yet to be fully evaluated, a report published in 
2009 [101] showed that in the subsequent seven years following the enactment of the law, 
changes in lifetime prevalence of drug use did not differ significantly from trends seen in other 
European countries, and the massive increase in drug use, as feared by opponents of the new 
law, did not materialize. It is notable that lifetime prevalence of drug use had in fact decreased 
among those younger than 18 years old, an important age group in terms of future drug 
trends [102]. This decrease has been seen among all drug types. In addition the number of 
drug-related deaths has declined from nearly 400 in 1999 to 290 in 2006, and HIV and AIDS 
notification among drug users has decreased, both in total numbers and in the proportional 
share of the national burden [103].
It is Important to note that in terms of limiting the spread of HIV and other drug-related 
harms among those already using drugs, Portugal has seen a huge increase in the number of 
people in substitution treatment, detoxification, therapeutic communities, and half-way houses 
since the change in law. This has been attributed to multiple factors including a reduction in 
fear of punishment previously associated with admitting drug use; the ability to seek treatment 
freely in an environment with increased capacity for dealing with drug use; increase in resources 
and the number of treatment places available; and reduced waiting times for treatment [104].
case study 4.5 trends toward an enabling environment: portugal (continued)
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case study 4.5 trends toward an enabling environment: portugal (continued)
Although the impact of the new strategy is yet to be fully evaluated, several reports have 
already been published interpreting the early results of the policy [101, 106]. Drug policy tends 
to provoke polarizing opinions and it is possible that data have been selectively used to 
support arguments on both sides of the debate [107]. However, it is likely that in the past 10 
years the improvements seen in health and social outcomes for PWID in the past 10 years can 
be attributed to a comprehensive and coordinated national strategy that is not centered 
around legal solutions, but instead strives to achieve goals by using the core tools of reducing 
harm and promoting treatment [108].
Source: Relatório Anual 2012, A situação do País em material de Drogas e Toxicodependências [294].
Hiv prevention responses among sWs
In this section, we consider selected targeted interventions in the development 
of HIV prevention responses for SWs, especially FSWs. We then consider aspects 
of the policy environment mediating HIV risk and prevention and emphasize the 
need for social-structural intervention responses to target harms associated with 
sex work in addition to STIs and HIV.
Targeted HIV Prevention for SWs
Specialist Services and Coverage
There is a wealth of evidence showing the positive impact of specialist services in 
reducing risk of HIV and STIs among SWs from both Europe and internationally. 
Targeted services have the advantages of opening at convenient times and are 
staffed by people familiar with sex work–related issues and are nonjudgmen-
tal [1]. Yet in many parts of Europe the provision of specialist services is low and 
narrowly focuses on STI/HIV treatment rather than addressing broader social and 
health issues that affect SWs (see case study 4.6). We collated data on the number 
of specialist services across the region that provide a range of social, legal, and 
sexual health services for SWs. These data exclude STI services provided at gen-
eral STI clinics. Across the region, Germany, Russia, Slovenia, and Spain have the 
fewest number of sex worker targeted services (<0.2 per 1000 FSWs). Finland, 
Luxembourg, and Norway have the largest number (>2.8) ( map 4.7).
Other data collected on coverage achieved by STI/HIV clinics are inconsistent 
and patchy. For example, the WHO indicator documenting the number of tar-
geted service delivery points for SWs where STI services are provided was only 
completed by nine countries in 2008 [2]. Within these countries interpretation 
of the indicator varied. For example Germany and Hungary which included all 
dermatovenerology (skin and venereal disease) services that treat SWs, reported 
350 and 125 services, respectively, whereas some countries report that they have 
no specialized services and did not include general STI services. Serbia reports a 
total of five preventive programs implemented by nongovernmental organiza-
tions among SWs in five cities [2].
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case study 4.6 sex Worker services in eastern europe
In the East, the vast majority of services for SWs are attached to harm-reduction services for 
PWID, which may have a separate component conducting outreach or providing sexual health 
information for SWs. There is some evidence to suggest male PWID resent women attending 
these services, which may restrict attendance by FSWs [14]. Evidence from the United States 
suggests that street SWs using drugs receive an enhanced intervention for SWs engaged in 
fewer acts of unprotected oral sex. They also experience less sexual violence than PWID who 
receive a standard harm-reduction intervention, suggesting that targeting interventions for 
SWs is important [15].
The majority of harm-reduction projects provide STI/HIV screening services for SWs, but 
don’t address broader sexual health issues [16]. Other evidence from Eastern Europe reported 
barriers to sexual health services including no links between sexual health and drug treatment 
services, as well as FSW concerns about losing custody of their children. Data from Russia 
suggest that pregnant drug users have poorer access to antiretroviral therapy than nondrug 
users for the prevention of mother-to-child transmission. Data from the region show that 
mother-to-child transmission rates among HIV-positive injecting drug users are higher than 
among other HIV-positive women [14]. Specialist services for SWs in the East need to expand 
their focus on broader sexual health issues.
2.0–4.0
No data
0.9–1.9
0.4–0.8
0.1–0.3
map 4.7 number of specialist sex Worker services per 1,000 FsWs
Sources: services4sexworkers.org; Global Fund; International HIV/AIDS Alliance; TAMPEP.
Note: Services offered include a wide range of sexual health, social support, and legal services and exclude standard STI clinics and health services 
that treat non-sex-working populations; FSWs = female sex workers.
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UNGASS indicators monitoring sex work measure the proportion of SWs 
reached with an HIV prevention program in the last 12 months; the proportion 
of female and male SWs reporting the use of a condom with their most recent 
client; and the proportion of SW who are HIV positive. There has been no analy-
sis of these indicators published, but an analysis of indicators for PWID suggests 
that reporting is inconsistent across the countries [3].
We looked at the relationship between numbers of services per 1000 FSWs and 
the prevalence of HIV among FSW (figure 4.7). When looking at the relationship 
between HIV and numbers of services restricting the analysis to the midrange 
number of services, HIV prevalence appears to decline in relation to the increase 
in the number of sex worker–specific services. It is worth noting that the scattering 
of data points around the regression lines is not very evenly distributed, and while 
a relationship may exist between the variables it may not be best represented by a 
straight line. However, this analysis does point to the importance of treating HIV/
STI in the context of broader social and health issues relating to sex work.
HIV Testing
Across the region mandatory health checks including HIV testing of SWs exist 
in Austria, Greece, Hungary, Latvia, Switzerland, and Turkey only. HIV testing in 
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Figure 4.7 Hiv prevalence and number of services per 1,000 FsWs
Sources: services4sexworkers.org; Global Fund; International HIV/AIDS Alliance; TAMPEP.
Note: Data restricted to the middle 50% range; FSW = female sex worker; HIV = human immunodeficiency virus.
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the Central Asian republics is compulsory and in other countries in the region it 
is frequently enforced following arrest or imprisonment. A qualitative study 
showed how forced HIV or STI testing following arrest was used by the police 
as another way of extorting bribes or controlling SWs [4]. A study of HIV testing 
patterns among SWs in St. Petersburg suggested that the majority of women had 
been tested for HIV (97%), but a large proportion had not voluntarily sought out 
testing; rather, testing had occurred during antenatal care or in prison [5].
In the United Kingdom, a study suggested that 37% of FSWs were tested 
for HIV in the last 12 months [6]. Of the 31 HIV-positive SWs recruited in 
the study in the Netherlands, 23 (74%) were unaware of their HIV-positive 
status [7]. In Russia proportions of FSWs who reported ever being tested for 
HIV was high overall (above 37%). High coverage is partly explained by the 
widespread availability of HIV testing in the region, which encourages volun-
tary testing, in addition to the compulsory testing following police arrest or 
imprisonment. A study examining factors associated with no history of HIV 
testing found that younger women who had engaged in sex work for shorter 
periods of time and who reported sharing drugs with clients had increased 
odds of not being tested for HIV, suggesting that the HIV screening program 
is missing some of the more vulnerable SWs [8]. Access to HIV testing was 
as high in Central Europe as it was in the East; among samples of SWs, more 
than 50% had been tested in Bulgaria, Croatia, and Romania [9–11] and 
between 28% and 40% had been tested in Kosovo and Bosnia and Herzegovina 
[12–13].
Managed Street Zones
Findings from the systematic review indicate that working on the street can 
increase risk of HIV among SWs. Previous research has shown that street-
based FSWs are more vulnerable to physical and sexual violence than off-street 
FSWs [17]. They are also more prone to arrests and problems with the police. 
However, street-based sex work has some advantages for women in that they are 
more mobile, they have fewer time restrictions, and they can more easily work 
 intermittently. From the perspective of intervention services it is also easier to 
find street SWs [18–19]. Nevertheless, it is evident that strategies are needed 
to increase safety among street-based SWs. Some examples of how sex work can 
be organized to minimize risks in both street and off-street settings are given in 
case study 4.7 below.
There are currently nine countries in Europe with managed street-based sex-
work zones (Austria, Belgium, the Czech Republic, Germany, Greece, Hungary, 
Luxembourg, the Netherlands, and Switzerland). The purpose of these managed 
areas is to provide a place where SWs can sell sex without fear of arrest; it also 
moves sex work away from residential or business areas. More established sys-
tems such as those operating in Utrecht (the Netherlands) provide security 
cameras to deter assaults on SWs and there are restrictions on drug use and drug 
dealing. They also provide health and social services and a registration system for 
SWs operating from the area [20]. Some evidence from Germany and the 
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Netherlands suggests that regulatory provision through managed street sex-work 
zones reduces incidences of violence and insecurity [19]. Legislation introduced 
in 1999 in Hungary made it mandatory to establish a “tolerance zone” in urban 
areas populated by more than 50,000 inhabitants. Nevertheless, only two zones 
were established in the towns of Miskolc and Nyiregyhaza; both were greeted 
with such intense protests from local communities that the Nyiregyhaza zone 
was dissolved. The legislation failed to provide details on how the zone should 
operate or what authority was responsible for its upkeep. As a consequence the 
remaining zone in Miskolc has little infrastructure and is run by criminal gangs. 
Projects report that the new legislation resulted in more abuse of SWs by clients 
and police rather than less [21]. Box 4.2 summarizes different types of systems 
to help legislate sex work.
Outreach Work
Both internationally and in the United Kingdom there is evidence to suggest that 
sending outreach workers into sex-work locations to distribute condoms, health 
promotion services, and STI testing reduces risk of HIV/STI among off-street and 
case study 4.7 the importance of location and organization of sex Work in 
Facilitating safer sex Work: examples from tallinn and moscow
In Moscow, street-based female sex workers (FSWs) are hired for a fixed price rather than a 
specific service and time. This can make a woman more vulnerable as she negotiates the 
service, particularly if she is outnumbered. Sixty-eight incidents of gang rape by multiple 
clients have been reported in qualitative studies among FSWs in Moscow [22–23]. In other 
Western European countries street workers negotiate a specific service and a price prior to 
leaving with the client and employ safety strategies such as working in pairs or groups or 
recording car registration numbers of clients [18].
Sex work in Tallinn (Estonia), however, almost exclusively operates from apartments and 
hotels, with street-based sex work mainly confined to drug users. Sex work is widely dispersed 
throughout the city. Soliciting and locating clients is conducted on the Internet, via mobile 
phones, and through taxi drivers who act as both pimp and security guard. This system 
illustrates a supportive working environment, as drivers provide effective security and screen 
clients for drunkenness and potential disruptive behaviors [24].
Qualitative data from Central and Eastern Europe suggest that SWs working in off-street 
locations experienced higher levels of sexual and physical violence from clients when there 
was a lack of cooperation from managements that supported women’s ability to refuse 
certain clients or provide certain services [4, 25]. Research from the United Kingdom 
suggests that women who work off-street employ a range of safety strategies to prevent and 
manage violence, including using security cameras and secure doors with peep holes, 
employing receptionists to screen clients, and working in groups. Both SWs and receptionists’ 
interpersonal skills were judged to be of paramount importance including the use of humor 
and the ability to defuse a tense situation [25].
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Box 4.2 models of regulation
Across Europe, sex-work legislation can be categorized into four groups:
 1. Regulatory systems that involve registering and licensing everyone working in the sex 
industry.
 2. Decriminalization, which involves the removal of most of the criminal penalties applied to 
adult sex work.
 3. Prohibitionist systems that prohibit or criminalizes most or all aspects of sex work.
 4. Abolitionist systems that are designed to abolish systematic sex work such as soliciting 
and living off the earnings of a sex worker [42, 43].
street-based SWs beyond the provision of fixed site STI clinics [1, 26–28]. With 
an increasing number of SWs working off-street, projects use more innovative 
ways to contact SWs such as (a) contacting SWs who advertise their services 
online by email and sending information about services; (b) reminding SWs 
about checkups and other information on a regular basis; and (c) using Internet 
chat rooms frequented by male sex workers to promote services [29].
Interventions with Clients
Evidence from this review suggests that condom use with clients is high, but 
when condoms are not used this is often related to violence from clients or police, 
the need to earn more money, or the experience of condom breakage in the past. 
Some of these problems could be addressed in part through interventions with 
clients. There are no documented examples of interventions among clients in 
Eastern Europe; however, there are some examples of innovative intervention 
in Western Europe, particularly in Germany, with clients of SWs. A study in 
Switzerland suggested that the provision of HIV testing to men who buy sex from 
street-based sex-work locations resulted in a high uptake of testing and a large 
proportion who had previously not been tested [30]. One innovative project in 
Germany targeting clients who want to purchase sex without a condom involved 
the distribution of cards to men presented in the same style as a sex worker adver-
tisement. If they call the phone number on the card, they will hear a prerecorded 
message between a client and SW discussing why the SW does not sell sex with-
out a condom. An evaluation of the project showed that following the campaign, 
there was in an increase in the number of male patients attending the local sexual 
health clinic. Similarly in France, health promotion experts used World AIDS Day 
to launch a media campaign to target clients. In Spain, services set up a designated 
website for clients informing them of sex work regulations and their rights [29].
Peer-Driven Interventions
There is some evidence to suggest that peer interventions among SWs in low- 
and high-income settings have proved successful in increasing condom use, 
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safety, and access to harm-reduction services [31–36]. Other research from the 
United Kingdom has shown that the peer-driven interventions may be compli-
cated by the diversification of the sex work industry. The increased representa-
tion of migrant SWs may reduce opportunities for peer-driven interventions. In 
a qualitative study examining social networks of migrant SWs conducted in 
London,  findings showed that relationships between colleagues were often lim-
ited by transience, competition, and racial prejudice, although peer networks 
were described as being highly effective sources of practical and informational 
support [37–38]. Projects in Eastern Europe report difficulties in recruiting peer 
outreach workers because of a lack of trust and respect from other SWs, prob-
lems with managers, and the transience of the sex work scene [16]. Other bar-
riers implementing peer-driven interventions are concerns from SWs that 
overdependence on peer networks in the sex industry may be seen as a potential 
barrier to ultimately leaving the industry [38, 39]. Studies in Montenegro, 
Russia, and Serbia found that due to the small size of sex work social networks, 
as well as the tightly controlled and hidden nature of sex work and inadequate 
financial incentives, recruitment of SWs into surveys via social networks was 
problematic [40]. The lack of specialist services with close links to SW popula-
tions in these sites may have limited further recruitment efforts. In London, 
SWs spoke very highly of specialist SW services, a factor that could be harnessed 
and potentially facilitate more positive interactions between peers in work and 
nonwork settings [38].
Policy Environments Mediating HIV Prevention among SWs
Legislation
Legislation regulating sex work is one of the most important structural factors 
influencing the health and safety of SWs. There is clear evidence of the influence 
of different policies and related activities in promoting supportive or discrimina-
tory practices towards SWs and their subsequent impact on the ability of SWs to 
access necessary services and protect their rights.
Legislation of sex work in Europe (i.e., most countries in the West) is largely 
characterized by a prohibitive model that does not criminalize the act of selling 
sex (map 4.8); however, it does criminalize activities around sex work such as 
working in groups or running brothels, which can limit SWs’ ability to organize 
their work safely (e.g., in Denmark, France, Iceland, Ireland, Italy, Sweden, and 
the United Kingdom) (map 4.9). In most countries in Central Europe and the 
East (with the exceptions of Hungary, Latvia, and Slovenia) the act of selling sex 
constitutes a criminal or administrative offense.
In countries where sex work–related activities are decriminalized (such as 
Germany or the Netherlands), they are often accompanied by licensing and regu-
lation. Critics of decriminalization argue that by distinguishing between legal and 
voluntary and illegal involuntary sex work may further marginalize the most 
vulnerable underaged, coerced or nonresident SWs.
In Germany and the Netherlands, benefits of regulation (such as social wel-
fare) are denied to migrant SWs without legal residency rights as they are not 
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accorded the same rights as nonmigrants [43, 44]. In other countries (Austria, 
Greece, Switzerland, and Turkey) where sex work–related activities are also legal, 
a system of mandatory testing operates. Some international evidence suggests 
that mandatory testing reduces access to STI clinics for more vulnerable popula-
tions [45]. However, research in Mexico suggested that SWs registered at a 
municipal health department used more condoms than nonregistered SWs. All 
SWs were involved in a behavioral intervention, but findings suggest that regis-
tration may play a role in reducing sexual risk behaviors [46, 47]. In all countries 
in Eastern Europe (except for Estonia and Lithuania) mandatory testing for 
HIV/STIs has been frequently reported by SWs and projects irrespective of 
whether sex work is unregulated or a criminal offense. Testing is generally con-
ducted following detention or arrest by the police, although there is no official 
legislation enforcing mandatory testing [4, 16].
An abolitionist model of regulation is in operation in Norway and Sweden, 
that criminalizes clients of SWs [42]. This model has been criticized as it rarely 
allows SWs freedom to practice sex work and it is often restricted by local 
administrative regulations or police harassment. Opponents of this model also 
state that it is not grounded in reduction of harm to women [48] but ignores the 
welfare of SWs and drives markets into more dangerous areas [49] [43].
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map 4.8 legal status of selling sex in europe
Sources: services4sexworkers.org; Global Fund; International HIV/AIDS Alliance; TAMPEP [4, 50–52].
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Structural Violence Arising from Legislation
The International Committee on the Rights of Sex Workers (ICRSW) in Europe 
has documented multiple human rights violations against SWs across Europe 
brought about as a function of sex worker regulation policies or as a result of 
prejudice and stigma associated with sex work. In Finland legislation prohibiting 
a third party from profiting from sex work or “pimping” has led to SWs being 
banned from working together for their own protection without facing prosecu-
tion for “pimping” one another. Similarly in France, a SW’s child, on reaching the 
age of majority, may be prosecuted with “living off” the SW’s earnings. In 
Portugal SWs lose custody of their children through social services or family 
courts solely because of their occupation. Other violations include refusal of 
access to health care in the Slovak Republic on the grounds of occupation and 
not being able to marry while working in sex work in Greece [44].
Police-Related Violence
Police violence was most frequently reported in the countries of Eastern 
Europe where the act of selling sex is primarily a criminal or administrative 
offense, and activities related to sex work are either unregulated or an admin-
istrative offense, creating opportunities for police corruption and abuses of 
SWs within the legal system. SWs report incidences of violence from the police, 
Legal
Criminal offense
Unregulated
No data
map 4.9 legal status of selling sex with others in europe
Sources: services4sexworkers.org; Global Fund; International HIV/AIDS Alliance; TAMPEP [4, 50–52].
180 Responses to HIV in Key Populations
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8
administered during detention or at sex work-locations. Reports from projects 
and qualitative studies in 11 countries across the region highlight police 
involvement, including demands for financial remuneration or sex in lieu of 
rent or avoiding arrest [4, 14]. Police involvement in the sex industry often 
means that women have nowhere to report other incidences of violence, par-
ticularly when police are the perpetrators [4, 22, 53, 54]. Fear of violence from 
police and a lack of legal recourse further entrenches the stigma attached to sex 
work [14]. Other qualitative work from the region documents very high levels 
of sexual and physical abuse from the police [55]. Police violence can increase 
the risk of HIV directly by confiscating condoms as evidence or by forcing 
women to have sex, as well as indirectly reducing their income through the 
enforcement of bribes, thereby increasing financial pressure and the need to 
engage in higher risk behaviors such as selling sex without a condom to make 
up for the loss of income [4, 54, 56]. The threat of police violence also reduces 
SWs ability to work independently and increases their need for boyfriends or 
pimps to be involved in their work.
There is little evidence showing that any criminalization of sex work reduces 
the demand for sex or the number of SWs [57]. We looked at the relationship 
between prevalence of HIV among FSWs and the size of the prison population 
at a country level (figure 4.8). Prevalence of HIV increases among FSWs in rela-
tion to the number of prisoners per 100,000 people. There are well-documented 
reasons why prison and individual-level risks of HIV are associated, but at a 
national level the reasons may be different. One possibility is that the indicator 
is a proxy for a national attitude toward prison as a punitive rather than rehabili-
tative environment but the relationship serves to demonstrate the detrimental 
effects of punitive approaches to HIV and SWs. At a macrostructural level, some 
researchers state that prohibitionist and abolitionist polices that criminalize the 
purchase of sex reinforces negative attitudes and violence towards SWs. Opinions 
on sex work and violence is dominated by the idea that people who engage in a 
criminal activity such as sex work are knowingly exposing themselves to violence 
and therefore are somehow at fault [41, 58]. Evidence suggests that prohibition-
ist policies such as anti-kerb crawling strategies serve to disperse SWs widely, 
further restricting women’s abilities to work in groups and look out for each 
others’ safety [41]. Other evidence suggests that SWs in the unregulated street-
based sector had poorer mental health than those working in regulated off-street 
locations [59]. In comparison, the mental health scores of off-street SWs were 
no worse than those among women who did not sell sex [60, 61].
Research from Europe and internationally has shown that criminalization and 
enforcement-based approaches toward sex work can increase the risk of physical 
and sexual violence against women [62–64] as well as the risk of STIs [48, 65], 
greater social stigma, loss of children, problems with family and friends, and 
housing [48]. Policies and legislation connected to sex work should focus on 
facilitating safer working environments rather than enforcing approaches that 
can further marginalize women. The recent Joint United Nations Programme on 
HIV/AIDS (UNAIDS) report on HIV and Sex Work define good practice in 
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relation to both public health and human rights to be (a) creating a legal and 
policy environment where policies regulating sex work do not violate SWs’ rights 
or dignity (including avoiding mandatory testing as part of regulations), nor hin-
der their access to due process of law; (b) ensuring policies that promote work 
place safety and protection from violence, exploitation and discrimination; and 
(c) ensuring unimpeded access to HIV prevention, treatment, and care [57]. 
Case study 4.8 above describes some successful interventions to reduce violence 
among SWs.
In 2002, the ICRSW created the “Declaration of the rights of Sex Workers in 
Europe.” This document identifies the current violations of the rights of SWs 
across Europe, affirms the rights SWs have under current human rights legisla-
tion in Europe, and identifies measures that need to be taken by states to respect, 
protect, and fulfill the rights of SWs. This declaration was elaborated on and 
endorsed by 120 SWs and 80 allies from 30 countries at the European 
Conference on Sex Work, Human Rights, Labour and Migration in Brussels, 
Belgium [44]. Fourteen other discrete advocacy projects were identified in 
Austria, Belgium, the Czech Republic, France, Germany, Italy, Norway, the 
Slovak Republic and Spain that target the general public, policy makers, and 
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police to raise awareness of SWs rights [29]. Governments and policy makers 
need to work closely with SWs and sex worker advocacy groups such as the 
ICRSW when designing policies and health programs for SWs in order to ensure 
that interventions are based on the needs of SWs in that local area to enable 
more effective policies and programs [57].
Social-Structural Interventions
There is a growing body of evidence demonstrating the effect of structural inter-
ventions in HIV prevention among SWs in changing the context of risk [67–71]. 
Structural interventions that promote community mobilization have been the 
most comprehensively documented. Evaluations have shown that reducing HIV/
STI prevalence and improving the health and safety of SWs is possible when 
SWs are encouraged to (a) advocate for their rights with the police, brothel 
 owners, and clients to implement HIV interventions at work; (b) organize 
case study 4.8 intervention to reduce violence
An example of a community-level intervention to reduce violence is the “Ugly Mugs” 
scheme in the United Kingdom that distributes warnings about dangerous clients. This 
has been successful in reducing client-perpetrated violence and is highly valued by FSWs. 
While 77% of U.K. projects (members of the United Kingdom Global Network of Sex 
Work Projects [NWSP]) currently run “Ugly Mugs” schemes [41], sex worker projects and 
police have also been criticized for being reactive rather than proactive. That is, they 
expect the FSW to be responsible for preventing violence rather than focusing on reducing 
opportunities for violence to occur by creating a safer work environment [19]. “Ugly Mugs” 
is currently only available in English, so it is of limited use to migrants with poor English-
language skills; funding is being sought for translation. The majority of “ugly mugs” 
schemes are also limited in that they focus on clients. One exception is the “Sex work 
Empowerment” project (SWEET) in Huddersfield that records all incidents of violence by 
perpetrator. Data from the project demonstrate that SWs often experience violence 
outside of sex work. Among the 61 incidences reported in a 9-month period in 2007, 34% 
were related to violence from a client, 31% to a partner or ex-pimp; 31% to other (including 
drug dealers, vigilantes, other SWs, etc.), and 3% related to violence from family members, 
suggesting that interventions are needed to reduce violence among women universally 
and not just among incidences related to sex work [41].
The recently established Sex Workers’ Rights Advocacy Network (SWAN) advocates for 
reduction in violence against SWs in the countries of Central and Eastern Europe and has 
participating organizations in each of the following countries: Albania, Bulgaria, the Czech 
Republic, Hungary, Kazakhstan, the Kyrgyz Republic, Latvia, Lithuania, the former Yugoslav 
Republic of Macedonia, Montenegro, Poland, Romania, Russia (Barnaul, St. Petersburg), Serbia, 
the Slovak Republic, and Ukraine. One advocacy tool has been to document SWs’ experiences 
of violence, including police violence, and disseminating the findings in a report [4]. This is an 
important step forward in addressing violence against SWs in the region.
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interventions to reduce illiteracy; (c) increase child immunization; and (d) seek 
legal advice [1, 68, 72]. A recent evaluation of a community mobilization inter-
vention in India showed that exposure to the intervention was associated with 
consistent condom use as well as increased control over type of sex sold and the 
amount charged [73]. The intervention combined a traditional HIV intervention 
strategy using peer educators distributing condoms and promoting condom use 
as well as promoting a sense of collective identity and agency by promoting 
the idea of sex work as labor similar to other manual labors and encouraging the 
organization of community-based organizations for SWs and led by SWs.
There is also evidence showing the impact of national policy changes in reduc-
ing HIV risk behaviors such as the national campaigns in the Dominican 
Republic and Thailand that promote 100% condom use [74, 75]. Other evidence 
shows the importance of economic interventions and microfinance at a commu-
nity level to reduce poverty, thereby reducing the number of sex work clients 
[68, 72, 76–78]. Evaluating the multiple determinants of health that are affected 
by structural interventions is complex. While methods of measuring the size of 
effect between structural factors and HIV prevalence or risk behaviors are well 
established, it is harder to measure or recognize the pathways that link the levels 
of determinants [79], and as a consequence, it is difficult to establish which 
aspects of the structural interventions are effective and why [1]. Methodological 
developments are needed to facilitate evaluation because the need for structural 
interventions and removing structural barriers is increasingly recognized as a core 
strategy of HIV prevention for SWs [80, 81].
Hiv prevention responses among men Who Have sex with men
We draw here on a variety of data sources, including data from the systematic 
review, European Men Who Have Sex with Men Internet Survey (EMIS), and 
other international evidence to describe the HIV prevention context for MSM in 
Europe. We draw attention to the role of selected targeted interventions in HIV 
prevention as well as how the legislative and policy environment mediates indi-
vidual and community capacities for risk reduction.
Targeted HIV Prevention for MSM
Two recent reviews have focused on the effectiveness of HIV-prevention inter-
ventions targeting MSM [1, 2]. In the first review [235], strategies that were 
found to be effective in reducing unprotected anal intercourse (UAI) among 
MSM included individual, small-group, and community-level interventions. 
Individual-level interventions included counseling and the provision of social and 
behavioral support. Small-group and community interventions included group 
counseling or workshops, interventions targeting community-wide areas, the 
training of community leaders, and  community-building empowerment activities 
[1]. The majority of the studies were conducted among predominantly white 
communities in high-income  countries, limiting the ability to generalize the find-
ings in the lower- and middle-income parts of Europe. The second review [2] 
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found that associations between peer education and gay-specific genitourinary 
medicine clinic (GUM) services were inconclusive. Cognitive behavioral tech-
niques and sexual diary keeping intended to reduce the number of self-identified 
high-risk men reporting sero-discordant or unknown status UAI were found to 
be more effective than standard counseling interventions alone. We further sum-
marize evidence relating to the coverage of selected targeted interventions below.
HIV Testing Interventions
It is desirable for both public and individual health that people know their cor-
rect HIV status. In most circumstances HIV testing is the only route through 
which this can be achieved. The ongoing validity of HIV test results is called into 
question by subsequent risk behavior, so the extent of HIV testing required in a 
population to ensure extensive and correct knowledge of HIV status will depend 
on the level of sexual risk behaviors in that population.
HIV testing interventions also provide an opportunity for MSM to access 
other prevention interventions, such as counseling. There is evidence from 
Croatia, Hungary, and Ukraine that HIV testing is associated with increased 
 condom use [3–5]. This association, however, is more likely when post-test 
 counseling is undertaken [4]. The coverage of HIV testing interventions can be 
summarized by the proportion of MSM who have ever been tested and the pro-
portion that have tested in the past year. The proportion of MSM who have ever 
been tested for HIV is variable across Europe, including for instance, 70% in 
Germany (recruited in 2006) [6] and 54% in the Netherlands (recruited in 
2002) [7]. Moreau-Gruet, et al. [246] found that 72% of Swiss MSM (surveyed 
online) had been tested for HIV in the past three years. There is some evidence 
that levels of HIV testing may be increasing in Denmark [10], Switzerland [11], 
and the United Kingdom [8, 9].
Recorded rates of HIV testing in the past 12 months also vary within and 
across subregions (figure 4.9). In the East it varies from 13% in Tajikistan to 
over 40% in Bulgaria, Georgia, Kazakhstan, and Russia. As a key public health 
intervention, HIV testing should be free of charge. In much of the region, this 
is not yet the case, and such fees may be a barrier to compliance. In Georgia, 
study participants cited unemployment and the cost of health care as barriers 
to seeking VCT services [12]. Provision of widespread and accessible HIV 
testing and treatment services are an essential element of a national HIV 
response. Ensuring that these services meet the needs of MSM should be a 
priority of service policy.
Antiretroviral Treatment for HIV Disease
There have been some promising results from international studies on the effi-
cacy of antiretroviral therapy (ART) to reduce HIV transmission by reducing 
viral load in people with HIV. However, there remain questions regarding the 
practical implications of making HIV prevention a core objective of HIV treat-
ment. Modeling has shown the effectiveness of ART in eliminating HIV trans-
mission in generalized epidemics, including both heterosexual [15, 16] and 
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Figure 4.9 percentage of msm tested for Hiv in the past Year and number of results
Source: EMIS (except the Kyrgyz Republic and Kazakhstan) [13, 14].
Note: Numbers in bars denote sample size. HIV = human immunodeficiency virus; MSM = men who have sex with men.
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homosexual transmission [17]. However, these models do not take account of 
the much higher risk of transmission from acute cases [18]. Other evidence 
 suggests that the population-level impact of widespread and effective treatment 
is likely to have a short-term impact only, since antiretroviral resistance typically 
takes several years to develop and spread within a population [19]. In HIV-
positive men who regularly acquire new UAI partners, the level of suppression 
offered by ART may decline over time as they acquire resistant HIV through 
mutation or super-infection [20].
Other evidence highlights the issue of “risk compensation,” suggesting that in 
Western Europe where ART has now been available for many years, the practice 
of UAI is more likely among MSM who reported less concern about HIV preven-
tion because of highly active antiretroviral therapy (HAART) [19, 21–25] 
(although this was a minority view among the MSM sampled) [24–27]. In 
Catalonia, data suggested that HIV positive MSM who believed that ART con-
siderably reduced the risk of transmission were 7.5 times more likely to engage 
in UAI with casual partners [21].
While ART reduces the infectivity of HIV-positive individuals, it is also 
thought to be able to reduce susceptibility to infection among HIV-negative 
people, thereby reducing the probability of transmission when exposure occurs. 
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A recent review of studies into the effectiveness of ART as pre-exposure prophy-
laxis (PrEP) located only one study meeting their criteria, but this study focused 
on women and was incomplete. It concluded that there is no current evidence 
for the effectiveness of PrEP, and more trials are needed. A recent study not 
included in the review and involving 2,499 high-risk males in a number of coun-
tries found that PrEP reduced HIV incidence by 44% (95% CI 15%–63%), 
though the strengths of this study are limited by the relatively short follow-up 
period, which did not exceed 2.8 years [28]. Further research is also needed to 
better understand drug resistance and risk compensation in relation to PrEP [29].
Strategic Positioning and Serosorting
With the advent of increased testing and improved access to ART in many 
 countries, especially Western Europe, some MSM are beginning to employ 
 intervention techniques other than condoms to reduce their risk of contracting 
HIV. One study noted several noncondom risk-reduction practices employed by 
MSM including (a) strategic positioning, in which the HIV-positive or unknown-
status partner takes the receptive role and the HIV-negative partner or unknown-
status partner takes the insertive role, thereby acknowledging that transmission 
is more effective from the insertive to the receptive partner rather than the other 
way around; (b) serosorting, in which men try to have sex only with those of their 
own serostatus; and (c) withdrawal, in which the insertive partner withdraws 
before ejaculation to limit the risk of passing on infections carried in semen [30].
Even in Western Europe, only a few studies focus on such interventions. 
Balthasar et al. [31], used a cross-sectional survey that recruited respondents via 
the gay press and other venues, and online on prominent Swiss gay websites. The 
survey restricted responses to the 1,689 men who reported at least one episode 
of anal intercourse with a casual partner in the previous 12 months. They found 
that 67% consistently used condoms; 24% did not, but employed one or more 
different risk reduction strategies; and 9% did not make any consistent attempt 
to reduce the chance of HIV transmission. Consistent condom use was similar 
(around 70%) among those who reported being HIV-negative or not knowing 
their status, but only 48% of HIV-positive respondents reported the same con-
dom use. Very few (7%) of the HIV-negative respondents reported using no risk-
reduction practice at all, compared to 10% of those of unknown status and 48% 
of the HIV-positive respondents. Respondents with unknown status (19%) 
reported using other risk-reduction strategies, compared with 24% of the HIV-
negative respondents and 35% of the HIV-positive respondents. Respondents 
using a risk reduction strategy other than condoms (74%) reported doing so 
intentionally. Of those using alternative strategies, 50% reported using serosort-
ing, 33% strategic positioning, and 62% withdrawal before ejaculation. Of the 
three practices, 53% reported using one, 38% reported using two, and 9% 
reported using all three.
International evidence suggests that of the three options, strategic positioning 
appears to have a greater risk-reduction effect than serosorting or withdrawal, 
with a hazard ratio of 1.54 (95% CI 0.45–5.26), which is not significantly 
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different from the reference category of no UAI [32]. This study differentiates 
between serosorting as UAI with HIV-negative partners, and a more reliable 
practice, termed here “negotiated safety,” which includes only UAI with primary 
regular partners and requires a number of other criteria that enable a man in a 
regular relationship to be more assured of his primary partner’s status [33]. This 
study found negotiated safety to have a hazard ratio of 1.67 (95% CI 0.59–4.76). 
This differs from the more general form of serosorting mentioned above, which 
was found to have a hazard ratio of 2.17 (95% CI 0.88–5.39). Withdrawal was 
found to have a hazard ratio of 5.00 (95% CI 1.94–12.92).
There are epidemiological consequences of serosorting and some evidence 
that identify this strategy as one of the factors that may account for the recent 
rise in German HIV prevalence after the country had successfully stabilized at 
low prevalence in the 1980s and 1990s [6]. A major risk of serosorting is that 
newly infected men, unaware of their status, will seek HIV-negative partners in 
order to protect themselves, thereby risking further transmission of HIV. 
Transmission could be to an HIV-negative partner [6] or to an HIV-positive 
partner who could be reinfected, possibly with a more aggressive subtype or a 
drug-resistant strain, which would be highly undesirable at an individual level, 
but also at a population level if viral recombination takes place before the HIV 
is transmitted further [2, 34, 35]. Because antibody-based HIV tests produce 
negative results for those in acute infection (i.e., the antibody response needs 
some weeks to develop), serosorting will tend to encourage unprotected sex with 
these very high-risk individuals [36, 37]. Studies suggest that around half of 
transmissions among MSM occur during this acute phase of infection, with clus-
ters of phylogenetically related incident cases accounting for a high proportion 
of incident cases [36, 37]. In addition to the limitations posed because of such 
“seroguessing,” serosorting has the disadvantage of not accounting for the pres-
ence of other STIs, leading in some cases to increases in their incidence and 
prevalence among communities where serosorting is a common practice [38].
STI Testing and Treatment Interventions
STIs can have synergistic effects with HIV whereby the presence of another 
infection makes the transmission of HIV more likely. This means swift or delayed 
detection and treatment of other STIs among MSM (both HIV infected and HIV 
uninfected) which has an impact on HIV incidence. Integrating HIV and STI 
testing and treatment services provides opportunities to normalize HIV within 
sexual health services and can provide lower threshold access to testing—people 
can attend for reasons other than HIV and get an HIV test at the same time. 
Since HIV is a risk factor for other STIs (and vice versa), those who get tested 
for HIV are proportionately more likely to need screening for other infections. 
Integrated services also emphasize on the needs of the whole person, unlike the 
states that focus on tracking down HIV (or people with HIV).
Many Western European cities have STI treatment facilities able to provide 
nonjudgmental services to MSM. Such facilities are far less available in Central 
Europe and the East. Consequently, MSM report reluctance to visit STI clinics and 
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VCT centers, some MSM experience mistreatment from staff when they become 
aware of their orientation. One tactic that MSM use to deal with this problem is 
nondisclosure of orientation to medical staff [39]. This results in inferior standards 
of care (especially in relation to rectal and oral STIs) and misattribution of HIV 
cases across exposure categories (hence the understatement of MSM in official 
HIV data). This lack of evidence of HIV transmission between MSM then per-
petuates neglect of the provision of targeted prevention and treatment services.
Rectifying this situation can be done in two ways. In the short term service 
planners can set up MSM-designated clinics, or directly advertise and promote 
general population clinics to MSM, ensuring and conveying that clinic staff are 
competent and nonjudgmental. Over the longer term institutional homophobia 
needs to be tackled.
Designated gay men’s services and interventions carried out in gay settings 
may disproportionately fail to reach men of lower socioeconomic status, men 
from minority cultures, and male sex workers [40]. In homophobic environ-
ments, MSM will not want to be indentified attending MSM specific services. 
The focus should be on generic services that are able to respond adequately to 
the range of human sexuality and that respect the diverse ways in which sexual 
lives are organized. Such services will benefit all sections of the sexually active 
population. Further barriers exist for migrants who may have difficulties in 
accessing prevention services. In the former Soviet Union, HIV and STI treat-
ment requires official residency; such a requirement excludes migrant MSM 
[41]. In migrant populations, the target groups were often unaware of existing 
programs to serve their needs. Case study 4.9 below describes the issues around 
measuring coverage of interventions for MSM.
Access to the Internet
The settings in which MSM meet have long been used as places of contact for 
interventions and the Internet is increasingly exploited as an HIV prevention 
interface. Like other populations, MSM use the Internet for a wide variety of 
purposes, including to meet potential sexual partners. Internet access is not 
equally distributed across countries, or across demographic groups within coun-
tries. It is generally less accessible to many in Eastern Europe, especially in less-
affluent areas. However, access is only likely to grow in coming years.
MSM HIV prevention programs need to go beyond gay-scene settings (bars, 
clubs, saunas, and shops) to reach a significant and diverse proportion of the 
population. Websites for MSM are an essential part of HIV prevention programs 
since they are used both by men who are involved with the gay-scene and those 
who are not. Educational mass media messaging targeting all sexually active men 
can also be designed to be of benefit to MSM through sensitive use of language 
and imagery [41].
Community Mobilization
In the presence of widespread institutional homophobia (see below), community 
mobilization is a social intervention that has a long history in HIV prevention [45]. 
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case study 4.9 measuring coverage of interventions for msm
The EMIS 2010 used three criteria to determine if individual MSM are eligible for coverage in 
prevention programs: (a) not having engaged in UAI in the last 12 months solely due to the 
lack of a condom; (b) having seen or heard MSM-specific information about HIV or STIs in the 
last 12 months, or having called a telephone helpline; and (c) if diagnosed HIV positive, having 
seen a doctor for medical monitoring in the last six months, or if not HIV positive, being 
confident of the ability to access an HIV test.
The five key United Nations General Assembly Special Session (UNGASS) indicators [42] 
include (a) the proportion of MSM who have been diagnosed with HIV; (b) the number of men 
who have used a condom the last time they had anal sex with a male partner; (c) the ability to 
correctly identify ways of preventing the sexual transmission of HIV and reject major 
misconceptions about HIV transmission; (d) the receipt of an HIV result in the past 12 months; 
and (e) contact with HIV prevention programs in the last 12 months. No analysis has been 
published as yet; however, an analysis of the indicators for PWID suggest inconsistent reporting 
across countries [43].
The 2010 Dublin Declaration report on the progress of European countries in their HIV 
response summarizes the UNGASS indicator data provided by the countries through the 
UNGASS reports. It should be noted that the problem of nonrepresentative sampling in MSM 
research becomes acute in the case of intervention coverage. In many cases sampling was 
carried out in the same settings in which interventions were delivered, giving a greatly inflated 
coverage figure. In addition, coverage was measured differently in most countries and can 
include websites for MSM, peer education, counseling, or community press. We should 
therefore be extremely cautious about these data as they suggest that the coverage of 
interventions in different countries is almost certainly uneven [44].
The driver for mobilization can come from volunteer work within the community 
or externally through donors and advocates. Wright (2005) [275] notes that mobi-
lization by MSM against HIV in Western Europe benefited from two elements 
largely historically absent in Eastern and Central Europe [40]. The first is the 
politicization of MSM in the 1960s and 1970s around human rights causes and the 
consequent creation of an open gay community. This political mobilization 
enabled a strategic response to the emergence of HIV in some Western communi-
ties. The second factor is the presence of long-standing civil society networks that 
are relatively absent in most of the transition countries. Initiatives led by civil 
society agencies tend to have greater impact among people engaging in stigmatized 
behaviors than those led by government or other formal authorities [40].
Policy Environments Mediating HIV Prevention among MSM
The legal environment framing MSM varies widely across the region. Map 4.10 
summarizes an aggregated index of social-inclusivity to explore how the 
 legislative and social environment in which MSM live differ across the region. 
190 Responses to HIV in Key Populations
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8
The index includes the following indicators: (a) the existence of legislation 
against male–male sex; (b) the existence of legislation that pre-dates 1981; 
(c) the existence of legislation against discrimination on the grounds of sexual 
orientation; (d) the presence of an annual Gay Pride activity; and (e) the recogni-
tion of civil partnership or marriage between people of the same gender.
Although a somewhat crude measure of the restrictiveness of environments in 
which MSM live, there is a clear pattern of increased restrictiveness in the East 
compared to the West. In part this is because membership in the EU requires the 
repeal of antihomosexuality legislation, and the Treaty of Amsterdam requires its 
member states to enact antidiscrimination legislation [46]. However, there are 
only six countries in the European region (Belgium, Norway, the Netherlands, 
Spain, Sweden, and the United Kingdom) that legally recognize same sex part-
nerships. In Turkmenistan and Uzbekistan criminal codes state that MSM is 
punishable by imprisonment of up to two and three years, respectively.
The legal situation facing MSM varies widely across the region. Although this 
is a very crude measure of the environments in which MSM live, there is a clear 
pattern of increased restrictiveness in the East compared to the West. Nineteen 
countries displayed every feature of an enabling environment that we used here 
(Austria, Belgium, Croatia, the Czech Republic, Denmark, Finland, France, 
Germany, Hungary, Iceland, Luxembourg, the Netherlands, Norway, Portugal, 
map 4.10 legislative and social environments Affecting msm throughout europe
Source: Aggregated index of social-inclusivity of MSM, based on literature review.
Note: Index composed of five indicators: (1) legislation against male–male sex; (2) whether the legislation predates 1981; (3) legislation against 
discrimination on the grounds of sexual orientation; (4) the presence of an annual Gay Pride activity; and (5) the recognition of civil partnership or 
marriage between people of the same gender; MSM = men who have sex with men.
Highest index value
No data
Lowest index value
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Slovenia, Spain, Sweden, Switzerland, and the United Kingdom). Turkmenistan 
and Uzbekistan scored lowest on the index, with neither country displaying any 
features of an enabling policy environment. They are also the only two countries 
where sex between two consenting male adults remains illegal. In Turkmenistan 
and Uzbekistan criminal codes state that MSM is punishable by imprisonment of 
up to two and three years, respectively. However, only 26 of the 51 countries 
(51%) included in the index had such a law in place prior to 1981; the remaining 
23 countries have made changes in the intervening years. In 33 countries (65%), 
discrimination on the grounds of sexual orientation is legislated against. In part 
this is because membership in the EU requires the repeal of antihomosexuality 
legislation, and the Treaty of Amsterdam requires its member states to enact 
antidiscrimination legislation [46]. An annual Gay Pride event is held in 37 of 
the 51 countries (73%). Within the European region, only 21 countries (41%) 
recognize civil partnerships or same-sex marriages.
Legislative equality is an important step toward social inclusion. It also 
increases the validity of surveillance systems by reducing the need to suppress 
information on risk behaviors. Governments should act to (a) remove legal pro-
hibitions on sex between MSM; (b) set up a mechanism to prosecute police 
involved in harassment, assault or extortion of MSM; (c) require police to 
enforce the laws against assault for MSM on equal terms with the rest of the 
population; and (d) provide legal recognition and protection of same-sex 
relationships.
Supportive Policy Environments and HIV Prevalence
Results from the systematic review and HIV case reports indicate that HIV 
prevalence among MSM is higher in countries in the West than in the East. 
Comparing these data with our policy index suggests that the more supportive 
the policy environment, the higher the HIV prevalence. More supportive envi-
ronments will lead to more openness in reporting sex with men as a risk factor 
in HIV case reports. This could also partly be explained by timing: liberalization 
of policies towards MSM may have occurred after increases in HIV prevalence 
as well as the scale-up of HIV interventions. Higher HIV prevalence may also be 
attributed to migration of MSM from countries with less-supportive environ-
ments. A more supportive policy environment might lead to the increased avail-
ability of venues where gay men can meet and have sex, increasing the chances 
of unprotected sex. Findings from the systematic review from studies in France 
and Switzerland suggest how a core group of HIV-positive MSM engage in UAI 
[31, 47]. There is also evidence that other structural factors will interact with the 
policy environment to mediate risk of HIV among MSM. When looking at the 
relationship between gross national income (GNI) and HIV prevalence among 
MSM, for example, it is evident that prevalence increases along with GNI per 
capita, with higher GNI in the West than in the East (figure 4.10).
While more liberal policies might create environments in which HIV trans-
mission can occur, less liberal policies may breach fundamental human rights 
conventions as well lead to adverse health outcomes. Evidence from the review 
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suggests little regional difference in the numbers of sex partners reported in the 
East with more repressive environments than in Central Europe or the West. 
Repressive polices do not support MSM in maintaining exclusive and cohabiting 
relationships. Instead, they encourage clandestine networks of casual sex partners 
that provide sexual relief but little of the social capital of regular partnerships. 
Paradoxically then, suppression fosters sexual partner turnover that carries risk 
but prevents supportive longer term relationships. Our systematic review noted 
that UAI was more frequently reported in samples in the East and condom use 
at last AI less frequently reported [14]. An example of the detrimental effects of 
homophobic policies is given in case study 4.10 below.
Violence against MSM
The systematic review identified the experience of internalized homophobia or 
feeling negative about one’s sexuality to be associated with increased risk of UAI. 
Few studies in the review addressed homophobic violence but those that did sug-
gest that verbal, physical, and sexual attacks on the basis of sexual orientation are 
common. In the West, a Spanish study found that 10.7% of respondents had been 
the victim of aggression or verbal assaults in the past 12 months alone [48]. In 
the East, in Georgia, 21% of respondents reported ever having experienced 
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Figure 4.10 relationship between Hiv prevalence among msm and Gni
Source: Tables C.23–C.25, GNI from World Development Indicators, World Bank.
Note: GNI = gross national income; HIV = human immunodeficiency virus; MSM = men who have sex with men.
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physical violence; 14% reported verbal attacks and 7% reported sexual attacks 
including rape [49]. Personal homophobia among the social contacts of MSM 
(family, neighbors, social circles) has multiple negative effects on MSM. For 
example, in Georgia, stigma mitigates against the development of regular partner-
ships among men, who are afraid to meet a new partner again, in case others 
notice this new friendship [12]. In much of the region, hostile and exploitative 
police attitudes effectively create impunity for sexual assault against MSM 
[50–54].
Institutional Homophobia
Institutional homophobia is the behavior of organizations that is differentially 
detrimental to MSM independent of any of the individuals within it. While it is 
difficult for homophobes to act homophobically in nonhomophobic institutions, 
homophobic institutions encourage everyone (including gay people) to act 
homophobically. One manifestation of institutional homophobia is workplace 
tolerance of hate speech. A study in Northern Ireland of 752 lesbian, gay, bisexual, 
case study 4.10 the impact of Homophobic polices in the russian Federation
Although homosexuality in Russia was decriminalized in 1993 with the fall of the Soviet 
Union, homophobic activities are widespread, with demonstrations to mark the decriminal-
ization of homosexuality frequently banned by city authorities, and attempts to protest the 
ban met with physical violence from homophobic mobs and police [55]. Evidence suggests 
that policies in Russia towards men who have sex with men (MSM) are becoming more 
repressive. In March 2012, the government put forward a homophobic bill banning “propa-
ganda of sodomy, lesbianism, bisexualism and transgenderism, and pedophilia to minors.” 
Passing of this bill would mean that fines could be imposed on people engaging in “public 
activities to promote sodomy, lesbianism, bisexuality and transsexuality” that might be 
observed by minors. The vague terminology of the language could lead to a ban on wearing 
a gay-supportive logo or holding lesbian, gay, bisexual, transgender (LGBT) themed rallies in 
the city. Similar laws have been passed in other cities in Russia. The bill also links pedophilia 
and homosexuality, further reinforcing homophobic sentiment in the society. The environ-
ment for LGBT is already hostile, and reports of activists being physically attacked are com-
mon [56]. There is little published about sexual identity in Russia, with scant data on lifetime 
experience of same-sex activities. Evidence suggests that many gay men marry in order to 
conceal their identity. The Russian LGBT Network and Helsinki Group have documented inci-
dences of discrimination in relation to employment as well as restrictions to setting up non-
government organizations (NGOs) to support LGBT groups [57]. While the HIV epidemic 
remains concentrated among PWID, it is likely that discrimination and stigma will lead to 
major underreporting in HIV case reports and emerging evidence that HIV is growing among 
this population. Nevertheless, interventions and policies remain unsupportive to promoting 
effective interventions.
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transgender (LGBT) people found that 31% of community and voluntary sector 
workers, 40% of public sector staff, and 42.5% of private sector employees said 
they had heard antigay remarks at work. Around one-quarter reported hiding 
their sexuality at work [58]. Workplace conduct policy and the apparatus for its 
application determine how people behave at work.
Institutional homophobia manifests itself in different guises across the region. 
One manifestation of institutional homophobia is legal discrimination against 
MSM (and absence of protective legislation) [51]. Eliminating unequal treat-
ment in legislation and in law enforcement is essential to creating an environ-
ment in which MSM feel free to seek specific information about their HIV risks, 
and community organizations can provide it without harassment.
note
 1. This is because Liechtenstein data are reported via Switzerland.
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Conclusion
the Hiv epidemics of europe in Key populations at High risk
Despite decreases in the rate of the spread of human immunodeficiency virus 
(HIV) in the last decade, the  number of HIV cases in Europe continue to 
increase, and by 2011, reached over 1.2 million individuals, with over half a 
million diagnoses reported in the past five years. Between 2006 and 2010, there 
have been 127 new diagnoses each year per million people in Europe. Our 
review of national case reports indicates that the continuing increase in new 
HIV cases in Europe is fueled by epidemics in the East. Whereas an average of 
74 new diagnoses per million were reported in the West and 11 in Central 
Europe between 2006 and 2010, 273 per million people were diagnosed in the 
East. In the past five years, new diagnoses have been relatively stable in the 
West and Central Europe, but they have increased by around 30% in the East, 
with the highest rates of new diagnoses in Estonia, the Russian Federation, and 
Ukraine. The proportion of cases among women is declining in the West and 
Central Europe, but remains consistent in the East at 41%.
HIV among People Who Inject Drugs
Between 2006 and 2010, 25% of case reports in Europe were associated 
with injecting drug use, with higher proportions in the East (33%) than in the 
West (5%) and Central Europe (7%). Whereas there was an annual average 
of 89 reported HIV diagnoses associated with injecting drug use per million 
people in the East in this five year period, there were 3.6 per million in the 
West and 0.8 per million in Central Europe. The countries with the highest levels 
of reported diagnosed cases among people who inject drugs (PWID) in Europe 
were Ukraine (153 per million people), Russia (98 per million people), and 
Kazakhstan (78 per million people).
Findings from HIV prevalence studies show that prevalence among PWID 
is highest in Estonia (55.3%), Spain (34.5%), Russia (28.9%), Moldova (28.6%), 
and Ukraine (22.9%). Our review of multivariate risk factors linked to HIV 
among PWID shows that a history of injecting with previously used injecting 
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equipment, injecting with greater frequency, and a longer history of injecting 
career were linked to HIV. When aggregated across multivariate  studies, being of 
female gender emerges as a risk factor.
HIV among SWs
With few exceptions, European countries do not collate risk factor information 
concerning sex work as part of case reporting. Our review of HIV prevalence 
studies shows that HIV remains low among female sex workers (FSWs) who do 
not inject drugs, at less than 1% in the West [1–12]. HIV prevalence among 
FSWs in the East is generally higher than in the West and Central Europe, from 
around 2% to 8%).
Our review shows a clear relationship between higher HIV prevalence 
and higher prevalence of injecting drug use among sex workers (SWs). In our 
review of multivariate studies, a history of injecting drug use emerges as a 
prime risk factor for HIV among SWs in many countries [13–15], though not 
universally [16]. Other factors linked to higher odds of HIV or sexually trans-
mitted infections (STIs) among SWs included: migration from Africa [15], 
though other studies show no associations with migration [2, 4, 17], lack of 
service contact through outreach [17]; contact with HIV testing and STI 
services [2, 12, 13]; street-based sex work [12, 13, 16]; unprotected sex 
with nonpaying partners [17]; and unprotected sex with clients [18]. In the 
West, HIV prevalence is higher among male and transgender SWs than FSWs, 
even when injecting is lower, reflecting the higher prevalence of HIV among 
men who have sex with men (MSM), the main client group of male sex 
 workers (MSWs).
HIV among Men Who Have Sex with Men
Case reporting data show that MSM was reported for 10% of all HIV diagnoses 
in Europe, and it was higher in the West (36%), than in Central Europe (22%) or 
the East (0.5%). Between 2006 and 2010, the annual average diagnoses linked 
to MSM per million people was 27 in the West compared with 2.5 in Central 
Europe and 1.4 in the East, and it was highest in the United Kingdom (43.4), the 
Netherlands (43), and Spain (37.3). But Central Europe and the East have wit-
nessed marked increases in the number of reported diagnoses associated with 
MSM in the past five years.
Our review also shows that estimates of HIV prevalence are highest in the 
West, but vary from as low as 1.6% in Switzerland to nearly 20% in Spain. We 
also noted a relative lack of targeted HIV prevalence and risk behavior in a survey 
among MSM throughout the region. Our review of multivariate studies investi-
gating HIV risk factors among MSM linked HIV to inconsistent condom use, 
unprotected anal intercourse (UAI), and a history of STIs. Findings from our 
systematic review also suggest that the epidemics among MSM in the West may 
be perpetuated by a core group of MSM and HIV-positive MSM engaging in 
high-risk behaviors with a high number of sex partners [19, 20].
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Overview
We find, then, that the HIV epidemics of Europe are greatest in their burden 
and momentum in the East, where transmission remains primarily linked to 
injecting drug use. While the epidemics in the West remain primarily linked 
to MSM, we see recent increases in such case reports in the East and Central 
Europe. It is important to note that such case report data are only as robust 
as the HIV surveillance systems producing them. Underreporting of risk sta-
tus, especially among MSM, is likely in settings where social stigma is greatest, 
arguably in the East. Our synthesis of case report and HIV prevalence data 
suggest that the allocation of HIV prevention resources should concentrate 
on bolstering and expanding prevention responses targeting PWID and their 
sexual partners in the East, introducing prevention responses among MSM in 
the East and Central Europe, and reinvigorating prevention responses among 
MSM in the West.
intersecting epidemics
The HIV epidemics of Europe in key populations at high risk are intersecting 
epidemics, in which a key site is sexual risk intersecting with risks related to 
injecting drug use.
The Risk of Generalizing Epidemics through Sexual Transmission
Our review shows that there is potential for the epidemic to generalize beyond 
key populations of PWID, SW, and MSM, with increasing heterosexual transmis-
sion in some countries in the East, notably Estonia, Russia, and Ukraine, for 
instance, has seen an increased number of HIV case reports associated with 
 heterosexual exposure and a high proportion of them among women with high-
risk sex partners. This is further supported by outbreaks of STIs in the general 
population and high prevalence of syphilis (4%) and HIV (12%) among SWs in 
some cities, despite lower levels of recent injecting than reported elsewhere 
(15%) [21]. This study suggested that FSWs who reported having regular 
male partners who were injectors had increased odds of HIV (odds ratio [OR] = 
2.2 95% confidence interval [CI] 1.52–3.24) [21].
There is also emerging evidence in Europe of the potential for sexual trans-
mission of HIV among PWID involved in sex work. In Estonia, HIV was not 
associated with injecting drug use among SWs and they had correspondingly 
lower prevalence of Hepatitis C virus (HCV) suggesting less risky injecting 
behaviors [16]. A similar pattern has been observed in Russia where a study 
showed reduced odds of HCV among females who inject drugs (including both 
SWs and non-SWs), but increased odds of syphilis pointing to the potential for 
sexual transmission [22, 23]. The high prevalence of syphilis reported along with 
HIV observed in the Central Asian republics, Moldova, Russia, and Ukraine, sug-
gests that conditions may exist for increased sexual transmission of HIV among 
SWs in the East.
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Our review shows that SWs involved in injecting drug use have higher HIV 
prevalence than SWs who do not inject drugs, and that HIV prevalence among 
SWs is highest in the East where HIV prevalence is highest among PWID. There 
is considerable overlap between sex work and drug injecting in the East, with 
some studies of SWs suggesting that the majority are also PWID [24], and stud-
ies of PWID suggesting that between one-quarter and one-half have exchanged 
sex for money or drugs [25, 26]. Our review finds that SWs who inject drugs 
are more vulnerable not only to HIV, but also to violence, increased problems 
with mental health, reduced condom use and unwanted pregnancies [27, 29]. 
Furthermore, a high proportion of male and transgender SWs report injecting 
drugs [30–34]. HIV-prevention interventions need to give priority to targeting 
the intersection of sex work and injecting drug use.
Furthermore, among PWID in Europe the majority of men may have sexual 
partners who do not inject drugs. In Russia, for instance, one study among PWID 
suggested that 41% of male PWID had regular female partners who were also 
PWID, whereas this was the case for 70% of female PWID and 68% of female 
PWID also involved in sex work [35]. There are contradictory reports as to 
whether female PWID having a male partner who also injects acts as protective 
factor by reducing the likelihood of them engaging in risky sexual and injecting 
behaviors outside of their partnership or whether it increases the risk of sexual 
transmission because the female will engage in sex work to support both her and 
her partner’s drug use [28, 36–38].
While European studies suggest relatively high levels of noninjecting recre-
ational drug use among MSM, there are few estimates regarding injecting drug 
use, though some studies in the East suggest that high proportions of MSM may 
also inject drugs [39, 40]. Our review noted that a substantial proportion of 
MSM in the region, especially in the East, report also having sex with women.
Taken together, HIV surveillance systems need to increase the accuracy of 
risk-factor data among heterosexual exposures as well as target surveillance 
among the sexual partners of PWID. It is fundamental that HIV-prevention 
responses should integrate sexual health and drug-related health. Among SWs, 
sexual risk-reduction interventions need to better address sexual transmission 
risk in nonpaying and regular relationships. While our review shows consistent 
condom use with clients is generally the norm among SWs, it is much less com-
mon with nonpaying partners. Among PWID, sexual health concerns have been 
eclipsed by an almost exclusive focus on preventing viral transmission linked to 
the shared use of injecting equipment, and this may be particularly the case in 
the East, where the current potential for advancing sexual transmission appears 
greatest [41]. The majority of PWID in surveys across the region report inconsis-
tent condom use with their regular partners, the majority of whom are noninjec-
tors for male PWID.
Migration as an Intersecting Factor in HIV Vulnerability
European HIV case reports indicate the potential significance of migration. 
Among MSM in the West, 5.8% of diagnoses in 2010 were among men who 
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originated from elsewhere in the West and 2.8% (281) were among men from 
Central Europe or the East. Among diagnoses in the West associated with inject-
ing drug use, 4.3% originated from elsewhere in the West and 20% (181) in 
Central Europe or the East. Among cases associated with heterosexual exposure 
in the West, over one-third were among people who originated from a country 
with a generalized HIV epidemic. Evidence internationally indicates that local 
and international migration can have important effects on the dynamics of HIV 
transmission, both among vulnerable groups and in relation to heterosexual 
exposure [15, 42, 43].
There is a pattern among MSM to migrate into the cities, and from cities in 
the East toward the metropolises of Western Europe. An effect of homophobia 
in the region is generating mobility among MSM who tend to move or travel to 
urban centers, considered more gay-friendly and less stigmatizing [30, 44, 45]. 
The surveys we reviewed suggested that a significant minority of MSM are 
migrants, with up to 15% in many sites [30, 46–48]. Studies of MSM in some 
cities show higher prevalence of HIV among migrant MSM [49].
In the last 20 years, there are increasing numbers of migrant women working 
in the European sex industries. In the West, the majority of SWs are migrant 
women, most of whom are East European and African. Being a migrant emerges 
in some studies of SWs as a risk factor for HIV, but in others, there is no such 
association, most likely reflecting the HIV prevalence within country of origin 
[2, 15, 17, 50]. A systematic review examining the effect of migration on the 
risk of HIV among migrant SWs found that overall HIV prevalence was highest 
among migrants from Africa. Where there was no injecting drug use, HIV preva-
lence was lower among international migrants from Africa working in high-
income countries compared to internal African migrants working within other 
African countries. The risk of HIV among migrant SWs is likely mediated by 
local contexts such as the availability of services to migrants, immigration poli-
cies, and local organization of the sex industry [51].
Taken together, there is a need to better monitor migrant status in HIV sur-
veillance as well as to increase the accessibility of HIV-prevention responses to 
migrant PWID, SWs, and MSM, including through the translation of existing 
materials and messaging via the Internet and travel companies, including those 
servicing the gay tourist market [12, 17, 52].
environmental Factors shaping Hiv risk
While the epidemiological studies we reviewed rarely explicitly embraced explo-
ration of social determinants, our synthesis of data on HIV risk factors nonethe-
less points to the potential role of environmental-level factors in HIV transmission 
(chapter 3). Our discussion of HIV-prevention responses (chapter 4) also high-
lighted that the development and impact of interventions can be shaped by social 
and structural contexts.
Our review points to regional differences, suggesting that levels of risk behav-
ior among key populations tend to be highest in the East. While the frequency 
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of reported needle or syringe sharing is highly variable across Europe, there are 
instances of especially high levels of sharing in the East and Central Asia. Among 
SWs, the systematic review showed that condom use with clients was consis-
tently higher in the West than in the East or Central Europe. Among MSM, 
the highest rates of condom use during anal sex emanate from studies in the 
West, with rates around 15% higher than those reported in the East. Reports of 
UAI are also higher in the East than in the West or Central Europe. Most PWID 
across the region report inconsistent condom use with their regular partners, 
with a substantial minority reporting inconsistent condom use with their 
casual partners.
Among PWID, our review of multivariate studies pointed to unemployment, 
gender, and aspects of the legal environment as potentially important. Regarding 
gender, women who inject drugs tend to be younger than their male counter-
parts, engage in higher rates of needle and syringe sharing, and are more likely to 
share their sex partners’ injecting equipment and engage in riskier sexual prac-
tices [36, 53–59]. Regarding the legal environment, ever having been arrested 
and ever having spent time in prison emerged as risk factors for HIV. Rates of 
arrest were high among PWID surveyed, especially in the East. Qualitative stud-
ies in the region link police arrest, as well as the fear or experience of police 
violence with reduced capacity for risk reduction [60–62]. There is a need to 
systematically document the prevalence and contexts of policing practices, 
including extrajudicial practices, which may violate the human rights of PWID 
as well as potentially impact their HIV risk reduction capacity. These data also 
suggest that there is an urgent need to maximize the coverage and intensity of 
HIV-prevention interventions in prison settings. These findings are corroborated 
by studies internationally [60, 61, 63–67].
Among SWs, violence emerges as an important contextual determinant of 
HIV risk, linking to HIV both directly and indirectly. Reported levels of sexual 
and physical violence among SWs were high and appeared most common among 
minority groups (transvestites, Roma) and in the East [12, 52, 68–70]. Evidence 
also points to aggressive policing practices, especially in the East, exacerbating 
the potential for HIV risk by women having to work longer hours to make up 
time after arrest, having unprotected sex for more money to make up lost 
income, and not carrying condoms as they may be used as evidence of sex work 
[63, 71, 72]. Explicitly linked to policing is legislation regulating sex work, which 
is a key structural determinant of violence and HIV risk. The practice of criminal-
izing activities related to sex work can reduce opportunities for communication 
between SWs and often result in the concentration of sex work into tolerance 
zones [73, 74]. While the evidence shows a decriminalized approach results in a 
safer working environment and improved health, these benefits can be limited 
by other policies such as those related to migration and may exclude some of the 
more vulnerable populations [75, 76]. The evidence suggests that where sex 
work is unregulated and accompanied by police corruption, as it is in the East, it 
results in the most risky environments [72, 77]. Legislation may also influence 
community attitudes toward SWs with criminalization of sex work, reinforcing 
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negative attitudes and violence toward SWs; it also hinders the implementation 
of targeted services as reflected in the fewer number of targeted services for SWs 
in Russia [78, 79]. Repressive policies will reduce SWs access to HIV services, 
particularly, as is often reported in the East, when HIV testing is enforced follow-
ing detention by police.
In our ecological analysis, the strongest and most consistent association we 
found was a linear relationship between an increased number of people impris-
oned per 100,000 population and increased HIV prevalence among PWID and 
FSWs (“HIV-Prevention Responses among People Who Inject Drugs” and “HIV 
Prevention Responses among SWs” sections in chapter 4). Prison, an effect of 
criminalization of drug use and sex work, can constitute a risk environment for 
the acquisition of HIV.
Among MSM, the reviewed evidence suggests that social stigma in relation to 
male homosexuality emerges as a key factor influencing men’s capacity for risk 
reduction efforts. Feeling stigmatized also constrains the potential impacts of 
HIV surveillance and prevention efforts, disabling HIV-prevention help-seeking 
efforts as well as encouraging underreporting of same-sex activity as risk factors 
in HIV surveillance efforts. Institutionalized social stigma experienced by MSM 
can be viewed as a form of “structural violence” mediating HIV risk indirectly as 
well as directly.
toward a social epidemiology of Hiv vulnerability
Our review identified a number of cross-cutting environmental factors as key 
domains of future social epidemiological research investigating HIV risk and 
vulnerability in the region including (a) criminalization of key populations, drug 
use, and sexual practices; (b) the experience of social stigma and discrimination; 
(c) migration; (d) gender inequalities; and (e) material inequalities. This is not an 
exhaustive list and does not discount the potential importance of multiple other 
structural factors. Future epidemiological and intervention studies of HIV among 
key populations at high risk need to better systematically delineate how micro- 
and macroenvironmental factors combine to increase or reduce HIV risk.
Social determinants are often nonlinear and indirect in their effects, and this 
presents considerable challenges to delineating causative relationships. Researching 
the delineation of causal pathways to HIV transmission demands a shift from 
binary epidemiologic models of simple cause and effect to multilevel models, 
which emphasize HIV as an outcome of multiple contributing factors interacting 
together. HIV is best envisioned as an outcome of a complex system of interac-
tions occurring within and between individuals and their environments, with the 
challenge being to better capture the dynamism of these reciprocal relations.
Our review identified important structural indicators relating to criminaliza-
tion, low income, and gender inequality. But how these factors may directly or 
indirectly mediate pathways of risk towards HIV transmission is often unclear as 
well as dependent on the situation. Poverty, for example, does not have a straight-
forward relationship to HIV [80–82]. Our ecological analysis, for example, 
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illustrated how those settings with higher gross national income (GNI) per capita 
tended to have higher-HIV prevalence among MSM. Similarly, gender inequality 
is reproduced nonlinearly through situation specific interactions occurring simul-
taneously at the structural level (for example, via laws or policy), at the level 
of the community or household (for example, through social norms, values, 
and networks), and through individual and interpersonal actions (for example, 
through risk negotiation and behavior). A risk factor for HIV such as physical 
violence, for instance, may act as a proximal indicator of structurally determined 
social marginalization indirectly mediated through a combination of gender and 
material inequalities [83, 84]. There is a need for an iterative and mixed-methods 
research approach, in which qualitative evidence helps to map risk environment 
pathways, which are further elaborated through multilevel epidemiology, leading 
to empirically-informed models of social and structural HIV prevention.
strengthening Hiv surveillance
Our review noted the need for a systematic assessment of the robustness of 
methods used to monitor HIV prevalence and risk in key populations over time. 
We also noted the need to expand or introduce repeated studies to measures 
these, as well as indicators of HIV incidence, in some countries. HIV surveillance 
studies were found to be better established among PWID than among SWs and 
MSM, with very little data available among migrants and male SWs. Establishing 
mechanisms for repeated measures of HIV prevalence and risk is especially 
important, as is the development of a centralized portal for the synthesis of such 
data to enable cross-region comparisons.
Moreover, HIV surveillance systems provide unrealized opportunities to col-
late data on indicators of HIV-prevention intervention coverage, as outlined in 
third generation surveillance guidelines [85]. Data on the coverage of combina-
tion interventions are especially important. Where feasible, surveillance systems 
should also be geared toward monitoring indicators of how the social and struc-
tural context mediate HIV, for instance, by estimating the prevalence of violence 
among SWs and MSM and of police contact among PWID.
A key challenge in collecting data to inform interventions is the political con-
text in which sex work, drug use, and MSM takes place. In contexts where, for 
example, sex work is heavily regulated or MSM is stigmatized, conducting HIV 
related surveillance studies among people with few rights or representation may 
create ethical or safety challenges. Proposals for HIV related surveillance studies 
need to be conducted with full consultation with affected populations and with 
appropriate rights protections in place [86]. There are some useful lessons in 
good surveillance practice in Europe, including, for instance, the European Men 
Who Have Sex with Men Internet Survey, the sentinel surveillance of HIV and 
risk among PWID in Italy, Spain, and the United Kingdom; and sentinel surveil-
lance among SWs in Central Asia [50, 87–90].
Our review of surveillance data shows higher rates of HIV testing in the East, 
especially in Russia. This may result from mandatory testing of migrants and the 
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practice of “opt-out” rather than “opt in” testing policies at various clinic and 
health service settings [91, 92]. Evidence reviewed tends to show the protective 
effect of HIV testing in reducing HIV risk among PWID, and SWs, and UAI 
among MSM [35]. The uptake of HIV testing needs to be increased while simul-
taneously increasing access to treatment and reducing the stigma associated with 
HIV positivity and the removal of structural barriers to employment and dis-
crimination for those diagnosed.
strengthening Hiv prevention
People Who Inject Drugs
Among PWID, we noted the well-established scientific evidence in support of 
needle and syringe exchange programs (NSPs), opioid substitution therapy 
(OST), and antiretroviral therapy (ART) as methods of reducing HIV risk and 
preventing HIV transmission [93]. The combination of NSP, OST, and ART are 
to be reinforced as cornerstone interventions of HIV-prevention policy in 
Europe, and it is essential that they are sufficiently scaled-up. Estimates of NSP, 
OST, and ART coverage among PWID vary throughout the region, but coverage 
is generally lowest in the East, where HIV prevalence is higher.
Evidence, including in Europe [94], indicates that core HIV-prevention inter-
ventions targeting PWID have enhanced impact when they are delivered in 
combination [94, 95]. Stand-alone interventions may have limited impact on 
reducing HIV incidence even with good coverage [94, 96]. The enhanced HIV-
prevention effects of combining OST with NSP and ART have particular reso-
nance for countries—for instance, Russia and Ukraine—experiencing large HIV 
outbreaks among PWID. The effectiveness of HIV-prevention policies depends 
on the combined effects of multiple integrated interventions and bringing these 
to scale [96].
Findings from our modeling analysis show that high but achievable coverage 
levels of NSP can result in large decreases (>30%) in HIV incidence and preva-
lence in settings with high HIV prevalence among PWID. Required coverage 
levels are much lower when interventions are combined or in lower prevalence 
settings. The analysis also highlights the importance of combination interventions 
for reducing HIV incidence and prevalence to low levels in high-prevalence set-
tings, with no single intervention (or only at high coverage in the lower preva-
lence setting of Dushanbe) being able to reduce HIV incidence to less than 1% 
or prevalence to less than 10% in 20 years. Modeling shows that when core 
interventions are delivered in combination, coverage targets become more feasi-
ble, although they still remain considerable, with about 60% coverage of all three 
core interventions being required in Tallinn and St. Petersburg over 20 years and 
about 30% coverage in Dushanbe, to reduce HIV prevalence to less than 10%.
Intervention availability and coverage is shaped by the policy and social envi-
ronment, and as we have noted, how law enforcement, policing practices, and 
national commitments to HIV prevention can limit HIV-prevention coverage 
potential. We have also noted, for instance, how in Russia—a setting of a major 
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HIV epidemic—the legal and social environment has constrained, even prohib-
ited, the development of proven-to-be-effective HIV-prevention intervention, 
such as OST. Structural interventions bringing about policy, legal, or social 
change are required to enable sufficient HIV-prevention scale-up, and this is 
arguably most urgent in the East. The package of combination HIV-prevention 
interventions promoted by the World Health Organization (WHO) and other 
international agencies as core to national HIV prevention programming (which 
includes NSPs, OST, and ART) underemphasizes the potential role of social and 
structural intervention approaches. International evidence points to the potential 
HIV prevention impact of interventions fostering social and structural changes 
[97, 98]. For example, social network interventions encouraging PWID to pro-
mote risk reduction among their injection and drug using networks are associated 
with reduction in the risk behavior of participating PWID as well as their 
 network members [99–103]. The secondary distribution of sterile injecting 
equipment through peer networks of PWID is a practical yet underformalized 
example of how to diffuse HIV prevention through geometric progression in 
social networks [104–106]. The introduction of supervised injecting centers in 
six countries in Europe, as well as internationally, has been prompted by the need 
to create safer injecting environments, especially given elevated HIV risks linked 
to injecting in public, which in turn are linked to homelessness [96, 107–109]. 
Such interventions have attracted PWID at greater HIV risk, reduced syringe 
sharing, and facilitated access to withdrawal management, drug treatment, and 
other HIV-prevention interventions [107, 108, 110–121].
Moreover, combination HIV-prevention approaches should consider including 
interventions fostering policy reform as well as legal change. The WHO notes 
that “the alignment of drug control measures with public health goals [is] a prior-
ity” [122]. While lacking in rigorous evaluation, interventions targeting changes 
in the criminal justice environment include (a) the development of police HIV-
prevention training and partnerships; (b) the development of alternatives to 
prison programs, including coerced or mandated entry to drug treatment via 
community penalties and court orders; (c) the provision of sterile injecting 
equipment in prisons, which meta-analyses link to positive rather than adverse 
risk reduction effects; (d) the provision of OST in prisons, which is linked to 
improved drug treatment outcomes including post-release; and (e) the enact-
ment of interventions enabling legal aid and legal rights literacy to protect against 
rights violations, though the HIV-prevention impact of these interventions 
remains unknown.
Interventions that bring about change in the legal environment seek to mini-
mize the iatrogenic health effects of the criminalization of drug users and the 
prohibition of HIV-prevention interventions. Ecological evidence indicates ele-
vated odds of HIV and HIV risk among injecting drug users (IDUs) in settings 
without legal access to HIV-prevention interventions such as OST and NSP, 
compared to settings with access [123–125]. The relaxation of legal restrictions 
to the provision of sterile needles and syringes increases their availability and 
accessibility, reducing levels of risk behavior, as well as potentially reducing levels 
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of police harassment among IDUs [63, 84, 123, 126–130]. If HIV risks are in part 
associated with the criminalization of drug use per se, as increasingly evidenced 
internationally [131–134], then decriminalizing drug use is also a strategy to 
reduce such harm [111, 133].
Sex Workers
International evidence has shown the importance of targeted interventions for 
SWs as well data from our ecological analysis linking a reduction in HIV with 
increasing numbers of services that address not only HIV/STI but broader social 
and health problems (“HIV Prevention Responses among SWs” section in 
 chapter 4). HIV-prevention frameworks for SWs need to recognize that an 
 individual may not identify themselves as a sex worker sufficiently to engage 
consciously in behavior change to minimize sex-work–related harms. Many inter-
ventions targeting SWs exclude those who do not self identity as such [44, 135]. 
The focus of services in the East, for instance, has been among SWs who inject 
drugs rather than targeting the health and welfare needs of SWs more broadly 
[136]. Evidence internationally indicates that interventions that specifically tar-
get SWs show greater promise in reducing sexual risk, including the risk of sexual 
violence, when compared against drug-related harm reduction interventions 
targeting SWs who use drugs [137]. The vertical structure of health systems, 
especially in the East, compounds the problem of targeting HIV prevention to 
all those potentially in need, as there is often little linkage between drug treat-
ment and sexual health services. It is fundamental that HIV-prevention interven-
tions specifically target SWs, including those not involved in drug use and who 
may not define themselves as connected to the sex industry. It is also important 
that drug and sexual health services are sufficiently integrated to maximize their 
coverage potential.
Indicators of coverage by SW services across the region was limited. Data on 
HIV testing suggested that over one-third of SWs across the region had been 
tested for HIV, but this may reflect testing following arrest or detainment or as 
a result of mandatory testing through regulation (as it is done in Greece) rather 
than voluntary testing. The European Centre for Disease Control highlighted 
the limited scope of behavioral surveillance among SWs in European Union 
(EU) countries usually collected through one-time surveys rather than ongoing 
or repeated surveillance at a national level [86]. There was also little consis-
tency in the type of indicators collected, making comparisons difficult to draw. 
The routine collation of reported HIV or STI testing at SW service centers 
would facilitate an estimate of the effective coverage of services in relation to 
HIV prevention, taking into account the need for consultation and protection 
of privacy as discussed above. Routinely monitoring condom use with clients 
and nonpaying partners would also give an insight into sexual risk behaviors, as 
the high prevalence of gonorrhea underscores the persistent sexual vulnerabil-
ity of SWs.
The reviewed literature emphasizes the heterogeneous nature of sex-worker 
populations in Europe. This again emphasizes the need to tailor intervention 
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approaches accordingly. The rapidly changing sex-worker scene in Europe accen-
tuates the need for flexible and innovative approaches to health service provi-
sion, especially in relation to the diversification of indoor sex work and the 
increased involvement of migrant women in sex work. With the growing number 
of indoor SWs across the region, there is a need for interventions to reach off-
street SWs. Projects in the United Kingdom have attempted to address this by 
conducting outreach on line: contacting women via websites and circulating 
frequent emails about services. The increase in migrant women means that one 
of the main priorities for short-term intervention is provision of translation, espe-
cially in Western Europe experiencing migration from the East as well as South 
America and Sub-Saharan Africa.
There have been increased calls for applying a pragmatic “harm reduction” 
approach to sex work as more commonly applied in relation to drug use [138, 
139]. A harm reduction framework for sex work seeks to envisage how a variety 
of harms related to sex work might be relevant, directly or indirectly, to HIV 
prevention. Our review identified violence as a primary concern. Community-
level interventions, such as the Ugly Mugs scheme, implemented successfully 
throughout most of Western Europe should be introduced to projects in the East 
and Central Europe. Violence experienced by SWs in family, social, and work 
relationships is contextualized by broader social and structural violence feeding 
social stigma and discrimination [97, 140, 141]. Indirect pathways that mediate 
the risk of violence include low self-esteem and the inability to negotiate safer 
practices for fear of further violence; increasing drug use to manage the stress 
of violence; or forced relocation of sex work to less familiar or safe areas 
[84, 142–144].
The significance of violence in the everyday lives of SWs emphasizes the need 
for envisaging HIV prevention inside a social and structural intervention 
approach to reducing sex work risks, of which HIV is one. HIV-prevention inter-
ventions should be nested inside change strategies that simultaneously address 
the social welfare of SWs and their social determinants of health, including dis-
parities in employment opportunity, income, and access to welfare services [138, 
139, 145]. Key targets for health interventions targeting SWs, in addition to HIV 
risk reduction, include reducing violence and unwanted pregnancies and improv-
ing mental and emotional health [146]. For example, sexual health interventions 
throughout the region need to focus not only on sexual safety negotiations with 
clients of SWs but also on promoting contraceptive use among the nonpaying sex 
partners of SWs to prevent unplanned pregnancies and unprotected sex.
The evidence reviewed indicates that the criminalization of sex work can 
 disable rather than enable capacities for health protection [74, 139, 142, 147]. 
There is potential HIV-prevention impact linked to the decriminalization of sex 
work, including indirectly through the potential reduction in violence and pro-
tection of SWs’ mental health [148–150]. A long-term strategy of public health 
may include the decriminalization of sex work across the region. In the short- 
and medium-term, emphasis should be given to community-level interventions, 
such as the development of managed street-based sex-work zones, which have 
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shown positive effects in reducing incidences of violence and providing a safer 
place to work. Managed street zones need the consent of local communities and 
need to clearly assign responsibilities to authorities to manage the zone [151].
Men Who Have Sex with Men
An important finding of the review is that access to mainstream sexual health 
provision for MSM can be impeded by staff hostility borne out of the dual stigma 
of homosexuality and HIV, and patient fears concerning breaches of confidential-
ity [152–154]. Such concerns appear more acute in the East. For instance, social 
stigma appears to act as a deterrent to timely HIV testing and levels of HIV test-
ing are lower in Central Europe and the East.
Evidence suggests that HIV testing can increase condom use for anal inter-
course [155, 156], but for HIV-negative men testing is a more effective HIV-
prevention strategy when accompanied by effective counseling on risk reduction 
[40]. Effective counseling is rare in contexts where specialized services are rarely 
available, as is the case for example in Russia [153, 157]. Dedicated MSM-only 
test facilities are needed in countries where most physicians are inclined to be 
hostile toward MSM. For full impact, it is essential that links are made with other 
prevention services appropriate to the needs of MSM, particularly in the East 
where many MSM appear poorly informed of the HIV risks linked to certain 
practices [158]. Paying for tests and other medical care is a major barrier to 
uptake and should be discontinued.
While HIV prevention among MSM has traditionally focused on consis-
tent condom use, factors such as availability, cost, and “condom fatigue” have 
been considered as reasons why men participate in UAI [159–162]. To address 
these factors, condoms should be made freely available in all gay venues and 
known meeting places and required as a condition of local authority licensing. 
Additionally, strategies other than a reliance on 100% condom use are needed 
such as encouraging slower rates of partner change, fewer partners, and especially 
the avoidance of multiple concurrent partnerships. Concurrency is a key risk fac-
tor in the spread of HIV because people are more inclined to use condoms in 
casual relationships [20, 163], but the establishment and maintenance of trust in 
a relationship encourages unprotected intimacy and then sets up barriers to hon-
esty about any infidelity [164, 165]. Other strategies should involve encouraging 
the practices of sex acts other than anal sex [160].
In the West, social stigma appears to be a less prominent factor shaping 
access to help and risk reduction; HIV testing is more common, knowledge of 
the risks posed by UAI is higher, and condoms are widely available [166, 167]. 
However, many MSM continue to have unprotected sex frequently with casual 
partners. In a context of the widespread availability of highly active antiretroviral 
therapy (HAART), there may also be a misplaced reliance on negative HIV 
results when selecting sex partners [168, 169]. Only HIV-positive people can 
definitely “know their status.” The population groups in which HIV incidence 
is high are those in which unprotected sex and casual sex are more easily socially 
accepted, and the persistent focus of prevention strategies on “technical solutions” 
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(condoms, testing, HAART) may do little to shift such social norms, rendering a 
reliance on HIV testing for prevention dangerously misleading. Interventions 
need to question how strategies of serosorting are applied in practice, for they may 
promote a false sense of security. Counseling along with HIV testing is necessary 
to address any misconceptions regarding the safety of relying on recent HIV-
negative test results as a rationale for unprotected sex.
Complacency about infection and treatment availability complicates preven-
tion messages in the West. There is some evidence that good adherence to 
HAART can reduce viral load to undetectable levels and that HAART therefore 
acts as HIV prevention [170, 171]. This has led to much debate about “negoti-
ated safety strategy” as an HIV-prevention strategy. In this strategy, sexual part-
ners agree to dispense of condoms within their relationship while at the same 
time negotiate sexual agreement outside the regular relationship. However, some 
residual risk resulting from infidelity or lapses in the agreed condom use in sex 
outside the partnership still exists, resulting in some infections. Moreover, in gay 
communities where open relationships and casual sex with multiple partners is 
the norm, promotion of treatment as a prevention method can be unhelpful, 
leading to increased UAI [163, 172]. And perhaps, it may also be linked to the 
increase in HIV incidence seen among MSM in Western Europe.
Furthermore, patients with undetectable viral load may have detectable virus 
in semen and therefore may be infectious [173–175]. Many of the studies pro-
viding the evidence of effectiveness of treatment as prevention are based not on 
observed data but on mathematical models, which are highly sensitive to their 
parameters and underlying assumptions. The remaining studies are ecological 
studies that overall give mixed results and are unable to demonstrate causality 
[170–172, 176]. A retrospective cohort study of treatment as prevention [177] 
found that 5% of the partners of people living with HIV (PLHIV) on treatment 
seroconverted, as compared with 3% of controls (difference nonsignificant). A 
false sense of security, interacting with much higher risks from acute infections 
(pre-seroconversion), may result in elevation of risks. An assumption that treat-
ment is protective is particularly problematic in the case of MSM, given that the 
per-act probability of transmission is so much higher for anal sex [178] than for 
vaginal sex [179], and that partner numbers are typically higher. The promotion 
of HIV treatment as prevention as a strategy for HIV prevention in Europe 
therefore needs to be approached with some caution.
One difficulty with the targeting of HIV prevention in parts of the European 
region is that it tends to be based on “Western” models of experience, and these 
tend historically to be based on interventions targeting homosexually-identified 
men. Such approaches may tend to overinclude men who perform mainly or 
only the receptive role, since those who tend to take the insertive role may be 
more likely to identify themselves as heterosexual [180]. It is fundamentally 
important to recognize the heterogeneous nature of populations of MSM and to 
tailor interventions accordingly in different parts, and local settings, of Europe.
Our review notes a varied environment in relation to the criminalization 
and social regulation of homosexuality throughout Europe. Legal changes to 
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decriminalize homosexuality in the parts of the region where such laws remain 
(Turkmenistan, Uzbekistan) need to be made. It is important that discrimination 
on the grounds of sexual orientation should be afforded the same legal punish-
ment and redress in the East as in the West [181]. Shifts in Western Europe 
toward recognizing the social inclusion of MSM—for instance, through the legal-
ization of civil partnerships between men—are important social interventions in 
that they contribute to an enabling context for health and citizenship, including 
potentially for HIV prevention. Community-level interventions may facilitate 
some of the social changes required to enable the wider social acceptance of 
homosexuality, including the day-to-day practices of health, welfare, and regula-
tory institutions and especially the practices of police and health care profession-
als. Aside from HIV-prevention capacity, our review notes that HIV surveillance 
systems are much more likely to correctly attribute transmission of HIV between 
MSM, and thus better allocate treatments, in settings where homosexuality is less 
socially stigmatized.
A shift toward social-structural intervention Approaches
Social and structural interventions seek social or structural change not only at 
the level of the individual but also at the level of the society or community. 
We emphasize the need for HIV-prevention programs to embrace social and 
structural interventions that attempt to bring about a contextual change in the 
environments that mediate HIV risk, with the objectives of removing barriers to 
HIV prevention and enabling social conditions that protect against HIV vulner-
ability. Structural approaches emphasize the potential HIV prevention effects 
of multisectoral nonhealth interventions including stigma-reduction interven-
tions; decriminalizing drug use, sex work, and MSM; microfinance and access 
to employment interventions [97, 182–184]; poverty alleviation interventions 
[185, 186]; community mobilization and civil participation interventions 
[97, 144, 186]; access to housing and welfare interventions; and access to educa-
tion interventions [187].
There are a number of intervention approaches that show both theoretical, 
and some evidence-based promise. These include HIV prevention-focused inter-
ventions that attempt to (a) create safer physical environments (for instance, 
safer injecting facilities, safer brothel policies, managed sex-work zones, reduction 
in stigma toward MSM); (b) defuse changes in risk-related norms, values, and 
practices at the level of the peer group and social network (e.g., “indigenous-
leader” community mobilization interventions); (c) effect legal change and/or 
moderate risk related to legislative and policing practices (e.g., through police 
partnerships, developing legal and human rights literacy, offering legal aid, and 
advocating for legal or policy reform); and (d) institute non-HIV and nonhealth 
focused multisectoral initiatives that can theoretically have an indirect HIV 
 prevention effect. However, evidence assessing social and structural HIV preven-
tion among key populations at high risk remains embryonic, and creating this 
evidence is a key challenge for the future.
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 HIV OR (human immunodeficiency virus) OR (acquired immunodeficiency 
syndrome) OR (acquired immune deficiency syndrome)
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exp HIV/ OR exp HIV infections/
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 e.  risk* OR correlat* OR determinant* OR vulnerab* OR regression OR risk 
OR (enhanc* adj3 transmission) OR multivariate OR (route* adj3 trans-
mission) OR (factor* adj3 transmission) OR (social norm*) OR network 
OR socio-demographic OR socio-economic OR lifestyle OR epidemiol*
OR
Subject headings:
exp Risk/ OR Factor Analysis, Statistical/ OR exp Regression analysis/ OR 
exp Risk Factors/ OR exp Risk-Taking OR exp Epidemiology
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3. Countries
All countries in the European region as defined by the World Health 
Organization (WHO):
Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia 
and Herzegovina, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, 
Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, 
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Subject heading search string:
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 b. Central Asia
Keyword search string (to include adjectives as well as nouns for 
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4. Risk group
Keywords:
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OR opioid* OR syringe* OR (needle* adj3 shar*) OR (illegal* adj3 drug*)
Subject headings:
exp Substance Abuse, Intravenous/ OR exp Needle Sharing/ OR exp Heroin 
Dependence/
sex Workers
1. HIV
Keywords:
HIV OR (human immunodeficiency virus) OR (acquired immunodeficiency 
syndrome) OR (acquired immune deficiency syndrome)
OR
Chlamydia Trachomatis OR Chlamydia OR C Trachomatis OR Treponema 
Pallidum OR T Pallidum OR syphilis OR Neisseria gonorrhea OR N gonorrhea 
OR Gonorrhea OR Trichomonas vaginalis OR T vaginalis OR trichmoniasis
Subject headings:
exp HIV/ OR exp HIV infections/ Sexually Transmitted Diseases/ or 
Gonorrhea/or Risk Factors/or Chlamydia Infections/
2. Epidemiological terms
 a. Prevalence and incidence
Keywords:
Prevalence* OR incidence
OR
Subject headings:
Prevalence/ OR Incidence/
 b. Risk factors for acquiring HIV infection
Keywords:
risk* OR correlat* OR determinant* OR vulnerab* OR regression OR risk 
OR (enhanc* adj3 transmission) OR multivariate OR (route* adj3 trans-
mission) OR (factor* adj3 transmission) OR (social norm*) OR network 
OR socio-demographic OR socio-economic OR lifestyle OR epidemiol*
OR
Subject headings:
exp Risk/OR Factor Analysis, Statistical/ OR exp Regression analysis/OR 
exp Risk Factors/OR exp Risk-Taking OR exp Epidemiology
3. Countries
All countries in the European region as defined by WHO:
Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and 
Herzegovina, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, 
Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, 
Israel, Italy, Kazakhstan, the Kyrgyz Republic, Latvia, Lithuania, Luxembourg, 
the former Yugoslav Republic of Macedonia, Malta, Moldova, Monaco, 
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Federation, San Marino, Serbia, the Slovak Republic, Slovenia, Spain, Sweden, 
Switzerland, Tajikistan, Turkey, Turkmenistan, Ukraine, United Kingdom of 
Great Britain and Northern Ireland, and Uzbekistan.
 a. Europe
Keyword search string (to include adjectives as well as nouns for countries):
Europe* OR Albania* OR Andorra* OR Armenia* OR Austria* OR 
Azerbaijan* OR Bel#rus OR Byel#rus* OR Belgium OR Belgian OR 
Bosnia* OR Herzegovin* OR Bulgaria* OR Croatia* OR Cypr* OR Czech* 
OR Denmark OR Danish OR Estonia* OR Finland OR Finnish OR France 
OR French OR Georgia* OR German* OR Greece OR Greek OR Hungary 
OR Hungarian OR Iceland* OR Ireland OR Irish OR Israel* OR Italy OR 
Italian OR Kosovo OR Latvia* OR Lithuania* OR Luxembourg* OR Malta 
OR Maltese OR Monaco OR Montenegr* OR Netherland* OR Dutch OR 
Norway OR Norwegian OR Poland OR Polish OR Portugal OR Portuguese 
OR Moldova* OR Romania* OR Russia* OR USSR OR CIS OR Marino 
OR Serbia* OR the Slovak Republic* OR Slovenia* OR Spain OR Spanish 
OR Sweden OR Swedish OR Switzerland OR Swiss OR Macedonia* OR 
Transdniestria* OR Trans-Dniester* OR Transnistria* OR Turkey OR Turkish 
OR Ukrain* OR United Kingdom OR Britain OR British OR English OR 
England OR Scotland OR Scottish OR Wales OR Welsh OR Baltic* OR 
Balkan* OR Kosov* OR Dagestan* OR Chech?n* OR Ingush*
Subject heading search string:
exp Europe/
 b. Central Asia
Keyword search string (to include adjectives as well as nouns for 
countries):
Kazakh* OR Kyrg?#z* OR Kirg?#z OR Tajik* OR Turkmen* OR Uzbek*
Subject heading search string:
exp Asia, Central/
4. Risk group
Keywords:
(sex work*) OR prostitut* OR (entertainment worker*) OR (exchang* adj3 
sex) OR (sell* adj3 sex) OR (sold* adj3 sex) OR (sex adj3 money) OR (trans-
action* adj3 sex) OR (commerc adj3 sex) OR (surviv* adj3 sex) OR (sex adj3 
drug*) OR (sex trade) OR (sex industry) OR (sex* servic*) OR brothel* OR 
(red-light) OR solicit* OR (bar girl*) OR hostess* OR escort* OR masseu*
Subject headings:
exp Prostitution/
men Who Have sex with men
1. HIV
Keywords:
HIV OR (human immunodeficiency virus) OR (acquired immunodeficiency 
syndrome) OR (acquired immune deficiency syndrome)
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OR
Subject headings:
exp HIV/ OR exp HIV infections/
2. Epidemiological terms
 a. Prevalence and incidence
Keywords:
Prevalen* OR incidence
OR
Subject headings:
Prevalence/ OR Incidence/
 b. Risk factors for acquiring HIV infection
Keywords:
risk* OR correlat* OR determinant* OR vulnerab* OR regression OR risk 
OR (enhanc* adj3 transmission) OR multivariate OR (route* adj3 trans-
mission) OR (factor* adj3 transmission) OR (social norm*) OR network 
OR socio-demographic OR socio-economic OR lifestyle OR epidemiol*
OR
Subject headings:
exp Risk/ OR Factor Analysis, Statistical/ OR exp Regression analysis/ OR 
exp Risk Factors/ OR exp Risk-Taking OR exp Epidemiology
3. Countries
All countries in the Europe region as defined by WHO:
Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and 
Herzegovina, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, 
Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, 
Israel, Italy, Kazakhstan, the Kyrgyz Republic, Latvia, Lithuania, Luxembourg, 
Malta, Monaco, Montenegro, the Netherlands, Norway, Poland, Portugal, 
Moldova, Romania, the Russian Federation, San Marino, Serbia, the Slovak 
Republic, Slovenia, Spain, Sweden, Switzerland, Tajikistan, the former 
Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Ukraine, United 
Kingdom of Great Britain and Northern Ireland, and Uzbekistan.
 a. Europe
Keyword search string (to include adjectives as well as nouns for 
countries):
Europe* OR Albania* OR Andorra* OR Armenia* OR Austria* OR 
Azerbaijan* OR Bel#rus OR Byel#rus* OR Belgium OR Belgian OR 
Bosnia* OR Herzegovin* OR Bulgaria* OR Croatia* OR Cypr* OR Czech* 
OR Denmark OR Danish OR Estonia* OR Finland OR Finnish OR France 
OR French OR Georgia* OR German* OR Greece OR Greek OR Hungary 
OR Hungarian OR Iceland* OR Ireland OR Irish OR Israel* OR Italy OR 
Italian OR Kosovo OR Latvia* OR Lithuania* OR Luxembourg* OR Malta 
OR Maltese OR Monaco OR Montenegr* OR Netherland* OR Dutch OR 
Norway OR Norwegian OR Poland OR Polish OR Portugal OR Portuguese 
OR Moldova* OR Romania* OR Russia* OR USSR OR CIS OR Marino 
OR Serbia* OR the Slovak Republic* OR Slovenia* OR Spain OR Spanish 
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OR Sweden OR Swedish OR Switzerland OR Swiss OR Macedonia* 
OR Transdniestria* OR Trans-Dniester* OR Transnistria* OR Turkey OR 
Turkish OR Ukrain* OR United Kingdom OR Britain OR British OR 
English OR England OR Scotland OR Scottish OR Wales OR Welsh 
OR Baltic* OR Balkan* OR Kosov* OR Dagestan* OR Chech?n* OR 
Ingush*
Subject heading search string:
Exp Europe/
 b. Central Asia
Keyword search string (to include adjectives as well as nouns for 
countries):
Kazakh* OR Kyrg?#z* OR Kirg?#z OR Tajik* OR Turkmen* OR Uzbek*
Subject heading search string:
exp Asia, Central/
4. Risk group
Keywords:
Homosexual* OR gay* OR bisexual* OR (men who have sex with men) OR 
(male adj3 prostitut*) OR (male adj3 (sex worker)) OR (transgender*) OR 
(transsexual*) OR transvestit* OR LGBT OR (sexual minorit*)
Subject headings:
exp Homosexuality, Male/ OR exp Homosexuality/
Gray literature
Internet Sites Searched for Gray Literature—General
http://www.aids2006.org/
http://www.aids2008.org/
http://www.aids2010.org/
http://www.ihra.net/
http://www.euro.who.int/en/home
http://www.unaids.org
http://ecdc.europa.eu/en/Pages/home.aspx
http://www.soros.org/
http://www.usaid.gov/km/
http://www.eurohiv.org/
http://www.fhi.org/en/HIVAIDS/pub/index.htm
http://www.harm-reduction.org
http://www.afew.org
http://www.dfid.gov.uk/Media-Room/Publications/?t=HA
http://www.epinorth.org/eway/default.aspx?pid=230&trg=4148&MainArea 
_5260=5328:0:&4148=5326:2:0
http://www.episouth.org/relevant_links_docs.html
http://europa.eu.int
http://www.szu.cz
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http://www.iph.fgov.be/reitox/
http://www.sst.dk/
http://www.stakes.fi/
http://www.ift.de/
http://www.dimdi.de/
http://www.gbe-bund.de/
http://www.asl.bergamo.it
http://www.hrb.ie
http://www.inef.ie
http://www.hrb.ie/ndc
http://www.fhinst.se/
Internet Sites Searched for Gray Literature—PWID Specific
http://www.emcdda.europa.eu/
http://eusk.tai.ee/?lang=en
http://www.europad.org/europeanpartnerlinks.asp
http://www.univie.ac.at
http://www.beldrug.org
http://www.kaapeli.fi/nad/
http://www.terveysportti.fi/pls/kotisivut
http://www.drogues.gouv.fr
http://www.bisdro.uni-bremen.de/
http://www.indro-online.de
http://www.dgsuchtmedizin.de
http://business.hol.gr/~umhri/
http://www.sitd.org
http://www.relis.lu/
http://www.trimbos.nl/
http://www.frw.uva.nl/cedro/Welcome.html
http://www.ivo.nl/
http://www.aiar.nl
http://www.rusinfo.no
http://www.med.uio.no/ipsy/skr/
http://www.rusmiddeletaten.oslo.kommune.no
http://www.ipdt.pt/
http://www.addiction.ie
http://www.seea.net/about-seea
http://www.mir.es/pnd/index.htm
http://www.fad.es/
http://www.idea-prevencion.com/
http://www.ieanet.com
http://www.socidrogalcohol.org
http://www.can.se
http://www.sfa-ispa.ch
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http://www.isf.unizh.ch
http://www.abbeycarefoundation.com
http://www.sdf.org.uk
http://www.dundee.ac.uk
http://www.drugscope.org.uk
http://www.lau.org.uk
http://www.addiction-ssa.org
http://www.gla.ac.uk/Inter/DrugMisuse/
http://www.iop.kcl.ac.uk
http://www.smmgp.co.uk
http://www.staplefordcentre.co.uk
http://www.qed.org.uk
http://www.itacaeurope.org
http://www.erit.org/
http://www.q4q.nl/methwork/
http://www.elisad.org
http://www.pompidou.coe.int/
http://www.ecdp.net
http://www.ac-company.org
http://www.irefrea.org
Internet Sites Searched for Gray Literature—Sex Worker Specific
http://tampep.eu/
http://www.nswp.org/
http://www.uknswp.org/
Internet Sites Searched for Gray Literature—Specific to Men Who Have Sex 
with Men
http://www.gnpplus.net
http://www.aidsinfoonline.org
http://www.pridelife.co.uk
http://www.emis-project.eu
http://www.ilga-europe.org
http://www.non-discrimination.net
http://www.rki.de/EN/Home/homepage__node.html
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Figure A.1 Flowchart of study selection of pWiD
5,644 documents collected 
from peer-reviewed literature
419 documents selected after 
review of titles and abstracts
88 peer-reviewed documents
5,225 documents excluded 
due to lack of relevance
331 documents excluded due to 
content not meeting exclusion criteria
40 documents collected from gray 
literature sources
128 documents used to generate HIV prevalence and incidence 
estimates and demographic profile of PWID in Europe
91 documents provide unique estimates of 
HIV prevalence and incidence among PWID
22 documents report multivariate 
risk factors for HIV among PWID
study selection Flowcharts
Note: HIV = human immunodeficiency virus; PWID = people who inject drugs.
Figure A.2 Flowchart of study selection of sWs
1,993 documents collected 
from peer-reviewed literature
498 documents selected after 
review of titles and abstracts
45 peer-reviewed documents
1,495 documents excluded 
due to lack of relevance
453 documents excluded due to 
content not meeting exclusion 
criteria
28 documents collected from gray 
literature sources
73 documents used to generate HIV/STI prevalence and incidence 
estimates and demographic profile of SWs in Europe
63 documents provide unique estimates of 
HIV prevalence and incidence among SWs
15 documents report multivariate risk
factors for HIV/STIs among SWs
Note: HIV = human immunodeficiency virus; STI = sexually transmitted infection; SW = sex worker.
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Box A.1 Key indicators of an enabling environment for pWiD
meaningful engagement of stakeholders
 1. The meaningful involvement of PWID in policies affecting their health and welfare and 
in related HIV prevention programming is accepted as an important indicator of ‘health 
policy’ formation [1, 2]. While assessing “meaningful involvement” is complex, we adopt 
a simple indicator: the presence of a national organization of drug users. 
coordinated national strategy to Hiv prevention and Drug Use
 2. Explicit and supportive reference to “harm reduction” in national policy documents can 
mark a commitment to evidence-based interventions as part of HIV prevention responses 
targeting PWID. International agencies advocate institutional and national-level endorse-
ment of harm reduction as a feature of national strategy [3, 4]. We adopt evidence of 
explicit supportive reference to harm reduction in national strategy as an indicator of 
enabling policy environment. 
 3. Monitoring and evaluating the state of the epidemic and response is an important element 
of building evidence-based responses [5, 6]. Targeted seroprevalence and behavioral 
box continues next page
Figure A.3 Flowchart of study selection of msm
3,000 documents collected 
from peer-reviewed literature
305 documents selected after 
review of titles and abstracts
38 peer-reviewed documents
10 documents report 
multivariate risk factors for UAI 
among MSM
2,895 documents excluded 
due to lack of relevance
267 documents excluded due to 
content not meeting exclusion 
criteria
35 documents collected from gray 
literature sources
73 documents used to generate HIV/STI prevalence and incidence 
estimates and UAI estimates and demographic profile of MSM
in Europe
55 documents provide unique 
estimates of HIV/STI prevalence and 
incidence among MSM
7 documents report multivariate risk 
factors for HIV/STIs among MSM
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men; STI = sexually transmitted 
infection; UAI = unprotected anal intercourse.
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surveillance is recommended in concentrated HIV epidemics [7]. We adopt as an indicator 
of enabling policy evidence of at least one HIV seroprevalence and one behavioral study 
among PWID since 2000. 
implementation of public Health-oriented Approaches to reducing Harm
 4. Drug control policies that seek to distinguish drug users from drug traders and traffickers, 
and which deemphasizes the criminalization of drug users, can give priority to public 
health-oriented approaches to reducing drug-related harm. We adopt the application of 
administrative rather than criminal penalties for drug use and possession of quantities for 
personal use as an indicator of an enabling policy environment.
 5. We adopt the legal availability of OST and needle and syringe exchange programs (NSPs) in 
a country as an indicator of enabling policy environment. These are core components of 
the recommended nine combination HIV prevention interventions for PWID [3]. Many 
countries have adopted at least some recommended measures, but often the components 
missing are OST and NSPs. The  effectiveness of both in improving the health of PWID is well 
established [8–10], especially for OST [11–17]. OST also facilitates access to and augments 
the effects of other interventions, such ART [10, 18].
 6. The availability of OST and NSPs in prison can show a country’s willingness to address the 
needs of even the most marginalized of its citizens, as well as demonstrating noteworthy 
scale of the programs. Because of existing laws concerning drug use and possession, 
PWID in many countries account for disproportionately high rates of incarceration [19]. 
Prisons may act as a risk environment for HIV transmission linked to drug injecting. 
International guidelines [20] recommend continuity of services between prison and com-
munities and some countries have developed successful partnerships between penal 
 systems and HIV services, including in the European region [21].
Note: NSPs = needle and syringe exchange programs; OST = opioid substitution therapy; PWID = people who inject drugs.
table A.1 Behavioral and intervention coverage parameter estimates Used in the model Fits
Parameter Tallinn St. Petersburg Dushanbe
Average duration inject in years 16 30 8
Infection rate per month in 
latent phase of HIV
0.014 0.011 0.011
Seed HIV prevalence in 1996 1.5% 4% 2%
Baseline intervention coverage assumptions
NSP Assumed to scale-up from 
nothing in 2003 to 40% 
reduction in HIV 
incidence in 2008. 
Effect on intermediate 
years proportional to 
syringes distributed.
0% Assumed to scale-up 
from nothing in 1999 
to about 20% 
reduction in HIV risk by 
2010 because 
achieved half NSP 
coverage of Tallinn. 
OST 0% 0% 0%
ART 0% 0% 0%
Note: ART = antiretroviral therapy; NSPs = needle and syringe exchange programs; OST = opioid substitution therapy.
Box A.1 Key indicators of an enabling environment for pWiD (continued)
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A p p e n D i x  B
table B.1 Annual number of Diagnostic tests for Hiv Undertaken in the WHo european region
Country Year Number of HIV tests
Proportion of 
total (%)
Proportion of total 
for subregion (%)
Tests per 1,000 
people
Western Europe
Andorra 2010 2,678 0 0 32
Austria 2008 751,749 2 7 90
Belgium 2010 651,095 1 6 61
Denmark 2006 154,332 0 1 28
Finland 2010 185,114 0 2 35
France 2010 4,977,463 10 47 80
Germany 2004 2,277,000 5 21 28
Greece 2009 2,083 0 0 0
Iceland 2010 7,318 0 0 23
Ireland 2009 184,980 0 2 42
Israel 2010 286,368 1 3 41
Italy — — — — —
Liechtenstein — — — — —
Luxembourg 2008 13,366 0 0 28
Malta 2007 11,957 0 0 29
Monaco — — — — —
Netherlands — — — — —
Norway 2006 188,550 0 2 40
Portugal 2005 917,117 2 9 86
San Marino 2010 5,090 0 0 164
Spain — — — — —
Sweden — — — — —
Switzerland — — — — —
United Kingdom — — — — —
Subtotal 10,616,260 33
Central Europe
Albania 2006 3,098 0 0 1
Bosnia and Herzegovina 2010 20,793 0 1 6
table continues next page
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table B.1 Annual number of Diagnostic tests for Hiv Undertaken in the WHo european region (continued)
Country Year Number of HIV tests
Proportion of 
total (%)
Proportion of total 
for subregion (%)
Tests per 1,000 
people
Bulgaria 2010 150,000 0 4 20
Croatia 2008 38,996 0 1 9
Cyprus 2008 42,294 0 1 49
Czech Republic 2010 353,507 1 10 34
Hungary 2010 89,137 0 3 9
Macedonia, FYR 2007 10,574 0 0 5
Montenegro 2008 4,229 0 0 7
Poland 2010 187,600 0 6 5
Romania 2010 291,915 1 9 14
Serbia 2010 51,727 0 2 5
Slovak Republic 2010 109,261 0 3 20
Slovenia 2008 31,183 0 1 15
Turkey 2007 1,998,163 4 59 27
Subtotal 3,382,477 17
Eastern Europe
Armenia 2010 60,731 0 0 20
Azerbaijan 2010 353,772 1 1 41
Belarus 2010 638,190 1 2 66
Estonia 2010 78,054 0 0 58
Georgia 2010 25,370 0 0 6
Kazakhstan 2009 2.297,588 5 7 148
Kyrgyz Republic 2007 227,879 0 1 42
Latvia 2010 58,826 0 0 26
Lithuania 2010 178,554 0 1 54
Moldova 2006 216,566 0 1 60
Russian Federation 2010 25.209,546 53 75 178
Tajikistan 2010 280,281 1 1 41
Turkmenistan 2007 211,789 0 1 42
Ukraine 2008 2.280,442 5 7 50
Uzbekistan 2010 1.506,724 3 4 55
Subtotal 33.624,312 119
Total 47.623,049 57
Sources: ECDC/WHO European Office HIV Report 2011 and Russian AIDS Centre Report 2011.
Note: — = not available; HIV = human immunodeficiency virus; WHO = World Health Organization.
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table B.2 Annual number of Hiv case reports in europe: 2006–10 and cumulative total
Sub-region
Year, number of reports, and proportion 
of total
2010 
diagnoses 
per 
million
Five-year period, 
2006–10
Since start of 
reporting
2006 2007 2008 2009 2010
Cumulative 
total and 
proportion 
of total
Annual 
average
Cumulative 
total and 
proportion 
of total
Per 
million
West 26,374 27,520 28,235 27,441 25,659 70 135,229 27,046 379,353 1,042
30% 28% 25% 24% 22% 25% 30%
Central 
Europe
1,870 2,039 2,247 2,464 2,478 13 11,098 2,220 33,308 172
2% 2% 2% 2% 2% 2% 3%
East 60,941 69,565 81,948 86,836 87,564 309 386,854 77,371 867,457 3,057
68% 70% 73% 74% 76% 73% 68%
All (100%) 89,185 99,124 112,430 116,741 115,701 138 533,181 106,636 1,280,118 1,521
Sources: ECDC/WHO European Office HIV Report 2011 and Russian AIDS Centre Report 2011.
Note: Data for the most recent years may be revised because of delays in case reporting. HIV = human immunodeficiency virus.
table B.3 Hiv case reports in europe by country and main exposure categories
Country
Cumulative cases 
associated with 
MSM
Cumulative cases 
associated with IDU
Cumulative cases 
associated with 
heterosexual exposure
Cumulative 
number of 
cases: MSM, 
IDU or 
heterosexual 
exposure 
only
All cases: 
cumulative total
Total
Proportion 
of cases 
associated 
with MSM 
of the 
main 
exposure 
categories 
(%) Total
Proportion 
of cases 
associated 
with IDU 
exposure 
of the 
main 
exposure 
categories 
(%) Total
Proportion 
of cases 
associated 
with 
heterosexual 
exposure of 
the main 
exposure 
categories 
(%) Total
Case 
per 
million 
people
Western Europe
Andorra 17 37 13 28 16 35 46 57 679
Austria — — — — — — — — —
Belgium 5,175 34 797 5 9,210 61 15,182 23,406 2,210
Denmark 2,350 43 485 9 2,604 48 5,439 5,872 1,076
Finland 891 38 360 15 1,112 47 2,363 2,778 524
France 10,227 34 1,254 4 18,867 62 30,348 43,199 696
Germany 17,905 57 3,045 10 10,540 33 31,490 40,144 488
Greece 4,918 65 347 5 2,355 31 7,620 10,531 946
Iceland 104 44 36 15 94 40 234 257 816
Ireland 1,391 28 1,247 25 2,307 47 4,945 5,599 1,262
Israel 1,403 24 913 16 3,513 60 5,829 6,579 933
Italy 3,988 33 1,096 9 6,927 58 12,011 14,438 404
Liechtenstein — — — — — — — — —
table continues next page
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table B.3 Hiv case reports in europe by country and main exposure categories (continued)
Country
Cumulative cases 
associated with 
MSM
Cumulative cases 
associated with IDU
Cumulative cases 
associated with 
heterosexual exposure
Cumulative 
number of 
cases: MSM, 
IDU or 
heterosexual 
exposure 
only
All cases: 
cumulative total
Total
Proportion 
of cases 
associated 
with MSM 
of the 
main 
exposure 
categories 
(%) Total
Proportion 
of cases 
associated 
with IDU 
exposure 
of the 
main 
exposure 
categories 
(%) Total
Proportion 
of cases 
associated 
with 
heterosexual 
exposure of 
the main 
exposure 
categories 
(%) Total
Case 
per 
million 
people
Luxembourg 377 42 124 14 404 45 905 1,013 2,106
Malta 23 21 6 5 81 74 110 132 324
Monaco — — — — — — — — —
Netherlands 10,217 61 713 4 5,849 35 16,779 18,599 1,125
Norway 1,450 33 575 13 2,387 54 4,412 4,626 970
Portugal 3,398 13 10,221 38 13,376 50 26,995 27,840 2,607
San Marino 17 39 11 25 16 36 44 68 2,194
Spain 6,696 43 2,011 13 6,809 44 15,516 17,183 594
Sweden 3,197 38 1,142 14 4,098 49 8,437 9,427 1,024
Switzerland 4,653 31 3,654 25 6,480 44 14,787 32,214 4,272
United 
Kingdom 50,610 47 5,436 5 51,906 48 107,952 115,391 1,885
Central Europe
Albania 38 10 1 0 328 89 367 415 132
Bosnia and 
Herzegovina 33 22 21 14 95 64 149 170 45
Bulgaria 146 12 292 24 795 64 1,233 1,272 168
Croatia 452 56 58 7 292 36 802 862 195
Cyprus 228 35 9 1 409 63 646 681 790
Czech Republic 907 64 72 5 448 31 1,427 1,522 147
Hungary 1,061 76 22 2 322 23 1,405 1,953 195
Macedonia, FYR 12 38 2 6 18 56 32 37 18
Montenegro 47 47 3 3 51 50 101 119 191
Poland 1,049 13 5,844 74 960 12 7,853 14,393 378
Romania 121 7 23 1 1,555 92 1,699 4,764 223
Serbia 638 29 938 43 590 27 2,166 2,593 264
Slovak Republic 226 70 10 3 86 27 322 357 66
Slovenia 302 76 13 3 85 21 400 487 242
Turkey 218 9 83 4 2,053 87 2,354 3,683 50
Eastern Europe
Armenia 16 2 386 43 497 55 899 971 316
Azerbaijan 22 1 1,681 71 662 28 2,365 2,723 312
Belarus 61 1 5,421 50 5,425 50 10,907 11,204 1,158
table continues next page
Data Tables and Statistics 257
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8 
table B.3 Hiv case reports in europe by country and main exposure categories (continued)
Country
Cumulative cases 
associated with 
MSM
Cumulative cases 
associated with IDU
Cumulative cases 
associated with 
heterosexual exposure
Cumulative 
number of 
cases: MSM, 
IDU or 
heterosexual 
exposure 
only
All cases: 
cumulative total
Total
Proportion 
of cases 
associated 
with MSM 
of the 
main 
exposure 
categories 
(%) Total
Proportion 
of cases 
associated 
with IDU 
exposure 
of the 
main 
exposure 
categories 
(%) Total
Proportion 
of cases 
associated 
with 
heterosexual 
exposure of 
the main 
exposure 
categories 
(%) Total
Case 
per 
million 
people
Estonia 93 2 3,670 87 449 11 4,212 7,692 5,736
Georgia 83 3 1,537 59 970 37 2,590 2,691 625
Kazakhstan 82 1 10,271 72 3,998 28 14,351 15,754 1,015
Kyrgyz Republic 2 0 2,163 71 864 29 3,029 3,287 607
Latvia 222 5 2,775 68 1,104 27 4,101 4,888 2,164
Lithuania 106 7 1,251 78 246 15 1,603 1,734 522
Moldova 36 1 2,580 42 3,480 57 6,096 6,356 1,750
Russian 
Federation 2,643 1 237,586 77 67,627 22 307,856 630,222 4,457
Tajikistan 0 0 1,490 68 691 32 2,181 2,768 405
Turkmenistan 0 0 0 0 2 0
Ukraine 406 0 87,771 60 59,185 40 147,362 153,108 3,329
Uzbekistan 29 0 11,410 71 4,730 29 16,169 24,057 885
Sources: ECDC/WHO European Office HIV Report 2011 and Russian AIDS Centre Report 2011.
Note: HIV = human immunodeficiency virus; IDU = injecting drug user; MSM = men who have sex with men; — = not available.
table B.4 Annual number of Hiv case reports in europe: 2006–10 and cumulative total by Gender
Subregion Subgroup
Year, number of reports, and proportion of total Cumulative total and 
proportion of total2006 2007 2008 2009 2010
Western Europe Male 17,762 19,135 19,866 19,645 18,776 264,105
Female 8,571 8,339 8,330 7,744 6,861 110,560
Female (%) 33 30 30 28 27 30
Alla 26,374 27,520 28,235 27,441 25,659 379,353
Central Europe Male 1,338 1,470 1,662 1,878 1,885 22,776
Female 484 471 486 493 454 8,353
Female (%) 27 24 23 21 19 27
Alla 1,870 2,039 2,247 2,464 2,478 33,308
Eastern Europeb Male 35,864 41,049 68,863 50,839 51,625 559,342
Female 25,073 28,252 12,594 35,997 35,736 305,862
Female (%) 41 41 15 41 41 35
Alla 60,941 69,565 81,948 86,836 87,564 867,457
table continues next page
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table B.4 Annual number of Hiv case reports in europe: 2006–10 and cumulative total by Gender (continued)
Subregion Subgroup
Year, number of reports, and proportion of total Cumulative total and 
proportion of total2006 2007 2008 2009 2010
All Male 54,964 61,654 90,391 72,362 72,286 846,223
Female 34,128 37,062 21,410 44,234 43,051 424,775
Female (%) 38 38 19 38 37 33
Alla 89,185 99,124 112,430 116,741 115,701 1,280,118
Sources: ECDC/WHO European Office HIV Report 2011; and Russian AIDS Centre Report 2011.
Note: Data for the most recent years may be revised because of delays in case reporting. The proportion of cases of females was reported in the 
text and a figure, and this was used to divide the total number of cases into males and females for individual years (proportion female 2006: 43.5%; 
2007: 43%; 2008: 42%; 2009: 41.5%; 2010: 41%). HIV = human immunodeficiency virus.
a. Includes those where gender not reported.
b. For the Russian Federation data yearly number by gender was not given.
table B.5 Annual number of Hiv case reports in europe: 2006–10 and cumulative total by Age
Subregion Subgroup
Year, number of reports, and proportion of total Cumulative total and 
proportion of total2006 2007 2008 2009 2010
Western Europe <15 277 265 246 217 210 5,679
1% 1% 1% 1% 1% 1%
15–19 406 468 475 457 468 7,351
2% 2% 2% 2% 2% 2%
20–29 6,052 6,240 6,271 5,887 5,805 102,938
23% 23% 22% 21% 23% 27%
30–39 9,124 9,264 9,125 8,446 8,544 134,893
35% 34% 32% 31% 33% 36%
40–49 5,657 6,052 6,500 6,263 6,451 71,600
21% 22% 23% 23% 25% 19%
50+ 3,130 3,400 3,676 3,790 3,900 40,630
12% 12% 13% 14% 15% 11%
Unknown 1,728 1,831 1,942 2,381 281 16,262
7% 7% 7% 9% 1% 4%
Alla 26,374 27,520 28,235 27,441 25,659 379,353
<15 49 38 34 26 28 2,641
3% 2% 2% 1% 1% 8%
15–19 66 82 70 74 50 1,549
4% 4% 3% 3% 2% 5%
20–29 651 701 727 792 834 11,360
35% 34% 32% 32% 34% 34%
Central Europe 30–39 602 590 723 856 824 8,746
32% 29% 32% 35% 33% 26%
40–49 268 267 339 384 385 3,790
14% 13% 15% 16% 16% 11%
50+ 142 203 220 256 260 2,223
8% 10% 10% 10% 10% 7%
Unknown 92 158 134 76 97 2,999
5% 8% 6% 3% 4% 9%
table continues next page
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table B.5 Annual number of Hiv case reports in europe: 2006–10 and cumulative total by Age (continued)
Subregion Subgroup
Year, number of reports, and proportion of total Cumulative total and 
proportion of total2006 2007 2008 2009 2010
Alla 1,870 2,039 2,247 2,464 2,478 33,308
<15 763 980 1,585 1,916 2,145 10,563
1% 1% 2% 2% 2% 1%
Eastern Europeb 15–19 3,098 2,754 2,588 2,259 1,776 74,741
5% 4% 3% 3% 2% 9%
20–29 23,551 27,209 36,828 36,784 33,906 369,477
39% 39% 45% 42% 39% 43%
30–39 18,629 23,097 28,799 32,554 34,787 219,989
31% 33% 35% 37% 40% 25%
40–49 5,881 7,218 8,691 9,864 11,071 65,213
10% 10% 11% 11% 13% 8%
50+ 1,919 2,409 2,946 3,436 3,873 20,935
3% 3% 4% 4% 4% 2%
Unknown 7,100 5,899 512 22 6 106,539
12% 8% 1% 0% 0% 12%
Alla 60,941 69,565 81,948 86,836 87,564 867,457
<15 1,089 1,283 1,865 2,159 2,383 18,883
1% 1% 2% 2% 2% 1%
15–19 3,570 3,304 3,133 2,790 2,294 83,641
Eastern Europeb 4% 3% 3% 2% 2% 7%
20–29 30,254 34,150 43,826 43,463 40,545 483,775
34% 34% 39% 37% 35% 38%
Total 30–39 28,355 32,951 38,647 41,856 44,155 363,628
32% 33% 34% 36% 38% 28%
40–49 11,806 13,537 15,530 16,511 17,907 140,603
13% 14% 14% 14% 15% 11%
50+ 5,191 6,012 6,842 7,482 8,033 63,788
6% 6% 6% 6% 7% 5%
Unknown 8,920 7,888 2,588 2,479 384 125,800
10% 8% 2% 2% 0% 10%
Alla 89,185 99,124 112,430 116,741 115,701 1,280,118
Sources: ECDC/WHO European Office HIV Report 2011; and Russian AIDS Centre Report 2011.
Note: Data for the most recent years may be revised because of delays in case reporting. The annual proportion by age group was reported in a 
figure, and this was used to divide total number of cases into age groups for the individual years. HIV = human immunodeficiency virus.
a. Includes those where age not reported.
b. The Russian Federation data yearly number by age was not reported.
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table B.6 Annual Average Hiv case reports in europe: 2006–10 by country and exposure
Country
Cases associated 
with MSM
Cases associated with 
injecting drug use
Cases associated with 
heterosexual exposure
Cases associated with 
mother-to-child 
transmission Exposure not known or othera All cases
Total
Cases per 
million 
people Total
Cases per 
million 
people Total
Cases per 
million 
people Total
Cases per 
million 
people Total
Cases per 
million 
people
Proportion 
of total Total
Cases per 
million 
people
Western Europe
Andorra 2 19 0 0 1 10 0 — 0 5 14% 3 33
Belgium 343 32 16 2 415 39 9 1 320 30 29% 1,102 104
Denmark 119 22 13 2 125 23 3 1 9 2 3% 269 49
Finland 54 10 10 2 84 16 1 0 32 6 18% 180 34
France 1,328 21 135 2 2,130 34 29 0 1,659 27 31% 5,281 85
Germany 1,572 19 128 2 695 8 19 0 410 5 15% 2,824 34
Greece 249 22 10 1 112 10 2 0 173 16 32% 546 49
Iceland 2 7 3 10 6 20 0 0 3 10 21% 15 46
Ireland 108 24 39 9 162 36 6 1 60 13 16% 375 84
Israel 123 17 42 6 191 27 11 2 15 2 4% 382 54
Italy 650 18 151 4 1,096 31 7 0 351 10 16% 2,255 63
Luxembourg 20 41 3 6 23 47 0 0 2 4 4% 47 98
Malta 3 8 1 2 13 32 0 0 3 8 16% 20 50
Netherlands 714 43 8 0 327 20 7 0 61 4 5% 1,117 68
Norway 86 18 11 2 163 34 5 1 7 2 3% 273 57
Portugal 287 27 282 26 976 91 9 1 41 4 3% 1,595 149
San Marino 0 0 0 0 0 6 0 0 2 77 92% 3 84
Spain 1,079 37 233 8 974 34 8 0 274 9 11% 2,568 89
Sweden 110 12 33 4 207 22 10 1 60 7 14% 420 46
Switzerland 261 35 36 5 281 37 4 1 134 18 19% 715 95
United Kingdom 2,659 43 169 3 3,697 60 106 2 425 7 6% 7,057 115
TOTAL 9,768 27 1,323 4 11,676 32 237 0 4,043 11 27,046 74
table continues next page
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table B.6 Annual Average Hiv case reports in europe: 2006–10 by country and exposure (continued)
Country
Cases associated 
with MSM
Cases associated with 
injecting drug use
Cases associated with 
heterosexual exposure
Cases associated with 
mother-to-child 
transmission Exposure not known or othera All cases
Total
Cases per 
million 
people Total
Cases per 
million 
people Total
Cases per 
million 
people Total
Cases per 
million 
people Total
Cases per 
million 
people
Proportion 
of total Total
Cases per 
million 
people
Central Europe
Albania 4 1 0 0 36 12 2 1 3 1 7% 47 15
Bosnia and 
Herzegovina 3 1 0 0 4 1 0 0 0 0 0% 7 2
Bulgaria 22 3 52 7 59 8 1 0 0 0 0% 135 18
Croatia 44 10 1 0 12 3 0 0 1 0 2% 59 13
Cyprus 13 16 1 1 23 26 0 0 3 3 7% 39 46
Czech Republic 92 9 7 1 36 3 0 0 5 0 4% 139 13
Hungary 81 8 1 0 18 2 1 0 33 3 25% 133 13
Macedonia, FYR 2 1 0 0 2 1 0 0 0 0 8% 5 2
Montenegro 7 11 0 0 3 5 0 0 1 1 7% 11 18
Poland 71 2 70 2 72 2 3 0 657 17 75% 874 23
Romania 15 1 2 0 101 5 7 0 57 3 31% 182 9
Serbia 63 6 9 1 27 3 1 0 15 2 13% 114 12
Slovak Republic 26 5 2 0 8 2 0 0 5 1 12% 40 7
Slovenia 29 14 0 0 4 2 0 0 7 3 16% 40 20
Turkey 18 0 2 0 226 3 4 0 144 2 37% 394 5
Total 489 3 147 1 632 3 20 0 931 5 — 2,220 11
Eastern Europe
Armenia 2 1 37 12 72 24 3 1 7 2 6% 121 39
Azerbaijan 3 0 263 30 90 10 5 1 44 5 11% 405 46
Belarus 7 1 234 24 678 70 20 2 11 1 1% 949 98
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table B.6 Annual Average Hiv case reports in europe: 2006–10 by country and exposure (continued)
Country
Cases associated 
with MSM
Cases associated with 
injecting drug use
Cases associated with 
heterosexual exposure
Cases associated with 
mother-to-child 
transmission Exposure not known or othera All cases
Total
Cases per 
million 
people Total
Cases per 
million 
people Total
Cases per 
million 
people Total
Cases per 
million 
people Total
Cases per 
million 
people
Proportion 
of total Total
Cases per 
million 
people
Estonia 0 0 98 73 18 13 4 3 406 303 77% 526 392
Georgia 11 3 194 45 142 33 10 2 3 1 1% 360 84
Kazakhstan 13 1 1,202 77 615 40 27 2 169 11 8% 2,026 131
Kyrgyz Republic 0 0 305 56 139 26 14 3 34 6 7% 492 91
Latvia 17 8 102 45 128 57 5 2 59 26 19% 311 138
Lithuania 7 2 77 23 26 8 0 0 16 5 13% 127 38
Moldova 4 1 143 39 527 145 11 3 25 7 3% 710 196
Russian Federation 260 2 13,910 98 8,128 57 430 3 29,844 211 57% 52,572 372
Tajikistan 0 0 231 34 128 19 7 1 87 13 19% 452 66
Turkmenistan 0 0 0 0 0 0 0 0 0 0 — 0 0
Ukraine 66 1 7,056 153 7,385 161 189 4 365 8 2% 15,061 327
Uzbekistan 0 0 1,459 54 744 27 68 3 986 36 30% 3,257 120
Total 391 1 25,310 89 18,820 66 793 0 32,057 116 — 77,371 273
Sources: ECDC/WHO European Office HIV Report 2011 and Russian AIDS Centre Report 2011.
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men; — = not available.
a. Between 2006 and 2010 there were 740 with other transmission risk, that is, either hemophiliac/transfusion recipient or nosocomial infection.
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table B.7 characteristics of Hiv prevalence studies among pWiD across europe
Country 
Name
Seroprevalence studies Best Estimates of seroprevalence studiesa Behavioral studiesb
Number of studiesc Repeated
Area 
covered Sitesc Recruitment strategy n Year Reference Undertaken/Repeated
Western 
Europe
Austria 1 Y — National 41 Drug treatment and LT 417 2009 [14] N —
Belgium 1 Y — City 1 Drug treatment and LT 329 2009 Y Y —
Denmark 1 Y — National 5 Overdose death post 
mortem
188 2009 [14] N —
Finland 1 Y Methods 
inconsistent
National 4 Needle exchanges 1,560 2009 [14] Y Y —
France 3 Y Methods 
inconsistent
City 5 Community and LT 342 2009 [14] Y Y —
Germany 2 Y Last data 2007 National Overdose death post 
mortem
1,394 2009 [14] N —
Greece 3 Y — National 19 Drug treatment, HIV test 
centers, and LT
741 2009 [14] Y Y —
Iceland — — — — — — — — N —
Ireland 2 N — City 1 Drug treatment 64 2003 [14] Y Y —
Israel 1 N — National 1 Note review of addiction 
treatment
743 2003/05 [15] N —
Italy 4 Y — National 522 Drug treatment centers 63,989 2009 [14] N —
Luxembourg 1 N — National 13 Drug treatment, HIV test 
centers, prisons, 
antenatal care, and LT
202 2005 [14] Y Y —
Malta 1 N — National 1 Drug treatment centers 175 2006 [14] N —
Netherlands — Y Cohort study 
(n<50)
— — — — — — Y Y —
Norway 2 Y — National 14 Drug treatment centers 3,905 2009 [14] N —
Portugal 3 Y — National Drug treatment centers 2,381 2009 [14] N —
Spain 8 Y Last data 2007 National Drug treatment centers 8,643 2007 [14] Y Y —
table continues next page
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table B.7 characteristics of Hiv prevalence studies among pWiD across europe (continued)
Country 
Name
Seroprevalence studies Best Estimates of seroprevalence studiesa Behavioral studiesb
Number of studiesc Repeated
Area 
covered Sitesc Recruitment strategy n Year Reference Undertaken/Repeated
Sweden 5 Y Prison sample — 2 Prisons, HIV testing 259 2009 [34] N —
Switzerland 2 Y No recent data 
found
City 5 HIV testing 1,063 1996/2006 [123] Y Y —
United Kingdom 9 Y — Nationala 4 Drug treatment, HIV 
testing, NSP, and LT
5,590 2009 [14] Y Y —
Central 
Europe
Albania 2 Y — City 1 Community 200 2008 [124] Y Y 2005 and 2008 only
Bosnia and 
Herzegovina 2 Y — Citya 3 Community 780 2009 [26] Y Y 2007 and 2009 only
Bulgaria 3 Y — National 8 Community and brothels 1,421 2008 [125] Y Y Since 2004 annual
Croatia 7 Y Methods 
inconsistent
City 3 Drug treatment, HIV test 
centers and LT
399 2007 [14] Y N —
Cyprus 2 Y — National Drug treatment 89 2009 [14] N
Czech Republic 3 Y — National — Drug treatment, HIV test 
centers, prisons and LT
1,363 2009 [14] Y Y Details not clear
Hungary 6 Y — National 18 Drug treatment, needle 
exchanges
590 2009 [14] Y N Multiple surveys at 
different time 
points
Macedonia, FYR 1 Y — National 6 Community 597 2007 [18] Y Y —
Montenegro 1 Y First study in 2008 
due to be 
repeated every 
2 or 3 years
— — Community—RDS 317 2008 [40] Y Y —
Poland 2 Y — National — Public health laboratories 1,713 2009 [14] Y N Under consideration
Romania 2 Y Methods 
inconsistent
City 1 Community—RDS 449 2009 [126] Y Y Repeated 2010
Serbia 2 Y First study in 2008 
due to be 
repeated 2010
Citya 3 Community 960 2010 [24] Y Y Will be repeated 
every 2–3 years
Slovak Republic 1 Y — City 1 Drug treatment centers 97 2009 [14] N
table continues next page
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table B.7 characteristics of Hiv prevalence studies among pWiD across europe (continued)
Country 
Name
Seroprevalence studies Best Estimates of seroprevalence studiesa Behavioral studiesb
Number of studiesc Repeated
Area 
covered Sitesc Recruitment strategy n Year Reference Undertaken/Repeated
Slovenia 3 Y — National 18 Drug treatment centers 266 2009 [14] Y Y
Turkey 2 N — National 3 Community 68 2006–07 [16] Y N
Armenia 1 Y — — — — — 2007 [127] Y Y
Central 
Europe
Azerbaijan 2 Y Methods 
inconsistent
City 7 Community 1,000 2007–08 [36] Y Y Methods inconsistent
Belarus 2 Y — National 16 — 1,770 2008 [25] Y Y Methods and 
frequency 
inconsistent
Eastern 
Europe
Estonia 7 N — Citya 2 Community—RDS 350 2007 Y Y
Georgia 9 Y — City 6 Community 1,289 2008–09 [23] Y Y
Kazakhstan 1 Y — National 22 Community 4,860 2009 [20] Y Y
Kyrgyz Republic 1 Y — National 5 Community—RDS 900 2009 [20] Y Y
Latvia 3 Y — National — Drug treatment and HIV 
testing
987 2003 [14] Y Y
Lithuania 8 Y Methods and sites 
inconsistent
National — Drug treatment, needle 
exchange and HIV testing
1,112 2003 [14] Y Y
Moldova 2 Y — Citya 2 Community 663 2009 [45] Y Y Method has varied 
over time
Russian Federation 16 Y Methods and sites 
inconsistent
Citya 5 — 1,799 2008/9 [66] Y Y Consistency over 
time not clear
Tajikistan 2 Y — 8 Community—RDS 1,657 2009 [20] Y Y
Turkmenistan — — — — — — —
Ukraine 8 Y National 28 Community 6,459 2009 [22] Y Y
Uzbekistan 2 Y National 14 Community 3,743 2007 [19] Y Y
Note: HIV = human immunodeficiency virus; LT = low threshold; N = no; n = sample size; NSP = Needle Syringe Program; RDS = respondent-driven sampling; Y = Yes; — = not available.
a. Estimates from single studies with the exception of the following countries where a weighted estimate was calculated from multiple studies (n): Bosnia and Herzegovina (2), Estonia (2), Moldova (2), the Russian 
Federation (2), and United Kingdom (3).
b. Behavioral studies not necessarily linked into biological data—this column documents only whether they have been undertaken among people who inject drugs.
c. Number of studies identified during the period 2005–11.
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table B.8 characteristics of Hiv prevalence studies among FsWs across europe
Country name
Seroprevalence studies Best estimates of seroprevalence studiesa
Behavioral 
studiesb
Number 
of studiesc Repeated
Area 
covered Sitesc
Recruitment 
strategy n Year Reference Undertaken
Western 
Europe
Austria 4 N National — STI Clinics 1,184 2002 [128] N
Belgium 1 N City 1 — 1,016 2008 [10] Y Y
Denmark — — — — N
Finland — — — — N
France 1 City 1 — 46 2008 [10] N
Germany 2 N National — STI Clinics 3,880 2010–11 [77] N
Greece 1 N City 1 STI Clinics 299 2005 [129] N
Iceland — — — — — — N
Ireland — — — — — — N
Israel 2 N City 1 Work 300 — [130] Y N
Italy 4 Y Methods 
inconsistent
City 1 HIV Clinics 229 1992–07 [86] Y Y
Luxembourg — — — — — — Y Y
Malta — — — — — — N
Netherlands 2 N Nationala 1 Clinics and Work 1,417 2002–05 [80, 128] Y Y
Norway 1 N City 1 Clinics and Work 746 2008 [10] N
Portugal 1 N City 1 Work (street) 96 2000–01 [10, 84] N
Spain 4 N Citya 4 STI Clinics 4,485 2000–01 [82, 83] Y Y
Sweden 1 N n<50 Region 1 Prison 45 2006–07 [10] N
Switzerland — — — — — — Y Y
Central 
Europe
United Kingdom 5 N City 1 STI clinics and Work 268 2008–09 [82, 83, 85] Y Y
Albania 1 N City 1 RDS 90 2008 [44] Y N
Bosnia and 
Herzegovina 1 N City — — 42 2007 [125] Y N
table continues next page
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table B.8 characteristics of Hiv prevalence studies among FsWs across europe (continued)
Country name
Seroprevalence studies Best estimates of seroprevalence studiesa
Behavioral 
studiesb
Number 
of studiesc Repeated
Area 
covered Sitesc
Recruitment 
strategy n Year Reference Undertaken
Bulgaria 3 Y National 8 — 799 2008 [17] Y Y
Croatia 1 N City 7 NGO 43 2003–05 [131] Y N
Czech Republic 2 N City 7 — 585 1999–00 [132] Y N
Hungary 1 N — — Screening 500 2006 [10] N
Macedonia, FYR 3 Y n<70 Nationala — — 118 2006, 2007 [18] Y N
Montenegro N — — N
Poland 2 Y City 13 Work/Clinics 650 2002–05 [128] Y N
Romania 1 City 1 Work (street) 204 2006 [10] Y N
Serbia 1 Y 2 years City 1 — 250 2010 [133] Y Y 2 years
Slovak Republic — — — — N
Slovenia — — — — N
Turkey 1 N City 3 Work 252 2006–07 [16] Y N
Eastern 
Europe
Armenia 3 Y Infrequent National 3 Work/HIV and STI 
Clinics
250 2005 [128] Y N
Azerbaijan 2 Y 2 years City 2 Work 300 2007–08 [134] Y Y 2 years
Belarus 3 Y Methods unclear Citya 7 — 937 2004–09 [25, 135] Y N
Estonia 1 N City 1 Work 257 2005–06 [136] Y Y
Georgia 4 Y 2 years so far City 1 Work 160 2009 [137] Y Y
Kazakhstan 6 Y National 2 Work/STI Clinics 1,960 2005 [128] Y Y
Kyrgyz Republic 4 Y City 2 STI Clinics 352 2006 [91] Y Y
table continues next page
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table B.8 characteristics of Hiv prevalence studies among FsWs across europe (continued)
Country name
Seroprevalence studies Best estimates of seroprevalence studiesa
Behavioral 
studiesb
Number 
of studiesc Repeated
Area 
covered Sitesc
Recruitment 
strategy n Year Reference Undertaken
Eastern 
Europe
Latvia 2 Y 2 years so far City 1 Work 93 2004 [128] N
Lithuania 2 Y City 1 Work 101 2005 [128] Y Y
Moldova 4 Y City 1 RDS 300 2009 [45] Y Y
Russian Federation 17 Y Methods and sites 
inconsistent
Nationala 48 — 4,209 2000–09 [32, 66, 78, 79, 
128, 138]
Y Y
Tajikistan 4 Y Region 5 STI Clinics 1,800 2008 [32, 66, 78, 79, 
91, 128, 138]
Y Y
Turkmenistan — — — N
Ukraine 3 Y 2 years so far Citya 16 Work 2,278 2008 [22, 139] Y Y 2 years
Uzbekistan 3 Y Citya Multiple — 2,000 2005–07 [140] Y Y 2 years
Note: FSW = female sex worker; HIV = human immunodeficiency virus; N = No; n = sample size; NGO = nongovernmental organization; RDS = respondent-driven sampling; STI = sexually transmitted infection; 
SW = sex worker; Y = Yes; — = not available.
a. Estimates from single studies with the exception of the following countries where a weighted estimate was taken from multiple studies in Belarus (2), Montenegro (2), the Netherlands (2), Spain (2), the Russian 
Federation (7), Ukraine (2), and Uzbekistan (unclear—possibly 3 between 2005–07).
b. Behavioral studies not necessarily linked into biological data; this column documents only whether they have been undertaken among SWs.
c. Number of studies identified during the period 2005–11.
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table B.9 characteristics of Hiv prevalence studies among male and transgender sWs across europe
Country name
Number 
of 
studiesc
Area 
covered Sitesa
Recruitment 
strategy n Year
Behavioral 
data Reference
Western 
Europe
Belgium 1 City 1 Outreach 120 1999–2004 Yes [141]
Italy 2 City 1 Clinics 752 1992–2007 Yes [86]
Netherlands 1 City 2 Clinics/Work 70 2002–05 Yes [142]
Spain 1 National 19 Clinics 1,935 2000–07 Yes [143]
United Kingdom 2 City 1 STI clinics 636 1999–2003 Yes [120]
Eastern 
Europe
Russian 
Federation 1 City 1 Work 50 2005–06 Yes [119]
Note: HIV = human immunodeficiency virus; n = sample size; STI = sexually transmitted infection; SWs = sex workers.
a. Number of studies identified during the period 2005–11.
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table B.10 characteristics of Hiv prevalence studies among msm across europe
Country Name
Seroprevalence studies Best estimates of seroprevalence studiesa Behavioral studiesb
Number 
of studiesc Repeated
Area 
covered Sitesc Recruitment strategy n Year Reference Undertaken/Repeated
Western 
Europe
Austria — — — — — — N
Belgium 3 N City 2 Community 649 2009–10 [98] Y Y
Denmark — — — — — — Y Y
Finland — — — — — — Y N
France 2 N City 1 Community 886 2009 [105] Y Y
Germany — — — — — — Y Y
Greece — — — — — — Y Y NGO service 
provider data
Iceland — — — — — — N
Ireland — — — — — — Y Y
Israel — — — — — — Y N
Italy 2 N City 1 Community—TLS 342 2008–09 [102] Y N
Luxembourg — — — — — — N
Malta — — — — — — N
Netherlands 4 N National — STI clinics 3,483 2004 Y Y
Norway — — — — — — Y Y
Portugal 1 N City 1 STI clinics 468 2002 [128] N
Spain 5 Y Regional National 19 STI clinics 4,165 2003 [128] Y Y
Sweden — — — — — — Y Y
Switzerland 3 Unclear if still ongoing National — HIV testing 1,091 2004 [128] Y Y
United Kingdom 11 Y City 5 Community—TLS 3,501 2009 [96] Y Y
Central 
Europe
Albania 2 Y 2 surveys, 3 years City 1 Community—RDS 198 2008 [103] Y Y
Bosnia and 
Herzegovina 1 N — — — 224 2007 [125] Y N
table continues next page
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table B.10 characteristics of Hiv prevalence studies among msm across europe (continued)
Country Name
Seroprevalence studies Best estimates of seroprevalence studiesa Behavioral studiesb
Number 
of studiesc Repeated
Area 
covered Sitesc Recruitment strategy n Year Reference Undertaken/Repeated
Bulgaria 1 Y National 3 HIV testing 452 2008 [17] Y Y
Croatia 3 N Unclear City 1 Community—RDS 360 2006 [99] Y N
Cyprus — — — — — — N
Czech Republic 2 Y City 1 Community—TLS 390 2008–09 [102] Y N
Hungary 2 Y 2 surveys, 2 years — — — 388 2009 [144] Y N Unclear
Macedonia, FYR 1 Y Unclear National — Community 37 2007 [18] Y Y
Montenegro — — — — — — N
Poland 1 N National 8 Community 404 2004 [101] Y N
Romania 1 N City 1 Community—TLS 389 2008–09 [102] Y N
Serbia 2 Y First in 2008 City 2 Community — 2008 [24] Y Y First in 2008
Slovak Republic 1 N City 1 Community—TLS 345 2008–09 [102] Y N
Slovenia 2 Y City 1 Community—TLS 387 2008–09 [102] Y Y
Turkey 1 N National — Community 166 2006–07 [16] Y N
Armenia 1 N — — — — 2007 [127] Y Y Last data in 2007, 
small sample 
sizes
Eastern 
Europe
Azerbaijan 1 N City 1 Community 100 2007–08 [36] Y N
Belarus 2 Y National 7 — 480 2009 [25] Y Y
Estonia 1 N City 1 Community and 
health services
79 2008 [35] Y Y
Georgia 1 Y 2 surveys, 2 years 
apart
City 1 Community—RDS 136 2007 [104] Y Y Last data for 2007
Kazakhstan 2 Y — — Sentinel surveillance 880 2009 [97] Y Y
Kyrgyz Republic 1 Y — — Community—RDS 84 2008 [106] Y Y
table continues next page
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table B.10 characteristics of Hiv prevalence studies among msm across europe (continued)
Country Name
Seroprevalence studies Best estimates of seroprevalence studiesa Behavioral studiesb
Number 
of studiesc Repeated
Area 
covered Sitesc Recruitment strategy n Year Reference Undertaken/Repeated
Latvia — — — — — — Y N
Lithuania 1 Y 2 surveys (2008 and 
2009)
— — — — 2009 [145] Y Y
Moldova 1 Y City 1 — — 2009 [45] Y Y
Russian 
Federation
5 Y Methods inconsistent City 5 Community 1,179 2006 [79] [66] Y Y Methods 
and sites 
inconsistent
Tajikistan — — — — — — Y N
Turkmenistan — — — — — — N
Ukraine 1 Y Methods inconsistent National 13 Community — 2009 [22] Y Y
Uzbekistan 1 Y National 4 — — 2009 [94] Y Y
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men; N = No; n = sample size; NGO = nongovernmental organization; RDS = respondent-driven sampling; STIs = sexually transmitted 
infections; TLS = time location sampling; Y = Yes; — = not available.
a. Estimates from single studies with the exception of the following countries where a weighted estimate was calculated from multiple studies in the Russian Federation (2).
b. Behavioral studies not necessarily linked to biological data—this column documents only whether they have been undertaken among MSM.
c. Number of studies identified during the period 2005–11.
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table B.11 countries with population size estimates of pWiD, sWs, and msm
Country
PWID estimate MSM estimate SW estimate
Year n Reference Year n Reference Year n Reference
Western 
Europe
Austria 2000 17,500 [146] — — — 2000 29,060 [147]
Belgium 1997 25,800 [146] — — — 2000 16,972 [147]
Denmark 2006 12,754 [14] — — — 2000 6,370 [147]
Finland 2002 15,650 [146] — — — 2000 5,625 [147]
France 1999 122,000 [146] — — — 2000 35,421 [147]
Germany 2005 94,250 [14] — — — 2000 387,719 [147]
Greece 2009 10,658 [14] — — — 2000 12,446 [147]
Iceland — — — — — — No — —
Ireland 1996 6,289 [146] — — — No — —
Israel — — — — — — No — —
Italy 1996 326,000 [146] — — — 2000 64,468 [147]
Luxembourg 2007 1,482 [14] — — — 2000 2,828 [147]
Malta — — — — — — No — —
Netherlands 2008 2,390 [14] — — — 2000 23,979 [147]
Norway 2008 10,238 [14] — — — 2000 3,974 [147]
Portugal 2005 16,425 [14] — — — 2007 9,695 [90]
Spain 1998 83,972 [146] — — — 2000 61,868 [147]
Sweden 2007 29,513 [14] — — — 2000 2,976 [147]
Switzerland 1997 31,653 [146] — — — No — —
United Kingdom 2004–07 147,900 [14] — 5% men “not entirely 
heterosexual”
[148] 2000 83,043 [147]
table continues next page
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table B.11 countries with population size estimates of pWiD, sWs, and msm (continued)
Country
PWID estimate MSM estimate SW estimate
Year n Reference Year n Reference Year n Reference
Central 
Europe
Albania Yes, year not 
known
4,000 GF R5 Proposal 
midpoint [149]
— — — 2004 7,217 [147]
Bosnia and 
Herzegovina 2009 7,500 [150] — — — 2004 6,665 [147, 149]
Bulgaria 2005 20,250 [146] — — — 2004 12,962 [147]
Croatia 2009 3,145 [14] — — — 2004 7,480 [147]
Cyprus 2009 481 [14] — — — — [147]
Czech Republic 2009 35,300 [14] — — — 2004 13,842 [147]
Hungary 2008–09 5,699 [14] — — — 2004 18,018 [147]
Macedonia, FYR 2007 17,500 [151] — — — 2004 6,120 [147]
Montenegro Yes, year not 
known
1,980 — — — — 2004 1,284 [147]
Poland — — — — — — 2004 45,968 [147]
Romania 2009 17,767 [14] — — — 2004 32,065 [147]
Serbia Yes, year not 
known
18,000 [133] 2006 3,745–10,691 according to 
the multiplier method and 
between 4,476–5,996 
using capture-recapture. 
2.4% of men had AI with a 
man in past 12 months
[152] 2004 14,994 [147]
Slovak Republic 2006 18,841 [14] — — — 2004 7,642 [147]
Slovenia 2001 7,320 [146] 1999–2001 3.3% some homosexual 
experience; 1% AI
— 2004 6,323 [147]
Turkey — — — — — 2004 29,000 [153]
table continues next page
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table B.11 countries with population size estimates of pWiD, sWs, and msm (continued)
Country
PWID estimate MSM estimate SW estimate
Year n Reference Year n Reference Year n Reference
Eastern 
Europe
Armenia 2000 2,000 [146] 17,000–65,000 [154] 2004 11,770 [147]
Azerbaijan 2006 300,000 [146] No — — 2004 43,723 [147, 149]
Belarus 2005 6,308 [146] No — — 2004 20,605 [147, 149]
Estonia 2004 13,886 [14] No — — 2004 3,202 [147]
Georgia 2004 127,833 [146] No — — 2004 16,135 [147]
Kazakhstan 2006 124,400 [92] 1.9% of men aged >15 have 
ever had sex with a man
[155] 2004 32,080 [147, 149]
Kyrgyz Republic 2006 25,000 [146] 2% of sexually active men [156] 2004 5,466 [147, 149]
Latvia — 3,429 Imputed using [14] No — — 2004 7,545 [147]
Lithuania 2006 5,123 [146] No — — 2004 4,951 [147]
Moldova 2001 3,810 [146] 2% of men reporting AI [157] 2005 5,000 [149]
Russian Federation 2007 1,825,000 [146] No — — 2004 263,480 [147]
Tajikistan 2006 25,000 [158] No — — 2004 5,988 [147]
Turkmenistan — No — — 2004 2,487 [147]
Ukraine 2006 375,000 [146] No — — 2004 79,180 [147]
Uzbekistan 2006 80,000 [146] No — — 2004 25,671 [147]
Note: AI = anal intercourse; GF = Global Fund Project Monitoring Report; MSM = men who have sex with men; n = sample size; PWID = people who inject drugs; R = round; SW = sex worker; — = not available.
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table c.1 summary of studies included in systematic review and range of Hiv prevalence estimates among pWiD in Western european countries
Country City Population sample
Survey 
year Survey design
No. of 
studies
HIV 
prevalence 
range (%)
“Best” 
prevalence 
estimate (%) References
Austria National IDUs 2008 Diagnostic testing 1 1 1 [175]
Belgium Antwerp IDUs 2008 Diagnostic testing 1 6.4 6.4 [175]
Denmark National IDUs 2006 Prevalence study using unlinked, 
anonymous testing
1 2.1 2.1 [175]
Finland National IDUs 2009 Accessibility 1 0.7 0.7 [98]
France Lille, Strasbourg, Paris, 
Bordeaux, Marseille
Ever or current injectors 
or snorters, IDUs
2002–06 Cross-sectional, prevalence 
study using unlinked 
anonymous testing
3 8–22 8 [17, 24, 175]
Germany National Drug users including 
ever IDUs
1998–2007 Cross-sectional, diagnostic testing 2 3.4–18 3.4 [99, 175]
Greece National IDUs 2004–09 Diagnostic testing, Inpatient 
detox facility
3 0–0.7 0.7 [100, 175]
Ireland Dublin Opiate users, IDUs 2001–03 Cross-sectional 2 11–12.5 12.5 [101, 175]
Israel National Ever IDUs 2003–05 Hospital data 1 1.9 1.9 [56]
Italy National Drug users (76–89 IDUs) 2002–08 Cross-sectional, diagnostic testing, 
outpatient records review
4 6.5–14.4 11.7 [22, 23, 61, 175]
Luxembourg National IDUs 2005 Prevalence study 1 2.5 2.5 [65]
Malta National IDUs 2006 Diagnostic testing 1 0 0 [175]
Norway 14 sites IDUs 2008 Prevalence study 2 0.6–2.8 2.8 [175]
Portugal National IDUs 2008 Diagnostic testing 3 9.2–18.4 9.2 [175]
Spain National Ever injected, current 
heroin users, VCT users
1999/2006 Cross-sectional 8 6.5–58.1 34.5 [64, 102, 104–106, 
175–178]
Sweden Stockholm, Gothenburg, 
Stockholm county
IDUs 2007–09 Diagnostic testing, prevalence 
study
5 0–9.3 9.3 [175, 179]
Switzerland National Entering heroin assisted 
therapy for first time, 
Ever IDUs
2000–06 Cross-sectional 2 2.0–12.6 2.0 [108, 180]
United Kingdom National Ever and current IDUs 2001–10 Diagnostic testing, prevalence 
study, sentinel survey, 
prospective cohort
9 0.5–4.2 1.1 [57, 110, 113, 
175, 181]
Note: HIV = human immunodeficiency virus; IDU = injecting drug user; PWID = people who inject drugs; VCT = voluntary counseling and testing.
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table c.2 summary of studies included in systematic review and range of Hiv prevalence estimates among pWiD in central european countries
Country City
Population 
sample Survey year Survey design
No. of 
studies
HIV 
prevalence 
range (%)
“Best” 
prevalence 
estimate (%) References
Albania Tirana IDUs 2005/08 Cross-sectional 2 0 0 [141, 142]
Bosnia and 
Herzegovina
Zenica, Luka, Sarajevo IDUs 2007/09 Descriptive 2 0.3–0.6 0.4 [143, 182]
Bulgaria Sofia and National IDUs 2003/08 Cross-sectional, diagnostic 
testing
3 0.5–6.8 6.8 [49, 145, 175]
Croatia National IDUs 2001/08 Convenience, prevalence 
study, diagnostic testing
7 0–1.5 0 [54, 146–148, 175]
Cyprus National IDUs 2008 Diagnostic testing, 
prevalence study
2 0 0 [175]
Czech Republic Cheb, Usti nad Labem, 
Ostrava and Prague
IDUs 1999/2008 Cross-sectional, diagnostic 
testing
3 0.07–0.2 0.07 [97, 175]
Hungary  National IDUs 1999/2008 Cross-sectional, prevalence 
study
6 0–0.8 0 [55, 75, 79, 92, 175, 183]
Macedonia, FYR National IDUs 2007 Convenience 1 0 0 [151]
Montenegro Unclear IDUs 2008 RDS 1 0.4 0.4 [152]
Poland National IDUs 2005–08 Diagnostic testing, 
prevalence survey
2 2.4–29.6 9.2 [175]
Romania Bucharest IDUs 2007–09 RDS, Diagnostic testing 2 1–1.6 1 [175, 184]
Serbia Belgrade, Podgorica, 
Novi Sad, and Nis
IDUs 2005–08 Cross-sectional 2 0–3.5 2.0 [42, 154, 185]
Slovak Republic Bratislava IDUs 2008 Diagnostic testing 1 1 1 [175]
Slovenia  National IDUs 2005–09 UAI survey of service users, 
prevalence study, 
diagnostic testing
3 0 0 [155, 175]
Turkey Gaziantep, Ankara, 
Istanbul, and Izmir
IDUs 2006–08 Diagnostic testing, 
convenience sampling
2 0–1.5 1.5 [156, 175]
Note: HIV = human immunodeficiency virus; IDU = injecting drug user; PWID = people who inject drugs; RDS = respondent-driven sampling; UAI = unprotected anal intercourse.
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table c.3 summary of studies included in systematic review and range of Hiv prevalence estimates among pWiD in eastern european and 
central Asian countries
Country City
Population 
sample Survey year Survey design
No. of 
studies
HIV prevalence 
range (%)
“Best” 
prevalence 
estimate (%) References
Armenia Unclear IDUs 2007 Unclear 1 6.8 6.8 [115]
Azerbaijan National IDUs 2003–08 Accessibility, street, 
snowball
2 1.3–33.0 10.3 [11, 116]
Belarus National IDUs 2004–09 Descriptive, UAI 
sentinel testing 
survey
2 1.0–33.0 10.7 [117, 186]
Estonia Tallinn, 
Kohtla-Jarve
IDUs 2002–09 Cross-sectional 7 26.7 (amphetamine 
only users)–90
53.5 [47, 48, 70, 119–121, 187]
Georgia National Ever and current 
IDUs
1997–2009 Cross-sectional 9 0.5–11.7 2.1 [7–10, 13, 188, 189]
Kazakhstan National IDUs 2009 Snowball 1 2.90 2.9 [190]
Kyrgyz Republic National IDUs 2009 RDS 1 14.3 14.3 [15]
Latvia Riga IDUs 2003–08 RDS, diagnostic testing, 
prevalence study
3 6.6–22.6 6.6 [48, 124, 175]
Lithuania Vilnius, Alytus IDUs, drug users 
including IDUs
2003–09 RDS, diagnostic testing, 
prevalence study
8 0.6–9.8 2.4 [48, 92, 175, 191]
Moldova Chisinau, Balti IDUs 2009 RDS 2 16–39 28.6 [125]
Russian Federation National Ever and current 
IDUs
1999–2009 Cross-sectional 16 8.6–61.1 28.9 [18, 27, 44, 85, 90, 93, 126, 
127, 130, 132, 164, 
192–197]
Tajikistan National IDUs 2004–09 Cross-sectional, RDS 2 12.1–17.3 17.3 [15, 41, 163] 
Ukraine National IDUs 1999–2009 Cross-sectional 8 3–80 22.9 [18, 25, 26, 69, 135–137, 
198, 199]
Uzbekistan Tashkent and 
National
IDUs 2003–09 Cross-sectional 2 11.0–29.8 13 [15, 95, 138, 200]
Note: HIV = human immunodeficiency virus; IDU = injecting drug user; PWID = people who inject drugs; RDS = respondent-driven sampling; UAI = unprotected anal intercourse.
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table c.4 Demographic and Drug Use characteristics of study respondents in Western europe
Country Male Age (midpoints)
Duration of 
injecting Frequency injected Main drug injected
% Shared needle/ 
syringe References
Finland — — — — — 28 d: 32% [98]
France 71%–75% Mean 34–36 Average age at 
first injection 
20.4–21.2
— (injected or snorted); 
30% crack/freebase; 
27% cocaine; 20% 
heroin; 12% ecstasy
13% [17, 24, 53]
Germany — Median 31 72% ≥5 years 4 m: median f 8 times, 
m 23 times
95% heroin — [99]
Ireland 60% Median 26 — — — — [101]
Israel 85% Mean 33.8 0.7 among IDUs — Among whole sample: 
heroin (with or 
without methadone)
— —
Italy 84%–86% Mean 29–35 years Median 14.5 years — 49%–92% heroin — [22, 23, 61]
Luxembourg — — — — 100% Lifetime heroin; 
84.2% speedball
6 m: 37% borrowed 
paraphernalia, 37% 
lent paraphernalia
[65]
Netherlands 61% Median age at 
entry: 30 
Median since first 
injection 7.2
6 m: 82% > weekly 6 m: 52% speedball — [63]
Spain 66%–81% Mean 25.7–30.2 
years
mean 7.6–11.6 
years
6 m: 45% daily 67% heroin; 78%–80% 
cocaine; 68% 
speedball
6 m: 18%, 12 m: 19%; 
ever 25%–66%
[20, 64, 102, 103, 105, 106, 
177, 178, 201–205]
Sweden 67% Median 42.5 years median 19 years — — 61.9% [62]
Switzerland 75%–82% Mean 33.7, median 
36 years
mean 11.6 years, 
median 15 
years
6 m: median # 
injections in 
past week: 7
— 6 m: 9%; 30 d: 5% [108, 180]
United Kingdom 69%–76% Mean 27.4–31 
years
7 years Median: 2.5 times 
daily, 80% daily
71% opiates, 53% 
cocaine/crack in past 
12 m; 92% heroin
28 d: 21%–31% [57, 111, 113]
Note: d = days; f = frequency; IDU = injecting drug user; m = months; — = not available.
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table c.5 Demographic and Drug Use characteristics of study respondents in central europe
Country Male Age (midpoints)
Duration of 
injecting Frequency injected Main drug injected
% Shared needle/
syringe References
Albania Majority 
(over 90%)
Mean 25.4; 
35%–48% <25
81%–91% = <5 
years; 20% <12m
More than once per 
day 20%
90% heroin; 51% diazepam Last time injected: 18%; 
30 d: 54%
[141, 142]
Bosnia and 
Herzegovina
88%–96% Mean 29–30 years Mean age at first 
injection: 
21 years
54% inject 2–3 times 
daily
97% heroin 30 d: 21%–31% [143, 144]
Bulgaria 79% Mean 25.9 years — — — Last time injected: 14% [49]
Croatia 83% Median 26–30 
years
Median 5–10 years — — 12 m: 30%–48% [54]
Czech Republic 70% 60% 18–22 years — — 48% heroin; 42% 
methamphetamine
— [97]
Hungary 69%–77% Mean 22.6–27.9 
years; 60% ≤ 30
Mean 6.8; 39.2% ≤ 5 Daily heroin 32%; daily 
amphetamine 9%
52%–79% heroin; 28%–51% 
amphetamine
30 d: 22%–33%; (unclear 
period, includes 
syringe, cooker, filter, 
rinsewater) 62%–68%
[55, 75, 76, 79, 92]
Macedonia, FYR 83% Mean 26.8 years 11% aged <15 years 
at first injection
15%–37% daily 92% heroin; methadone 50%; 
49% benzodiazepines
30 d: 34% [151]
Montenegro 89% 23% ≤ 25, 
29% ≥ 31
— — — — [152]
Romania 78% Mean 28 years Mean age at first 
injection 20 years
 30 d: 97% heroin Last injection: 15% 
did not use sterile 
equipment
[184]
Serbia (and 
Montenegro)
78%–93% 20%–41% <25 
years
27%–58% <5 years 39%–53% daily 94%–96% heroin 30 d: 15%–30% [42, 154]
Turkey — Mean 30.3 years — — 51.5% heroin 30 d: 67% [156]
Note: d = days; m = months; — = not available.
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table c.6 Demographic and Drug Use characteristics of study respondents in eastern europe and central Asia
Country Male Age (midpoints)
Duration of 
injecting
Frequency 
injected Main drug injected
% Shared needle/
syringe References
Armenia At last injection: 5% [115]
Azerbaijan 95% Mean 27–31.6 years Mean 9 21%–46% 
daily
66%–93% heroin, 36% homemade 
opiates
56%–68% [11, 116]
Belarus 75%–77% 35% 25–29 years; 
32% 30–39 years; 
mean 24 years
42% >7; 
mean 4–5
57%–59% 
daily
79%–86% heroin 6 m: 30%–32% [18, 117]
Estonia 53%–88% Mean 23–26 years; 
40%–62% 
≤20 years
Mean 7.9 Daily 61% Fentanyl 61%–74%; 90% mak; 
59%–83% heroin, 31%–45% 
amphetamines
28 d: 18%–32% [47, 48, 70, 71, 96, 
119, 121, 187]
Georgia 92%–100% Mean 27.5–40.5 years Mean 5–15.6; 
median 7
— 59%–97% heroin; 78% 
Buprenorphine; 30 d: 34% 
only heroin; 18% only 
buprenorphine; 9% only 
ephedrine, 36% multiple drugs
Ever: 85%, at last 
injection 6%–63%
[7–10, 13]
Kazakhstan 83% Median 31 years Mean 6.7 — 92% heroin — [15]
Kyrgyz Republic 82% Median 37 years Mean 8.6 — 98% heroin — [15]
Latvia 70% Mean 29.9 Mean 9.7 Daily 27% 45% heroin; 44% amphetamine 28 d: 31% [48]
Lithuania 76–82% Mean 30 Mean 10.4 76%–91% 58% hanka 28 d: 2–98% [48, 92]
Moldova 78%–87% 14%–20% <25 years — — — Last injection: 1%–2% [125]
Russian Federation 57%–83% Mean 20.7–29 years; 
median 29 years
48% ≤ 5 years; 
mean 5.5–9.6; 
median 8
15%–92% 
daily
66%–100% heroin, 
20% methamphetamine
30 d: 8%–79% [18, 27, 44, 52, 85, 93, 
126, 127, 132, 164, 
174, 192–194, 
196, 197]
Tajikistan 85%–90% Median 34 years Mean 4.6–11.6 
years
39.1% daily 98%–99% heroin Last injection: 37%, 
6 m 65%
[15, 41]
Ukraine 74%–83% Mean 24–32.7, years; 
median 31 years
Mean 5–13 50%–91% 
daily
30 d: 79%–94% hanka; 73–78% 
opiates, 12–35% stimulants, 
36–56% opiate/sedative mix
30 d: 13%–22%; 6 m 
47%–52%. Used 
prefilled syringe 
in 30 d: 55%
[18, 25, 26, 86, 134, 
136, 137, 206]
Uzbekistan 87%–95% Mean 28.7–34 years Mean 5.3 — 91% heroin 59% [95, 140]
Note: d = days; m = months; — = not available.
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table c.7 sexual and sociostructural characteristics of study respondents in Western europe
Country Inconsistent condom use Sex work HIV tested HCV infection (%) Income/employment Prison/arrest References
Finland — — 12 m: 63% tested 
and know result
— — — [98]
France — — Ever tested: 95% — 17.5%–33% employed; 
65% on benefits
Ever: 61% [17, 24, 53]
Germany — — — 82% — — [99]
Ireland — — Ever tested: 86% 66% — — [101]
Israel — — — 35.7% — — [56]
Italy — — — 71.2%–72% 79% employed (Male: 
81%; female 72%)
Ever committed a 
crime: 57%
[22, 23, 61]
Luxembourg — — — — — At least once in past 
10 years: 70%
[65]
Spain 13%–60% 11.5%–17.9% Ever tested: 82% 83.4%–93.5% Regular income 
4.8%–32.3%
Ever arrested: 
11%–64%
In past 12 months; 
0.5%–9.1%; 
Ever for >1 month 
43.1%
[20, 64, 102, 
103, 105, 
106, 177, 
178, 
201–205]
Sweden 40% — 12 m: 75% HIV—PWID: 88% — — [62]
Switzerland 28%–72% Females: 20% 95.80% 78.3% — — [108, 180]
United Kingdom — — Ever 54% 44% (PWID aged <30, or 
injecting = <6 years)
— Ever: 66%–75% [57, 111, 113]
Note: HCV = hepatitis C virus; HIV = human immunodeficiency virus; m = months; PWID = people who inject drugs; — = not available.
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table c.8 sexual and sociostructural characteristics of study respondents in central europe
Country Inconsistent condom use Sex work HIV tested
HCV 
infection
Income/ 
employment % Prison References
Albania Last casual sex partner: 
64%; 12 m: 86%
4.30% Ever: 30% — — — [141, 142]
Bosnia and 
Herzegovina
Last time had sex: 
58%–73%
— Ever: 46%–77%, of 
which 36%–44% 
in past 12 m
— — Ever: 2%–55% [143, 144]
Bulgaria Last sexual intercourse: 
62%
Sold sex for money or drugs 
in past 6 m: 8.4%
12 m: 48% tested and 
know result 
73.9% 30.7% employed Ever: 18% [49]
Croatia — — Ever: 83%–93% — — — [54]
Czech Republic — 0.20% — — — — [97]
Hungary 30 d: 89.3% — Ever: 56%–59% 37% 20.4%–46.2% work 
at least part time
— [55, 75, 76, 79, 92]
Macedonia, FYR 30 d: 56% 30 d: 14% 12 m: 44% — — — [151]
Montenegro — — — — — — [152]
Romania 30 d: 76% Ever exchanged sex for 
money, drugs; or other 
goods: 13% (male 12%; 
female 14%)
12 m: 19% tested and 
know result
— — Ever: 40% [184]
Serbia (and 
Montenegro)
Last time had sex: 71% Ever: 5%–10% 12 m: 22% tested and 
know result
63% — Ever: 43%–50% [42, 154]
Turkey 56% — — — — — [156]
Note: d = days; f = frequency; HCV = hepatitis C virus; HIV = human immunodeficiency virus; m = months; — = not available. 
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table c.9 sexual and sociostructural characteristics of study respondents in eastern europe and central Asia
Country
% Inconsistent 
condom use % Sex work % HIV tested HCV infection
Income/ 
employment % Prison References
Armenia At last sexual 
intercourse: 44%
 12 m: 23% tested and 
know result
 [115]
Azerbaijan 87%–98%  12 m: 4.9% tested 
and know result
 [11, 116]
Belarus 6 m: 20% (casual)–58% 
(regular)
Female 3%; 
male 1%
  [18, 117]
Estonia 12 m: 60%, 2%–17% Ever: 49%–87%; 
12 m: 57%
96% 14%–57.3% some 
regular income
Ever in prison: 
58%–66%; new 
injectors (= <3 years) 
32%–40%; Ever 
arrested: 49%–66%
[47, 48, 70, 71, 96, 
119, 121, 187]
Georgia 33%–74%; UAI at last 
sex with regular 
partners: 79%; 
casual partners: 
52%; paid 
partners 22%
28% paid for sex 
with median 
of 3 people
Ever: 11%–33% 
tested and 
know result
58.2%–70.4% 40% regular income 6%–21% [7–10, 13]
Kazakhstan 24% Female: 15%; 
male: 14% 
56%  [15]
Kyrgyz Republic 40% Female: 4%; 
male: 4%
40%  [15]
Latvia 52% 3% Ever: 72%, 12 m 44% Ever: 45% [48]
table continues next page
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table c.9 sexual and sociostructural characteristics of study respondents in eastern europe and central Asia (continued)
Country
% Inconsistent 
condom use % Sex work % HIV tested HCV infection
Income/ 
employment % Prison References
Lithuania 89%–93% 5% Ever: 95%, 12 m 73% 71% [48, 92]
Moldova 50%–67%  32%–47%  [125]
Russian 
Federation
12%–87%; 6 m; 
all partners: 59%; 
casual partners: 34%
6%; females: 
24%–32%; 
males: <1%–5%
Ever: 56%–81% 63.4%–96% 13%–49.4% regular 
income
Ever in prison: 6%–46% 
(female 19%; male: 
55%); Ever arrested: 
26.5%–76%; arrested 
in past 12 m 
60.4%–67.2%
[18, 27, 44, 52, 85, 
93, 126, 127, 132, 
164, 174, 192–194, 
196, 197]
Tajikistan 55%–100% 21%; female: 31%; 
male 13%, 
15%–36% 61.3% 20% employed  44.5% ever arrested [15, 41]
Ukraine 30 d: 38%–55%; 
6 m: regular 83%; 
casual: 27%
3.4%–11%; 
female: 3%–7%; 
male <1%
12 m: 26%–61% 73% 44%–69% employed Ever arrested: 58%–72% [18, 25, 26, 86, 134, 
136, 137, 206]
Uzbekistan 44% Female: 36%; 
male: 18% 
13%  [95, 140]
Note: HCV = hepatitis C virus; HIV = human immunodeficiency virus; m = months; UAI = unprotected anal intercourse.
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table c.10 summary of multivariate studies for Hiv risk Factors among pWiD in Western europe Derived from systematic review
Study, year Location Sample Individual-level risk factors Environmental-level risk factors
Stark et al. 2005 [99] Germany, Berlin 166 prisoners (117 females, 57 males) 
reporting having ever injected 
Injecting drugs during a previous 
incarcerationa; HCV+
Adjusted for syringe sharing, duration of 
injecting career, year injecting started
Camoni et al. 2009 [61] Italy, national 1,330 people who use drugs, of whom 
1,009 (75.9%) ever injected and 
were randomly sampled at public 
drug treatment centers
Injectinga Agea; area; unemployed; years of 
education
Quaglio et al. 2006 [22] Italy, Northern Opiate-dependent drug users on OST 
for at least 6 months, of whom 89% 
reported injecting as their principal 
route of administration 
Duration of injecting career Recruitment site; Age; Gender; 
Education; Employmenta; Living 
status; Marital status
Van den Berg et al. 2006 [63] 
Outcome is HIV seroconversion
Netherlands, 
Amsterdam
710 PWID (ever) who were HIV 
negative at entry to cohort study
Duration of injecting career; HIV 
status of steady partner; level 
of harm reduction accessed
—
Barrio et al. 2006 [102] Spain, Madrid, 
Barcelona, 
and Seville
621 heroin-injecting users recruited 
from street (same sample as below)
Ever injected with a used syringe; 
first drug injected at least weekly; 
ever sniffed with tubes; ever been 
pierced; backloaded in past year
Gender; ever in prison; city of residence
De La Fuente et al. 2006 [103] Spain, Madrid, 
Barcelona, 
and Seville
628 heroin-injecting users recruited 
from street (same sample as above)
Adjusted for gender, employment, 
education, prison, and injecting 
and sexual behavior risks
Stratified by duration of injecting career: 
≤5 years: city of residence (AOR ref.: 
Barcelona; Madrid AOR 1.3, 95% 
CI 0.5–3.5; Seville AOR 0.7, 95% CI 0.7, 
0.1–4.3); >5 years: city of residence 
(AOR ref.: Barcelona; Madrid AOR 3.1, 
95% CI 1.5–6.2; Seville AOR 1.5, 95% 
CI 0.5–4.8) 
Hurtado et al. 2008 [105] Spain, Valencia 5,948 PWID attending VCT and 
self-identifying
model adjusted for age Gender
Tested in more recent calendar year 
Interaction: gender x calendar year
Note: AOR = adjusted odds ratio; CI = confidence interval; HCV = hepatitis C virus; HCV+ = HCV-positive; HIV = human immunodeficiency virus; OST = opioid substitution therapy; PWID = people who inject drugs; 
ref = reference; VCT = voluntary counseling and testing; — = not available.
a. Adjusted for age, education, ethnicity, and employment status.
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table c.11 summary of multivariate studies for Hiv risk Factors among pWiD in eastern europe and central Asia Derived from systematic review
Study, year Location Sample Individual-level risk factors Environmental-level risk factors
Platt et al. 
2006 [161]
Estonia, Tallinn 350 PWID who injected in 
past 4 weeks recruited 
by RDS
Primary injection of opioid or amphetamine in past 4 weeks; 
duration of injecting career; shared needle in past 4 weeks; 
shared equipment in past 4 weeks; injected with a used needle 
from a sex partner in past 4 weeks; number of sexual partners 
in past year
Age; gender; main source of income in 
past 4 weeks; ethnicity; ever registered 
in drug treatment; ever been in prison; 
ever attended needle exchange
Abel-Ollo et al. 
2009 [70]
Estonia, 
Tallinn and 
Kohtla-Järve
450 PWID (350 from Tallinn 
and 100 from Kohtla-
Järve) who injected in 
past 4 weeks recruited 
by RDS. For analysis 
the participants were 
categorized as HIV−, 
HIV+ aware of their 
status, and HIV+ unaware 
of their status, according 
to self-reported status at 
the time of testing.
The data from Tallinn are 
also analyzed above.
Analysis of risk factors for HIV among participants aware of their 
status (ref HIV− participants): sharing used needles/syringes in 
past 4 weeks;a unprotected sex in past 4 weeks; sharing water; 
PWID as sex partner in past year; sharing injection equipment 
with sexual partner in past year; having 2 or more sex partners 
in past year; unprotected intercourse in past year; ever sharing 
needles with HIV+ person 
Uusküla et al. 
2010 [121]
Estonia, Tallinn 350 PWID, aged 18+, who 
injected in past 2 months 
recruited by RDS
Earlier age of initiation to injecting; primary injection of opioid 
or amphetamine; receptive sharing in past 6 months
Ever attended syringe exchange; main 
source of income other than work; 
unemployment at habitat level; 
residential change at habitat level
Platt et al. 
2005 [90]
Russian 
Federation, 
Togliatti
268 male PWID who 
injected in past 4 weeks 
recruited in 2001 by 
outreach workers
Duration of injection; injected with used paraphernalia in past 
4 weeksa; injected with used needle in past 4 weeks; ever 
injected homemade drugs; injected with used needle from 
someone known to be HIV+; injected with used needle from 
someone known to be HCV+a; unprotected anal or vaginal sex 
with a regular partner in past 4 weeks; unprotected anal or 
vaginal sex with a casual partner in past 4 weeksa; ever 
had an STI
Ever been in prison; ever been in drug 
treatment; ever been arrested
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table c.11 summary of multivariate studies for Hiv risk Factors among pWiD in eastern europe and central Asia Derived from systematic review (continued)
Study, year Location Sample Individual-level risk factors Environmental-level risk factors
— Russian 
Federation, 
Togliatti
89 female non-sex worker 
PWID who injected in 
past 4 weeks, recruited 
in 2001 by outreach 
workers
Duration of injection; injected with used paraphernalia in past 
4 weeks; injected with used needle in past 4 weeks; ever 
injected homemade drugs; injected with used needle from
someone known to be HIV+; injected with used needle from 
someone known to be HCV+; unprotected anal or vaginal sex 
with a regular partner in past 4 weeks; ever had an STI
Ever been in prison; ever been in drug 
treatment; ever been arrested
— Russian 
Federation, 
Togliatti
66 female sex worker PWID 
who injected in past 
4 weeks, recruited in 
2001 by outreach 
workers
Duration of injection; injected with used paraphernalia in past 
4 weeks; injected with used needle in past 4 weeks; ever 
injected homemade drugs; injected with used needle from 
someone known to be HIV+; injected with used needle from 
someone known to be HCV+; unprotected anal or vaginal sex 
with a regular partner in past 4 weeks; ever had an STI
ever been in prison; ever been in drug 
treatment; ever been arrested
Platt et al. 
2008 [162]
Russian 
Federation, 
Togliatti
230 PWID (134 in 2001 from 
the study above, and 96 
from 2004) who reported 
injecting for 3 years or 
less and injected in past 
4 weeks, recruited by 
outreach workers in 2001 
and through RDS in 2004
Duration of injecting career; frequency of injection; ever injected 
homemade drugs; injected with used needles in past 4 weeks; 
used a previously used filter; frontloading in past 4 weeks; 
injected with a prefilled syringe; frequency of reusing the same 
needle; ever exchanged sex for money, drugs or goods; history 
of STIs
Year of study; gender; age; district of 
residence; education; main source 
of income in past 4 weeks; history of 
prison; police arrest in past year; ever 
in drug treatment; main source of 
needles in past 4 weeks; ever been 
tested for HIV
Kozlov et al. 
2006 [85]
Outcome is HIV 
incidence at 
12-month 
follow-up to 
enrollment
Russian 
Federation, 
St. Petersburg
520 seronegative PWID 
enrolled in cohort study 
who injected at least 
3 times/week in past 
month or reused 
another’s injecting 
equipment at least 
3 times in past 3 months
Frequency of injecting psychostimulants; number of sex partners 
in past 6 months; selling sex for money or goods in past 
6 months
Niccolai et al. 
2010 [164]
Russian 
Federation, 
St. Petersburg
387 ever injectors who were 
enrolled through RDS
Unsafe injection in past 30 days; has STI Unemployed
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table c.11 summary of multivariate studies for Hiv risk Factors among pWiD in eastern europe and central Asia Derived from systematic review (continued)
Study, year Location Sample Individual-level risk factors Environmental-level risk factors
Rhodes et al. 
2006 [93]
Russian 
Federation, 
Moscow
455 PWID who injected in 
past 4 weeks, recruited 
by outreach workers
Duration of injecting career; last day injected, number of times 
injected; frequency of injection; main drug injected in past 
4 weeks; injected with used needle in past 4 weeks; shared 
paraphernalia in past 4 weeks; ever injected with used needles; 
number of sex partners in past year; history of STI
Gender; age; education; main source of 
income in past 4 weeks; ever been in 
prison; ever registered as a drug user
Russian 
Federation, 
Volgograd
517 PWID who injected in 
past 4 weeks, recruited 
by outreach workers
Duration of injecting career; frequency of injection; ever injected 
homemade drugs; injected with used needle in past 4 weeks; 
shared paraphernalia in past 3 weeks; ever injected with used 
needles; injected with needle previously used by sex partner 
in past 12 months; number of sex partners in past year; history 
of STI
Gender; age; education; main source of 
income in past 4 weeks; ever registered 
as a drug user
Russian 
Federation, 
Barnaul
501 PWID who injected in 
past 4 weeks, recruited 
by outreach workers
Duration of injecting career; last day injected, number of times 
injected; frequency of injection; main drug injected in past 
4 weeks; ever injected homemade drugs; injected with 
used needle in past 4 weeks; shared paraphernalia in past 
4 weeks; filled syringe from working syringe in past 4 weeks; 
ever injected with used needles; number of sex partners in 
past year; history of STI
Gender; age; education; main source of 
income in past 4 weeks; ever been in 
prison; ever registered as a drug user
Beyrer et al. 
2009 [41]
Tajikistan, 
Dushanbe
419 PWID, aged 17+ who 
injected in past month, 
recruited through 
snowball technique
Daily injection in past 6 months Ethnicity model adjusted for gender
Stachowiak et al. 
2006 [163]
Tajikistan, 
Dushanbe
207 ethnic Tajik PWID 
(subsample of above), 
aged 17+, recruited 
through snowball 
technique
Injecting at least daily for past 6 months; less than 3 years since 
initiation of injection; injects “alone”; injected with used needle 
in past 6 months
Reports narcotics “very easy” to obtain; 
ever experienced drug treatment
Booth et al. 
2006 [134]
Ukraine, Kiev, 
Odessa, 
Makeevka/ 
Donetsk
778 PWID aged 18+, who 
injected in past 30 days 
and were unaware of 
their HIV status, recruited 
through outreach 
workers
Injected sedative/opiate mix in past 30 days; daily injection in past 
30 days; sex in past 30 days; sex with HIV+ or unknown status 
partner in past 30 days
Age; gender; city of origin
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table c.11 summary of multivariate studies for Hiv risk Factors among pWiD in eastern europe and central Asia Derived from systematic review (continued)
Study, year Location Sample Individual-level risk factors Environmental-level risk factors
Dumchev et al. 
2009 [25]
Ukraine, 
Vinnitsya
268 PWID aged 18+, 
who reported at least 
3 injections in past 
30 days and have lived 
in Vinnitsya for past year, 
recruited through 
snowball sampling
Shared needles with HIV+ person in past year; injected opiates 
daily
HIV knowledge score 
Taran et al. 
2011[26]
Ukraine, 
16 cities
3,487 PWID, aged 16+, who 
injected in past 30 days 
and were recruited 
through RDS
Type of drug injected in past month; duration of injecting career; 
injecting frequency in past month; used alcohol with drugs in 
past month; shared needle at last injection; frequency of 
sharing paraphernalia in past month; sexual contact in 
past year 
Gender; marital status; occupation; 
education
Sanchez et al. 
2006 [138]
Uzbekistan, 
Tashkent
701 self-identified PWID 
aged 18+ available for 
2 weeks after enrolment 
by outreach workers
Age at first drug use; first illicit drug of use; duration of injecting 
career; current heroin use; injecting frequency; poppy-straw 
use; group drug use; sharing needles; own syringe; blood 
transfusion; STI history; Hepatitis history; TB history; STI 
symptoms; sell sex for drugs; condom use; number of sexual 
partners in past month
Age; gender; nationality; marital status; 
employment status; education status; 
needle exchange program; AIDS 
knowledge; protection for AIDS; 
donated blood for money
Note: AIDS = acquired immune deficiency syndrome; HCV = hepatitis C virus; HCV+ = HCV-positive; HIV = human immunodeficiency virus; HIV+ = HIV-positive; HIV– = HIV-negative; PWID = people who inject drugs; 
RDS = respondent-driven sampling; STI = sexually transmitted infection; TB = tuberculosis; — = not available.
a. Adjusted for age, education, ethnicity, and employment status.
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table c.12 summary of Hiv prevalence among samples of sWs in Western europe
Country Area Population sampled Injecting drug use Migrants Survey year HIV prevalence Category n References
Austria Vienna FSWs recruited from STI 
clinics
— — 2002 1% Low 1,184 [107]
Registered FSWs — — — 0% — 642 —
Illegal FSWs — — — 4% Medium 246 —
Unregistered FSWs 
working in bars
— — — 0% — 296 —
Belgium Antwerp SWs — — 2008 0% Low 1,016 [64]
France Paris Chinese SWs — 100% 2008 0% Low 46 [64]
Germany National 
(multisite)
FSWs recruited through 
STI clinics VCT sites, 
and private clinics
— — 2002 0.30% Low 290 [107]
National 
(multisite)
FSWs recruited through 
STI clinics VCT sites, 
and private clinics
5% (n = 518) 63% (n = 1,425) 2010–11 0.20% Low 3,880 [69]
Greece Athens FSWs applying for 
official license to 
work as SWs, 
recruited at STI 
clinics (migrants and 
non-migrants)
0 Drug use 19.7% Migrants 
(Ukraine, Georgia, 
Russian Federation, 
Bulgaria, Romania, 
Albania)
2005 0% Low 299 [20]
Bologna Street migrant FSWs 
attending STI clinics
— 76% Eastern Europe 1995–99 1.60% Low 558 [100]
Italy Rome Female migrant SWs 
attending an HIV 
testing site
8.9% cocaine users — 1992–2007 5% High 229 [91]
Sicily Migrant street-based 
SWs, recruited via 
outreach workers
0 reported using 
illegal substances 
64.4% Colombian 
35.6% Dominican
2001–02 0% Low 118 [67]
Italy Palermo Migrant SWs, recruited 
from the street
— — 2008 8% High 123 [71]
Netherlands Rotterdam, 
The Hague
FSWs recruited from 
work settings
0 75% migrants 2002–05 1.50% Low 399 [19]
table continues next page
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Country Area Population sampled Injecting drug use Migrants Survey year HIV prevalence Category n References
Female drug users 52% 65% migrants  13.6% High 88 —
All FSWs 16% 76% migrants  5.7% High 557 —
National 
(multi-site)
FSWs — — 2005 0.50% Low 1,018 [107]
Norway Oslo STI clinics for SWs 
(includes MSWs)
— — 2008 1% Low 746 [64]
Portugal Lisbon FSWs recruited from 
street including 
migrants and IDUs
50%–60% 
cocaine/heroin
51% migrants 2000–01 13.50% High 96 [108]
Spain Madrid Immigrant FSWs, 
transsexuals (60), and 
MSW (3) recruited 
from work settings
— 75% Sub-Saharan 
Africa; 18% Central 
and South America; 
6% EE
1998–2003 5.2% High 762 [65]
Female African SWs — — — 4.5% Medium 574 —
Ecuador (MSW = 62) — 100% Ecuador — 11% High 128 —
Madrid, Alicante, 
Bilbao, 
Pamplona, 
Oviedo, Gijon
FSWs (largely migrants) 0.6% 83.3% migrants (83% 
from LA; 8% EE; 
5% SSA; 2% no 
information)
2000–01 0.7% Low 3,149 [27]
Injecting drug users — — — 15.8% High 19 [92]
Barcelona Female street-based 
SWs
— 95% migrants 
(31% LA; 25% SSA; 
24% EE)
2002–03 1% Low 301 [21]
Female migrant SWs 
recruited at work
1.0% 100% migrants 
(Eastern Europe, 
Africa, Latin 
America)
2003–04 0.8% Low 357 [28]
Sweden Stockholm region Recruited in prison — — 2006–07 2.2% Medium 45 [64]
Israel 2 sites FSWs who had entered 
Israel illegally and 
were working 
without permits
— 100% EE/FSU — 0% Low 43 [9]
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table c.12 summary of Hiv prevalence among samples of sWs in Western europe (continued)
Country Area Population sampled Injecting drug use Migrants Survey year HIV prevalence Category n References
Tel Aviv Female brothel workers 
(except for 12 street 
workers)
— 89.6% migrants from 
FSU
— 0.3% Low 300 [66]
United 
Kingdom
London Recruitment at 
specialist sex work 
clinics
11% 33% migrants 1986–93 and 
1997–2000
0% Low 130 [108]
London (East) Female street workers 92% heroin/crack  2004 4.10% Medium 24 [83]
 Female street workers, 
drug users (crack, 
heroin) recruited via 
outreach workers
96% (crack, heroin, 
cocaine)
28% (Somali, 
European, 
West Indian)
2006–07 24% Very high 25 [6]
London FSWs and migrant SWs 
from Eastern Europe, 
recruitment at 
specialist sex work 
clinics
 4.4% IDU 60.8% EE/FSU 
migrants
2008–09 1.10% Low 268 [109]
Scotland FSWs recruited from 
VCT sites, STI clinics, 
hospitals
— — 2002 0% Low 103 [107]
Note: EE = Eastern Europe; FSU = former Soviet Union; FSW = female sex worker; HIV = human immunodeficiency virus; IDU = injecting drug user; LA = Latin America; MSW = male sex worker; n = sample size; 
SSA = Sub-Saharan Africa; STIs = sexually transmitted infections; SW = sex worker; VCT = voluntary counseling and testing; — = not available.
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table c.13 summary of Hiv prevalence among samples of sWs in central europe
Country Area Population sampled Injecting drug use Migrants Survey year HIV prevalence Category n References
Albania Tirana FSWs working on the 
street and in bars
— — 2008 1.10% Low 90 [110]
Bosnia and 
Herzegovina
— FSWs — — 2007 0% Low 42 [111]
 Bulgaria 8 cities MSWs (16%) and 
FSWs recruited 
from street, brothels
— — 2005 1% Low 874 [112]
— — 2008 0.63% Low 799 [113]
Croatia Brod, Dubrovnik, 
Osijek, Rijeka, 
Slavonski, Split, 
Zadar, and 
Zagreb 
SWs recruited 
through NGOs
— — 2003–05 2.3% Medium 43 [114]
Czech Republic Cheb, Usti nad 
Labem, Ostrava
FSWs 10% 40% (non-Czech) 1999–2000 0.7% Low 585 [115]
Prague and two 
regions
FSWs recruited from 
street
— — — 0.1% Low 797 [107]
Macedonia, FYR National FSWs — — 2005 0% Low 48 [116]
2006 1.9%  51
2007 0%  67
Hungary — SWs screened at bus 
pilot programs
— — 2006 0% Low 500 [64]
Montenegro — Female and Male 
SWs (MSWs = 14)
— — 2007 0.76% Low 133 [117]
Poland 13 cities SWs recruited from 
clinics and 
community
2%  2002–05 0%–2% Low 650 [107]
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table c.13 summary of Hiv prevalence among samples of sWs in central europe (continued)
Country Area Population sampled Injecting drug use Migrants Survey year HIV prevalence Category n References
National (multisites) SWs recruited from 
VCT sites, STI 
clinics, and 
hospitals
— — 2005 0% Low 250 [107]
Romania Bucharest Street SWs — — 2006 1% Low 204 [64]
Serbia Belgrade Female (62%), 
Male (22%), 
Transsexuals (16%)
27%  2010 0.8% Low 250 [118]
Serbia (Kosovo) Ferizaj, Urosevac, 
Prizren
Street and indoor 
SWs, mostly 
migrants (Albania, 
Bulgaria, Moldova, 
Ukraine)
1.3% IDU in last 
12 months
34% Bulgaria, 
28% Albania, 
16% Moldova, 
and 9% 
Ukraine
2006 0% Low 157 [119]
Turkey Ankara, Istanbul, 
Izmir
Unregistered FSWs  26% 2006–07 0.8% Low 252 [120]
Note: FSW = female sex worker; HIV = human immunodeficiency virus; IDU = injecting drug user; LA = Latin America; MSWs = male sex workers; n = sample size; NGOs = nongovernment organizations; 
SSA = Sub-Saharan Africa; STIs = sexually transmitted infections; SW = sex worker; VCT = voluntary counseling and testing; — = not available.
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table c.14 summary of Hiv prevalence among samples of sWs in eastern europe
Country Area Population sampled
Injecting drug 
use Migrants
Survey 
year HIV prevalence Category n References
Armenia National FSWs recruited through 
VCT sites and STI clinics
1.20% — 2000 1.2% Low 168 [107]
FSWs recruited from 
street and VCT sites
0.40% — 2005 0.4% Low 250 [107]
Gegharkunik, Lori, 
Yerevan, Shirak, 
Syunik
Female sex worker — — 2007 0.4% Low — [121, 122]
Azerbaijan Baku, Gandja, Sumgait SWs — — 2007–08 2.5% (all cases 
in Baku)
Medium 300 [123]
Street-based and indoor 
SWs
<1% used 
drugs in 
last month
4% migrants 
from Russian 
Federation
2003 8.50% High 200 [124]
Belarus Brest, Gomel, Grodno, 
Minsk, Mogilev, 
Vitebsk 
FSWs recruited from the 
street and STI clinics
— — 2004 0%, 0.98±0.5 Low 208 [107]
7 areas — — — 2004, 2006, 
2009
0% Low 481 [125]
Minsk FSW 15.50% — 2009 6.40% High 453 [125]
Estonia Talinn FSWs recruited via chain 
referral 
6.60% 0% 2005–06 7.6% High 227 [36]
Georgia Tblisi SWs recruited through 
TLS
1.3% 20% 2002 0% — 153 [35]
5.6% 22% 2004 1.3% — 158 —
1.8% 13% 2006 0.6% — 160 —
— — 2009 1.9% Low 160 [78] 
Georgia Batumi SWs recruited through 
TLS
1.7% 18% 2004 0% — 120 [35]
5.8% 13% 2006 0.1% — 114
— — 2009 0.8% Low 120 [78]
Latvia Riga FSWs — — 2002 16% High 92 [107]
Riga and regions — 53% IDU — 2004 18% High 93 [107]
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table c.14 summary of Hiv prevalence among samples of sWs in eastern europe (continued)
Country Area Population sampled
Injecting drug 
use Migrants
Survey 
year HIV prevalence Category n References
Lithuania Vilnius FSWs recruited from 
street
— — 2005 0% Low 101 [107]
— FSWs recruited at 
Lithuanian AIDS 
Center
— — 2007 0% Low 67 [126]
Moldova Chisinau — 11.2% IDUs 1.3% from 
Moldova, rest 
from Russian 
Federation
2001 4.60% Medium 151 [124]
SWs recruited through 
harm reduction 
programs
— — 2004 8.50% High 151 [127]
— — — 2007 2.90% Medium 242
SWs recruited through 
RDS
— — 2009 6.10% High 300
Moscow Street-based FSW 4.80% 75% 2002 14.1% High 147 [124]
Russian 
Federation
St Petersburg Street-based FSW IDUs 97.20% 11% 2003 48.1% Very high 109
Ekaterinburg Street/apartment based 
FSWs
27.30% 43.50% 2003 14.8% High 151
Moscow IDU SWs recruited from 
community settings 
100% 82% 2003 13.3% (4/30) High 34 [82] 
Volgograd — 100% 20.60% 2003 2.9% (1/34) Medium 36
Barnaul — 100% 20.70% 2003 6.1% (2/33) High 34
Togliatti IDU SWs recruited from 
community settings 
100% 13% 2001 62.1% Very high 66 [13]
Russian 
Federation
Togliatti  100%  2005 57.8% Very high 38
Moscow SWs recruited from the 
street
  2000 15% High 170 [107]
table continues next page
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table c.14 summary of Hiv prevalence among samples of sWs in eastern europe (continued)
Country Area Population sampled
Injecting drug 
use Migrants
Survey 
year HIV prevalence Category n References
Nizhny Novgorod CSWs   2006 5.80% High 200 [81]
Krasnoyarsk CSWs   2007 8% High 200
Tomsk CSWs   2007 2% Medium 200
Chelyabinsk CSWs   2007 6% Medium 200 [128]
Irkutsk CSWs   2008 20% Very high 201
Moscow SWs recruited at STI 
clinics
  2009 4.50% Medium 750
15 Russian cities CSWs 30%  2009 4.50% Medium 1,777
Ukraine Donetsk, Kharkiv, Lutsk, 
Nikolaev, Odessa, 
Poltava, Simferopol.
FSWs recruited from 
street
  2002 20% Very high 646 [107]
23 cities FSWs recruited from 
community
  2008–09 13.20% High 3,284 [129]
Ukraine 16 cities FSWs recruited from 
community settings
24% ever used 
drugs; 15% 
IDU in last 
30 days
39% internal 
migrants
2009 12.90% High 2,278 [130]
Kazakhstan  SWs recruited from 
community settings; 
sold sex in last 6 
months
9.80% — 2006 2.50% Medium — [88]
18.20% — 2007 2.20% Medium — —
12.30% — 2008 1.40% Low — —
11.10% — 2008 1.30% Low 2,249 —
National FSWs recruited from STI 
clinics
— — — 0.10% Low 3,903 [107]
19 cities FSWs recruited from the 
street/STI clinics
12% — 2005 2.10% Medium 1,960 [107]
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table c.14 summary of Hiv prevalence among samples of sWs in eastern europe (continued)
Country Area Population sampled
Injecting drug 
use Migrants
Survey 
year HIV prevalence Category n References
Kyrgyz Republic Bishkek, Osh FSWs in past 6 months 4.8% — 2006 1.4% Low 352 [88]
2.3% — 2007 1.3% Low — —
0.5% — 2008 1.9% Low — —
0.4% — 2008 1.6% Low — —
Tajikistan 5 regions FSWs 0.3% — 2006 3.7% Medium 1,200 —
1.50% — 2007 1.6% Low — —
1.70% — 2008 2.8% Medium — —
1.50% — 2008 2.7% Medium — —
Uzbekistan Samarkand FSWs and MSWs 5% — 2004–05 6.20% High 372 [85]
Tashkent FSWs 9% — 2003–04 10% (45/448) High 448 [84]
FSWs IDU 100% — — 58.50% Very high 41 —
FSWs non-IDU 0% — — 5.20% High 407 —
Multisites FSWs — — 2005–07 4.70% Medium 2,000 [89]
Note: AIDS = acquired immune deficiency syndrome; CSWs = commercial sex workers; FSWs = female sex workers; IDU = injecting drug user; MSW = male sex worker; n = sample size; RDS = respondent-driven 
sampling; STIs = sexually transmitted infections; SWs = sex workers; TLS = time location sampling; VCT = voluntary counseling and testing; — = not available.
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table c.15 summary of Hiv prevalence among samples of male and transgender sWs
Country City Population sample Migrant IDU Survey year HIV Prevalence Category n References
Belgium Antwerp MSWs recruited through 
outreach
72% (Eastern Europe, Middle 
East, North America, South 
Africa, Western Europe)
5% 1999–2004 10.80% High 120 [95]
Czech Republic Cheb, Ostrava, 
Prague, Usti 
nad Labem
MSW 7% (Bulgaria, Russian 
Federation, Ukraine)
38% 1999–2003  0.9% Low 1,480 [115]
— — — — — — — [107]
 Italy Rome MSWs/Transgender 80%–96% (mostly South 
America)
8.9% 
cocaine
1992–2007 23% Very high 752 [91]
Brescia Transgender 100% (South America) — 2002–04 27% Very high 85 [90]
Netherlands Rotterdam, The 
Hague
Transgender 96% (mostly South America) — 2002–05 18.80% High 70 [19]
Russian 
Federation 
Moscow MSW 84% internal migrants 8% 2005–06 16% High 50 [55]
Spain 19 cities MSW and transgender 67% migrants (mostly South 
America)
3.30% 2000–02 12% High 418 [92]
Spain 19 cities MSW and transgender 70% 2% 2000–07 9.9% High 1,935 [131]
United Kingdom London MSWs recruited at STI 
clinics
62.8% (SA, SSA, WE, EE, 
Australia)
26.70% 1994–2003 8.90% High 636 [86]
— — — 2003 9.3% High 257 [107]
Note: EE = Eastern Europe; HIV = human immunodeficiency virus; IDU = injecting drug user; LA = Latin America; MSM = men who have sex with men; MSWs = male sex workers; n = sample size; SA = South America; 
SSA = Sub-Saharan Africa; STI = sexually transmitted infection; SW = sex worker; WE = Western Europe; — = not available.
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table c.16 prevalence of Hiv and syphilis among samples of male and transgender sWs
Country City Population HIV Syphilis n Year Reference
Italy Brescia Transgender 27% 14% 86 2002–04 [90]
United Kingdom London MSW 9% 21% 746 1994–2003 [86]
Belgium Antwerp MSW 10.8% 12.5% 120 1999–2004 [95]
Spain Madrid Transgender 22.6% 30.6% 62 1998–2003 [65]
Note: HIV = human immunodeficiency virus; MSW = male sex worker; n = sample size; SW = sex worker.
table c.17 prevalence of Hiv and syphilis among samples of FsWs
Country City Population HIV Syphilis n Year Reference
Albania Tirana FSW 1.1% 6% 90 2011 [110]
Bulgaria 8 cities FSW 1% 10% 799 2005 [113]
Serbia Belgrade FSWs, MSW, Transgender 1% 4% 250 2010 [118]
Kyrgyz Republic Bishkek, Osh FSWs 1.4% 34.9% 352 2006 [132]
Azerbaijan Baku, Gandja, Sumgait FSWs 3% 9% 200 2001 [124]
Moldova Kishinev FSWs including IDUs 5% 12% 148 2001
Russian Federation Moscow FSWs including IDUs 14% 26% 147 2001
Ekaterinburg FSWs including IDUs 15% 22% 151 2001
Barnaul, Moscow, 
Volgograd 
FSWs including IDUs
7% 16% 98 2003 [14]
Italy Bologna FSWs including migrants 2% 12% 558 1995–99 [100]
Greece Athens FSWs including migrants 0% 18% 299 2005 [20]
United Kingdom London FSW including migrants 1% 2% 268 2007–08 [109]
Spain Madrid FSW including migrants 0% 3% 66 1998–2003 [65]
Ukraine 15 cities FSW including IDUs 12.9% 4.4% 2,278 2009 [130]
Georgia Tblisi, Batumi FSWs including IDUs 0.4% 34.1% 985 2002–06 [133]
Turkey Ankara, Istanbul, Izmir FSWs (unregistered) 0.8% 7.5% 252 2006–07 [120]
Note: FSW = female sex worker; HIV = human immunodeficiency virus; IDU = injecting drug user; MSW = male sex worker; n = sample size.
table c.18 prevalence of chlamydia and Gonorrhea among samples of FsWs
Country City Population Chlamydia Gonorrhea n Year Reference
Israel Tel Aviv FSWs (indoor) 6% 5% 300  [66]
Turkey Gazaniantep FSWs (registered) 5% — 92 1997–98 [134]
Turkey Ankara, Istanbul, Izmir FSWs (unregistered) 1.2% 2.8% 252 2006–07 [120]
United 
Kingdom
London FSWs incl. migrants 4% 2% 233 2008–09 [109]
Belgium Ghent FSWs incl. migrants 7% — 950 1998–2003 [93]
Italy Bologna Migrant FSWs 6% 1% 558 1995–99 [100]
Brescia Migrant FSWs 14% — 101 1998–2000 [29]
Spain Barcelona FSWs (street) 5% 4% 301 2002–03 [21]
Serbia 
(Kosovo)
Ferizaj, Prizren, 
Urosevac 
Migrant FSWs 
(street/indoor)
45% — 153 2006 [119]
Georgia Tblisi FSWs (street) 23% 18% 160 2002–06 [133]
Batumi FSWs (indoor) 22% 12% 160 2004–06 [133]
Note: FSWs = female sex workers; n = sample size; — = not available.
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table c.19 Demographic characteristics, Harms Associated with sex Work, and Hiv testing among samples of male and transgender sWs
Country City n Year
Recruitment 
location Population Age
Condom use 
with clients 
Condom use with 
nonpaying 
partners
Testing for 
HIV Violence Ref.
Netherlands Rotterdam, 
The Hague
70 2002–05 Drug relief center 
and community 
settings
Transgender Median = 
30 years 
(26–37)
Inconsistent = 
26%
Inconsistent = 81% 
(steady partners); 
50% (casual 
partners) 
82% ever 
tested
— [19]
Spain National 418 2002 22 HIV/STI 
counseling and 
testing clinics
MSW, 
Transgender 
(18%)
Mean = 
29.2 years; 
SD = 7.3 
years
— — 100% — [92]
1,935 2000–07 19 HIV/STI 
counseling and 
testing clinics
MSW, 
Transgender 
Mean = 29.7; 
SD = 7.8 
years
— — — — [131]
United 
Kingdom
London 636 1994–
2003
Targeted sexual 
health clinics
 Mean = 
25.4 years 
(15–59)
96% reported 
consistent 
condom use 
for anal sex 
with last 
4 clients
19% (10/52) 
unprotected 
vaginal sex; 
37% of MSW 
(128/319) did 
use condoms for 
anal sex with 
regular male 
partner
— — [86]
Belgium Antwerp 120 1999–
2004
Street, red light 
district
MSW (all 
transvestite or 
transsexual)
Median = 
26.5 years 
(12–58)
— 79.1% always 
used condoms 
for anal 
intercourse
— — [95]
table continues next page
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table c.19 Demographic characteristics, Harms Associated with sex Work, and Hiv testing among samples of male and transgender sWs (continued)
Country City n Year
Recruitment 
location Population Age
Condom use 
with clients 
Condom use with 
nonpaying 
partners
Testing for 
HIV Violence Ref.
Czech 
Republic
Cheb, Usti nad 
Labem, 
Ostrava, 
Prague
1,480  Community 
settings and via 
specialist 
project
MSW Mean = 
22.9 years 
(18–54)
— — — — [115]
Russian 
Federation
Moscow 50 2005–06 Community 
settings via 
RDS, outreach 
workers
MSW 36% aged 
between 
17–20 years
— — — 28% ever 
experienced 
violence 
from clients
[55]
Italy Brescia 85 2002–04 STI clinics Transgender mean = 
27.8 years
79% regular 
condom use
— — — [90]
Rome 65 1992–
2007
HIV clinics MSWs — 69% regular 
condom use 
with clients
— — — [91]
602 — — Transgender — 76% regular 
condom use 
with clients
— — — —
Note: HIV = human immunodeficiency virus; MSWs = male sex workers; n = sample size; RDS = respondent-driven sampling; ref. = reference; SD = standard deviation; STI = sexually transmitted infection; SW = sex worker; 
— = not available. 
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table c.20 Demographic characteristics, Harms Associated with sex Work, and Hiv testing among samples 
of FsWs in europe
Country City Year
Recruitment 
location
Location of 
sex work Age Drug use Migrants
Condom use 
with clients 
Condom use with 
non paying 
partners Violence HIV testing Ref.
No. 
studies
Greece Athens 2005 STI/HIV clinics Brothels 39.7 years 0% 19.7% Migrants 
(Albania, 
Bulgaria, Georgia, 
Romania, Russian 
Federation, 
Ukraine)
— — — Mandatory 
ever: 15 
days in 
order to 
obtain 
permit
[20] 1
Israel Tel Aviv, 2 sites — Community 
settings
Brothels 22–27 years — Mostly migrants 
from FSU
<5% reporting 
inconsistent 
condom use 
with clients
— — — [66] 2
Italy Brescia, Catania, 
Milan
1999–2003 Work settings and 
STI clinics
89%–100% 
street
23–38 years No IDU reported 91%–100% 
migrants
12–16% reported 
not using a 
condom with 
clients
 84% reported not 
using condoms 
with stable 
partner
— — [7, 29, 67] 3
Spain National 2000–05 STI clinics, SW 
services, work
31.4%–100% 
street
28–38 years <1% IDUs 83%–100% 
migrants
<5% reporting not 
using a condom 
with clients; 90% 
reporting non-
condom use 
with nonpaying 
partners
— — — [21, 27–28] 3
Netherlands Rotterdam, The 
Hague
2002–05 Drug relief center 
and community 
settings
24% Street 30 years No IDU reported 75% migrants 
(Africa, SE, LA)
inconsistent = 11% inconsistent = 89% 
(steady 
partners); 65% 
casual partners
— 82% ever 
tested
[19] 1
United 
Kingdom
London 2000–09 Clinics and work 
settings
70% indoors 26–27 years 4%–11% 
ever IDU
33%–60% migrants <1% did not use 
condom last 
time had vaginal 
sex with client 
or partner
 69.3% did not use 
condoms last 
time they had 
vaginal sex with 
a nonpaying 
partner
30.2% experience 
violence from 
clients in the 
last 12 months
37% tested for 
HIV in past 
12 months
[108–109] 2
Bosnia and 
Herzegovina
— 2007 Cross-sectional 
biobehavioral 
survey
HIV clinics — — — — — — 28.8% ever HIV 
tested; 13.6% 
tested in the 
past 12 
months
[111] 1
Bulgaria 8 cities 2008 Cross-sectional 
biobehavioral 
survey
— — — — — — — 58.3% report 
having a test 
and knowing 
the result
[113] 1
Croatia Split and Zagreb 2006–08 Community 
recruitment
46%–49% 
street
— 9.2%–55% IDUs — <5% reporting no 
condom at last 
commercial sex
— 30%–52% report 
physical abuse 
from client in 
last year
78.5%–91% 
ever tested 
for HIV
[54] 1
Czech Republic Cheb, Ostrava, 
Usti nad 
Labem
1999–2000 Community 
settings
— 24.8 years 10% ever IDUs 40% migrants — — — — [115] 1
table continues next page
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table c.20 Demographic characteristics, Harms Associated with sex Work, and Hiv testing among samples 
of FsWs in europe
Country City Year
Recruitment 
location
Location of 
sex work Age Drug use Migrants
Condom use 
with clients 
Condom use with 
non paying 
partners Violence HIV testing Ref.
No. 
studies
Greece Athens 2005 STI/HIV clinics Brothels 39.7 years 0% 19.7% Migrants 
(Albania, 
Bulgaria, Georgia, 
Romania, Russian 
Federation, 
Ukraine)
— — — Mandatory 
ever: 15 
days in 
order to 
obtain 
permit
[20] 1
Israel Tel Aviv, 2 sites — Community 
settings
Brothels 22–27 years — Mostly migrants 
from FSU
<5% reporting 
inconsistent 
condom use 
with clients
— — — [66] 2
Italy Brescia, Catania, 
Milan
1999–2003 Work settings and 
STI clinics
89%–100% 
street
23–38 years No IDU reported 91%–100% 
migrants
12–16% reported 
not using a 
condom with 
clients
 84% reported not 
using condoms 
with stable 
partner
— — [7, 29, 67] 3
Spain National 2000–05 STI clinics, SW 
services, work
31.4%–100% 
street
28–38 years <1% IDUs 83%–100% 
migrants
<5% reporting not 
using a condom 
with clients; 90% 
reporting non-
condom use 
with nonpaying 
partners
— — — [21, 27–28] 3
Netherlands Rotterdam, The 
Hague
2002–05 Drug relief center 
and community 
settings
24% Street 30 years No IDU reported 75% migrants 
(Africa, SE, LA)
inconsistent = 11% inconsistent = 89% 
(steady 
partners); 65% 
casual partners
— 82% ever 
tested
[19] 1
United 
Kingdom
London 2000–09 Clinics and work 
settings
70% indoors 26–27 years 4%–11% 
ever IDU
33%–60% migrants <1% did not use 
condom last 
time had vaginal 
sex with client 
or partner
 69.3% did not use 
condoms last 
time they had 
vaginal sex with 
a nonpaying 
partner
30.2% experience 
violence from 
clients in the 
last 12 months
37% tested for 
HIV in past 
12 months
[108–109] 2
Bosnia and 
Herzegovina
— 2007 Cross-sectional 
biobehavioral 
survey
HIV clinics — — — — — — 28.8% ever HIV 
tested; 13.6% 
tested in the 
past 12 
months
[111] 1
Bulgaria 8 cities 2008 Cross-sectional 
biobehavioral 
survey
— — — — — — — 58.3% report 
having a test 
and knowing 
the result
[113] 1
Croatia Split and Zagreb 2006–08 Community 
recruitment
46%–49% 
street
— 9.2%–55% IDUs — <5% reporting no 
condom at last 
commercial sex
— 30%–52% report 
physical abuse 
from client in 
last year
78.5%–91% 
ever tested 
for HIV
[54] 1
Czech Republic Cheb, Ostrava, 
Usti nad 
Labem
1999–2000 Community 
settings
— 24.8 years 10% ever IDUs 40% migrants — — — — [115] 1
table continues next page
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table c.20 Demographic characteristics, Harms Associated with sex Work, and Hiv testing among samples of 
FsWs in europe (continued)
Country City Year
Recruitment 
location
Location of 
sex work Age Drug use Migrants
Condom use 
with clients 
Condom use with 
non paying 
partners Violence HIV testing Ref.
No. 
studies
Kosovo Ferizaj/
Urosevac/
Prizren
2006 Clinic recruitment Street and 
indoor SWs
28 years 1.3% IDUs 
in past 
12 months
34% Bulgaria; 28% 
Albania; 16% 
Moldova; and 
9% Ukraine
38% never used 
condoms with 
clients in past 
30 days 
45% reported 
never using 
condoms with 
nonpaying 
partners in last 
12 months.
16% forced to have 
sex against their 
will in past 12 
months
40% ever 
tested for 
HIV
[119] 3
Romania Bucharest, 
Constanta, 
Timisoar
2008 Community 
settings via key 
informants
Street Range 
15–24 
years 
22.2% ever 
injected 
— 35% reported 
inconsistent 
condom use 
with clients in 
past 12 months
52–60% report not 
using condom 
with regular 
partner
46% forced to 
have sex in the 
last 12 months
52% ever 
tested for 
HIV
[135] 1
Serbia Belgrade 2006–10 Community 
recruitment
Street and 
indoor
— 12.8%–27% IDUs 42.5%–55.1% 
Roma
<11% reporting 
not using 
condom at last 
commercial sex
— — — [118, 136] 2
Turkey Gaziantep, 
Izimir, and 
Manisa
1997–2006 Clinic recruitment — 21–74 years 2% ever used 
illegal drugs
— 38% did not always 
use a condom 
with clients
— — — [16, 134] 3
Ankara, Istanbul, 
and Izmir
2006–07 Peer recruitment — — — — 29% did not use a 
condom with 
last client
— — — [120] 1
Armenia Yerevan 2007–08 Community 
settings
100% Street 33.7 years no illegal drugs; 
96.7% 
reported 
alcohol
— 32.5% inconsistent 
condom use in 
past 7 days for 
vaginal sex
— 30% ever forced 
to have sex
— [137] 1
Azerbaijan Baku 2003 Community 
settings
50% 64.5% aged 
20–30 
years
<1% used drugs 
in past month
4% migrants from 
Russian 
Federation
78% did not use 
condoms with 
clients
86% did not use 
condoms with 
regular partners
— 13% tested for 
HIV past 12 
months
[124] 1
Estonia Tallinn 2005–06 Community 
settings via 
RDS, TLS
— 29.5 years 6.6% IDUs — 25% did not always 
use condoms for 
vaginal and anal 
sex with clients
— — 65.5% had 
ever been 
tested for 
HIV
[36] 1
Georgia Batum, Tblisis 2002–09 Community 
setting
100% 21–32 years 6% IDU 10%–20% 10% inconsistent 
condom use 
with clients 
90% inconsistent 
with nonpaying 
partners; 19% 
did not use 
condom for 
last sex 
17.7%, 29%, 26.9% 
experience 
physical/sex 
violence during 
past year (Tblisi); 
13% physical 
violence 
(Batumi)
52% ever 
tested for 
HIV (Tblisi)
[78] 6
Lithuania Vilnius 2008 Women’s Health 
site at 
Lithuanian AIDS 
Center
— 27.5 years — — 8% did not use a 
condom with 
last client
  53.4% had 
been tested 
for HIV in 
past 12 
months and 
knew result
[126] 1
table continues next page
Systematic Review and Summary Tables 309
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8 
table c.20 Demographic characteristics, Harms Associated with sex Work, and Hiv testing among samples of 
FsWs in europe (continued)
Country City Year
Recruitment 
location
Location of 
sex work Age Drug use Migrants
Condom use 
with clients 
Condom use with 
non paying 
partners Violence HIV testing Ref.
No. 
studies
Kosovo Ferizaj/
Urosevac/
Prizren
2006 Clinic recruitment Street and 
indoor SWs
28 years 1.3% IDUs 
in past 
12 months
34% Bulgaria; 28% 
Albania; 16% 
Moldova; and 
9% Ukraine
38% never used 
condoms with 
clients in past 
30 days 
45% reported 
never using 
condoms with 
nonpaying 
partners in last 
12 months.
16% forced to have 
sex against their 
will in past 12 
months
40% ever 
tested for 
HIV
[119] 3
Romania Bucharest, 
Constanta, 
Timisoar
2008 Community 
settings via key 
informants
Street Range 
15–24 
years 
22.2% ever 
injected 
— 35% reported 
inconsistent 
condom use 
with clients in 
past 12 months
52–60% report not 
using condom 
with regular 
partner
46% forced to 
have sex in the 
last 12 months
52% ever 
tested for 
HIV
[135] 1
Serbia Belgrade 2006–10 Community 
recruitment
Street and 
indoor
— 12.8%–27% IDUs 42.5%–55.1% 
Roma
<11% reporting 
not using 
condom at last 
commercial sex
— — — [118, 136] 2
Turkey Gaziantep, 
Izimir, and 
Manisa
1997–2006 Clinic recruitment — 21–74 years 2% ever used 
illegal drugs
— 38% did not always 
use a condom 
with clients
— — — [16, 134] 3
Ankara, Istanbul, 
and Izmir
2006–07 Peer recruitment — — — — 29% did not use a 
condom with 
last client
— — — [120] 1
Armenia Yerevan 2007–08 Community 
settings
100% Street 33.7 years no illegal drugs; 
96.7% 
reported 
alcohol
— 32.5% inconsistent 
condom use in 
past 7 days for 
vaginal sex
— 30% ever forced 
to have sex
— [137] 1
Azerbaijan Baku 2003 Community 
settings
50% 64.5% aged 
20–30 
years
<1% used drugs 
in past month
4% migrants from 
Russian 
Federation
78% did not use 
condoms with 
clients
86% did not use 
condoms with 
regular partners
— 13% tested for 
HIV past 12 
months
[124] 1
Estonia Tallinn 2005–06 Community 
settings via 
RDS, TLS
— 29.5 years 6.6% IDUs — 25% did not always 
use condoms for 
vaginal and anal 
sex with clients
— — 65.5% had 
ever been 
tested for 
HIV
[36] 1
Georgia Batum, Tblisis 2002–09 Community 
setting
100% 21–32 years 6% IDU 10%–20% 10% inconsistent 
condom use 
with clients 
90% inconsistent 
with nonpaying 
partners; 19% 
did not use 
condom for 
last sex 
17.7%, 29%, 26.9% 
experience 
physical/sex 
violence during 
past year (Tblisi); 
13% physical 
violence 
(Batumi)
52% ever 
tested for 
HIV (Tblisi)
[78] 6
Lithuania Vilnius 2008 Women’s Health 
site at 
Lithuanian AIDS 
Center
— 27.5 years — — 8% did not use a 
condom with 
last client
  53.4% had 
been tested 
for HIV in 
past 12 
months and 
knew result
[126] 1
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table c.20 Demographic characteristics, Harms Associated with sex Work, and Hiv testing among samples of 
FsWs in europe (continued)
Country City Year
Recruitment 
location
Location of 
sex work Age Drug use Migrants
Condom use 
with clients 
Condom use with 
non paying 
partners Violence HIV testing Ref.
No. 
studies
Moldova Kishinev 2003–10 Community 
recruitment, 
RDS
100% 23–25 years 11.2% IDUs 99% migrants from 
Russian 
Federation
17% did not use 
condom with 
last client
 53.4% experience 
violence or 
have been 
threatened 
by client
13.9% tested 
for HIV over 
last 12 
months
[124, 127] 2
Russian 
Federation 
Chelyabinsk, 
Ekaterinburg, 
Irkutsk, 
Moscow, 
Samara, 
Saratov
2001–03 Community 
recruitment, 
RDS
Mostly street 20–25 years 4.8%–14% ever 
injecting 
7%–100% internal 
migrants
0%–32.4% did not 
use a condom 
with last client 
— 19.7%–76% 
reporting some 
kind of sexual or 
physical 
violence from a 
client in the last 
year
37.8%–57% 
ever tested 
for HIV
[52, 124, 138] 5
Ukraine National 2003–09 Community via 
NGOs 
Mostly street 23.1 years 71% ever IDU; 
59% regular
— 12%–44% did not 
use a condom 
for last sexual 
contact
— — 59% tested for 
HIV in past 
12 months 
and know 
results
[129, 139] 2
2009 TLS 43.4% street 26 years 24% ever used 
drugs; 15% 
IDU in last 30 
days
39% internal 
migrants
10% did not use 
condom for last 
sexual act with 
client
42% did not use 
condom for last 
sexual act with 
permanent 
partner
— 56% tested for 
HIV in past 
12 months 
and know 
results
[130] —
Uzbekistan Samarkand and 
Tashkent
2003–05 Community 
settings via 
NGOs
2.3%–47.5% 
street
25–27 years 5.30% — — — — 83.9% ever 
tested for 
HIV
[85, 140] 2
Kyrgyz Republic Bishkek and Osh 2006–09 Community 
settings
— 25–26 years 0.4%–5.0% IDUs — <20% reporting 
noncondom use 
with clients for last 
sex act; 20%–50% 
reporting non-
condom use with 
regular partner 
— — 42.5%–55.7% 
tested in 
past 12 
months 
voluntarily
[88] 4
Kazakhstan Multisites 2006–09 Community 
settings
— 25–27 years 7.1%–9.8% IDUs — <20% reporting 
noncondom use 
with clients for last 
sex act; 20%–50% 
reporting 
noncondom use 
with regular 
partner 
— — 61.2%–76.4% 
tested in 
past 12 
months 
voluntarily
[88] 4
Tajikistan Multisites 2006–09 Community 
settings
— 26–31 years 4.0%–6.3% IDUs — <30% reporting 
noncondom use 
with clients for 
last sex act
— — 26.7%–55.0% 
tested in 
past 12 
months
[88] 4
Note: FSWs = female sex workers; FSU = former Soviet Union; HIV = human immunodeficiency virus; IDUs = injecting drug users; 
LA = Latin America; NGOs = non government organizations; RDS = respondent-driven sampling; Ref. = reference; SE = standard error; 
STIs = sexually transmitted infections; SW = sex worker; TLS = time location sampling; — = not available.
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table c.20 Demographic characteristics, Harms Associated with sex Work, and Hiv testing among samples of 
FsWs in europe (continued)
Country City Year
Recruitment 
location
Location of 
sex work Age Drug use Migrants
Condom use 
with clients 
Condom use with 
non paying 
partners Violence HIV testing Ref.
No. 
studies
Moldova Kishinev 2003–10 Community 
recruitment, 
RDS
100% 23–25 years 11.2% IDUs 99% migrants from 
Russian 
Federation
17% did not use 
condom with 
last client
 53.4% experience 
violence or 
have been 
threatened 
by client
13.9% tested 
for HIV over 
last 12 
months
[124, 127] 2
Russian 
Federation 
Chelyabinsk, 
Ekaterinburg, 
Irkutsk, 
Moscow, 
Samara, 
Saratov
2001–03 Community 
recruitment, 
RDS
Mostly street 20–25 years 4.8%–14% ever 
injecting 
7%–100% internal 
migrants
0%–32.4% did not 
use a condom 
with last client 
— 19.7%–76% 
reporting some 
kind of sexual or 
physical 
violence from a 
client in the last 
year
37.8%–57% 
ever tested 
for HIV
[52, 124, 138] 5
Ukraine National 2003–09 Community via 
NGOs 
Mostly street 23.1 years 71% ever IDU; 
59% regular
— 12%–44% did not 
use a condom 
for last sexual 
contact
— — 59% tested for 
HIV in past 
12 months 
and know 
results
[129, 139] 2
2009 TLS 43.4% street 26 years 24% ever used 
drugs; 15% 
IDU in last 30 
days
39% internal 
migrants
10% did not use 
condom for last 
sexual act with 
client
42% did not use 
condom for last 
sexual act with 
permanent 
partner
— 56% tested for 
HIV in past 
12 months 
and know 
results
[130] —
Uzbekistan Samarkand and 
Tashkent
2003–05 Community 
settings via 
NGOs
2.3%–47.5% 
street
25–27 years 5.30% — — — — 83.9% ever 
tested for 
HIV
[85, 140] 2
Kyrgyz Republic Bishkek and Osh 2006–09 Community 
settings
— 25–26 years 0.4%–5.0% IDUs — <20% reporting 
noncondom use 
with clients for last 
sex act; 20%–50% 
reporting non-
condom use with 
regular partner 
— — 42.5%–55.7% 
tested in 
past 12 
months 
voluntarily
[88] 4
Kazakhstan Multisites 2006–09 Community 
settings
— 25–27 years 7.1%–9.8% IDUs — <20% reporting 
noncondom use 
with clients for last 
sex act; 20%–50% 
reporting 
noncondom use 
with regular 
partner 
— — 61.2%–76.4% 
tested in 
past 12 
months 
voluntarily
[88] 4
Tajikistan Multisites 2006–09 Community 
settings
— 26–31 years 4.0%–6.3% IDUs — <30% reporting 
noncondom use 
with clients for 
last sex act
— — 26.7%–55.0% 
tested in 
past 12 
months
[88] 4
Note: FSWs = female sex workers; FSU = former Soviet Union; HIV = human immunodeficiency virus; IDUs = injecting drug users; 
LA = Latin America; NGOs = non government organizations; RDS = respondent-driven sampling; Ref. = reference; SE = standard error; 
STIs = sexually transmitted infections; SW = sex worker; TLS = time location sampling; — = not available.
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table c.21 summary of Hiv incidence and prevalence estimates among msm in Western europe
Country City # studies Study year Recruitment location Population sample
HIV Prevalence 
range
“Best” HIV 
prevalence HIV Incidence Reference
Belgium National 3 2002–10 Anonymous testing 
sites; gay venues
MSM 1.90%–6.06% 6.06% — [57, 86, 87]
France National 2 2004–09  VCT sites; gay venues MSM 2.0%–17.70% 17.70% — [57, 60]
Italy Rome, 
Verona
2 2000–09 HIV testing center; 
community settings
MSM 11.80% 11.80% IR 4.97/100 PY [21, 31]
Netherlands National 4 1999–2004 HIV testing center; 
community settings
MSM, Dutch speaker 2.80%–4.20% 4.20% IR 1.2–3.8/100 PY [10–12, 88]
Portugal Lisbon 1 2002 STI clinics MSM 6.40% 6.40% — [57]
Spain National 5 2003–09 Gay venues; mail to 
members of a LGBT 
association; VCT 
clinics
MSM 1.60%–19.80% 5.50% — [5, 7, 21, 57, 61] 
Switzerland National 3 1996–2006 Anonymous VCT MSM 1.60%–3.40% 1.60% — [8, 9, 57]
United 
Kingdom
National 11 1999–2007 Gay venues; online; 
sexual health clinics
MSM, Central and Eastern 
European MSM
3.10%–13.70% 9.10% — [14, 16, 57, 65, 66, 
83, 89–93]
Note: HIV = human immunodeficiency virus; IR = incidence rate; LGBT = lesbian, gay, bisexual, transgender; MSM = men who have sex with men; PY = person-year; STIs = sexually transmitted infections; 
VCT = voluntary counseling and testing; — = not available. 
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table c.22 summary of Hiv incidence and prevalence estimates among msm in central europe
Country City # studies Study year Recruitment location
Population 
sample HIV Prevalence
“Best” HIV 
prevalence
HIV 
Incidence Reference
Albania Tirana 2 2005–08 Community MSM 0.80%–1.80% 1.80% — [23, 94]
Bosnia and 
Herzegovina
 Unclear 1 2007 Unclear MSM 0.70% 0.70% — [33]
Bulgaria  National 1 2008 Gay venues MSM 3.32% 3.32% — [34]
Croatia National 3 2006 Community; gay venues MSM, HIV− men 3.30%–4.60% 4.5% — [35–37]
Czech Republic Prague 2 2004–09 Community; gay venues MSM 0.5%–2.60% 2.60% — [21, 57]
Hungary Budapest 2 2007–09 Community MSM 2.60%–10.40% 10.40% — [22, 38]
Macedonia, FYR National 1 2007 Community MSM 0% 0.00% — [39]
Poland National 1 2004 Community MSM 4.70% 4.70% — [40]
Romania Bucharest 1 2008–09 Gay venues MSM 4.60% 4.60% — [21]
Serbia  Belgrade, 
Novi Sad, Pristina
2 2006–10 Community MSM 0%–4.25% 4.25% — [41, 42]
Slovak Republic Bratislava 1 2008–09 Gay venues MSM 6.10% 6.10% — [21] 
Slovenia Ljubljana 2 2008–09 Gay venues MSM 0.90%–5.10% 5.10% — [21, 43]
Turkey Ankara, Istanbul, 
Izmir
1 2006–07 Community MSM 1.8% 1.80% — [18]
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men; — = not available. 
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table c.23 summary of Hiv incidence and prevalence estimates among msm in eastern europe
Country City # studies Study year Recruitment location
Population 
sample HIV Prevalence
“Best” HIV 
prevalence
HIV 
Incidence Reference
Armenia Unclear 1 2007 Unclear MSM 2% 2% — [44]
Azerbaijan Baku 1 2007–08 Community settings MSM 1% 1% — [45]
Belarus National 2 2006–09 Sentinel surveillance MSM 0.17%–2.10% 0.17% — [95, 96]
Estonia Tallinn 1 2008 Health and community services MSM 2.50% 2.50% — [48]
Georgia Tbilisi 1 2007 RDS MSM 3.70% 3.70% — [49]
Kazakhstan Unclear 2 2007–09 Community, sentinel 
surveillance
MSM 0.20%–0.30% 0.20% — [59, 97]
Kyrgyz Republic Unclear 1 2007–08 Community settings MSM 1.2% 1.20% — [59]
Lithuania Unclear 1 2009 Unclear MSM 2.7% 2.70% — [51]
Moldova Chisinau 1 2007 Unclear MSM 4.80% 4.80% — [52]
Russian Federation 7 cities 5 2003–09 Community settings MSM 0%–18% 6.39% — [20, 22, 54, 58, 98, 99]
Ukraine National 1 2009 Community settings MSM 1.50%–21.70% 8.60% — [55]
Uzbekistan National 1 2009 Unclear MSM 6.80% 6.80% — [56]
Note: HIV = human immunodeficiency virus; MSM = men who have sex with men; RDS = respondent-driven sampling; — = not available.
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table c.24 Demographic characteristics of study respondents in Western europe
Country Age Country of origin Education
Income/ 
employment HIV test previous
STI incidence/ 
prevalence Violence References
Belgium Mean 
31.3 years
— — — Ever 88%; 12 m: 
52.2%
— — [87]
France Median 
38 years
Metropolitan France 
83%; elsewhere 17%; 
visible minority 7.6%
High school/University: 
64%–65%
— Ever 86.2% Self-report 12 m: 
8.8%–20.4%
— [60, 84]
Israel Mean 
26–27 years
90.7% Israeli born High school/University: 
53%–65%
Above average 
income 54%
Ever: 64% — — [17, 85]
Italy Median 
35 years
— — — 12 m: 53% tested 
and know result
— — [21, 31]
Netherlands Median 28–39 
years; mean 
36 years
Netherlands 
87.2%–93.2%
Low-level: 9–21%; 
medium: 33%–40%; 
high: 38%–58%
— Ever: 63.4% Gonorrhea 5.7–
6/100 PY; Syphilis 
1.4–5.4 /100 PY
— [10–12, 88]
Norway — — — — Ever: 74.7%; 12 m: 
56% tested and 
know result
— — [100]
Spain Median 31–38 
years; mean 
41 years
Spanish 9%–79.7%; 
Latin American 
11.5%–77%; Eastern 
European 4%–5%; 
Western European 
2%; North African 2% 
High school or less: 
47%–52%; 
university: 48%–54%
Employed: 
61%–69%; 
self-
employed: 
12%–14%; 
student: 
10%–20%
Ever: 63%–86.8%; 
12 m: 46%–56% 
tested and 
know result
12 m: Syphilis 
2%–5%; 
Gonorrhea 5%; 
chlamydia 3%; 
Herpes 2%; Public 
lice 8%; genital 
warts 2%
12 m: 10.7%–
11% victim 
of 
aggression 
or verbal 
assaults
[5–7, 21, 61, 
81]
Switzerland Mean 33 years Switzerland 73.6%–
77%; other European 
15.7%–16.7% 
— — — — — [8, 9, 82]
United 
Kingdom
Median 27–39 
years; mean 
35 years
White 85%–96.7% No qualification 
12%–19%, 
secondary 
17%–23%, further/ 
vocational 36%, 
university 47%–54%
Employed 
77%–84%, 
student 
5%–8%, 
unemployed 
8%–18%
Ever: 59%–90.1%; 
12 m: 
34%–50.8%
Any 12 m 36%–45.7%, 
gonorrhea 9%–
27%, chlamydia 
10%–19%, warts 
8%–9%, syphilis 
1%–7%, pubic lice 
6%–11%, herpes 
3%–4%
 [14–16, 65, 
66, 83, 91, 
101–103]
Note: HIV = human immunodeficiency virus; m = months; PY = person-year.; STIs = sexually transmitted infections; — = not available. 
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table c.25 Demographic characteristics of study respondents in central europe
Country Age Country of origin Education Income/employment HIV test previous STI incidence/prevalence References
Albania 44% <25 years — 26.1% did not attend school — — Syphilis 2.6%; HCV 3.5% [23] 
Bulgaria — — — 12 m: 42% tested and 
know results
— [34]
Croatia Median 27 years — 57%–61% secondary; 
36%–39% university
— Ever 48%–57% Syphilis 13.2%; gonorrhea 
13.1%; chlamydia 9%
[26, 35]
Czech Republic Mean 28 years — University 27% — 12 m testing and 
received result 42%
— [21]
Hungary — Non-Hungarians 
excluded
Mean 28%–29%; 44% high 
school; 40% university/ 
vocational; 15.3 years in 
education
72%–88% employed: 
61% “white collar,” 
16% “blue collar”
— All 4.3% [22]
Macedonia, FYR — — — — 12 m: 56% tested and 
know results
— [39]
Romania Median 25 years — — — 12 m: 43.2% tested 
and know result
—  [21]
Serbia — — — 12 m: 31% tested and 
know results
— [41]
Slovak Republic Median 28 years — — — 12 m: 32% tested and 
know results
—  [21]
Slovenia Median 30 years — — — 12 m: 38% tested and 
know results
— [21] 
Turkey Median 26 years 93% Turkish 5% Just literate; 11% 
primary; 11% secondary; 
58% higher; 14% still 
studying
— — Prevalence HBV 3.6%; 
syphilis 10.8%; gonorrhea 
3%; chlamydia 1.8%
[18]
Note: HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; m = months; STIs = sexually transmitted infections; — = not available. 
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table c.26 Demographic characteristics of study respondents in eastern europe and central Asia
Country Age Country of origin Education Income/employment HIV test previous
STI incidence/ 
prevalence Violence References
Azerbaijan — — — — — Syphilis 8%; 
HCV 14% 
 [45]
Estonia Median 
30 years
Estonia 71%, 
Russian 
Federation 21% 
<secondary 13%; 
secondary 18%; 
vocational 18%; 
post-secondary 
51%
≤7,500 EEK pa 34%; 
7,500 EEK+ 66%
Ever: 67% — — [19]
Georgia Median 
27 years
Georgia 83.4%; 
Armenia 3.6%; 
Russian 
Federation 
3.6%
57% secondary; 
56% post-
secondary
— Ever: 41% tested 
and knows 
results
Syphilis 31.4%; 
HCV 15.7%
Ever experienced 
violence because of 
sexual orientation 
21%: physical 14%; 
verbal 12%; sexual 7%
[25]
Kazakhstan Median 
27 years
Kazakhstan 26.4%; 
Russian 
Federation 
63.6%
Elementary 7%; 
secondary 54%; 
higher 39%
Median income 
US$324; no income 
8%; no certain 
occupation 4%
12 m: 40% tested 
and knows the 
results
Syphilis 4.1%, 
HCV 4.2%; 12 m 
suspected: 8.3%
— [59, 76]
Kyrgyz 
Republic
Median 
24 years
Kyrgyz Republic 
43.8%; Russian 
Federation 
63.6%
Elementary 5%, 
secondary 40%; 
higher 56%
Median income 
US$114; no income 
13%; no certain 
occupation 18%
12 m: 24%–52% 
tested and 
knows results
Prevalence syphilis 
10.7%; HCV 
1.2%; 12 m: 
suspected 13.7%
— [59, 76]
Lithuania — — — — 12 m: 41% tested 
and knows 
result
— — [51]
table continues next page
318 
table c.26 Demographic characteristics of study respondents in eastern europe and central Asia (continued)
Country Age Country of origin Education Income/employment HIV test previous
STI incidence/ 
prevalence Violence References
Russian 
Federation
Mean 
28 years
Russian Federation 
62%
Middle school 
34%; high 
school 24%; 
mean 
15.3 years 
in education
72% permanently 
employed; 
18%–40% currently 
studying
— 10.5% syphilis; 12%, 
HPV 8%, HSV-2 
4%, HCV 8%
Male SW sample: 
ever violence from 
clients 28%
[20, 22]
Tajikistan Tajikistan 65.9%; 
Uzbekistan 
26.8%; Russian 
Federation 7%
— — 12 m: 2.8% tested 
and knows 
results
12 m suspected: 
4.2%
— [76]
Ukraine Median 
27 years
— Completed 
secondary 
school or 
higher 92%
— 12 m: tested and 
knows results 
43%; 6 m: 35%
— — [24, 55]
Note: EEK = Estonian Kroon; HCV = hepatitis C virus; HIV = human immunodeficiency virus; HPV = human papilloma virus; HSV-2 = herpes simplex virus 2; m = months; STIs = sexually transmitted infections; 
SW = sex worker; — = not available. 
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table c.27 sexual and Drug Use characteristics of msm in Western europe
Country UAI
Condom use 
at last AI 
Other risk (reduction) 
practices
Partner types and 
numbers Alcohol/drugs Sex work References
Belgium — c 72.1%, 
r 38.1%
— — 12 m: alcohol 46.4%; poppers 
36.3%; ecstasy 14.7%; 
cocaine 13.1%; Viagra 
12.2%; GHB/GBL 9.7%; 
cannabis 8.5%; speed 6.4%; 
methamphetamine 1.4%
— [87]
France c (HIV discordant or 
unknown) 23.5%
— 12 m: Barebacked 30.5%; 
esoteric sexual practice 
41.8%
12 m: mean 18.1; 
median 6; 9.5% 
1 partner; 77.9% 
2–50, 12.6% 50+
— 12 m: sold sex 
8.1%
[60, 84]
Israel 6 m: 23% — 12% sex with males and 
females
— 6 m: 53% none, of those 
who use, alcohol 47%; 
marijuana 28%; poppers 
27%; Viagra 11%; ecstasy 
9%; 33% used 2 or more 
drugs
Paid for sex 
11%
[17, 85]
Italy 6 m: anal sex c 45.9%, r 59.8%; 
oral sex c 91.9%, r 94.2%
45.6% — 6 m: c median 6, r 1 6 m: before/during sex: 
alcohol 54.2%; poppers 
21.6%; ecstasy 3%; Viagra 
8.6%; marijuana 13.4%; 
cocaine 8.3%; 
amphetamine 1.9%
— [21, 31]
Netherlands 6 m: anal sex c 15.1%, oral sex 
r 26.1%; c and r 11.6%
— — 6 m: 8 — — [10–12, 88]
Norway 6 m: c 24% — — — — — [100]
table continues next page
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table c.27 sexual and Drug Use characteristics of msm in Western europe (continued)
Country UAI
Condom use 
at last AI 
Other risk (reduction) 
practices
Partner types and 
numbers Alcohol/drugs Sex work References
Spain 12 m: c 23%–31%, r 55%; 
c <30 years 41%, 30+ 34%; 
r <30 years 69%, 30+ 60%
33%–57%; — 6 m: median 6; 
12 m: 10+ 64%; 
12 m: 9.8% 
female partner
12 m: before/during sex: none 
36%; alcohol 64%; 
marijuana 26%; cocaine 
19%; amphetamine 5%; 
poppers 41%; Viagra 13%; 
ketamine 5%; 
methamphetamine 3%. # 
drugs used: none 44%; 1–3 
46%; 4%–6 8%, 7+ 2%
12 m: 4.1% 
charged for 
sex; Valencia 
study 
recruited 
from SW 
apartments
[5–7, 21, 61, 81]
Switzerland Ever 98%; c 45.7%; 12 m: 
32.6% (HIV+ 52.4%, 
HIV− 31%)
— 24%–73.8% used such 
practice intentionally; 
50% practiced sorting; 
33% strategic 
positioning; 62% 
withdrawal before 
ejaculation; 53% used 1 
of the 3 practices; 38%: 
used 2; and 9% used all 3.
12 m: anal sex: none 
32.8%; 1 20.4%; 
2–3 23.4%; 4–10 
15.4%; 10+ 8%; 
24 m: 0–1 7.9%; 
2–5 42.4%; 
6+ 46.4%
— — [8, 9, 82]
United 
Kingdom
24 m: any receptive: 55%–
83%; >1 partner 26%–60%, 
>5 partners 6%–27%; 
r 38–59%; c 25%–55%; any 
insertive: 61%–76%; >1 
partner 30%–65%; >5 
partners 13%–27%; 12 m: 
0–1 partner 86%; 2+ 14%; 
c 10%; UAI with partners of 
unknown or discordant 
status: 26%
— — 12 m: female 
partner 12.2%; 
12 m: 10+ 
partners 10.7%–
11.3%; 13+ 
24.8%; 30+ 
16.7%
12 m: any 59.9%; poppers 
44%; marijuana 32%; 
ecstasy 34%; cocaine 22%; 
ketamine 13%; 
amphetamine 9.4%; GHB 
5.4%; methamphetamine 
4.7%; LSD 3.5%; crack 2.1%; 
heroin 1%
Paid for sex 
with a man 
15% 
(London 
based); 9.8% 
(elsewhere)
[14–16, 65, 66, 
83, 91, 
101–103]
Note: AI = anal intercourse; c = casual partner; HIV = human immunodeficiency virus; HIV+ = HIV-positive; HIV– = HIV-negative; GBL = gamma-Butyrolactone; GHB = gamma hydroxybutyric acid; LSD = lysergic acid 
diethylamide; m = months; MSM = men who have sex with men; r = regular partner; SW = sex worker; UAI = unprotected anal intercourse; — = not available. 
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table c.28 sexual and Drug Use characteristics of msm in central europe
Country UAI Condom use at last AI Partner types and numbers Alcohol/drugs Sex work References
Albania 6 m: commercial 42%; 
noncommercial 56%
6 m: commercial: 77%; 
noncommercial 60% 
Female partners: ever 50%; of 
whom 84% in 6 m, and 71% 
having had 1–3 female 
partners.
42% daily alcohol; 65% have 
ever tried drugs; 59% 
inject, heroin most popular
6 m: 74% AI with 
commercial 
partner.
[23]
Male partners: 6 m: >50% 
insertive MSM have 4+ 
partners; 34.2% have 5+ 
noncommercial partners
Bulgaria — c 70.4% — — — [34]
Croatia 12 m: 1+ c 46%–60% c 58%, r 37–44%; (29% 
never had a c)
Female partner: ever 52%–
53%; current 7%. Male 
partners: 6 m: median 3; 
12 m: none 23.4%; 1 20.5%; 
2–3 17.5%; 4–7 5%; 8+ 5.6%
12 m: drugs before sex 33%; 
alcohol before sex 51%
Ever sold sex 5% [26, 35]
Czech Republic 6 m: c 64%; r 74% 30%  6 m: median 4 6 m: before/during sex: 
alcohol 85%; poppers 38%, 
ecstasy 11%, Viagra 13%, 
marijuana 24%, cocaine 
5%, amphetamine 9%
— [21]
Hungary 3 m: 72%: c 28%, r 
57.6%: with multiple 
partners 24.6%
All 49.6%; c 74%, 
r 35.3%, 
Female: ever 96.8%, 12 m: 
96.2%. Male median 4.9
— 12 m: 5.1% paid 
for sex
[22]
Macedonia, FYR — Last AI: 57% — — — [39]
Romania 6 m: c 48%, r 57% 42.7%  6 m: median 3 6 m: before/during sex: 
alcohol 62%; poppers 21%; 
ecstasy 8%; Viagra 5%; 
marijuana 12%; cocaine 
6%; amphetamine 3%
— [21]
table continues next page
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table c.28 sexual and Drug Use characteristics of msm in central europe (continued)
Country UAI Condom use at last AI Partner types and numbers Alcohol/drugs Sex work References
Serbia — 67% — — — [41]
Slovak Republic 6 m: AI: c 58%, r 80% 31%  6 m: median 3 6 m: before/during sex: 
alcohol 84%; poppers 34%; 
ecstasy 8%; Viagra 9%; 
marijuana 13%; cocaine 
5%; amphetamine 4%
— [21]
Slovenia 6 m: AI: c 41%, r 63%. I43%  6 m: median 3 6 m: before/during sex: 
alcohol 70%; poppers 50%; 
ecstasy 11%; Viagra 10%; 
marijuana 19%; cocaine 
10%; amphetamine 10%
— [21] 
Turkey — Ever: always 30%; 
almost always 7%; 
sometimes 12%; 
never 4%; do not 
know/no answer 
46%
Female partner: ever 36%; 
male partner: 0 8%; all sex in 
past 6 m: ins. 1 8.4%; ins. >1 
7.2%; rec. 1 6%; rec. >1 
10.2%; rec. and ins. 8.4%; 
rec. and ins. >1 28.9%
— 44% sold sex, 
both ins. and 
rec. with >1 
partner 37%; 
rec. only 16%; 
ins. only 16% 
[18]
Note: AI = anal intercourse; c = casual partner; ins. = insertive; MSM = men who have sex with men; m = months; r = regular partner; rec. = receptive; UAI = unprotected anal intercourse; — = not available. 
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table c.29 sexual and Drug Use characteristics of msm in eastern europe and central Asia
Country UAI Condom use at last AI Partner types and numbers Alcohol/drugs Sex work Ref.
Estonia 12 m: 49% 56%  30 d: none 6%; 1 or less/week 49%; more 
than 1/week 42%; every day 4%; illicit 
drug use: none 57%; not regular 37%; 
frequent/regular 7%
 [19]
Georgia 12 m: all 65%, commercial 
partners (male and 
female) 72% 
All 62%, male 
commercial partner 
38%
Female partners: 12 m: c 47%; 
Commercial: 18%. Male partners: 
1–5 69.3%; 6–10 15%; 11+ 15.7%
Daily alcohol 5%; any drugs 39%; 
marijuana 89%; Subutex 22%; injected 
24%; none with a used needle 
12 m: sold 
to a man 
21%
[25]
Kazakhstan All 57.1%; c 79%, r 52%; 
commercial 
partner 78%
3 m: 0 1%; 1 18%; 2+ 81%; 12 m: 
mean: all 10.3; male 9.4; female 0.9
Ever injected 2.1%; mean age at first 
injection 15.9 years; of injectors, 
injected daily in past 6 m: 25%
 [59, 76]
Kyrgyz 
Republic
— All 47.8%; c 54%, r 58%; 
commercial partner 
100%
3 m: 0 1%, 1 17%; 2+ 82%; 12 m: 
mean: all 10.2; male 7.9; female 2.5
Ever injected 1.0%; mean age at first 
injection, 23 years: of injectors, 
injected daily in past 6 m: none
— [59, 76]
Lithuania — 47% — — — [51]
Russian 
Federation
3 m: any UAI 53%; c 16%, 
r 45%; multiple 
partners 16%
44.2% 12 m: 24% male and female partners 30 d: alcohol 92%–96% (male mean 6.6 
days, median 5 days; 41% were drunk); 
poppers 21%; marijuana/hash 15%; 
amphetamines 4%; injecting <1%–8%
12 m: 16% 
paid for 
sex
[20, 22]
Tajikistan 12 m: c 70.3%, r: 97.2%; 
commercial 96.4%
24.9% 12 m: mean (median) all 74.7(26), 
male 69 (23), female 6.6 (1)
Ever injected 4.5%; mean age at first 
injection 17.2 years; of injectors, 
injected daily in past 6 m: 23.1%
— [76]
Ukraine — r 55%, c 82%, 
commercial 
partners 80%.
Female partners 6 m: 29%; 
6 m: median: 4
30 d: alcohol 86%; daily alcohol 8%;1–2 
times weekly 43%; current drug use 
5%; IDU 1%
6 m: 21% 
paid 
for sex
[24, 55]
Note: AI = anal intercourse; c = casual partner; d = days; IDU = injecting drug user; m = months; MSM = men who have sex with men; r = regular partner; Ref. = reference; UAI = unprotected anal intercourse; 
— = not available. 
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table c.30 summary of multivariate studies for Hiv incidence risk Factors among msm in europe
Study, year Location Sample
Individual-level 
risk factors 
Environmental-level 
risk factors
Van der Bij et al. 
2005 [11]
Netherlands, 
Amsterdam
603 HIV− men in cohort ≤30 years 
until age 35 (ACS, see below)
UAI with casual 
partner
Educationa
Dukers et al. 
2007 [12]
Netherlands, 
Amsterdam
3,733 HIV− men in cohort recruited 
from STI clinics
STI coinfection;
history of HIV testing
Age
Nationality
Netherlands, 
Amsterdam
1,498 HIV− men in cohort recruited 
from community (ACS, see above)
STI coinfection Age
Nationalitya
Netherlands, 
Rotterdam
265 HIV− men in cohort recruited 
from community
STI coinfection Age
Nationality
Note: ACS = Amsterdam Cohort Studies; HIV = human immunodeficiency virus; MSM = men who have sex with men; STIs = sexually transmitted 
infections; UAI = unprotected anal intercourse.
a. Adjusted for age, education, ethnicity, and employment status.
table c.31 summary of multivariate studies for Hiv prevalence risk Factors among msm in europe
Study, year Location Sample Individual-level risk factors 
Environmental-
level risk factors
Prasad et al. 
2009 [9]
Switzerland, 
5 cities
10,103 men attending 
anonymous HIV testing;
knowledge of HIV infected 
partnera;
condom use with 
occasional partnera;
history of STIsa
Number of partners in past two yearsa Agea
Nationalitya
Year of testing
Dodds et al. 
2007 [66]
United Kingdom, 
London
1,436 men recruited at 
gay venues
Attended GUM in past yeara;
STI in past yeara;
UAI with >1 partner in past yeara;
UAI with casual partners in past yeara;
UAI with partners of unknown or 
discordant status in past yeara
Employmenta
Educationa
Dodds et al. 
2007 [66]
United Kingdom, 
Brighton
373 men recruited at 
gay venues
Attended GUM in past yeara;
STI in past yeara;
UAI with >1 partner in past yeara;
UAI with casual partners in past yeara;
UAI with partners of unknown or 
discordant status in past year
Employmenta
Education
Dodds et al. 
2007 [66]
United Kingdom, 
Manchester
348 men recruited at 
gay venues
Attended GUM in past yeara;
STI in past year;
UAI with >1 partner in past year;
UAI with casual partners in past year;
UAI with partners of unknown or 
discordant status in past year
Employment
Education
Macdonald 
et al. 2008 
[15]
United Kingdom, 
London, 
Brighton, 
Manchester
232: 75 cases, 157 
controls recruited from 
sexual health clinics
Ancillary sexual behaviorsa;
STIsa;
Substance usea;
Venues used to 
meet mena
Williamson 
et al. 2007 
[65]
United Kingdom, 
Glasgow, 
Edinburgh
1,350 men recruited at gay 
venues
Number of sex partners in past year;
Number of anal sex partners in 
past yeara;
UAI with >1 sex partner in past year;
STI in past yeara
Agea
Recruitment 
location
Survey venue
Area of residence
Note: GUM = genitourinary medicine clinic; HIV = human immunodeficiency virus; MSM = men who have sex with men; STI = sexually 
transmitted infection; UAI = unprotected anal intercourse.
a. Adjusted for age, education, ethnicity, and employment status.
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table c.32 summary of multivariate studies for sti incidence risk Factors among msm 
in europe
Study, year Location Sample
Individual-level 
risk factors 
Environmental-level 
risk factors
Van der Bij et al. 
2005 [11]
Netherlands, 
Amsterdam
603 HIV− men in 
cohort ≤30 years 
until age 35 (ACS)
Sells sex Calendar time
Note: ACS = Amsterdam Cohort Studies; HIV = human immunodeficiency virus; MSM = men who have sex with men; 
STI = sexually transmitted infections.
table c.33 summary of multivariate studies for UAi risk Factors among msm in europe
Study, year Location Sample Individual-level risk factors 
Environmental-
level risk factors
Folch et al. 
2006 [81]
Spain, Barcelona 354 men reporting 
steady male 
partners, recruited 
at gay venues
UAI with steady male partners:
• HIV status of couple
• Attitudes about HIV 
prevention given 
availability of ART
Living 
arrangements
543 men reporting 
casual male 
partners, recruited 
at gay venues
UAI with casual male partners: 
• HIV status (self-report)
• Drug use before/during sex
• Index reflecting acceptance 
of gay men’s orientation
• Attitudes about HIV 
prevention given 
availability of ART
Victim of 
aggression or 
verbal assaults
Recruitment site
Circle of friends
Folch et al. 
2009 [6]
Spain, Catalonia 850 men recruited 
at gay venues
UAI with casual male partners:
• Number of male sex partners
• Number of drugs used
• HIV status (self-report)
Country of origin
Internalized 
homophobia
Met casual 
partners online
Balthasar et al. 
2010 [82]
Switzerland, 
nationwide
1,689 men recruited 
online and 
through gay 
media
No or inconsistent condom 
use in past year:
• Number of partners in 
past year
• Stable relationship in 
past year
• HIV status (self-report)
• Visited risk reduction HIV 
prevention site
• HIV status × number of 
partners (interaction)
Age
Internet 
partner-seeking
Štulhofer et al. 
2008 [26]
Croatia, Zagreb 216 men recruited 
through snowball 
techniques
Condom use at last AI with 
casual partner:
• HIV knowledge
• HIV risk self-assessment
• Number of partners in past 
5 years
• Ever tested for HIV
• Sex with a woman
• Sold sex
• In a stable relationship
• Used drugs before sex
• Used alcohol before sex
Age
Frequency of 
cruising
Education
Internet 
partner-seeking
table continues next page
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table c.33 summary of multivariate studies for UAi risk Factors among msm in europe (continued)
Study, year Location Sample Individual-level risk factors 
Environmental-
level risk factors
Amirkhanian 
et al. 2009 
[22]
Russian Federation, 
St. Petersburg and 
Budapest, Hungary
38 men in 
St. Petersburg 
and 118 men in 
Hungary recruited 
through RDS
Any UAI
• Safer sex intentions
• Condom and safer sex 
attitudes
UAI with casual partner
• Safer sex intentions
• Safer sex self-efficacy
Education
UAI with multiple partners
• Safer sex intentions
• Safer sex self-efficacy
Mor et al. 
2008 [17]
Israel, nationwide 2,873 men recruited 
through 
gay-oriented 
websites
UAI and substance use:
• Casual contacts in past 
6 months
• Sells sex
• Steady and casual partners
• Dislikes condoms
• Negotiation skills
• HIV knowledge
• Age at first sexual intercourse
• Number of sexual encounters
Lives in Tel Aviv
Education
Living situation, 
model adjusted 
for age
Mor et al. 2011 
[85]
Israel, nationwide
Outcome “sex risk 
behavior” defined as 
performing insertive 
or receptive UAI 
during the past 
6 months with at 
least one of the 
following cases: 
(a) not knowing his 
own HIV status; 
(b) not knowing his 
steady partner’s HIV 
status; (c) UAI with 
an HIV+ steady 
partner; (d) UAI with 
a casual partner; 
(e) participant who 
performed UAI with 
their HIV– steady 
partner, while 
concurrently having 
UAI with the casual 
partner.
896 men recruited 
through 
gay-orientated 
websites reporting 
sex with casual 
partners
Sex risk behavior among MSM 
with casual partners: 
• Number of partners
• Receptive oral with 
ejaculation
• Substance use before/
during sex
• Insufficient negotiation skills
• Negative attitude to condoms
• Risk-taker personality
Education
Meeting sexual 
partners in 
venues that 
encourage 
sexual activity
907 men recruited 
through 
gay-oriented 
websites reporting 
sex with steady 
partners
Sex risk behavior among MSM 
with steady partners:
• Number of partners
• Insufficient negotiation skills
• Negative attitude to condoms
• Risk-taker personality
• Length of relationships
Being at high 
risk of HIV, 
model adjusted 
for age
Kasianczuk et al. 
2009 [24]
Ukraine, 10 cities 1,764 men recruited 
through snowball 
methods
Condom use at last AI:
• Insertive/receptive role in past 
6 months
• Partner’s type in past 
6 months
• Alcohol/drugs
Age
table continues next page
Systematic Review and Summary Tables 327
HIV Epidemics in the European Region • http://dx.doi.org/10.1596/978-1-4648-0388-8 
table c.33 summary of multivariate studies for UAi risk Factors among msm in europe (continued)
Study, year Location Sample Individual-level risk factors 
Environmental-
level risk factors
• Knows where to test for HIV
• Ever had an HIV test
• Perceived risk of HIV
Léobon et al. 
2011 [84]
France, nationwide 11,768 HIV− men 
recruited through 
gay-oriented 
general interest 
and specialized 
websites
12 m regular unprotected sex 
with casual partners: 
• Sensation seeking
• number of casual partners
• Barebacked with a couple
• Oral contact with sperm
• Esoteric activity
• Traded sex
• Used drugs
• Used alcohol
• Had an STI
Recruitment 
website
Education
Live in Paris
Venues used to 
find sexual 
partners
2,130 HIV− men 
recruited through 
gay-oriented 
general interest 
and specialized 
websites
12 m regular unprotected sex 
with casual partners: 
• Sensation seeking
• Number of casual partners
• Sex with a casual partner 
while couples
• Barebacked with a couple
• Oral contact with sperm
• Esoteric activity
• Traded sex
• Used drugs
• Used alcohol
• Had an STI
Recruitment 
website
Age
Education
Live in Paris
Venues used to 
find sexual 
partners
Evans et al. 
2011 [83]
United Kingdom, 
nationwide
691 Central and 
Eastern European 
migrant men 
recruited through 
gay-oriented 
websites
UAI with casual partners in 
past year:
• Self-reported HIV status
• Ever injected drugs
• Recreational drug use in 
past year
• Been paid for sex in United 
Kingdom
Age
Employment
Education
Country of origin
Completed 
questionnaire 
in native 
language
Time in United 
Kingdom
Lives in London
Recruitment 
website
Note: AI = anal intercourse; ART = antiretroviral therapy; HIV = human immunodeficiency virus; HIV+ = HIV-positive; HIV– = HIV-negative; 
m = months; MSM = men who have sex with men; RDS = respondent-driven sampling; STI = sexually transmitted infection; 
UAI = unprotected anal intercourse.
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